{"3dca139f506eb6b6e80aa3f4d363ab314aef6440": [["1 In their battle against the raging COVID-19 pandemic, the use of medical masks and respirators as personal protective equipment is pivotal to reducing the level of biological hazard to which healthcare workers are exposed during the outbreak of this highly diffusible pathogen.", [["medical masks", "TREATMENT", 67, 80], ["respirators", "TREATMENT", 85, 96], ["personal protective equipment", "TREATMENT", 100, 129], ["this highly diffusible pathogen", "PROBLEM", 247, 278]]], ["2 HCWs employed on the frontline are at maximum risk of catching this deadly infection.", [["infection", "DISEASE", 77, 86], ["this deadly infection", "PROBLEM", 65, 86], ["infection", "OBSERVATION", 77, 86]]], ["It becomes imperative to educate the frontline workers regarding the proper donning and doffing techniques for personal protective equipment (PPE) for controlling the disease spread.", [["doffing techniques", "TREATMENT", 88, 106], ["personal protective equipment (PPE)", "TREATMENT", 111, 146], ["the disease spread", "PROBLEM", 163, 181], ["disease", "OBSERVATION", 167, 174]]]], "PMC7295866": [["Coronaviruses ::: IntroductionCoronaviruses are a large group of single-stranded RNA viruses that are common among mammals and birds.5 6 Coronaviruses cause respiratory and, less frequently, gastrointestinal diseases.5 The respiratory symptoms caused by coronaviruses can range from common cold-like or mild influenza-like symptoms to severe pneumonia.", [["respiratory", "ANATOMY", 157, 168], ["gastrointestinal", "ANATOMY", 191, 207], ["respiratory", "ANATOMY", 223, 234], ["gastrointestinal diseases", "DISEASE", 191, 216], ["respiratory symptoms", "DISEASE", 223, 243], ["coronaviruses", "DISEASE", 254, 267], ["influenza-like symptoms", "DISEASE", 308, 331], ["pneumonia", "DISEASE", 342, 351], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 30, 43], ["birds", "ORGANISM", 127, 132], ["gastrointestinal", "ORGAN", 191, 207], ["coronaviruses", "ORGANISM", 254, 267], ["stranded RNA viruses", "PROBLEM", 72, 92], ["respiratory and, less frequently, gastrointestinal diseases", "PROBLEM", 157, 216], ["The respiratory symptoms", "PROBLEM", 219, 243], ["coronaviruses", "PROBLEM", 254, 267], ["common cold", "PROBLEM", 283, 294], ["mild influenza-like symptoms", "PROBLEM", 303, 331], ["severe pneumonia", "PROBLEM", 335, 351], ["large", "OBSERVATION_MODIFIER", 50, 55], ["RNA viruses", "OBSERVATION", 81, 92], ["respiratory", "ANATOMY", 157, 168], ["gastrointestinal", "ANATOMY", 191, 207], ["diseases", "OBSERVATION", 208, 216], ["respiratory", "ANATOMY", 223, 234], ["mild", "OBSERVATION_MODIFIER", 303, 307], ["influenza", "OBSERVATION", 308, 317], ["severe", "OBSERVATION_MODIFIER", 335, 341], ["pneumonia", "OBSERVATION", 342, 351]]], ["In December 2019, a new type of coronavirus causing pneumonia and death was identified in Wuhan, China3 4; this new coronavirus is called SARS-CoV-2 because it is genetically similar to SARS-CoV which caused the 2002 outbreak of severe acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 242, 253], ["coronavirus", "DISEASE", 32, 43], ["pneumonia", "DISEASE", 52, 61], ["death", "DISEASE", 66, 71], ["coronavirus", "DISEASE", 116, 127], ["SARS-CoV", "DISEASE", 186, 194], ["acute respiratory distress syndrome", "DISEASE", 236, 271], ["ARDS", "DISEASE", 273, 277], ["coronavirus", "ORGANISM", 32, 43], ["coronavirus", "ORGANISM", 116, 127], ["SARS-CoV-2", "ORGANISM", 138, 148], ["SARS-CoV", "ORGANISM", 186, 194], ["coronavirus", "SPECIES", 116, 127], ["SARS-CoV", "SPECIES", 138, 146], ["SARS-CoV", "SPECIES", 186, 194], ["coronavirus", "PROBLEM", 32, 43], ["pneumonia", "PROBLEM", 52, 61], ["death", "PROBLEM", 66, 71], ["this new coronavirus", "PROBLEM", 107, 127], ["SARS", "PROBLEM", 138, 142], ["SARS", "PROBLEM", 186, 190], ["severe acute respiratory distress syndrome", "PROBLEM", 229, 271], ["ARDS", "PROBLEM", 273, 277], ["coronavirus", "OBSERVATION", 32, 43], ["pneumonia", "OBSERVATION", 52, 61], ["severe", "OBSERVATION_MODIFIER", 229, 235], ["acute", "OBSERVATION_MODIFIER", 236, 241], ["respiratory distress syndrome", "OBSERVATION", 242, 271], ["ARDS", "OBSERVATION", 273, 277]]], ["In fact, SARS-CoV-2 is the seventh known human coronavirus.7 However, SARS-CoV-2 is new to the human immune system and so there was no underlying existing natural immunity against it.", [["immune system", "ANATOMY", 101, 114], ["SARS-CoV-2", "ORGANISM", 9, 19], ["human", "ORGANISM", 41, 46], ["coronavirus", "ORGANISM", 47, 58], ["SARS-CoV-2", "ORGANISM", 70, 80], ["human", "ORGANISM", 95, 100], ["immune system", "ANATOMICAL_SYSTEM", 101, 114], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 95, 100], ["SARS-CoV", "SPECIES", 9, 17], ["human coronavirus", "SPECIES", 41, 58], ["SARS-CoV", "SPECIES", 70, 78], ["human", "SPECIES", 95, 100], ["SARS", "TEST", 9, 13], ["SARS", "PROBLEM", 70, 74], ["coronavirus", "OBSERVATION", 47, 58], ["no underlying", "UNCERTAINTY", 132, 145]]], ["This is probably why SARS-CoV-2 has spread so rapidly.", [["SARS", "DISEASE", 21, 25], ["SARS-CoV-2", "ORGANISM", 21, 31], ["SARS", "PROBLEM", 21, 25], ["probably why", "UNCERTAINTY", 8, 20], ["SARS", "OBSERVATION", 21, 25]]], ["SARS-CoV-2 infects respiratory epithelial cells causing the symptoms described above, and in severe cases requires ventilatory support.", [["respiratory epithelial cells", "ANATOMY", 19, 47], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["respiratory epithelial cells", "CELL", 19, 47], ["respiratory epithelial cells", "CELL_TYPE", 19, 47], ["SARS-CoV-2", "SPECIES", 0, 10], ["SARS", "TEST", 0, 4], ["respiratory epithelial cells", "PROBLEM", 19, 47], ["the symptoms", "PROBLEM", 56, 68], ["ventilatory support", "TREATMENT", 115, 134], ["respiratory epithelial cells", "OBSERVATION", 19, 47], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["ventilatory support", "OBSERVATION", 115, 134]]], ["Older people, especially those with existing morbidities like diabetes, cardiovascular disease, respiratory disease and hypertension, are particularly susceptible to severe symptoms and mortality, as are individuals with suppressed immune systems.3 4 There is currently no treatment for infection with SARS-CoV-2 or for COVID-19.", [["cardiovascular", "ANATOMY", 72, 86], ["respiratory", "ANATOMY", 96, 107], ["diabetes", "DISEASE", 62, 70], ["cardiovascular disease", "DISEASE", 72, 94], ["respiratory disease", "DISEASE", 96, 115], ["hypertension", "DISEASE", 120, 132], ["infection", "DISEASE", 287, 296], ["SARS", "DISEASE", 302, 306], ["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["diabetes", "PROBLEM", 62, 70], ["cardiovascular disease", "PROBLEM", 72, 94], ["respiratory disease", "PROBLEM", 96, 115], ["hypertension", "PROBLEM", 120, 132], ["severe symptoms", "PROBLEM", 166, 181], ["suppressed immune systems", "PROBLEM", 221, 246], ["treatment", "TREATMENT", 273, 282], ["infection", "PROBLEM", 287, 296], ["SARS", "TEST", 302, 306], ["CoV", "TEST", 307, 310], ["COVID", "TEST", 320, 325], ["diabetes", "OBSERVATION", 62, 70], ["cardiovascular", "ANATOMY", 72, 86], ["disease", "OBSERVATION", 87, 94], ["respiratory disease", "OBSERVATION", 96, 115], ["hypertension", "OBSERVATION", 120, 132], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["no treatment for", "UNCERTAINTY", 270, 286], ["infection", "OBSERVATION", 287, 296]]], ["Current strategies aim to limit the spread of the virus by preventing contact between people.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["Current strategies", "TREATMENT", 0, 18], ["the virus", "TREATMENT", 46, 55]]], ["The search for vaccines to offer immune protection against SARS-CoV-2 and for pharmacological treatments to prevent the virus from replicating is underway.", [["SARS", "DISEASE", 59, 63], ["SARS-CoV-2", "ORGANISM", 59, 69], ["SARS-CoV", "SPECIES", 59, 67], ["vaccines", "TREATMENT", 15, 23], ["immune protection", "TREATMENT", 33, 50], ["SARS", "PROBLEM", 59, 63], ["CoV", "TEST", 64, 67], ["pharmacological treatments", "TREATMENT", 78, 104], ["the virus", "PROBLEM", 116, 125]]], ["Nutrition should be at the forefront of these approaches.Introductory comments ::: The immune system ::: IntroductionThe immune system becomes vital once an individual is exposed to an infectious agent.", [["immune system", "ANATOMY", 121, 134], ["Nutrition", "TREATMENT", 0, 9], ["an infectious agent", "TREATMENT", 182, 201], ["infectious", "OBSERVATION", 185, 195]]], ["However, the nature of infectious agents varies and so different approaches are required by the immune system to deal with different types of infectious agent.", [["infectious agents", "TREATMENT", 23, 40], ["infectious agent", "TREATMENT", 142, 158], ["infectious", "OBSERVATION", 23, 33], ["infectious", "OBSERVATION", 142, 152]]], ["For example, most bacteria do not invade host cells and remain accessible to the host\u2019s immune system; often these bacteria will be engulfed by innate phagocytic cells (typically neutrophils, monocytes, macrophages, dendritic cells), killed within intracellular phagocytic vacuoles and then digested.", [["cells", "ANATOMY", 46, 51], ["phagocytic cells", "ANATOMY", 151, 167], ["neutrophils", "ANATOMY", 179, 190], ["monocytes", "ANATOMY", 192, 201], ["macrophages", "ANATOMY", 203, 214], ["dendritic cells", "ANATOMY", 216, 231], ["intracellular phagocytic vacuoles", "ANATOMY", 248, 281], ["host cells", "CELL", 41, 51], ["immune system", "ANATOMICAL_SYSTEM", 88, 101], ["phagocytic cells", "CELL", 151, 167], ["neutrophils", "CELL", 179, 190], ["monocytes", "CELL", 192, 201], ["macrophages", "CELL", 203, 214], ["dendritic cells", "CELL", 216, 231], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 248, 261], ["phagocytic vacuoles", "CELLULAR_COMPONENT", 262, 281], ["host cells", "CELL_TYPE", 41, 51], ["innate phagocytic cells", "CELL_TYPE", 144, 167], ["neutrophils", "CELL_TYPE", 179, 190], ["monocytes", "CELL_TYPE", 192, 201], ["macrophages", "CELL_TYPE", 203, 214], ["dendritic cells", "CELL_TYPE", 216, 231], ["most bacteria", "PROBLEM", 13, 26], ["these bacteria", "PROBLEM", 109, 123], ["neutrophils", "TEST", 179, 190], ["monocytes", "TEST", 192, 201], ["phagocytic cells", "OBSERVATION", 151, 167], ["dendritic cells", "OBSERVATION", 216, 231], ["phagocytic vacuoles", "OBSERVATION", 262, 281]]], ["Remnants of the digested bacteria (antigens) can then be displayed via major histocompatibility class (MHC) II on the surface of the phagocyte.", [["surface", "ANATOMY", 118, 125], ["phagocyte", "ANATOMY", 133, 142], ["major histocompatibility class (MHC) II", "GENE_OR_GENE_PRODUCT", 71, 110], ["surface", "CELLULAR_COMPONENT", 118, 125], ["phagocyte", "CELL", 133, 142], ["antigens", "PROTEIN", 35, 43], ["major histocompatibility class (MHC) II", "PROTEIN", 71, 110], ["phagocyte", "CELL_TYPE", 133, 142], ["the digested bacteria", "PROBLEM", 12, 33], ["phagocyte", "ANATOMY", 133, 142]]], ["These antigens are recognised by antigen-specific CD4+ helper T lymphocytes and this triggers the acquired (also called adaptive) immune response to the bacteria, which involves the orchestrating T lymphocytes, B lymphocytes (which produce antigen-specific antibodies) and the further activation of innate immune cells.", [["CD4+ helper T lymphocytes", "ANATOMY", 50, 75], ["T lymphocytes", "ANATOMY", 196, 209], ["B lymphocytes", "ANATOMY", 211, 224], ["immune cells", "ANATOMY", 306, 318], ["antigen", "GENE_OR_GENE_PRODUCT", 33, 40], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["T lymphocytes", "CELL", 196, 209], ["B lymphocytes", "CELL", 211, 224], ["antigen-specific antibodies", "GENE_OR_GENE_PRODUCT", 240, 267], ["innate immune cells", "CELL", 299, 318], ["CD4", "PROTEIN", 50, 53], ["helper T lymphocytes", "CELL_TYPE", 55, 75], ["T lymphocytes", "CELL_TYPE", 196, 209], ["B lymphocytes", "CELL_TYPE", 211, 224], ["antigen-specific antibodies", "PROTEIN", 240, 267], ["innate immune cells", "CELL_TYPE", 299, 318], ["antigen", "TEST", 33, 40], ["the bacteria", "PROBLEM", 149, 161], ["B lymphocytes", "TEST", 211, 224], ["antigen", "TEST", 240, 247], ["innate immune cells", "TREATMENT", 299, 318], ["lymphocytes", "ANATOMY", 213, 224], ["immune cells", "OBSERVATION", 306, 318]]], ["This response to extracellular bacteria is clearly targeted at killing those bacteria.", [["extracellular", "ANATOMY", 17, 30], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 30], ["extracellular bacteria", "PROBLEM", 17, 39], ["bacteria", "OBSERVATION", 31, 39]]], ["Viruses (and some bacteria) invade host cells rather than remaining exclusively extracellular; this can trigger presentation of antigens via MHC I on the surface of the infected cells.", [["cells", "ANATOMY", 40, 45], ["extracellular", "ANATOMY", 80, 93], ["surface", "ANATOMY", 154, 161], ["cells", "ANATOMY", 178, 183], ["host cells", "CELL", 35, 45], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["MHC I", "GENE_OR_GENE_PRODUCT", 141, 146], ["surface", "CELLULAR_COMPONENT", 154, 161], ["cells", "CELL", 178, 183], ["host cells", "CELL_TYPE", 35, 45], ["antigens", "PROTEIN", 128, 136], ["MHC I", "PROTEIN", 141, 146], ["infected cells", "CELL_TYPE", 169, 183], ["Viruses", "PROBLEM", 0, 7], ["some bacteria) invade host cells", "PROBLEM", 13, 45], ["the infected cells", "PROBLEM", 165, 183], ["bacteria", "OBSERVATION_MODIFIER", 18, 26], ["host cells", "OBSERVATION", 35, 45], ["infected cells", "OBSERVATION", 169, 183]]], ["Recognition of these antigens by CD8+ cytotoxic T lymphocytes results in killing of the host cell that is presenting the antigen.", [["CD8+ cytotoxic T lymphocytes", "ANATOMY", 33, 61], ["cell", "ANATOMY", 93, 97], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["host cell", "CELL", 88, 97], ["CD8", "PROTEIN", 33, 36], ["cytotoxic T lymphocytes", "CELL_TYPE", 38, 61], ["these antigens", "TEST", 15, 29], ["CD8", "TEST", 33, 36], ["cytotoxic T lymphocytes", "TEST", 38, 61], ["host cell", "OBSERVATION", 88, 97]]], ["Natural killer cells also recognise virally infected cells and act in an analogous way to cytotoxic T lymphocytes by killing the infected cells.", [["Natural killer cells", "ANATOMY", 0, 20], ["cells", "ANATOMY", 53, 58], ["T lymphocytes", "ANATOMY", 100, 113], ["cells", "ANATOMY", 138, 143], ["Natural killer cells", "CELL", 0, 20], ["cells", "CELL", 53, 58], ["T lymphocytes", "CELL", 100, 113], ["cells", "CELL", 138, 143], ["Natural killer cells", "CELL_TYPE", 0, 20], ["virally infected cells", "CELL_TYPE", 36, 58], ["cytotoxic T lymphocytes", "CELL_TYPE", 90, 113], ["infected cells", "CELL_TYPE", 129, 143], ["Natural killer cells", "TREATMENT", 0, 20], ["virally infected cells", "PROBLEM", 36, 58], ["cytotoxic T lymphocytes", "PROBLEM", 90, 113], ["the infected cells", "PROBLEM", 125, 143], ["killer cells", "OBSERVATION", 8, 20], ["virally", "OBSERVATION_MODIFIER", 36, 43], ["infected cells", "OBSERVATION", 44, 58], ["infected cells", "OBSERVATION", 129, 143]]], ["Thus, this response to virally infected cells is targeted at killing the host cells that harbour viruses.", [["cells", "ANATOMY", 40, 45], ["cells", "ANATOMY", 78, 83], ["cells", "CELL", 40, 45], ["cells", "CELL", 78, 83], ["virally infected cells", "CELL_TYPE", 23, 45], ["host cells", "CELL_TYPE", 73, 83], ["virally infected cells", "PROBLEM", 23, 45], ["harbour viruses", "PROBLEM", 89, 104], ["infected cells", "OBSERVATION", 31, 45], ["harbour viruses", "OBSERVATION", 89, 104]]], ["Killing host cells of course liberates viruses and the battle between host immune cells and virally infected cells continues.Introductory comments ::: The immune system ::: IntroductionThere are four general functions of the immune system that enable effective host defence:Barrier function ::: The immune system ::: IntroductionThe barrier function of the immune system acts to prevent pathogens from entering the body from the external environment.", [["cells", "ANATOMY", 13, 18], ["immune cells", "ANATOMY", 75, 87], ["cells", "ANATOMY", 109, 114], ["immune system", "ANATOMY", 225, 238], ["immune system", "ANATOMY", 357, 370], ["body", "ANATOMY", 415, 419], ["host cells", "CELL", 8, 18], ["host immune cells", "CELL", 70, 87], ["cells", "CELL", 109, 114], ["body", "ORGANISM_SUBDIVISION", 415, 419], ["host immune cells", "CELL_TYPE", 70, 87], ["virally infected cells", "CELL_TYPE", 92, 114], ["course liberates viruses", "PROBLEM", 22, 46], ["host immune cells", "TREATMENT", 70, 87], ["virally infected cells", "PROBLEM", 92, 114], ["the immune system", "TREATMENT", 353, 370], ["pathogens", "PROBLEM", 387, 396], ["host cells", "OBSERVATION", 8, 18], ["viruses", "OBSERVATION", 39, 46], ["immune cells", "OBSERVATION", 75, 87], ["infected cells", "OBSERVATION", 100, 114], ["external environment", "OBSERVATION", 429, 449]]], ["This includes physical barriers like the skin and mucosal layers (gastrointestinal tract, respiratory tract, genitourinary tract); chemical barriers like the acid pH of the stomach; and biological barriers like the presence of commensal organisms on the skin and in the intestinal tract, secretions like IgA and antimicrobial proteins in saliva and tears, and the complement system.Identification of pathogens ::: The immune system ::: IntroductionPathogens are recognised by cells of the innate immune system, such as macrophages, monocytes and dendritic cells.", [["skin", "ANATOMY", 41, 45], ["mucosal layers", "ANATOMY", 50, 64], ["gastrointestinal tract", "ANATOMY", 66, 88], ["respiratory tract", "ANATOMY", 90, 107], ["genitourinary tract", "ANATOMY", 109, 128], ["stomach", "ANATOMY", 173, 180], ["skin", "ANATOMY", 254, 258], ["intestinal tract", "ANATOMY", 270, 286], ["secretions", "ANATOMY", 288, 298], ["saliva", "ANATOMY", 338, 344], ["tears", "ANATOMY", 349, 354], ["cells", "ANATOMY", 476, 481], ["immune system", "ANATOMY", 496, 509], ["macrophages", "ANATOMY", 519, 530], ["monocytes", "ANATOMY", 532, 541], ["dendritic cells", "ANATOMY", 546, 561], ["gastrointestinal tract, respiratory tract, genitourinary tract", "DISEASE", 66, 128], ["skin", "ORGAN", 41, 45], ["mucosal layers", "TISSUE", 50, 64], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 66, 88], ["respiratory tract", "ORGANISM_SUBDIVISION", 90, 107], ["genitourinary tract", "ORGANISM_SUBDIVISION", 109, 128], ["stomach", "ORGAN", 173, 180], ["skin", "ORGAN", 254, 258], ["intestinal tract", "ORGAN", 270, 286], ["secretions", "ORGANISM_SUBSTANCE", 288, 298], ["IgA", "GENE_OR_GENE_PRODUCT", 304, 307], ["saliva", "ORGANISM_SUBSTANCE", 338, 344], ["tears", "TISSUE", 349, 354], ["cells", "CELL", 476, 481], ["innate", "ANATOMICAL_SYSTEM", 489, 495], ["immune system", "ANATOMICAL_SYSTEM", 496, 509], ["macrophages", "CELL", 519, 530], ["monocytes", "CELL", 532, 541], ["dendritic cells", "CELL", 546, 561], ["IgA", "PROTEIN", 304, 307], ["antimicrobial proteins", "PROTEIN", 312, 334], ["macrophages", "CELL_TYPE", 519, 530], ["monocytes", "CELL_TYPE", 532, 541], ["dendritic cells", "CELL_TYPE", 546, 561], ["physical barriers", "TREATMENT", 14, 31], ["the skin and mucosal layers (gastrointestinal tract, respiratory tract, genitourinary tract", "PROBLEM", 37, 128], ["chemical barriers", "TREATMENT", 131, 148], ["the acid pH", "TEST", 154, 165], ["biological barriers", "TREATMENT", 186, 205], ["commensal organisms on the skin", "PROBLEM", 227, 258], ["secretions like IgA and antimicrobial proteins in saliva and tears", "PROBLEM", 288, 354], ["pathogens", "PROBLEM", 400, 409], ["IntroductionPathogens", "TREATMENT", 436, 457], ["monocytes", "PROBLEM", 532, 541], ["dendritic cells", "PROBLEM", 546, 561], ["skin", "ANATOMY", 41, 45], ["mucosal layers", "ANATOMY", 50, 64], ["gastrointestinal tract", "ANATOMY", 66, 88], ["respiratory tract", "ANATOMY", 90, 107], ["genitourinary tract", "ANATOMY", 109, 128], ["stomach", "ANATOMY", 173, 180], ["commensal organisms", "OBSERVATION", 227, 246], ["skin", "ANATOMY", 254, 258], ["intestinal tract", "ANATOMY", 270, 286], ["antimicrobial proteins", "OBSERVATION", 312, 334], ["pathogens", "OBSERVATION", 400, 409], ["macrophages", "ANATOMY", 519, 530], ["dendritic cells", "OBSERVATION", 546, 561]]], ["This is achieved through the presence of pattern recognition receptors (PRRs) that recognise general molecular structures that are broadly shared by groups of pathogens.", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 41, 70], ["pattern recognition receptors", "PROTEIN", 41, 70], ["PRRs", "PROTEIN", 72, 76], ["pathogens", "PROBLEM", 159, 168], ["pathogens", "OBSERVATION", 159, 168]]], ["These structures are termed microbe-associated molecular patterns or MAMPs.", [["MAMPs", "GENE_OR_GENE_PRODUCT", 69, 74], ["MAMPs", "PROTEIN", 69, 74], ["molecular patterns", "OBSERVATION", 47, 65]]], ["When PRRs recognise MAMPs, the first line of host defensive responses is activated.", [["PRRs", "GENE_OR_GENE_PRODUCT", 5, 9], ["MAMPs", "GENE_OR_GENE_PRODUCT", 20, 25], ["PRRs", "PROTEIN", 5, 9], ["MAMPs", "PROTEIN", 20, 25]]], ["PRRs include Toll-like receptors (TLRs).", [["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 13, 32], ["TLRs", "GENE_OR_GENE_PRODUCT", 34, 38], ["PRRs", "PROTEIN", 0, 4], ["Toll-like receptors", "PROTEIN", 13, 32], ["TLRs", "PROTEIN", 34, 38]]], ["More than 10 functional TLRs have been identified in humans, each one detecting distinct MAMPs from bacteria, viruses, fungi and parasites.", [["TLRs", "GENE_OR_GENE_PRODUCT", 24, 28], ["humans", "ORGANISM", 53, 59], ["MAMPs", "GENE_OR_GENE_PRODUCT", 89, 94], ["TLRs", "PROTEIN", 24, 28], ["humans", "SPECIES", 53, 59], ["humans", "SPECIES", 53, 59], ["bacteria", "PROBLEM", 100, 108], ["viruses", "PROBLEM", 110, 117], ["fungi", "PROBLEM", 119, 124], ["parasites", "PROBLEM", 129, 138]]], ["The best described of these are TLR4 which recognises the lipopolysaccharides from the cell wall of Gram-negative bacteria and TLR2 which recognises the lipoteichoic acid from the cell wall of Gram-positive bacteria.", [["cell wall", "ANATOMY", 87, 96], ["cell wall", "ANATOMY", 180, 189], ["lipoteichoic acid", "CHEMICAL", 153, 170], ["lipoteichoic acid", "CHEMICAL", 153, 170], ["TLR4", "GENE_OR_GENE_PRODUCT", 32, 36], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 58, 77], ["cell wall", "CELLULAR_COMPONENT", 87, 96], ["Gram", "GENE_OR_GENE_PRODUCT", 100, 104], ["TLR2", "GENE_OR_GENE_PRODUCT", 127, 131], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 153, 170], ["cell wall", "CELLULAR_COMPONENT", 180, 189], ["Gram", "GENE_OR_GENE_PRODUCT", 193, 197], ["TLR4", "PROTEIN", 32, 36], ["TLR2", "PROTEIN", 127, 131], ["the lipopolysaccharides", "TEST", 54, 77], ["Gram", "TEST", 100, 104], ["TLR2", "PROBLEM", 127, 131], ["the lipoteichoic acid", "TEST", 149, 170], ["Gram", "TEST", 193, 197], ["positive bacteria", "PROBLEM", 198, 215], ["TLR4", "OBSERVATION", 32, 36], ["lipopolysaccharides", "OBSERVATION_MODIFIER", 58, 77], ["cell", "ANATOMY", 87, 91], ["wall", "ANATOMY_MODIFIER", 92, 96], ["negative bacteria", "OBSERVATION", 105, 122], ["lipoteichoic acid", "OBSERVATION", 153, 170], ["cell", "OBSERVATION", 180, 184], ["wall", "ANATOMY_MODIFIER", 185, 189], ["positive bacteria", "OBSERVATION", 198, 215]]], ["Several TLRs are expressed on the cell surface of innate immune cells because the pathogens they recognise, mainly bacteria, are extracellular.", [["cell surface", "ANATOMY", 34, 46], ["immune cells", "ANATOMY", 57, 69], ["extracellular", "ANATOMY", 129, 142], ["TLRs", "GENE_OR_GENE_PRODUCT", 8, 12], ["cell surface", "CELLULAR_COMPONENT", 34, 46], ["innate immune cells", "CELL", 50, 69], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 129, 142], ["TLRs", "PROTEIN", 8, 12], ["innate immune cells", "CELL_TYPE", 50, 69], ["innate immune cells", "TREATMENT", 50, 69], ["the pathogens", "PROBLEM", 78, 91], ["mainly bacteria", "PROBLEM", 108, 123], ["immune cells", "OBSERVATION", 57, 69], ["mainly", "OBSERVATION_MODIFIER", 108, 114], ["bacteria", "OBSERVATION_MODIFIER", 115, 123], ["extracellular", "OBSERVATION_MODIFIER", 129, 142]]], ["Because viruses enter host cells, it is important that there are also intracellular TLRs.", [["cells", "ANATOMY", 27, 32], ["intracellular", "ANATOMY", 70, 83], ["host cells", "CELL", 22, 32], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 83], ["TLRs", "GENE_OR_GENE_PRODUCT", 84, 88], ["host cells", "CELL_TYPE", 22, 32], ["intracellular TLRs", "PROTEIN", 70, 88], ["host cells", "OBSERVATION", 22, 32], ["intracellular TLRs", "OBSERVATION", 70, 88]]], ["Indeed, intracellular TLRs that recognise viral DNA, viral double-stranded RNA and viral single-stranded RNA exist.", [["intracellular", "ANATOMY", 8, 21], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 8, 21], ["TLRs", "GENE_OR_GENE_PRODUCT", 22, 26], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["intracellular TLRs", "PROTEIN", 8, 26], ["viral DNA", "DNA", 42, 51], ["viral double-stranded RNA", "RNA", 53, 78], ["viral single-stranded RNA", "RNA", 83, 108], ["viral DNA", "PROBLEM", 42, 51], ["viral double", "TEST", 53, 65], ["stranded RNA", "TEST", 66, 78], ["viral single-stranded RNA exist", "PROBLEM", 83, 114], ["viral DNA", "OBSERVATION", 42, 51], ["viral double", "OBSERVATION", 53, 65], ["stranded RNA", "OBSERVATION_MODIFIER", 66, 78], ["stranded RNA", "OBSERVATION_MODIFIER", 96, 108]]], ["Among these, TLR7 and TLR8 are found in macrophages, monocytes, dendritic cells and some other cell types and are likely to be important in innate recognition of the single-stranded RNA of coronaviruses.", [["macrophages", "ANATOMY", 40, 51], ["monocytes", "ANATOMY", 53, 62], ["dendritic cells", "ANATOMY", 64, 79], ["cell", "ANATOMY", 95, 99], ["TLR7", "GENE_OR_GENE_PRODUCT", 13, 17], ["TLR8", "GENE_OR_GENE_PRODUCT", 22, 26], ["macrophages", "CELL", 40, 51], ["monocytes", "CELL", 53, 62], ["dendritic cells", "CELL", 64, 79], ["cell types", "CELL", 95, 105], ["coronaviruses", "ORGANISM", 189, 202], ["TLR7", "PROTEIN", 13, 17], ["TLR8", "PROTEIN", 22, 26], ["macrophages", "CELL_TYPE", 40, 51], ["monocytes", "CELL_TYPE", 53, 62], ["dendritic cells", "CELL_TYPE", 64, 79], ["single-stranded RNA", "RNA", 166, 185], ["macrophages", "PROBLEM", 40, 51], ["monocytes", "TEST", 53, 62], ["dendritic cells", "PROBLEM", 64, 79], ["some other cell types", "PROBLEM", 84, 105], ["coronaviruses", "PROBLEM", 189, 202], ["macrophages", "ANATOMY", 40, 51], ["monocytes", "ANATOMY", 53, 62], ["dendritic cells", "OBSERVATION", 64, 79], ["cell types", "OBSERVATION", 95, 105], ["likely to be", "UNCERTAINTY", 114, 126], ["stranded RNA", "OBSERVATION_MODIFIER", 173, 185]]], ["However, proteins, including the spike glycoprotein, of the coronavirus coat are also likely to be recognised by both intracellular and extracellular PRRs.8\u201311", [["intracellular", "ANATOMY", 118, 131], ["extracellular", "ANATOMY", 136, 149], ["coronavirus coat", "ORGANISM", 60, 76], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 131], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 149], ["PRRs", "GENE_OR_GENE_PRODUCT", 150, 154], ["spike glycoprotein", "PROTEIN", 33, 51], ["coronavirus coat", "PROTEIN", 60, 76], ["intracellular and extracellular PRRs", "PROTEIN", 118, 154], ["coronavirus", "SPECIES", 60, 71], ["proteins", "TEST", 9, 17], ["the spike glycoprotein", "PROBLEM", 29, 51], ["the coronavirus coat", "PROBLEM", 56, 76], ["coronavirus coat", "OBSERVATION", 60, 76], ["likely to be", "UNCERTAINTY", 86, 98], ["extracellular PRRs", "OBSERVATION", 136, 154]]]], "e7c1d4ea87ef4b807c68d41ce90d8a1347e1439d": [["Abstract:In response to the COVID-19 pandemic, Ontario issued a declaration of emergency, implementing public health interventions on March 16, 2020.", [["the COVID", "TEST", 24, 33], ["public health interventions", "TREATMENT", 103, 130]]], ["We compared cardiac catheterization procedures for STEMI between January 1 and May 10, 2020 to the same timeframe in 2019.", [["cardiac", "ANATOMY", 12, 19], ["STEMI", "DISEASE", 51, 56], ["cardiac", "ORGAN", 12, 19], ["cardiac catheterization procedures", "TEST", 12, 46], ["STEMI", "PROBLEM", 51, 56], ["catheterization", "OBSERVATION", 20, 35]]], ["From March 16 to May 10, 2020, after implementation of provincial directives, STEMI cases significantly decreased by up to 25%.", [["STEMI", "DISEASE", 78, 83], ["STEMI cases", "TEST", 78, 89]]], ["The proportion of patients achieving guideline targets for FMC-balloon for PPCI decreased substantially to 28% (Median 101 min) for patients presenting directly to a PCI-site and to 37% (Median 149 min) for patients transferred from a non-PCI site, compared to 2019.", [["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 207, 215], ["FMC-balloon", "TREATMENT", 59, 70], ["PPCI", "TREATMENT", 75, 79], ["a PCI", "TREATMENT", 164, 169]]], ["STEMI cases across Ontario have been substantially impacted during the COVID-19 pandemic.Brief Summary:The COVID-19 pandemic prompted Ontario to implement emergency public health measures.Brief Summary:During the following 8 weeks from March 16 to May 10, 2020 we observed substantial decreases in the number of emergency cardiac catheterization lab procedures for STEMI as well as increases in treatment times.", [["cardiac", "ANATOMY", 322, 329], ["STEMI", "DISEASE", 0, 5], ["STEMI", "DISEASE", 365, 370], ["cardiac", "ORGAN", 322, 329], ["substantially impacted", "PROBLEM", 37, 59], ["the COVID", "TEST", 67, 76], ["pandemic", "PROBLEM", 80, 88], ["The COVID", "TEST", 103, 112], ["emergency public health measures", "TREATMENT", 155, 187], ["emergency cardiac catheterization", "TEST", 312, 345], ["STEMI", "PROBLEM", 365, 370], ["substantially", "OBSERVATION_MODIFIER", 37, 50], ["impacted", "OBSERVATION", 51, 59], ["substantial", "OBSERVATION_MODIFIER", 273, 284], ["decreases", "OBSERVATION_MODIFIER", 285, 294], ["STEMI", "OBSERVATION", 365, 370]]], ["STEMI cases in Ontario have been substantially impacted by COVID-19.Introduction:In response to the COVID-19 pandemic, the Province of Ontario declared a state of emergency on March 16, 2020 and many public health interventions were implemented including social distancing, halting of non-essential businesses and cancelling of elective health procedures and surgeries (1) .", [["STEMI", "DISEASE", 0, 5], ["STEMI cases", "TEST", 0, 11], ["COVID", "TEST", 59, 64], ["elective health procedures", "TREATMENT", 328, 354], ["surgeries", "TREATMENT", 359, 368]]], ["Although STEMI management requires emergent intervention and was not directly halted by these measures, the indirect effects of the pandemic on cardiac health and management may be important.", [["cardiac", "ANATOMY", 144, 151], ["STEMI", "DISEASE", 9, 14], ["cardiac", "ORGAN", 144, 151], ["STEMI management", "TREATMENT", 9, 25], ["emergent intervention", "TREATMENT", 35, 56], ["cardiac health", "TREATMENT", 144, 158], ["management", "TREATMENT", 163, 173]]], ["Whether these interventions have impacted the number of patients presenting with STEMI and their treatment times is unknown.Introduction:Outcomes in patients presenting with STEMI are sensitive to both the timeliness of presentation (symptoms to first medical contact (FMC)) as well as the promptness of treatment (first medical contact to first balloon/device (FMC-balloon)).", [["STEMI", "DISEASE", 81, 86], ["STEMI", "DISEASE", 174, 179], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 149, 157], ["STEMI", "PROBLEM", 81, 86], ["STEMI", "PROBLEM", 174, 179], ["symptoms", "PROBLEM", 234, 242], ["treatment", "TREATMENT", 304, 313], ["first balloon/device (FMC-balloon)", "TREATMENT", 340, 374]]], ["Ontario has a well-developed STEMI System of Care with designated care pathways (Ontario STEMI Bypass Protocol for patients calling 911 and Ontario Emergency Department (ED) STEMI Protocol for patients presenting to an ED) and regional partnerships for both primary percutaneous coronary interventions (PPCI) and pharmaco-invasive PCI performed by 17 cardiac centres.", [["coronary", "ANATOMY", 279, 287], ["cardiac", "ANATOMY", 351, 358], ["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 193, 201], ["coronary", "MULTI-TISSUE_STRUCTURE", 279, 287], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 193, 201], ["Ontario STEMI Bypass Protocol", "TREATMENT", 81, 110], ["STEMI Protocol", "TREATMENT", 174, 188], ["both primary percutaneous coronary interventions", "TREATMENT", 253, 301], ["PPCI", "TREATMENT", 303, 307], ["pharmaco-invasive PCI", "TREATMENT", 313, 334], ["coronary", "ANATOMY", 279, 287]]], ["CorHealth Ontario routinely monitors STEMI activity and provides productivity reports quarterly.", [["STEMI", "DISEASE", 37, 42]]], ["In response to the changing landscape, and in consultation with provincial STEMI stakeholders and national societies, CorHealth developed a STEMI guidance document aiming to preserve the established regional practices of PPCI or pharmacoinvasive PCI during the COVID-19 pandemic, while maintaining the safety of patients and health care workers (2, 3) .Introduction:Brief reports from other jurisdictions affected by the COVID-19 pandemic show a substantial decrease in the number of patients presenting to hospital with STEMI, delayed patient presentations, and potential delays in treatment times due to a limited capacity for regional transfers or availability of front-line health care workers (4) (5) (6) .", [["STEMI", "DISEASE", 521, 526], ["patients", "ORGANISM", 312, 320], ["patients", "ORGANISM", 484, 492], ["patient", "ORGANISM", 536, 543], ["patients", "SPECIES", 312, 320], ["patients", "SPECIES", 484, 492], ["patient", "SPECIES", 536, 543], ["a STEMI guidance", "TREATMENT", 138, 154], ["PPCI", "TREATMENT", 221, 225], ["pharmacoinvasive PCI", "TREATMENT", 229, 249], ["the COVID", "TEST", 257, 266], ["the COVID", "TEST", 417, 426], ["STEMI", "PROBLEM", 521, 526], ["treatment", "TREATMENT", 583, 592], ["a limited capacity", "PROBLEM", 606, 624], ["substantial", "OBSERVATION_MODIFIER", 446, 457], ["decrease", "OBSERVATION_MODIFIER", 458, 466]]], ["These studies were based on a selected number of centres and none reported treatment times.", [["These studies", "TEST", 0, 13]]], ["Herein we report our observations for STEMI care during the initial few weeks following declaration of an emergency and the subsequent public health measures advising the public to stay home.Methods:Data maintained in the CorHealth Ontario Cardiac Registry were used for this analysis.", [["STEMI", "DISEASE", 38, 43], ["STEMI care", "TREATMENT", 38, 48], ["this analysis", "TEST", 271, 284]]], ["Inclusion criteria for the reports are cases with STEMI diagnosis on referral where a coronary angiogram is performed at a hospital with PPCI capabilities as the initial procedure.", [["coronary", "ANATOMY", 86, 94], ["STEMI", "DISEASE", 50, 55], ["coronary", "MULTI-TISSUE_STRUCTURE", 86, 94], ["a coronary angiogram", "TEST", 84, 104], ["PPCI capabilities", "TREATMENT", 137, 154], ["the initial procedure", "TREATMENT", 158, 179], ["coronary", "ANATOMY", 86, 94]]], ["Variables included in this analysis include age, sex, diabetes, hypertension, hyperlipidemia, prior MI > 30 days, prior heart failure, prior PCI, prior coronary artery bypass surgery (CABG), chronic obstructive pulmonary disease (COPD), mode of presentation (EMS vs self), location of first presentation (Direct to PCI site, Transferred from non-PCI site), reperfusion type (PPCI, pharmaco-invasive PCI, rescue PCI, Late PCI > 24 hrs) and FMC-balloon time.", [["heart", "ANATOMY", 120, 125], ["coronary artery", "ANATOMY", 152, 167], ["pulmonary", "ANATOMY", 211, 220], ["diabetes", "DISEASE", 54, 62], ["hypertension", "DISEASE", 64, 76], ["hyperlipidemia", "DISEASE", 78, 92], ["MI", "DISEASE", 100, 102], ["heart failure", "DISEASE", 120, 133], ["chronic obstructive pulmonary disease", "DISEASE", 191, 228], ["COPD", "DISEASE", 230, 234], ["heart", "ORGAN", 120, 125], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 152, 167], ["pulmonary", "ORGAN", 211, 220], ["diabetes", "PROBLEM", 54, 62], ["hypertension", "PROBLEM", 64, 76], ["hyperlipidemia", "PROBLEM", 78, 92], ["prior MI", "PROBLEM", 94, 102], ["prior heart failure", "PROBLEM", 114, 133], ["prior PCI", "TREATMENT", 135, 144], ["prior coronary artery bypass surgery", "TREATMENT", 146, 182], ["CABG", "TREATMENT", 184, 188], ["chronic obstructive pulmonary disease", "PROBLEM", 191, 228], ["COPD", "PROBLEM", 230, 234], ["PCI site", "TREATMENT", 315, 323], ["reperfusion type (PPCI", "TREATMENT", 357, 379], ["pharmaco", "TREATMENT", 381, 389], ["invasive PCI", "TREATMENT", 390, 402], ["rescue PCI", "TREATMENT", 404, 414], ["Late PCI", "TREATMENT", 416, 424], ["FMC-balloon time", "TREATMENT", 439, 455], ["diabetes", "OBSERVATION", 54, 62], ["hypertension", "OBSERVATION", 64, 76], ["hyperlipidemia", "OBSERVATION", 78, 92], ["heart", "ANATOMY", 120, 125], ["failure", "OBSERVATION", 126, 133], ["PCI", "OBSERVATION", 141, 144], ["coronary artery", "ANATOMY", 152, 167], ["bypass", "OBSERVATION", 168, 174], ["CABG", "OBSERVATION", 184, 188], ["chronic", "OBSERVATION_MODIFIER", 191, 198], ["obstructive", "OBSERVATION_MODIFIER", 199, 210], ["pulmonary", "ANATOMY", 211, 220], ["disease", "OBSERVATION", 221, 228], ["COPD", "OBSERVATION", 230, 234]]], ["Key performance indicators were percentage of STEMI cases presenting directly to a PCI-site achieving time < 90 minutes from FMC-balloon and percentage of STEMI cases transferred from a Non-PCI site achieving time < 120 minutes from FMC-balloon.Methods:For this analysis, STEMI activity across the province was compared between January 1 to May 10, 2020 and the same time period in 2019.", [["STEMI", "DISEASE", 46, 51], ["STEMI", "DISEASE", 155, 160], ["STEMI", "DISEASE", 272, 277], ["STEMI cases", "PROBLEM", 46, 57], ["a PCI", "TREATMENT", 81, 86], ["FMC-balloon", "TREATMENT", 125, 136], ["STEMI cases", "PROBLEM", 155, 166], ["FMC-balloon", "TREATMENT", 233, 244], ["this analysis", "TEST", 257, 270], ["STEMI activity", "PROBLEM", 272, 286], ["balloon", "ANATOMY", 129, 136], ["STEMI", "OBSERVATION", 155, 160], ["balloon", "OBSERVATION", 237, 244]]], ["Baseline characteristics were statistically compared across all timeframes for cardiac catheterization procedures for STEMIs between January 1 and May 10, 2020 to the same timeframe in 2019, and, after the implementation of provincial directives, from March 16 to May 10, 2020 using a Chi-Square test for categorical variables and ANOVA for continuous variables.", [["cardiac", "ANATOMY", 79, 86], ["cardiac", "ORGAN", 79, 86], ["cardiac catheterization procedures", "TEST", 79, 113], ["STEMIs", "TEST", 118, 124], ["a Chi-Square test", "TEST", 283, 300], ["categorical variables", "TEST", 305, 326], ["catheterization", "OBSERVATION", 87, 102]]], ["The rate of the number of STEMI cases reported in bi-weekly periods in 2019 and 2020 were compared using a Poisson model ( Figure 1 ).", [["STEMI", "DISEASE", 26, 31], ["STEMI", "OBSERVATION", 26, 31]]], ["In addition, FMC-balloon times for PPCI were assessed on a bi-weekly basis, coordinating with Monday to Sunday calendar weeks ( Figure 2 ).", [["FMC-balloon", "TREATMENT", 13, 24], ["PPCI", "TREATMENT", 35, 39]]], ["The median times reported in bi-weekly periods in 2019 and 2020 were compared using a 2-sided Wilcoxon Two-Sample Test.Results:Between January 1 and May 10, 2020, there were 2221 STEMI cases reported to CorHealth, compared to 2513 cases during the same timeframe in 2019 (Table 1 ).", [["STEMI", "DISEASE", 179, 184], ["Sample Test", "TEST", 107, 118]]], ["There were no differences observed in baseline characteristics of age and sex.", [["no", "UNCERTAINTY", 11, 13]]], ["Compared to 2019 or first 3 months of 2020 there were less patients with hyperlipidemia, prior MI and COPD and an approximate 8% increase in patients presenting by EMS after March 16, 2020.", [["hyperlipidemia", "DISEASE", 73, 87], ["MI", "DISEASE", 95, 97], ["COPD", "DISEASE", 102, 106], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 141, 149], ["hyperlipidemia", "PROBLEM", 73, 87], ["prior MI", "PROBLEM", 89, 97], ["COPD", "PROBLEM", 102, 106], ["hyperlipidemia", "OBSERVATION", 73, 87], ["COPD", "OBSERVATION", 102, 106], ["increase", "OBSERVATION_MODIFIER", 129, 137]]], ["There were no changes observed in proportion of patients referred for cardiac catheterization presenting greater than 12 hours after symptom onset.", [["cardiac", "ANATOMY", 70, 77], ["patients", "ORGANISM", 48, 56], ["cardiac", "ORGAN", 70, 77], ["patients", "SPECIES", 48, 56], ["cardiac catheterization", "TEST", 70, 93], ["symptom onset", "PROBLEM", 133, 146], ["no", "UNCERTAINTY", 11, 13], ["catheterization", "OBSERVATION", 78, 93]]], ["The majority (more than 70%) of STEMI cases continued to be treated with PPCI.6A sustained and significant reduction in STEMI cases of up to 25% was observed after March 16, 2020 ( Figure 1 ).", [["STEMI", "DISEASE", 32, 37], ["STEMI", "DISEASE", 120, 125], ["STEMI cases", "PROBLEM", 32, 43], ["PPCI", "TREATMENT", 73, 77], ["significant reduction in STEMI cases", "PROBLEM", 95, 131], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["STEMI", "OBSERVATION", 32, 37], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["reduction", "OBSERVATION_MODIFIER", 107, 116], ["STEMI", "OBSERVATION", 120, 125]]], ["The decrease in STEMI volumes also correlated with an increase in reported active COVID-19 cases (Figure 1 ).", [["STEMI", "DISEASE", 16, 21], ["The decrease in STEMI volumes", "PROBLEM", 0, 29], ["active COVID", "TEST", 75, 87], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["STEMI volumes", "OBSERVATION", 16, 29], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["active", "OBSERVATION_MODIFIER", 75, 81]]], ["Starting in the week of March 16, 2020, the proportion of patients achieving FMC-balloon benchmarks for PPCI decreased substantially to 28% (FMC-balloon < 90 min) for patients presenting directly to a PCI-site and to 37% (FMCballoon <120 min) for patients transferred from a non-PCI site ( Figure 2 ).", [["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 167, 175], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 247, 255], ["FMC-balloon benchmarks", "TREATMENT", 77, 99], ["PPCI", "TREATMENT", 104, 108], ["FMC-balloon", "TREATMENT", 141, 152], ["a PCI", "TREATMENT", 199, 204]]], ["The corresponding biweekly median times significantly increased to 101 min for direct to PCI-site group and nonsignificantly increased to 149 min for patients transferred from a non-PCI site, compared to 2019.Discussion:Our early observations for STEMI care during COVID-19 across Ontario show a substantial and sustained decrease in cardiac catheterization procedures for STEMI over several weeks starting mid-March, 2020.", [["cardiac", "ANATOMY", 334, 341], ["STEMI", "DISEASE", 247, 252], ["STEMI", "DISEASE", 373, 378], ["patients", "ORGANISM", 150, 158], ["cardiac", "ORGAN", 334, 341], ["patients", "SPECIES", 150, 158], ["STEMI care", "TREATMENT", 247, 257], ["COVID", "TEST", 265, 270], ["cardiac catheterization procedures", "TREATMENT", 334, 368], ["STEMI", "PROBLEM", 373, 378], ["decrease", "OBSERVATION_MODIFIER", 322, 330], ["cardiac", "ANATOMY", 334, 341], ["catheterization", "OBSERVATION", 342, 357]]], ["Although the majority of STEMI patients continued to receive primary PCI, a decrease in key performance metrics was noted especially in patients being transferred from non-PCI sites.", [["STEMI", "DISEASE", 25, 30], ["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 136, 144], ["non-PCI sites", "DNA", 168, 181], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 136, 144], ["STEMI", "PROBLEM", 25, 30], ["primary PCI", "TREATMENT", 61, 72], ["STEMI", "OBSERVATION", 25, 30], ["decrease", "OBSERVATION_MODIFIER", 76, 84]]], ["An increase in cardiac catheterization lab procedures for patients with symptom onset to FMC greater than 12 hours was not observed.", [["cardiac", "ANATOMY", 15, 22], ["cardiac", "ORGAN", 15, 22], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["cardiac catheterization", "TEST", 15, 38], ["symptom", "PROBLEM", 72, 79], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["cardiac", "ANATOMY", 15, 22], ["catheterization", "OBSERVATION", 23, 38]]], ["It is an area of ongoing analysis to determine if there were a greater number of out-of-hospital cardiac deaths potentially due to untreated STEMI and if the short-term outcomes for treated STEMI patients were affected due to delays in presentation.", [["cardiac", "ANATOMY", 97, 104], ["cardiac deaths", "DISEASE", 97, 111], ["STEMI", "DISEASE", 141, 146], ["STEMI", "DISEASE", 190, 195], ["cardiac", "ORGAN", 97, 104], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["ongoing analysis", "TEST", 17, 33], ["untreated STEMI", "PROBLEM", 131, 146], ["STEMI", "PROBLEM", 190, 195], ["greater", "OBSERVATION_MODIFIER", 63, 70], ["number", "OBSERVATION_MODIFIER", 71, 77], ["STEMI", "OBSERVATION", 141, 146]]], ["CorHealth data only includes STEMI patients who have a cardiac catheterization procedure.", [["cardiac", "ANATOMY", 55, 62], ["STEMI", "DISEASE", 29, 34], ["patients", "ORGANISM", 35, 43], ["cardiac", "ORGAN", 55, 62], ["patients", "SPECIES", 35, 43], ["a cardiac catheterization procedure", "TREATMENT", 53, 88], ["cardiac", "ANATOMY", 55, 62], ["catheterization", "OBSERVATION", 63, 78]]], ["Therefore, we could not determine the number of STEMI patients who present to non-PCI hospitals and did not get referred for cardiac catheterization.Discussion:The increase in treatment times from first medical contact for patients receiving PPCI is concerning but not unexpected.", [["cardiac", "ANATOMY", 125, 132], ["STEMI", "DISEASE", 48, 53], ["patients", "ORGANISM", 54, 62], ["cardiac", "ORGAN", 125, 132], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 223, 231], ["cardiac catheterization", "TEST", 125, 148], ["PPCI", "TREATMENT", 242, 246], ["catheterization", "OBSERVATION", 133, 148]]], ["Meeting performance indicators for timely reperfusion in STEMI is highly dependent on tight alignments of rapid diagnosis and rapid transfers between STEMI providers.", [["STEMI", "DISEASE", 57, 62], ["STEMI", "DISEASE", 150, 155], ["STEMI", "PROBLEM", 57, 62], ["STEMI providers", "TREATMENT", 150, 165], ["STEMI", "OBSERVATION", 57, 62]]], ["In a well-organized STEMI system, longer treatment times for PPCI are generally associated with ambiguity in patient clinical presentation (e.g. atypical symptoms) or diagnostic findings (e.g. complex ECG).", [["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["PPCI", "TREATMENT", 61, 65], ["ambiguity", "PROBLEM", 96, 105], ["atypical symptoms", "PROBLEM", 145, 162], ["diagnostic findings", "TEST", 167, 186], ["STEMI", "OBSERVATION", 20, 25]]], ["It is possible that safety measures aimed to protect both the patient and health care workers may have negatively affected timely delivery of PPCI.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["safety measures", "TREATMENT", 20, 35], ["PPCI", "TREATMENT", 142, 146]]], ["These safety measures including newly implemented screening protocols at every step of the patient encounter as well as donning of personal protective equipment by health care workers.", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["screening protocols", "TREATMENT", 50, 69]]], ["In addition, symptoms of dyspnea and chest pain related to possible presence of COVID-19 may have further delayed definitive STEMI diagnosis and activation.", [["chest", "ANATOMY", 37, 42], ["dyspnea", "DISEASE", 25, 32], ["chest pain", "DISEASE", 37, 47], ["COVID-19", "CHEMICAL", 80, 88], ["STEMI", "DISEASE", 125, 130], ["COVID-19", "CHEMICAL", 80, 88], ["chest", "ORGANISM_SUBDIVISION", 37, 42], ["symptoms", "PROBLEM", 13, 21], ["dyspnea", "PROBLEM", 25, 32], ["chest pain", "PROBLEM", 37, 47], ["COVID", "TEST", 80, 85], ["chest", "ANATOMY", 37, 42]]], ["Most concerning is that the lower proportion of patients achieving performance indices are noted in the setting of reduced STEMI volumes.", [["STEMI", "DISEASE", 123, 128], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["reduced STEMI volumes", "PROBLEM", 115, 136], ["lower", "OBSERVATION_MODIFIER", 28, 33], ["reduced", "OBSERVATION_MODIFIER", 115, 122], ["STEMI", "OBSERVATION", 123, 128]]], ["This suggests, that although the province of Ontario did not experience a significant limitation in intensive care unit beds due to COVID-19 (between March and May 2020) and hospital systems were not directed to limit essential activity, there was an observed reduction in the performance of the Ontario STEMI system to provide timely care (7) .", [["COVID", "TEST", 132, 137], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["limitation", "OBSERVATION_MODIFIER", 86, 96], ["reduction", "OBSERVATION_MODIFIER", 260, 269]]], ["Whether this is a temporary phenomenon related to initial challenges of implementation and accommodation to new processes that will improve over time remains to be seen.Discussion:Despite increasing COVID-19 activity across the province more than 70% of STEMI procedures across Ontario were for PPCI.", [["STEMI", "DISEASE", 254, 259], ["a temporary phenomenon", "PROBLEM", 16, 38], ["increasing COVID", "TREATMENT", 188, 204], ["STEMI procedures", "TREATMENT", 254, 270], ["PPCI", "TREATMENT", 295, 299], ["temporary phenomenon", "OBSERVATION", 18, 38]]], ["Some groups have proposed a move to a routine fibrinolyticbased reperfusion strategy during the pandemic (8, 9) .", [["a routine fibrinolyticbased reperfusion strategy", "TREATMENT", 36, 84]]], ["A pharmacoinvasive strategy as reported in the Strategic Reperfusion Early after Myocardial Infarction (STREAM) study, may be an alternative to PPCI when timeline metrics cannot be met, especially during COVID-19 (10).Discussion:While increased risks of intracranial bleed have been a concern with this strategy, recent realworld data from the Vital Heart Response Strategy Alberta, Canada has shown that a pharmacoinvasive strategy was associated with improved clinical outcomes (including core lab ST-segment resolution) compared to PPCI with similar intracranial and major bleeding rates, when incorporating half-dose in elderly patients (11) .", [["Myocardial", "ANATOMY", 81, 91], ["intracranial", "ANATOMY", 254, 266], ["intracranial", "ANATOMY", 553, 565], ["Myocardial Infarction", "DISEASE", 81, 102], ["intracranial bleed", "DISEASE", 254, 272], ["intracranial and major bleeding", "DISEASE", 553, 584], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 81, 91], ["intracranial bleed", "PATHOLOGICAL_FORMATION", 254, 272], ["patients", "ORGANISM", 632, 640], ["patients", "SPECIES", 632, 640], ["A pharmacoinvasive strategy", "TREATMENT", 0, 27], ["Myocardial Infarction", "PROBLEM", 81, 102], ["COVID", "TEST", 204, 209], ["intracranial bleed", "PROBLEM", 254, 272], ["a pharmacoinvasive strategy", "TREATMENT", 405, 432], ["PPCI", "TREATMENT", 535, 539], ["similar intracranial and major bleeding rates", "PROBLEM", 545, 590], ["Myocardial", "ANATOMY", 81, 91], ["Infarction", "OBSERVATION", 92, 102], ["intracranial", "ANATOMY", 254, 266], ["bleed", "OBSERVATION", 267, 272], ["Heart", "ANATOMY", 350, 355], ["intracranial", "ANATOMY", 553, 565], ["major", "OBSERVATION_MODIFIER", 570, 575], ["bleeding", "OBSERVATION", 576, 584]]], ["Fibrinolysis time of thirty minutes may be a more achievable mode of reperfusion with less personnel and allows more time for further evaluation of patient status and testing for COVID-19.", [["COVID-19", "CHEMICAL", 179, 187], ["patient", "ORGANISM", 148, 155], ["patient", "SPECIES", 148, 155], ["Fibrinolysis time", "TEST", 0, 17], ["further evaluation", "TEST", 126, 144], ["patient status", "TEST", 148, 162], ["testing", "TEST", 167, 174], ["COVID", "TEST", 179, 184]]], ["Additionally, transfer for a less emergent cardiac catheterization procedure further protects cardiac catheterization laboratory staff from inadvertent exposure and risks.", [["cardiac", "ANATOMY", 43, 50], ["cardiac", "ANATOMY", 94, 101], ["cardiac", "ORGAN", 43, 50], ["cardiac", "ORGAN", 94, 101], ["a less emergent cardiac catheterization procedure", "TREATMENT", 27, 76], ["catheterization", "OBSERVATION", 51, 66]]], ["In addition to the STEMI guidance document (2), CorHealth informed Provincial Emergency Departments of the need to be adequately prepared including consideration of a pharmacoinvasive approach during this pandemic and future waves of COVID-19 (12) .", [["COVID-19", "CHEMICAL", 234, 242], ["a pharmacoinvasive approach", "TREATMENT", 165, 192], ["COVID", "TEST", 234, 239]]], ["However, challenges of routine fibrinolysis administration include ability to rapidly ramp-up local supplies, ability of emergency departments to rapidly switch practice, and ongoing need for rescue PCI.", [["routine fibrinolysis administration", "TREATMENT", 23, 58], ["rescue PCI", "TREATMENT", 192, 202]]], ["Additionally, specific concerns related to administration of fibrinolysis during COVID-19 include atypical STEMI presentations and reports of a myocarditis-like syndrome that mimics STEMI and possible increased risks of fibrinolysis (13).The recently organized North American COVID-19 ST-Segment-Elevation MyocardialInfarction (NACMI) registry will provide further insights into these clinical presentations and outcomes (14) .", [["STEMI", "DISEASE", 107, 112], ["myocarditis", "DISEASE", 144, 155], ["STEMI", "DISEASE", 182, 187], ["COVID-19", "CHEMICAL", 81, 89], ["fibrinolysis", "TREATMENT", 61, 73], ["COVID", "TEST", 81, 86], ["atypical STEMI presentations", "PROBLEM", 98, 126], ["a myocarditis", "PROBLEM", 142, 155], ["like syndrome", "PROBLEM", 156, 169], ["STEMI", "PROBLEM", 182, 187], ["fibrinolysis", "PROBLEM", 220, 232], ["COVID", "TEST", 276, 281], ["ST-Segment-Elevation MyocardialInfarction", "PROBLEM", 285, 326], ["atypical", "OBSERVATION_MODIFIER", 98, 106], ["STEMI", "OBSERVATION", 107, 112], ["myocarditis", "OBSERVATION", 144, 155], ["fibrinolysis", "OBSERVATION", 220, 232], ["Elevation MyocardialInfarction", "OBSERVATION", 296, 326]]], ["Previous observational studies have demonstrated that every 10-minute treatment delay in PPCI leads to an additional 3.3 deaths among 100 PPCI-treated patients for FMC-to-balloon times ranging from 60 to 180 minutes (15).", [["deaths", "DISEASE", 121, 127], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["Previous observational studies", "TEST", 0, 30], ["PPCI", "TREATMENT", 89, 93], ["FMC", "TEST", 164, 167]]], ["Although the proportion of patients receiving PPCI within 90 min decreased substantially in the direct to PCI-centre group, the actual increase in median times was less than ten minutes.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["PPCI", "TREATMENT", 46, 50], ["increase", "OBSERVATION_MODIFIER", 135, 143]]], ["However, the increase in median FMC-to-balloon time for the transferred patients increased by more than 20 minutes.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["median", "OBSERVATION_MODIFIER", 25, 31], ["increased", "OBSERVATION_MODIFIER", 81, 90]]], ["Ongoing surveillance and monitoring are needed as it is not clear at this time that the processes that contributed to increased FMC-to-balloon time would not also adversely affect door-to-needle time.", [["Ongoing surveillance and monitoring", "TEST", 0, 35], ["increased FMC", "PROBLEM", 118, 131], ["increased", "OBSERVATION_MODIFIER", 118, 127]]], ["Nevertheless, a pharmacoinvasive strategy may need to be reconsidered regardless of COVID-19 prevalence, for patients who present at hospitals across Ontario without PPCI where substantial treatment delays with PPCI are expected (16).Limitations:CorHealth relies on cardiac hospitals to provide timely data for reporting purposes.", [["cardiac", "ANATOMY", 266, 273], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["a pharmacoinvasive strategy", "TREATMENT", 14, 41], ["PPCI", "TREATMENT", 166, 170], ["substantial treatment delays", "TREATMENT", 177, 205], ["PPCI", "TREATMENT", 211, 215]]], ["While it is possible that data entry may be delayed, surveys of hospitals did not highlight any concerns with workload for data entry for this analysis.", [["data entry", "TEST", 123, 133], ["this analysis", "TEST", 138, 151]]], ["We did not observe changes in proportion of STEMI patients presenting late after symptom onset.", [["STEMI", "DISEASE", 44, 49], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["STEMI", "PROBLEM", 44, 49], ["STEMI", "OBSERVATION", 44, 49]]], ["This may be related to several factors including uncertainty and inconsistencies in defining symptom onset (i.e. when symptoms started versus when they were severe enough to seek medical attention), differences in coding of patients as STEMI or NSTEMI on the referral form and patients not being referred for cardiac catheterization.", [["cardiac", "ANATOMY", 309, 316], ["STEMI", "DISEASE", 236, 241], ["NSTEMI", "DISEASE", 245, 251], ["patients", "ORGANISM", 224, 232], ["patients", "ORGANISM", 277, 285], ["cardiac", "ORGAN", 309, 316], ["patients", "SPECIES", 224, 232], ["patients", "SPECIES", 277, 285], ["symptoms", "PROBLEM", 118, 126], ["STEMI", "PROBLEM", 236, 241], ["NSTEMI", "PROBLEM", 245, 251], ["cardiac catheterization", "TEST", 309, 332], ["may be related to", "UNCERTAINTY", 5, 22], ["catheterization", "OBSERVATION", 317, 332]]], ["However, the coding practices have remained unchanged over the last several years.", [["unchanged", "OBSERVATION_MODIFIER", 44, 53]]], ["Mortality data was not available for this cohort but will be the focus of further analysis.Conclusions:The COVID-19 pandemic and corresponding public health measures have had a significant impact on STEMI care across Ontario.", [["STEMI", "DISEASE", 199, 204], ["Mortality data", "TEST", 0, 14], ["further analysis", "TEST", 74, 90], ["The COVID", "TEST", 103, 112], ["pandemic", "PROBLEM", 116, 124], ["STEMI care", "TREATMENT", 199, 209], ["significant", "OBSERVATION_MODIFIER", 177, 188], ["impact", "OBSERVATION_MODIFIER", 189, 195]]], ["Cardiac catheterization lab procedures for STEMI have been reduced.", [["Cardiac", "ANATOMY", 0, 7], ["STEMI", "DISEASE", 43, 48], ["Cardiac", "ORGAN", 0, 7], ["Cardiac catheterization", "TEST", 0, 23], ["STEMI", "PROBLEM", 43, 48], ["catheterization", "OBSERVATION", 8, 23], ["STEMI", "OBSERVATION", 43, 48], ["reduced", "OBSERVATION_MODIFIER", 59, 66]]], ["The proportion of patients meeting reperfusion treatment goals for PPCI has decreased.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["reperfusion treatment", "TREATMENT", 35, 56], ["PPCI", "TREATMENT", 67, 71], ["decreased", "OBSERVATION_MODIFIER", 76, 85]]], ["Long-term consequences of these observations should be considered.", [["these observations", "TEST", 26, 44]]]], "2aa0a28e4246f367ffe104837e755b28d2021f45": [["Patients with malignancies are more susceptible for acquisition of infections than the general population and are thought to potentially develop more complications [1] .", [["malignancies", "ANATOMY", 14, 26], ["malignancies", "DISEASE", 14, 26], ["infections", "DISEASE", 67, 77], ["Patients", "ORGANISM", 0, 8], ["malignancies", "CANCER", 14, 26], ["Patients", "SPECIES", 0, 8], ["malignancies", "PROBLEM", 14, 26], ["infections", "PROBLEM", 67, 77], ["malignancies", "OBSERVATION", 14, 26], ["infections", "OBSERVATION", 67, 77]]], ["Due to many disruptions in both innate and acquired immunity, even organisms with low virulence potential are able to cause significant morbidity and mortality in cancer patients [2] .", [["cancer", "ANATOMY", 163, 169], ["cancer", "DISEASE", 163, 169], ["cancer", "CANCER", 163, 169], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["many disruptions", "PROBLEM", 7, 23], ["low virulence potential", "PROBLEM", 82, 105], ["significant morbidity", "PROBLEM", 124, 145], ["many", "OBSERVATION_MODIFIER", 7, 11], ["disruptions", "OBSERVATION", 12, 23]]]], "7195ff9a98e5d1ef211f2a36a0746c25f7e79f18": [["These two papers laid the groundwork for new types of paper-based devices to meet the growing need for complex, yet portable, diagnostics.", [["paper-based devices", "TREATMENT", 54, 73], ["diagnostics", "TEST", 126, 137]]], ["Most prominently this has included microfluidic paper-based analytical devices (\u03bcPADs) for the development of low-cost and portable devices.", [["microfluidic paper-based analytical devices (\u03bcPADs", "TREATMENT", 35, 85], ["low-cost and portable devices", "TREATMENT", 110, 139], ["low", "OBSERVATION_MODIFIER", 110, 113]]]], "39deebf0fa41b3cf9bf5a0ff3ce38424cbea01ec": [["IntroductionNewly emerging and re-emerging infections of the respiratory tract pose considerable medical and public health concerns as well as economic hardships to humans and countries.", [["respiratory tract", "ANATOMY", 61, 78], ["infections of the respiratory tract", "DISEASE", 43, 78], ["respiratory tract", "ORGANISM_SUBDIVISION", 61, 78], ["humans", "ORGANISM", 165, 171], ["humans", "SPECIES", 165, 171], ["humans", "SPECIES", 165, 171], ["the respiratory tract", "PROBLEM", 57, 78], ["respiratory tract", "ANATOMY", 61, 78]]], ["The last century witnessed at least five pandemics: 1918/1919, H (viral hemagglutinin) 1 N (viral neuraminidase) 1 Spanish influenza ; 1957, H2N2 Asia influenza; 1968, H3N2 Hong Kong influenza; 1977, H1N1 Russian influenza; and 1997, H5N1 bird influenza (reviewed Wright et al. 2007 ).", [["influenza", "DISEASE", 123, 132], ["influenza", "DISEASE", 151, 160], ["H1N1 Russian influenza", "DISEASE", 200, 222], ["H5N1 bird influenza", "DISEASE", 234, 253], ["H2N2 Asia influenza", "ORGANISM", 141, 160], ["H3N2", "ORGANISM", 168, 172], ["Hong Kong influenza", "ORGANISM", 173, 192], ["H2N2 Asia influenza", "SPECIES", 141, 160], ["H3N2 Hong Kong influenza", "SPECIES", 168, 192], ["H1N1 Russian influenza", "SPECIES", 200, 222], ["H5N1 bird influenza", "SPECIES", 234, 253], ["Asia influenza; 1968, H3N2 Hong Kong influenza; 1977, H1N1 Russian influenza", "SPECIES", 146, 222], ["viral hemagglutinin)", "TEST", 66, 86], ["viral neuraminidase", "TEST", 92, 111], ["influenza", "PROBLEM", 123, 132], ["influenza", "PROBLEM", 151, 160], ["H3N2", "PROBLEM", 168, 172], ["influenza", "PROBLEM", 213, 222]]], ["In twenty-first century alone, two viral pandemics have already occurred-the first was in 2002 when the new viral pandemic, severe acute respiratory syndrome (SARS), appeared (reviewed Oldstone 2010), followed by the first influenza virus pandemic in 2009, H1N1 swine influenza (Dawood et al. 2012) .", [["viral pandemics", "DISEASE", 35, 50], ["viral pandemic", "DISEASE", 108, 122], ["acute respiratory syndrome", "DISEASE", 131, 157], ["SARS", "DISEASE", 159, 163], ["influenza virus pandemic", "DISEASE", 223, 247], ["swine influenza", "DISEASE", 262, 277], ["influenza virus pandemic", "SPECIES", 223, 247], ["H1N1 swine influenza", "SPECIES", 257, 277], ["two viral pandemics", "PROBLEM", 31, 50], ["the new viral pandemic", "PROBLEM", 100, 122], ["severe acute respiratory syndrome", "PROBLEM", 124, 157], ["SARS", "PROBLEM", 159, 163], ["the first influenza virus pandemic", "PROBLEM", 213, 247], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["respiratory syndrome", "OBSERVATION", 137, 157]]], ["Moreover, Hantaviruses have infected humans in the past and recently in an outbreak at Yellowstone National Park.", [["Hantaviruses", "CHEMICAL", 10, 22], ["humans", "ORGANISM", 37, 43], ["humans", "SPECIES", 37, 43], ["humans", "SPECIES", 37, 43], ["Hantaviruses", "OBSERVATION", 10, 22], ["infected", "OBSERVATION", 28, 36]]], ["These viral infections loom as important zoonotic human diseases with the threat of human to human transmission and excessively high mortality rates.", [["viral infections", "DISEASE", 6, 22], ["zoonotic human diseases", "DISEASE", 41, 64], ["human", "ORGANISM", 50, 55], ["human", "ORGANISM", 84, 89], ["human", "ORGANISM", 93, 98], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 93, 98], ["These viral infections loom", "PROBLEM", 0, 27], ["excessively high mortality rates", "PROBLEM", 116, 148], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["infections", "OBSERVATION", 12, 22]]], ["For example, 1918/1919 H1N1 influenza infections caused the greatest loss of life from any infectious disease or medical condition known, visiting roughly 5 % of the world's population and killing 2 % or 40-50 million persons (Ahmed et al. 2007; Johnson and Mueller 2002) .", [["influenza infections", "DISEASE", 28, 48], ["infectious disease", "DISEASE", 91, 109], ["1918/1919 H1N1 influenza", "ORGANISM", 13, 37], ["persons", "ORGANISM", 218, 225], ["H1N1 influenza", "SPECIES", 23, 37], ["persons", "SPECIES", 218, 225], ["H1N1 influenza infections", "PROBLEM", 23, 48], ["any infectious disease or medical condition", "PROBLEM", 87, 130], ["greatest", "OBSERVATION_MODIFIER", 60, 68]]], ["The most recent influenza pandemic, 2009 H1N1 swine influenza, rapidly infected millions worldwide with estimates exceeding 290,000 deaths of which more than 201,000 resulted from respiratory failure and over 83,000 from cardiovascular complications (Dawood et al. 2012 ).", [["respiratory", "ANATOMY", 180, 191], ["cardiovascular", "ANATOMY", 221, 235], ["influenza pandemic", "DISEASE", 16, 34], ["swine influenza", "DISEASE", 46, 61], ["deaths", "DISEASE", 132, 138], ["respiratory failure", "DISEASE", 180, 199], ["cardiovascular complications", "DISEASE", 221, 249], ["2009 H1N1 swine", "ORGANISM", 36, 51], ["H1N1 swine influenza", "SPECIES", 41, 61], ["The most recent influenza pandemic", "PROBLEM", 0, 34], ["influenza", "PROBLEM", 52, 61], ["respiratory failure", "PROBLEM", 180, 199], ["cardiovascular complications", "PROBLEM", 221, 249], ["influenza", "OBSERVATION", 16, 25], ["respiratory failure", "OBSERVATION", 180, 199]]], ["All of the above diseases in humans (Arankalle et al. 2010; Cheng et al. 2010; Lee et al. 2011 ) and experimental animals (Baskin et al. 2009; Kobasa et al. 2007; Marcelin et al. 2011; Zhang et al. 2012 ) are accompanied by early exacerbation and dysregulation of innate immune responses, a combination of events called ''cytokine storm.''", [["humans", "ORGANISM", 29, 35], ["cytokine", "PROTEIN", 322, 330], ["humans", "SPECIES", 29, 35], ["humans", "SPECIES", 29, 35], ["early exacerbation", "PROBLEM", 224, 242], ["diseases", "OBSERVATION", 17, 25], ["early", "OBSERVATION_MODIFIER", 224, 229], ["exacerbation", "OBSERVATION", 230, 242]]], ["Severe disease and death following infection correlated strongly with the cytokine storm.IntroductionSusceptibility or resistance to any viral infection is determined by the balance between the virulence of the infecting agent and the resistance of the host including the aggressiveness of the latter's immune response against the virus infection.", [["death", "DISEASE", 19, 24], ["infection", "DISEASE", 35, 44], ["viral infection", "DISEASE", 137, 152], ["infection", "DISEASE", 337, 346], ["cytokine", "PROTEIN", 74, 82], ["Severe disease", "PROBLEM", 0, 14], ["death", "PROBLEM", 19, 24], ["infection", "PROBLEM", 35, 44], ["the cytokine storm", "PROBLEM", 70, 88], ["IntroductionSusceptibility", "PROBLEM", 89, 115], ["any viral infection", "PROBLEM", 133, 152], ["the infecting agent", "TREATMENT", 207, 226], ["the virus infection", "PROBLEM", 327, 346], ["disease", "OBSERVATION", 7, 14], ["infection", "OBSERVATION", 35, 44], ["viral", "OBSERVATION_MODIFIER", 137, 142], ["infection", "OBSERVATION", 143, 152]]], ["When the immune response is limited due to either host genetics, acquired defects like lymphoid diseases, immaturity of the immune system in fetuses, newborns, or young children, or loss of immune vigor in the aged, the advantage is firmly in the virus's court.", [["lymphoid", "ANATOMY", 87, 95], ["immune system", "ANATOMY", 124, 137], ["fetuses", "ANATOMY", 141, 148], ["lymphoid diseases", "DISEASE", 87, 104], ["immaturity of the immune system", "DISEASE", 106, 137], ["loss of immune vigor", "DISEASE", 182, 202], ["lymphoid", "ORGAN", 87, 95], ["immune system", "ANATOMICAL_SYSTEM", 124, 137], ["fetuses", "ANATOMICAL_SYSTEM", 141, 148], ["children", "ORGANISM", 169, 177], ["children", "SPECIES", 169, 177], ["acquired defects", "PROBLEM", 65, 81], ["lymphoid diseases", "PROBLEM", 87, 104], ["immaturity of the immune system in fetuses", "PROBLEM", 106, 148], ["loss of immune vigor", "PROBLEM", 182, 202], ["defects", "OBSERVATION", 74, 81], ["lymphoid diseases", "OBSERVATION", 87, 104]]], ["However, usually when the infection occurs in individuals with a developed and competent immune system, the advantage is the host's, unless the infecting virus overwhelms the individual's immune system or the immune response becomes hyperactive resulting in an excessive innate and adoptive immune reaction, the ''cytokine storm'' phenomenon.", [["immune system", "ANATOMY", 89, 102], ["immune system", "ANATOMY", 188, 201], ["infection", "DISEASE", 26, 35], ["hyperactive", "DISEASE", 233, 244], ["immune system", "ANATOMICAL_SYSTEM", 188, 201], ["cytokine", "PROTEIN", 314, 322], ["the infection", "PROBLEM", 22, 35], ["the infecting virus", "PROBLEM", 140, 159], ["the individual's immune system", "TEST", 171, 201], ["hyperactive", "PROBLEM", 233, 244], ["an excessive innate and adoptive immune reaction", "PROBLEM", 258, 306], ["the ''cytokine storm'' phenomenon", "TREATMENT", 308, 341], ["infection", "OBSERVATION", 26, 35]]], ["Cytokine storm leads to immune-mediated injury (immunopathology).IntroductionWhen available, vaccination is useful in protecting groups of previously uninfected (naive) individuals from acute viral respiratory diseases.", [["respiratory", "ANATOMY", 198, 209], ["immunopathology", "DISEASE", 48, 63], ["viral respiratory diseases", "DISEASE", 192, 218], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["Cytokine", "PROTEIN", 0, 8], ["Cytokine storm", "TREATMENT", 0, 14], ["immune-mediated injury", "PROBLEM", 24, 46], ["vaccination", "TREATMENT", 93, 104], ["acute viral respiratory diseases", "PROBLEM", 186, 218], ["injury", "OBSERVATION", 40, 46], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["viral respiratory diseases", "OBSERVATION", 192, 218]]], ["By this means, the spread of infection is diminished.", [["infection", "DISEASE", 29, 38], ["infection", "PROBLEM", 29, 38], ["diminished", "PROBLEM", 42, 52], ["spread", "OBSERVATION_MODIFIER", 19, 25], ["infection", "OBSERVATION", 29, 38], ["diminished", "OBSERVATION_MODIFIER", 42, 52]]], ["Additionally antiviral drugs, which were developed as effective therapies to diminish or in some instances prevent ongoing infections, are reasonably effective, nevertheless come with two marked limitations.", [["infections", "DISEASE", 123, 133], ["antiviral drugs", "TREATMENT", 13, 28], ["ongoing infections", "PROBLEM", 115, 133], ["antiviral drugs", "OBSERVATION", 13, 28], ["ongoing", "OBSERVATION_MODIFIER", 115, 122], ["infections", "OBSERVATION", 123, 133]]], ["First, antiviral drugs exert selective pressure on viral progeny, promoting their mutation and selection thereby creating a new generation that is more fit and resistant to the drug (Nguyen et al. 2012; Orozovic et al. 2011) .", [["antiviral drugs", "TREATMENT", 7, 22], ["selective pressure", "TREATMENT", 29, 47], ["viral progeny", "TREATMENT", 51, 64], ["selective", "OBSERVATION_MODIFIER", 29, 38], ["pressure", "OBSERVATION_MODIFIER", 39, 47], ["viral progeny", "OBSERVATION", 51, 64], ["new", "OBSERVATION_MODIFIER", 124, 127]]], ["Second, the injury associated with these acute viral respiratory diseases, including influenza, results from a combination of the virus's intrinsic virulence in lysing cells it infects and the intensity of the immune response which can damage tissues and promote a cytokine storm.", [["respiratory", "ANATOMY", 53, 64], ["cells", "ANATOMY", 168, 173], ["tissues", "ANATOMY", 243, 250], ["viral respiratory diseases", "DISEASE", 47, 73], ["influenza", "DISEASE", 85, 94], ["lysing cells", "CELL", 161, 173], ["tissues", "TISSUE", 243, 250], ["lysing cells", "CELL_TYPE", 161, 173], ["cytokine", "PROTEIN", 265, 273], ["the injury", "PROBLEM", 8, 18], ["these acute viral respiratory diseases", "PROBLEM", 35, 73], ["influenza", "PROBLEM", 85, 94], ["the virus's intrinsic virulence", "PROBLEM", 126, 157], ["lysing cells", "TREATMENT", 161, 173], ["the immune response", "PROBLEM", 206, 225], ["a cytokine storm", "TREATMENT", 263, 279], ["injury", "OBSERVATION", 12, 18], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["respiratory diseases", "OBSERVATION", 53, 73], ["lysing cells", "OBSERVATION", 161, 173], ["immune response", "OBSERVATION", 210, 225], ["cytokine storm", "OBSERVATION", 265, 279]]], ["Antiviral drugs are effective against the virus but not against cytokine storm or immune-mediated injury.IntroductionRecently, while studying human H1N1 2009 influenza virus infection in mice Teijaro et al. 2011 ) and ferrets (Teijaro et al. 2013) , we uncovered the first direct and definitive experimental evidence that cytokine storm, per se, was a major factor in the causation of morbidity and mortality from influenza virus and some other acute, severe respiratory infections rather than just the accompanying phenomena.", [["respiratory", "ANATOMY", 459, 470], ["influenza virus infection", "DISEASE", 158, 183], ["influenza virus", "DISEASE", 414, 429], ["respiratory infections", "DISEASE", 459, 481], ["human H1N1 2009 influenza virus", "ORGANISM", 142, 173], ["mice", "ORGANISM", 187, 191], ["ferrets", "ORGANISM", 218, 225], ["influenza virus", "ORGANISM", 414, 429], ["cytokine", "PROTEIN", 64, 72], ["cytokine", "PROTEIN", 322, 330], ["human", "SPECIES", 142, 147], ["influenza virus", "SPECIES", 158, 173], ["mice", "SPECIES", 187, 191], ["ferrets", "SPECIES", 218, 225], ["influenza virus", "SPECIES", 414, 429], ["human H1N1 2009 influenza virus", "SPECIES", 142, 173], ["mice", "SPECIES", 187, 191], ["ferrets", "SPECIES", 218, 225], ["influenza virus", "SPECIES", 414, 429], ["Antiviral drugs", "TREATMENT", 0, 15], ["the virus", "PROBLEM", 38, 47], ["cytokine storm", "PROBLEM", 64, 78], ["immune-mediated injury", "PROBLEM", 82, 104], ["influenza virus infection", "PROBLEM", 158, 183], ["cytokine storm", "PROBLEM", 322, 336], ["morbidity", "PROBLEM", 385, 394], ["influenza virus", "PROBLEM", 414, 429], ["severe respiratory infections", "PROBLEM", 452, 481], ["the accompanying phenomena", "PROBLEM", 499, 525], ["injury", "OBSERVATION", 98, 104], ["cytokine storm", "OBSERVATION", 322, 336], ["influenza virus", "OBSERVATION", 414, 429], ["acute", "OBSERVATION_MODIFIER", 445, 450], ["severe", "OBSERVATION_MODIFIER", 452, 458], ["respiratory", "ANATOMY", 459, 470], ["infections", "OBSERVATION", 471, 481], ["phenomena", "OBSERVATION", 516, 525]]], ["Further, we documented that cytokine storm was chemically treatable using an immunomodulatory small molecule, sphingosine-1phosphate agonist, which dramatically inhibited the production of cytokines/ chemokines and the innate cellular response, thereby blunting both the innate as well as the adoptive antiviral T cell response (Marsolais et al. 2009; Walsh et al. 2011; Teijaro et al. 2011 ).", [["cellular", "ANATOMY", 226, 234], ["T cell", "ANATOMY", 312, 318], ["sphingosine-1phosphate", "CHEMICAL", 110, 132], ["sphingosine-1phosphate", "CHEMICAL", 110, 132], ["sphingosine-1phosphate", "SIMPLE_CHEMICAL", 110, 132], ["cellular", "CELL", 226, 234], ["T cell", "CELL", 312, 318], ["cytokine", "PROTEIN", 28, 36], ["cytokines", "PROTEIN", 189, 198], ["chemokines", "PROTEIN", 200, 210], ["cytokine storm", "PROBLEM", 28, 42], ["an immunomodulatory small molecule", "TREATMENT", 74, 108], ["sphingosine-1phosphate agonist", "TREATMENT", 110, 140], ["cytokines/ chemokines", "TREATMENT", 189, 210], ["the adoptive antiviral T cell response", "TREATMENT", 289, 327]]], ["These events successfully limited immunopathologic injury.", [["immunopathologic injury", "PROBLEM", 34, 57], ["limited", "OBSERVATION_MODIFIER", 26, 33], ["immunopathologic", "OBSERVATION", 34, 50]]], ["Nevertheless, a sufficient host T cell response remained and coupled with the antiviral antibody response curtailed the acute infection while providing recall immunologic memory to any renewed insult by the virus.", [["T cell", "ANATOMY", 32, 38], ["infection", "DISEASE", 126, 135], ["T cell", "CELL", 32, 38], ["the antiviral antibody response", "PROBLEM", 74, 105], ["the acute infection", "PROBLEM", 116, 135], ["the virus", "PROBLEM", 203, 212], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["infection", "OBSERVATION", 126, 135]]], ["This review focuses primarily on our experimental work that provided these conclusions.Epidemiologic and Experimental Evidence for Cytokine StormAn overly aggressive innate immune response, the early recruitment of inflammatory leukocytes to the lung and dysregulated immune gene expression were key contributors to morbidity from the 1918/1919 influenza virus onslaught, as suggested by experimental infection of macaques with the 1918 H1N1 virus strain (Kobasa et al. 2007; Cilloniz et al. 2009 ).", [["inflammatory leukocytes", "ANATOMY", 215, 238], ["lung", "ANATOMY", 246, 250], ["influenza virus", "DISEASE", 345, 360], ["infection", "DISEASE", 401, 410], ["leukocytes", "CELL", 228, 238], ["lung", "ORGAN", 246, 250], ["1918/1919 influenza virus", "ORGANISM", 335, 360], ["macaques", "ORGANISM", 414, 422], ["1918 H1N1 virus", "ORGANISM", 432, 447], ["Cytokine", "PROTEIN", 131, 139], ["inflammatory leukocytes", "CELL_TYPE", 215, 238], ["influenza virus", "SPECIES", 345, 360], ["macaques", "SPECIES", 414, 422], ["1918 H1N1 virus", "SPECIES", 432, 447], ["1918 H1N1 virus", "SPECIES", 432, 447], ["Cytokine StormAn", "PROBLEM", 131, 147], ["inflammatory leukocytes", "PROBLEM", 215, 238], ["dysregulated immune gene expression", "PROBLEM", 255, 290], ["morbidity", "PROBLEM", 316, 325], ["influenza virus onslaught", "PROBLEM", 345, 370], ["experimental infection of macaques", "PROBLEM", 388, 422], ["the 1918 H1N1 virus strain", "PROBLEM", 428, 454], ["Evidence for", "UNCERTAINTY", 118, 130], ["early", "OBSERVATION_MODIFIER", 194, 199], ["recruitment", "OBSERVATION_MODIFIER", 200, 211], ["inflammatory leukocytes", "OBSERVATION", 215, 238], ["lung", "ANATOMY", 246, 250], ["dysregulated immune", "OBSERVATION", 255, 274], ["infection", "OBSERVATION", 401, 410]]], ["Clinical studies of humans infected by H5N1 bird influenza virus revealed a significant association between excessive early cytokine responses and immune cell recruitment as strongly predictive of poor medical outcomes (de Jong et al. 2006) .", [["immune cell", "ANATOMY", 147, 158], ["humans infected", "DISEASE", 20, 35], ["humans", "ORGANISM", 20, 26], ["H5N1 bird influenza virus", "ORGANISM", 39, 64], ["immune cell", "CELL", 147, 158], ["cytokine", "PROTEIN", 124, 132], ["humans", "SPECIES", 20, 26], ["H5N1 bird influenza virus", "SPECIES", 39, 64], ["humans", "SPECIES", 20, 26], ["H5N1 bird influenza virus", "SPECIES", 39, 64], ["Clinical studies", "TEST", 0, 16], ["humans infected", "PROBLEM", 20, 35], ["H5N1 bird influenza virus", "PROBLEM", 39, 64], ["excessive early cytokine responses", "PROBLEM", 108, 142], ["immune cell recruitment", "TREATMENT", 147, 170], ["immune cell recruitment", "OBSERVATION", 147, 170]]], ["Recently, similar results for influenza virus infections were reported for experimental animal models (Baskin et al. 2009; Marcelin et al. 2011 , Zhang et al. 2012 ) and for humans (Arankalle et al. 2010; Cheng et al. 2010; Lee et al. 2011 ).", [["influenza virus infections", "DISEASE", 30, 56], ["influenza virus", "ORGANISM", 30, 45], ["humans", "ORGANISM", 174, 180], ["influenza virus", "SPECIES", 30, 45], ["humans", "SPECIES", 174, 180], ["influenza virus", "SPECIES", 30, 45], ["humans", "SPECIES", 174, 180], ["influenza virus infections", "PROBLEM", 30, 56]]], ["Among reports of H1N1 2009 pandemic influenza infections in humans, that of Arankalle et al. (2010) is illuminating.", [["influenza infections", "DISEASE", 36, 56], ["H1N1 2009 pandemic influenza", "ORGANISM", 17, 45], ["humans", "ORGANISM", 60, 66], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66], ["H1N1", "PROBLEM", 17, 21], ["pandemic influenza infections", "PROBLEM", 27, 56]]], ["Analyzing viral events and cytokine storms in critically ill-hospitalized patients, the investigators showed that those who died had no difference in influenza viral load from those who recovered.", [["critically ill", "DISEASE", 46, 60], ["patients", "ORGANISM", 74, 82], ["cytokine", "PROTEIN", 27, 35], ["patients", "SPECIES", 74, 82], ["Analyzing viral events", "PROBLEM", 0, 22], ["cytokine storms", "PROBLEM", 27, 42], ["influenza viral load", "PROBLEM", 150, 170], ["cytokine storms", "OBSERVATION", 27, 42]]], ["However, the patients who recovered and left the hospital had significantly lower cytokine storm profiles than the population who succumbed from the infection.", [["infection", "DISEASE", 149, 158], ["patients", "ORGANISM", 13, 21], ["cytokine", "PROTEIN", 82, 90], ["patients", "SPECIES", 13, 21], ["significantly lower cytokine storm profiles", "PROBLEM", 62, 105], ["the infection", "PROBLEM", 145, 158], ["cytokine storm", "OBSERVATION", 82, 96], ["infection", "OBSERVATION", 149, 158]]], ["My colleague, Hugh Rosen, and I reasoned that calming the host's aggressive and exaggerated cytokine storm response might provide the opportunity to shift the balance from severe morbidity and mortality to survival.", [["cytokine", "PROTEIN", 92, 100], ["exaggerated cytokine storm response", "PROBLEM", 80, 115], ["severe morbidity", "PROBLEM", 172, 188]]], ["Our laboratories started jointly about 7 years ago to test this hypothesis (Marsolais et al. 2008) .", [["Our laboratories", "TEST", 0, 16]]], ["We selected the molecule sphingosine 1-phosphate (S1P) and sought to determine if harmful immunologic processes accompanying H1N1 2009 influenza infection could be modulated by S1P receptors in the lung.", [["lung", "ANATOMY", 198, 202], ["sphingosine 1-phosphate", "CHEMICAL", 25, 48], ["S1P", "CHEMICAL", 50, 53], ["influenza infection", "DISEASE", 135, 154], ["S1P", "CHEMICAL", 177, 180], ["sphingosine 1-phosphate", "CHEMICAL", 25, 48], ["S1P", "CHEMICAL", 50, 53], ["sphingosine 1-phosphate", "GENE_OR_GENE_PRODUCT", 25, 48], ["S1P", "GENE_OR_GENE_PRODUCT", 50, 53], ["H1N1 2009 influenza", "ORGANISM", 125, 144], ["S1P", "GENE_OR_GENE_PRODUCT", 177, 180], ["lung", "ORGAN", 198, 202], ["S1P receptors", "PROTEIN", 177, 190], ["the molecule sphingosine", "TEST", 12, 36], ["harmful immunologic processes", "PROBLEM", 82, 111], ["H1N1", "PROBLEM", 125, 129], ["influenza infection", "PROBLEM", 135, 154], ["lung", "ANATOMY", 198, 202]]], ["We selected S1P agonists because of their documented history of modulating lymphoid trafficking by inducing sequestration of lymphocytes in secondary lymphoid regions.", [["lymphoid", "ANATOMY", 75, 83], ["lymphocytes", "ANATOMY", 125, 136], ["lymphoid regions", "ANATOMY", 150, 166], ["S1P", "GENE_OR_GENE_PRODUCT", 12, 15], ["lymphoid", "CELL", 75, 83], ["lymphocytes", "CELL", 125, 136], ["lymphoid regions", "MULTI-TISSUE_STRUCTURE", 150, 166], ["lymphocytes", "CELL_TYPE", 125, 136], ["S1P agonists", "TREATMENT", 12, 24], ["modulating lymphoid trafficking", "PROBLEM", 64, 95], ["lymphocytes in secondary lymphoid regions", "PROBLEM", 125, 166], ["modulating lymphoid trafficking", "OBSERVATION", 64, 95], ["sequestration", "OBSERVATION_MODIFIER", 108, 121], ["lymphocytes", "OBSERVATION", 125, 136], ["secondary lymphoid", "OBSERVATION", 140, 158], ["regions", "ANATOMY_MODIFIER", 159, 166]]], ["By that means, S1P agonists limit the migration of effector lymphocytes to areas where such cells mediate immunologic injury (Rosen et al. 2007 ; see Chaps.", [["effector lymphocytes", "ANATOMY", 51, 71], ["cells", "ANATOMY", 92, 97], ["S1P", "CHEMICAL", 15, 18], ["immunologic injury", "DISEASE", 106, 124], ["S1P", "CHEMICAL", 15, 18], ["S1P", "GENE_OR_GENE_PRODUCT", 15, 18], ["effector lymphocytes", "CELL", 51, 71], ["cells", "CELL", 92, 97], ["effector lymphocytes", "CELL_TYPE", 51, 71], ["S1P agonists", "TREATMENT", 15, 27], ["effector lymphocytes", "TREATMENT", 51, 71], ["such cells", "PROBLEM", 87, 97], ["immunologic injury", "PROBLEM", 106, 124], ["migration", "OBSERVATION_MODIFIER", 38, 47], ["effector lymphocytes", "OBSERVATION", 51, 71]]], ["S1P is a signaling lipid present at a concentration of 1-3 nM in plasma and approximately 100 nM in lymph.", [["plasma", "ANATOMY", 65, 71], ["lymph", "ANATOMY", 100, 105], ["S1P", "CHEMICAL", 0, 3], ["S1P", "CHEMICAL", 0, 3], ["S1P", "GENE_OR_GENE_PRODUCT", 0, 3], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["lymph", "ORGAN", 100, 105], ["plasma", "TEST", 65, 71], ["lymph", "ANATOMY", 100, 105]]], ["Physiologically, S1P levels are under tight homeostatic control, and S1P signals through specific S1P receptors of which there are five (S1P receptors 1-5).", [["S1P", "CHEMICAL", 17, 20], ["S1P", "CHEMICAL", 17, 20], ["S1P", "CHEMICAL", 69, 72], ["S1P", "GENE_OR_GENE_PRODUCT", 17, 20], ["S1P", "GENE_OR_GENE_PRODUCT", 69, 72], ["S1P", "GENE_OR_GENE_PRODUCT", 98, 101], ["S1P", "GENE_OR_GENE_PRODUCT", 137, 140], ["S1P receptors", "PROTEIN", 98, 111], ["S1P receptors 1-5", "PROTEIN", 137, 154], ["S1P levels", "TEST", 17, 27], ["tight homeostatic control", "TREATMENT", 38, 63], ["S1P signals", "TEST", 69, 80], ["specific S1P receptors", "TEST", 89, 111], ["S1P receptors", "TEST", 137, 150]]], ["These five specific S1P receptors are coupled to different G proteins for the purpose of regulating a variety of downstream pathways specific for many cells, tissues, and organs (Rosen et al. 2007 (Marsolais et al. 2009 ).", [["cells", "ANATOMY", 151, 156], ["tissues", "ANATOMY", 158, 165], ["organs", "ANATOMY", 171, 177], ["S1P", "GENE_OR_GENE_PRODUCT", 20, 23], ["G proteins", "GENE_OR_GENE_PRODUCT", 59, 69], ["cells", "CELL", 151, 156], ["tissues", "TISSUE", 158, 165], ["organs", "ORGAN", 171, 177], ["S1P receptors", "PROTEIN", 20, 33], ["G proteins", "PROTEIN", 59, 69], ["organs", "ANATOMY", 171, 177]]], ["Kinetic study of infiltrating virus-specific CD8 T cells showed their arrival by day 4, peak amounts at days 6-8, and significant numerical decrease at day 10 postinfection (Fig. 1c ).", [["CD8 T cells", "ANATOMY", 45, 56], ["CD8 T cells", "CELL", 45, 56], ["CD8 T cells", "CELL_TYPE", 45, 56], ["Kinetic study", "TEST", 0, 13], ["infiltrating virus", "PROBLEM", 17, 35], ["significant numerical decrease", "PROBLEM", 118, 148], ["infiltrating virus", "OBSERVATION", 17, 35], ["significant", "OBSERVATION_MODIFIER", 118, 129], ["numerical", "OBSERVATION_MODIFIER", 130, 139], ["decrease", "OBSERVATION_MODIFIER", 140, 148]]], ["There are five S1P receptors, i.e., S1P1, S1P2, S1P3, S1P4, and S1P5.", [["S1P", "GENE_OR_GENE_PRODUCT", 15, 18], ["S1P1", "GENE_OR_GENE_PRODUCT", 36, 40], ["S1P2", "GENE_OR_GENE_PRODUCT", 42, 46], ["S1P3", "GENE_OR_GENE_PRODUCT", 48, 52], ["S1P4", "GENE_OR_GENE_PRODUCT", 54, 58], ["S1P5", "GENE_OR_GENE_PRODUCT", 64, 68], ["S1P receptors", "PROTEIN", 15, 28], ["S1P1", "PROTEIN", 36, 40], ["S1P2", "PROTEIN", 42, 46], ["S1P3", "PROTEIN", 48, 52], ["S1P4", "PROTEIN", 54, 58], ["S1P5", "PROTEIN", 64, 68], ["five S1P receptors", "TEST", 10, 28], ["S1P1", "TEST", 36, 40], ["S1P2", "TEST", 42, 46], ["S1P3", "TEST", 48, 52], ["S1P4", "TEST", 54, 58], ["five", "OBSERVATION_MODIFIER", 10, 14], ["S1P receptors", "OBSERVATION", 15, 28]]], ["Administration of S1P permissive agonist AAL-R, which signals on S1P1, S1P3, S1P4, and S1P5 receptors but not the S1P2 receptor, significantly reduced the numbers of virus-specific CD8 T cells entering the lung (Fig. 1d ).", [["CD8 T cells", "ANATOMY", 181, 192], ["lung", "ANATOMY", 206, 210], ["S1P", "CHEMICAL", 18, 21], ["S1P", "CHEMICAL", 18, 21], ["S1P", "GENE_OR_GENE_PRODUCT", 18, 21], ["AAL-R", "GENE_OR_GENE_PRODUCT", 41, 46], ["S1P1", "GENE_OR_GENE_PRODUCT", 65, 69], ["S1P3", "GENE_OR_GENE_PRODUCT", 71, 75], ["S1P4", "GENE_OR_GENE_PRODUCT", 77, 81], ["S1P5", "GENE_OR_GENE_PRODUCT", 87, 91], ["S1P2 receptor", "GENE_OR_GENE_PRODUCT", 114, 127], ["CD8 T cells", "CELL", 181, 192], ["lung", "ORGAN", 206, 210], ["S1P1", "PROTEIN", 65, 69], ["S1P3", "PROTEIN", 71, 75], ["S1P4", "PROTEIN", 77, 81], ["S1P5 receptors", "PROTEIN", 87, 101], ["S1P2 receptor", "PROTEIN", 114, 127], ["CD8 T cells", "CELL_TYPE", 181, 192], ["S1P permissive agonist", "TREATMENT", 18, 40], ["S1P1", "TEST", 65, 69], ["S1P3", "TEST", 71, 75], ["S1P4", "TEST", 77, 81], ["virus", "TEST", 166, 171], ["CD8 T cells", "OBSERVATION", 181, 192], ["lung", "ANATOMY", 206, 210]]], ["The result was significant protection from pulmonary tissue injury ( Fig. 1e ) and related mortality ( Fig. 1f ) when compared to the effects of vehicle alone or use of a control isomer, AAL-S, that is not able to be phosphorylated and cannot signal S1P receptors.", [["pulmonary tissue", "ANATOMY", 43, 59], ["pulmonary tissue injury", "DISEASE", 43, 66], ["AAL-S", "CHEMICAL", 187, 192], ["pulmonary tissue", "TISSUE", 43, 59], ["AAL-S", "SIMPLE_CHEMICAL", 187, 192], ["S1P receptors", "GENE_OR_GENE_PRODUCT", 250, 263], ["S1P receptors", "PROTEIN", 250, 263], ["pulmonary tissue injury", "PROBLEM", 43, 66], ["vehicle alone", "TREATMENT", 145, 158], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["protection", "OBSERVATION", 27, 37], ["pulmonary tissue", "ANATOMY", 43, 59], ["injury", "OBSERVATION", 60, 66]]], ["Blunting of innate cytokine and chemokine responses following AAL-R treatment was evident and remarkable at day 2 postinfluenza infection ( Fig. 1g ).", [["AAL-R", "CHEMICAL", 62, 67], ["infection", "DISEASE", 128, 137], ["AAL-R", "GENE_OR_GENE_PRODUCT", 62, 67], ["innate cytokine", "PROTEIN", 12, 27], ["chemokine", "PROTEIN", 32, 41], ["Blunting of innate cytokine and chemokine responses", "PROBLEM", 0, 51], ["AAL-R treatment", "TREATMENT", 62, 77], ["postinfluenza infection", "PROBLEM", 114, 137], ["innate cytokine", "OBSERVATION", 12, 27], ["infection", "OBSERVATION", 128, 137]]], ["All these observations were initially made with murine H1N1 WSN virus and later confirmed by use of the non-murine adopted human pathogenic H1N1 influenza viruses A/Wisconsin/WSLH34934/09 and A/California/04/09 .Epidemiologic and Experimental Evidence for Cytokine StormIn studies with all these influenza viruses, although cytokine/chemokine expression was significantly blunted by S1P agonist AAL-R, AAL-R-treated mice terminated the virus infection, displayed robust virus-specific CTL responses 7 days after influenza infection, as measured by 51 chromium release assay, and also mounted vigorous specific memory T cell responses upon rechallenge with virus 40 days after the infection.", [["T cell", "ANATOMY", 617, 623], ["influenza viruses", "DISEASE", 145, 162], ["influenza viruses", "DISEASE", 296, 313], ["S1P", "CHEMICAL", 383, 386], ["AAL-R, AAL-R", "CHEMICAL", 395, 407], ["infection", "DISEASE", 442, 451], ["influenza infection", "DISEASE", 512, 531], ["chromium", "CHEMICAL", 551, 559], ["infection", "DISEASE", 680, 689], ["chromium", "CHEMICAL", 551, 559], ["murine H1N1 WSN virus", "ORGANISM", 48, 69], ["human", "ORGANISM", 123, 128], ["H1N1 influenza viruses", "ORGANISM", 140, 162], ["WSLH34934/09", "ORGANISM", 175, 187], ["S1P", "GENE_OR_GENE_PRODUCT", 383, 386], ["AAL-R", "SIMPLE_CHEMICAL", 395, 400], ["AAL-R", "SIMPLE_CHEMICAL", 402, 407], ["mice", "ORGANISM", 416, 420], ["CTL", "CELL", 485, 488], ["chromium", "SIMPLE_CHEMICAL", 551, 559], ["memory T cell", "CELL", 610, 623], ["Cytokine", "PROTEIN", 256, 264], ["cytokine", "PROTEIN", 324, 332], ["chemokine", "PROTEIN", 333, 342], ["murine", "SPECIES", 48, 54], ["H1N1 WSN virus", "SPECIES", 55, 69], ["human", "SPECIES", 123, 128], ["H1N1 influenza viruses", "SPECIES", 140, 162], ["mice", "SPECIES", 416, 420], ["murine H1N1 WSN virus", "SPECIES", 48, 69], ["human pathogenic H1N1 influenza viruses A/Wisconsin/WSLH34934/09", "SPECIES", 123, 187], ["A/California/04/09", "SPECIES", 192, 210], ["mice", "SPECIES", 416, 420], ["murine H1N1 WSN virus", "TREATMENT", 48, 69], ["human pathogenic H1N1 influenza viruses", "PROBLEM", 123, 162], ["Cytokine StormIn studies", "TEST", 256, 280], ["all these influenza viruses", "PROBLEM", 286, 313], ["cytokine/chemokine expression", "TEST", 324, 353], ["AAL", "TEST", 395, 398], ["the virus infection", "PROBLEM", 432, 451], ["robust virus", "PROBLEM", 463, 475], ["influenza infection", "PROBLEM", 512, 531], ["virus", "TREATMENT", 656, 661], ["the infection", "PROBLEM", 676, 689], ["Evidence for", "UNCERTAINTY", 243, 255], ["infection", "OBSERVATION", 680, 689]]], ["Further, the kinetics, titers of neutralizing anti-influenza antibodies in sera, or immunoglobulin subtypes of either AAL-R or AAL-S or vehicle-treated mice were equivalent.", [["sera", "ANATOMY", 75, 79], ["AAL-S", "CHEMICAL", 127, 132], ["sera", "ORGANISM_SUBSTANCE", 75, 79], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 84, 98], ["AAL-R", "SIMPLE_CHEMICAL", 118, 123], ["AAL-S", "SIMPLE_CHEMICAL", 127, 132], ["vehicle", "SIMPLE_CHEMICAL", 136, 143], ["mice", "ORGANISM", 152, 156], ["neutralizing anti-influenza antibodies", "PROTEIN", 33, 71], ["immunoglobulin subtypes", "PROTEIN", 84, 107], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 152, 156], ["the kinetics", "TEST", 9, 21], ["neutralizing anti-influenza antibodies", "TEST", 33, 71], ["sera", "TEST", 75, 79], ["immunoglobulin subtypes", "TEST", 84, 107], ["vehicle", "TREATMENT", 136, 143]]], ["That is, the permissive S1P agonist AAL-R, which signals via S1P1, S1P3, S1P4, and S1P5 receptors, when given locally into the respiratory tract, down-modulated numbers of virus-specific T cells, decreased innate cytokine/chemokine expression in the lung parenchyma, and reduced the supply of innate inflammatory cells-NK, PMN, and macrophages (Marsolais et al. 2009; Walsh et al. 2011 )-sufficiently to abort cytokine storm.", [["respiratory tract", "ANATOMY", 127, 144], ["T cells", "ANATOMY", 187, 194], ["lung parenchyma", "ANATOMY", 250, 265], ["inflammatory cells", "ANATOMY", 300, 318], ["NK", "ANATOMY", 319, 321], ["PMN", "ANATOMY", 323, 326], ["macrophages", "ANATOMY", 332, 343], ["S1P", "CHEMICAL", 24, 27], ["S1P", "GENE_OR_GENE_PRODUCT", 24, 27], ["AAL-R", "GENE_OR_GENE_PRODUCT", 36, 41], ["S1P1", "GENE_OR_GENE_PRODUCT", 61, 65], ["S1P3", "GENE_OR_GENE_PRODUCT", 67, 71], ["S1P4", "GENE_OR_GENE_PRODUCT", 73, 77], ["S1P5", "GENE_OR_GENE_PRODUCT", 83, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 127, 144], ["T cells", "CELL", 187, 194], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 250, 265], ["innate inflammatory cells", "CELL", 293, 318], ["NK", "CELL", 319, 321], ["PMN", "CELL", 323, 326], ["macrophages", "CELL", 332, 343], ["S1P1", "PROTEIN", 61, 65], ["S1P3", "PROTEIN", 67, 71], ["S1P4", "PROTEIN", 73, 77], ["S1P5 receptors", "PROTEIN", 83, 97], ["T cells", "CELL_TYPE", 187, 194], ["cytokine", "PROTEIN", 213, 221], ["chemokine", "PROTEIN", 222, 231], ["innate inflammatory cells", "CELL_TYPE", 293, 318], ["NK", "CELL_TYPE", 319, 321], ["PMN", "CELL_TYPE", 323, 326], ["macrophages", "CELL_TYPE", 332, 343], ["cytokine", "PROTEIN", 410, 418], ["S1P1", "TEST", 61, 65], ["S1P3", "TEST", 67, 71], ["S1P4", "TEST", 73, 77], ["the respiratory tract", "PROBLEM", 123, 144], ["virus", "PROBLEM", 172, 177], ["decreased innate cytokine/chemokine expression in the lung parenchyma", "PROBLEM", 196, 265], ["innate inflammatory cells", "PROBLEM", 293, 318], ["PMN", "TEST", 323, 326], ["macrophages", "PROBLEM", 332, 343], ["respiratory tract", "ANATOMY", 127, 144], ["chemokine expression", "OBSERVATION", 222, 242], ["lung", "ANATOMY", 250, 254], ["parenchyma", "ANATOMY_MODIFIER", 255, 265], ["reduced", "OBSERVATION_MODIFIER", 271, 278], ["inflammatory cells", "OBSERVATION", 300, 318], ["macrophages", "ANATOMY", 332, 343]]], ["The successful outcome was protection of the host from influenza virus infection while still providing an antiviral response that curtailed and eventually impeded the influenza infection.", [["influenza virus infection", "DISEASE", 55, 80], ["influenza infection", "DISEASE", 167, 186], ["influenza virus", "ORGANISM", 55, 70], ["influenza virus", "SPECIES", 55, 70], ["influenza virus", "SPECIES", 55, 70], ["the host", "PROBLEM", 41, 49], ["influenza virus infection", "PROBLEM", 55, 80], ["an antiviral response", "TREATMENT", 103, 124], ["the influenza infection", "PROBLEM", 163, 186], ["influenza virus", "OBSERVATION", 55, 70], ["influenza", "OBSERVATION_MODIFIER", 167, 176], ["infection", "OBSERVATION", 177, 186]]], ["Our data indicated that 23 of 28 mice (82 %) receiving AAL-R were protected (P = .001; only five of 28 died from the infection) when compared to a dose of virus that killed approximately 80 % of Interestingly, when an optimal dose of the currently used antiviral drug Tamiflu was administered by itself, protection was significantly less effective 50 % (14 lived of 28 mice treated) compared to survival after AAL-R therapy alone (80 %).", [["infection", "DISEASE", 117, 126], ["Tamiflu", "CHEMICAL", 268, 275], ["AAL-R", "CHEMICAL", 410, 415], ["Tamiflu", "CHEMICAL", 268, 275], ["mice", "ORGANISM", 33, 37], ["AAL-R", "GENE_OR_GENE_PRODUCT", 55, 60], ["Tamiflu", "SIMPLE_CHEMICAL", 268, 275], ["mice", "ORGANISM", 369, 373], ["AAL-R", "SIMPLE_CHEMICAL", 410, 415], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 369, 373], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 369, 373], ["Our data", "TEST", 0, 8], ["AAL-R", "TREATMENT", 55, 60], ["the infection", "PROBLEM", 113, 126], ["virus", "TREATMENT", 155, 160], ["antiviral drug Tamiflu", "TREATMENT", 253, 275], ["AAL-R therapy", "TREATMENT", 410, 423], ["infection", "OBSERVATION", 117, 126]]], ["These results document a prominent role for cytokine storm as the cause of death from influenza infection.", [["death", "DISEASE", 75, 80], ["influenza infection", "DISEASE", 86, 105], ["cytokine", "PROTEIN", 44, 52], ["cytokine storm", "PROBLEM", 44, 58], ["death", "PROBLEM", 75, 80], ["influenza infection", "PROBLEM", 86, 105], ["prominent", "OBSERVATION_MODIFIER", 25, 34], ["influenza", "OBSERVATION_MODIFIER", 86, 95], ["infection", "OBSERVATION", 96, 105]]], ["Most important is the benefit of S1P agonist therapy for the victims of multiple influenza virus strains and especially those that are resistant to anti-neuraminidase therapy.", [["S1P", "CHEMICAL", 33, 36], ["influenza virus", "DISEASE", 81, 96], ["anti-neuraminidase", "CHEMICAL", 148, 166], ["S1P", "CHEMICAL", 33, 36], ["S1P", "GENE_OR_GENE_PRODUCT", 33, 36], ["influenza virus", "ORGANISM", 81, 96], ["anti-neuraminidase", "SIMPLE_CHEMICAL", 148, 166], ["S1P agonist therapy", "TREATMENT", 33, 52], ["multiple influenza virus strains", "PROBLEM", 72, 104], ["anti-neuraminidase therapy", "TREATMENT", 148, 174]]], ["Although greater benefit was obtained in blocking cytokine storms with the S1P agonist than with Tamiflu (82 % vs. 50 %) protection, administering both the antiviral drug and the S1P agonist as combined therapy was optimal, yielding a 96 % protection rate from influenza virus challenge (27 of 28 mice survived the infection) ).Pulmonary Injury and Disease Associated with Influenza and Resultant Cytokine Storm are Treatable with a Single S1P1 Receptor Agonist MoleculeAll five S1P receptors couple to different G proteins require many downstream signaling pathways (Fig. 2a ) (Rosen et al. 2007 1 in this volume).", [["Pulmonary", "ANATOMY", 328, 337], ["S1P", "CHEMICAL", 75, 78], ["Tamiflu", "CHEMICAL", 97, 104], ["S1P", "CHEMICAL", 179, 182], ["influenza virus", "DISEASE", 261, 276], ["infection", "DISEASE", 315, 324], ["Pulmonary Injury", "DISEASE", 328, 344], ["Influenza", "DISEASE", 373, 382], ["Tamiflu", "CHEMICAL", 97, 104], ["S1P", "GENE_OR_GENE_PRODUCT", 75, 78], ["Tamiflu", "SIMPLE_CHEMICAL", 97, 104], ["S1P", "GENE_OR_GENE_PRODUCT", 179, 182], ["influenza virus", "ORGANISM", 261, 276], ["mice", "ORGANISM", 297, 301], ["Pulmonary", "ORGAN", 328, 337], ["S1P1", "GENE_OR_GENE_PRODUCT", 440, 444], ["S1P", "GENE_OR_GENE_PRODUCT", 479, 482], ["G proteins", "GENE_OR_GENE_PRODUCT", 513, 523], ["cytokine", "PROTEIN", 50, 58], ["Cytokine", "PROTEIN", 397, 405], ["S1P receptors", "PROTEIN", 479, 492], ["G proteins", "PROTEIN", 513, 523], ["influenza virus", "SPECIES", 261, 276], ["mice", "SPECIES", 297, 301], ["mice", "SPECIES", 297, 301], ["the S1P agonist", "TREATMENT", 71, 86], ["Tamiflu", "TREATMENT", 97, 104], ["protection", "TREATMENT", 121, 131], ["the antiviral drug", "TREATMENT", 152, 170], ["the S1P agonist", "TREATMENT", 175, 190], ["combined therapy", "TREATMENT", 194, 210], ["a 96 % protection rate", "TREATMENT", 233, 255], ["influenza virus challenge", "TREATMENT", 261, 286], ["Pulmonary Injury", "PROBLEM", 328, 344], ["Disease", "PROBLEM", 349, 356], ["Influenza", "PROBLEM", 373, 382], ["Resultant Cytokine Storm", "TREATMENT", 387, 411], ["a Single S1P1 Receptor Agonist Molecule", "TREATMENT", 431, 470], ["All five S1P receptors", "TREATMENT", 470, 492], ["different G proteins", "TREATMENT", 503, 523], ["Injury", "OBSERVATION", 338, 344], ["Disease", "OBSERVATION", 349, 356], ["Cytokine Storm", "OBSERVATION", 397, 411]]], ["The biological functions of these various S1P receptors are dependent on the cell/tissue location of the receptors, their expression, and their activation.Pulmonary Injury and Disease Associated with Influenza and Resultant Cytokine Storm are Treatable with a Single S1P1 Receptor Agonist MoleculeKnowing that a broadly permissive S1P agonist AAL-R, which signals via S1P1, S1P3, S1P4, and S1P5 but not S1P2 receptors, significantly downregulated the cytokine storm and protected mice from the effects of a pathogenic human H1N1 influenza infection (Fig. 1 , Panels c-g) ), we repeated the experiments shown in Fig. 1 , Panels e-g, using two S1P1-specific agonists, CYM-5542 , or RP-002 .", [["cell", "ANATOMY", 77, 81], ["tissue", "ANATOMY", 82, 88], ["Pulmonary", "ANATOMY", 155, 164], ["Pulmonary Injury", "DISEASE", 155, 171], ["Influenza", "DISEASE", 200, 209], ["influenza infection", "DISEASE", 529, 548], ["CYM-5542", "CHEMICAL", 666, 674], ["RP-002", "CHEMICAL", 680, 686], ["CYM-5542", "CHEMICAL", 666, 674], ["RP-002", "CHEMICAL", 680, 686], ["S1P", "GENE_OR_GENE_PRODUCT", 42, 45], ["cell", "CELL", 77, 81], ["tissue", "TISSUE", 82, 88], ["Pulmonary", "ORGAN", 155, 164], ["S1P1", "GENE_OR_GENE_PRODUCT", 267, 271], ["S1P", "GENE_OR_GENE_PRODUCT", 331, 334], ["AAL-R", "GENE_OR_GENE_PRODUCT", 343, 348], ["S1P1", "GENE_OR_GENE_PRODUCT", 368, 372], ["S1P3", "GENE_OR_GENE_PRODUCT", 374, 378], ["S1P4", "GENE_OR_GENE_PRODUCT", 380, 384], ["S1P5", "GENE_OR_GENE_PRODUCT", 390, 394], ["S1P2", "GENE_OR_GENE_PRODUCT", 403, 407], ["mice", "ORGANISM", 480, 484], ["human", "ORGANISM", 518, 523], ["H1N1 influenza", "ORGANISM", 524, 538], ["Panels e-g", "SIMPLE_CHEMICAL", 620, 630], ["S1P1", "GENE_OR_GENE_PRODUCT", 642, 646], ["CYM-5542", "SIMPLE_CHEMICAL", 666, 674], ["RP-002", "SIMPLE_CHEMICAL", 680, 686], ["S1P receptors", "PROTEIN", 42, 55], ["Cytokine", "PROTEIN", 224, 232], ["S1P1", "PROTEIN", 368, 372], ["S1P3", "PROTEIN", 374, 378], ["S1P4", "PROTEIN", 380, 384], ["S1P5", "PROTEIN", 390, 394], ["S1P2 receptors", "PROTEIN", 403, 417], ["cytokine", "PROTEIN", 451, 459], ["S1P1", "PROTEIN", 642, 646], ["mice", "SPECIES", 480, 484], ["human", "SPECIES", 518, 523], ["H1N1 influenza", "SPECIES", 524, 538], ["mice", "SPECIES", 480, 484], ["human H1N1 influenza", "SPECIES", 518, 538], ["Pulmonary Injury", "PROBLEM", 155, 171], ["Disease", "PROBLEM", 176, 183], ["Influenza", "PROBLEM", 200, 209], ["Resultant Cytokine Storm", "PROBLEM", 214, 238], ["a Single S1P1 Receptor Agonist", "TREATMENT", 258, 288], ["S1P1", "TEST", 368, 372], ["a pathogenic human H1N1 influenza infection", "PROBLEM", 505, 548], ["Panels e-g", "TEST", 620, 630], ["CYM", "TEST", 666, 669], ["RP", "TEST", 680, 682], ["Injury", "OBSERVATION", 165, 171], ["Disease", "OBSERVATION", 176, 183], ["Cytokine Storm", "OBSERVATION", 224, 238], ["cytokine storm", "OBSERVATION", 451, 465]]], ["The results are displayed in Fig. 2 and indicate that either of the two specific S1P1 receptor agonists whose signal is entirely restricted to S1P1 receptors were as effective as the broadly permissive AAL-R that signals on S1P1, S1P3, S1P4, and S1P5.", [["S1P1", "GENE_OR_GENE_PRODUCT", 81, 85], ["S1P1", "GENE_OR_GENE_PRODUCT", 143, 147], ["AAL-R", "GENE_OR_GENE_PRODUCT", 202, 207], ["S1P1", "GENE_OR_GENE_PRODUCT", 224, 228], ["S1P3", "GENE_OR_GENE_PRODUCT", 230, 234], ["S1P4", "GENE_OR_GENE_PRODUCT", 236, 240], ["S1P5", "GENE_OR_GENE_PRODUCT", 246, 250], ["S1P1 receptor", "PROTEIN", 81, 94], ["S1P1 receptors", "PROTEIN", 143, 157], ["S1P1", "PROTEIN", 224, 228], ["S1P3", "PROTEIN", 230, 234], ["S1P4", "PROTEIN", 236, 240], ["S1P5", "PROTEIN", 246, 250], ["S1P1 receptors", "TEST", 143, 157], ["S1P1", "TEST", 224, 228], ["S1P3", "TEST", 230, 234], ["S1P4", "TEST", 236, 240]]], ["The S1P1-specific agonists CYM-5442 were administered intratracheally (2 mg/kg) and RP-002 intratracheally (3 mg/kg) or orally (6 mg/kg) ).", [["CYM-5442", "CHEMICAL", 27, 35], ["RP-002", "CHEMICAL", 84, 90], ["CYM-5442", "CHEMICAL", 27, 35], ["S1P1", "GENE_OR_GENE_PRODUCT", 4, 8], ["CYM-5442", "SIMPLE_CHEMICAL", 27, 35], ["S1P1", "PROTEIN", 4, 8], ["The S1P1", "TEST", 0, 8], ["CYM", "TEST", 27, 30], ["RP", "TREATMENT", 84, 86]]], ["Both S1P1 receptor agonist molecules provided protection against a lethal intranasal challenge with human H1N1 A/Wisconsin/WSLH34934/09 or A/California/04/09 (Fig. 2b) and blunted cytokine storm ( Fig. 2c and d) .", [["S1P1", "GENE_OR_GENE_PRODUCT", 5, 9], ["human", "ORGANISM", 100, 105], ["H1N1 A", "ORGANISM", 106, 112], ["A/California/04/09", "ORGANISM", 139, 157], ["S1P1 receptor", "PROTEIN", 5, 18], ["cytokine", "PROTEIN", 180, 188], ["human", "SPECIES", 100, 105], ["human H1N1 A/Wisconsin/WSLH34934/09 or A/California/04/09", "SPECIES", 100, 157], ["Both S1P1 receptor agonist molecules", "TREATMENT", 0, 36], ["protection", "TREATMENT", 46, 56], ["a lethal intranasal challenge", "TREATMENT", 65, 94], ["blunted cytokine storm", "PROBLEM", 172, 194]]], ["The S1P1 receptor agonists significantly inhibited secretions of cytokines and chemokines associated with influenza virus infection, namely IFN-a, CCL-2, IL-6, TNF-a, CCL-3, CCL-5, CxCl-2, IL-1a, and IFN-c.", [["influenza virus infection", "DISEASE", 106, 131], ["S1P1", "GENE_OR_GENE_PRODUCT", 4, 8], ["influenza virus", "ORGANISM", 106, 121], ["IFN-a", "GENE_OR_GENE_PRODUCT", 140, 145], ["CCL-2", "GENE_OR_GENE_PRODUCT", 147, 152], ["IL-6", "GENE_OR_GENE_PRODUCT", 154, 158], ["TNF-a", "GENE_OR_GENE_PRODUCT", 160, 165], ["CCL-3", "GENE_OR_GENE_PRODUCT", 167, 172], ["CCL-5", "GENE_OR_GENE_PRODUCT", 174, 179], ["CxCl-2", "GENE_OR_GENE_PRODUCT", 181, 187], ["IL-1a", "GENE_OR_GENE_PRODUCT", 189, 194], ["S1P1 receptor", "PROTEIN", 4, 17], ["cytokines", "PROTEIN", 65, 74], ["chemokines", "PROTEIN", 79, 89], ["IFN", "PROTEIN", 140, 143], ["TNF", "PROTEIN", 160, 163], ["CxCl", "PROTEIN", 181, 185], ["IL", "PROTEIN", 189, 191], ["IFN", "PROTEIN", 200, 203], ["influenza virus", "SPECIES", 106, 121], ["influenza virus", "SPECIES", 106, 121], ["The S1P1 receptor agonists", "TEST", 0, 26], ["secretions of cytokines", "PROBLEM", 51, 74], ["chemokines", "PROBLEM", 79, 89], ["influenza virus infection", "PROBLEM", 106, 131], ["IFN", "TEST", 140, 143], ["CCL", "TEST", 147, 150], ["IL", "TEST", 154, 156], ["TNF", "TEST", 160, 163], ["CCL", "TEST", 167, 170], ["CCL", "TEST", 174, 177], ["CxCl", "TEST", 181, 185], ["IL", "TEST", 189, 191], ["IFN", "TEST", 200, 203], ["influenza virus", "OBSERVATION", 106, 121]]], ["Observations from several experiments indicated that amounts of these cytokines/chemokines were inhibited to a degree similar to that from AAL-R treatment.", [["AAL-R", "CHEMICAL", 139, 144], ["AAL-R", "GENE_OR_GENE_PRODUCT", 139, 144], ["cytokines", "PROTEIN", 70, 79], ["chemokines", "PROTEIN", 80, 90], ["these cytokines/chemokines", "TREATMENT", 64, 90], ["AAL-R treatment", "TREATMENT", 139, 154]]], ["The S1P1 selective agonists also significantly blunted the accumulation of innate infiltrating inflammatory cells (Fig. 2, Panel d) .", [["infiltrating inflammatory cells", "ANATOMY", 82, 113], ["S1P1", "GENE_OR_GENE_PRODUCT", 4, 8], ["innate infiltrating inflammatory cells", "CELL", 75, 113], ["S1P1", "PROTEIN", 4, 8], ["innate infiltrating inflammatory cells", "CELL_TYPE", 75, 113], ["innate infiltrating inflammatory cells", "PROBLEM", 75, 113], ["accumulation", "OBSERVATION_MODIFIER", 59, 71], ["innate", "OBSERVATION_MODIFIER", 75, 81], ["infiltrating", "OBSERVATION_MODIFIER", 82, 94], ["inflammatory cells", "OBSERVATION", 95, 113]]], ["Notable were the reductions of macrophages/monocytes (marked by CD11b + , LyG6 -, F480 + ), neutrophils (CD11b + , LyG6+ -, F480 -), and natural killer cells (NK1.1 + , CD3 -).", [["macrophages", "ANATOMY", 31, 42], ["monocytes", "ANATOMY", 43, 52], ["CD11b + , LyG6 -, F480 + )", "ANATOMY", 64, 90], ["neutrophils", "ANATOMY", 92, 103], ["CD11b + , LyG6+ -, F480 -)", "ANATOMY", 105, 131], ["natural killer cells", "ANATOMY", 137, 157], ["macrophages", "CELL", 31, 42], ["monocytes", "CELL", 43, 52], ["CD11b", "GENE_OR_GENE_PRODUCT", 64, 69], ["LyG6", "GENE_OR_GENE_PRODUCT", 74, 78], ["F480", "GENE_OR_GENE_PRODUCT", 82, 86], ["neutrophils", "CELL", 92, 103], ["CD11b", "GENE_OR_GENE_PRODUCT", 105, 110], ["LyG6", "GENE_OR_GENE_PRODUCT", 115, 119], ["natural killer cells", "CELL", 137, 157], ["NK1.1", "GENE_OR_GENE_PRODUCT", 159, 164], ["CD3", "GENE_OR_GENE_PRODUCT", 169, 172], ["macrophages", "CELL_TYPE", 31, 42], ["monocytes", "CELL_TYPE", 43, 52], ["CD11b", "PROTEIN", 64, 69], ["LyG6", "PROTEIN", 74, 78], ["F480", "PROTEIN", 82, 86], ["neutrophils", "CELL_TYPE", 92, 103], ["LyG6", "PROTEIN", 115, 119], ["F480", "PROTEIN", 124, 128], ["natural killer cells", "CELL_TYPE", 137, 157], ["NK1.1", "PROTEIN", 159, 164], ["CD3", "PROTEIN", 169, 172], ["macrophages/monocytes", "TEST", 31, 52], ["CD11", "TEST", 64, 68], ["b", "TEST", 68, 69], ["LyG6", "TEST", 74, 78], ["F480", "TEST", 82, 86], ["neutrophils", "TEST", 92, 103], ["CD11", "TEST", 105, 109], ["b", "TEST", 109, 110], ["LyG6", "TEST", 115, 119], ["F480", "TEST", 124, 128], ["natural killer cells", "TEST", 137, 157], ["NK1.1", "TEST", 159, 164], ["CD3", "TEST", 169, 172], ["reductions", "OBSERVATION_MODIFIER", 17, 27], ["macrophages", "OBSERVATION", 31, 42], ["monocytes", "ANATOMY", 43, 52], ["natural killer cells", "OBSERVATION", 137, 157]]], ["Correspondingly, the quantity of activation marker CD69 was significantly reduced following S1P1 agonist therapy.", [["CD69", "GENE_OR_GENE_PRODUCT", 51, 55], ["S1P1", "GENE_OR_GENE_PRODUCT", 92, 96], ["CD69", "PROTEIN", 51, 55], ["S1P1", "PROTEIN", 92, 96], ["activation marker CD69", "TEST", 33, 55], ["S1P1 agonist therapy", "TREATMENT", 92, 112], ["quantity", "OBSERVATION_MODIFIER", 21, 29]]], ["Further, pulmonary tissues also reflected S1P1's beneficial outcome, since histologic study of mice given this remedy manifested mostly open alveolar air spaces, diminished to negligible inflammatory cell infiltrates and neither edema nor hemorrhage in the lung tissue.", [["pulmonary tissues", "ANATOMY", 9, 26], ["alveolar air", "ANATOMY", 141, 153], ["inflammatory cell", "ANATOMY", 187, 204], ["edema", "ANATOMY", 229, 234], ["lung tissue", "ANATOMY", 257, 268], ["edema", "DISEASE", 229, 234], ["hemorrhage", "DISEASE", 239, 249], ["pulmonary tissues", "TISSUE", 9, 26], ["S1P1", "GENE_OR_GENE_PRODUCT", 42, 46], ["mice", "ORGANISM", 95, 99], ["alveolar air", "MULTI-TISSUE_STRUCTURE", 141, 153], ["cell", "CELL", 200, 204], ["edema", "PATHOLOGICAL_FORMATION", 229, 234], ["lung tissue", "TISSUE", 257, 268], ["S1P1", "PROTEIN", 42, 46], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["histologic study", "TEST", 75, 91], ["open alveolar air spaces", "PROBLEM", 136, 160], ["negligible inflammatory cell infiltrates", "PROBLEM", 176, 216], ["neither edema", "PROBLEM", 221, 234], ["hemorrhage in the lung tissue", "PROBLEM", 239, 268], ["pulmonary tissues", "ANATOMY", 9, 26], ["alveolar", "ANATOMY_MODIFIER", 141, 149], ["air spaces", "OBSERVATION", 150, 160], ["diminished", "OBSERVATION_MODIFIER", 162, 172], ["negligible", "OBSERVATION_MODIFIER", 176, 186], ["inflammatory", "OBSERVATION_MODIFIER", 187, 199], ["cell infiltrates", "OBSERVATION", 200, 216], ["neither", "UNCERTAINTY", 221, 228], ["edema", "OBSERVATION", 229, 234], ["hemorrhage", "OBSERVATION", 239, 249], ["lung", "ANATOMY", 257, 261], ["tissue", "ANATOMY_MODIFIER", 262, 268]]], ["Importantly, S1P1 agonist treatment did not enhance viral titers.", [["S1P1", "GENE_OR_GENE_PRODUCT", 13, 17], ["S1P1", "PROTEIN", 13, 17], ["S1P1 agonist treatment", "TREATMENT", 13, 35], ["viral titers", "PROBLEM", 52, 64]]], ["Influenza infection was effectively terminated, and both anti-influenza neutralizing antibodies and antiinfluenza virus CD8 T cells were generated.", [["CD8 T cells", "ANATOMY", 120, 131], ["Influenza infection", "DISEASE", 0, 19], ["Influenza", "ORGANISM", 0, 9], ["antiinfluenza virus", "ORGANISM", 100, 119], ["CD8 T cells", "CELL", 120, 131], ["anti-influenza neutralizing antibodies", "PROTEIN", 57, 95], ["antiinfluenza virus CD8 T cells", "CELL_TYPE", 100, 131], ["Influenza infection", "PROBLEM", 0, 19], ["both anti-influenza neutralizing antibodies", "TEST", 52, 95], ["antiinfluenza virus CD8 T cells", "TEST", 100, 131], ["infection", "OBSERVATION", 10, 19]]], ["Although numbers of T cells were reduced compared to infected mice not receiving S1P1 agonist therapy, they were sufficient to terminate the infection.", [["T cells", "ANATOMY", 20, 27], ["infection", "DISEASE", 141, 150], ["T cells", "CELL", 20, 27], ["mice", "ORGANISM", 62, 66], ["S1P1", "GENE_OR_GENE_PRODUCT", 81, 85], ["T cells", "CELL_TYPE", 20, 27], ["S1P1", "PROTEIN", 81, 85], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 62, 66], ["T cells", "PROBLEM", 20, 27], ["S1P1 agonist therapy", "TREATMENT", 81, 101], ["the infection", "PROBLEM", 137, 150], ["infection", "OBSERVATION", 141, 150]]], ["Further, immune memory was established following this S1P1-specific therapy.Pulmonary Injury and Disease Associated with Influenza and Resultant Cytokine Storm are Treatable with a Single S1P1 Receptor Agonist MoleculeFig.", [["Pulmonary", "ANATOMY", 76, 85], ["Pulmonary Injury", "DISEASE", 76, 92], ["Influenza", "DISEASE", 121, 130], ["S1P1", "GENE_OR_GENE_PRODUCT", 54, 58], ["Pulmonary", "ORGAN", 76, 85], ["S1P1", "GENE_OR_GENE_PRODUCT", 188, 192], ["S1P1", "PROTEIN", 54, 58], ["Cytokine", "PROTEIN", 145, 153], ["this S1P1", "TREATMENT", 49, 58], ["Pulmonary Injury", "PROBLEM", 76, 92], ["Disease", "PROBLEM", 97, 104], ["Influenza", "PROBLEM", 121, 130], ["Resultant Cytokine Storm", "TREATMENT", 135, 159], ["a Single S1P1 Receptor Agonist MoleculeFig", "TREATMENT", 179, 221], ["Injury", "OBSERVATION", 86, 92], ["Disease", "OBSERVATION", 97, 104], ["Cytokine Storm", "OBSERVATION", 145, 159]]], ["2 S1P1 specific agonists CYM-5442 and RP-002 are therapeutically equivalent to the permissive AAL-R agonist that utilizes S1P1, S1P3, S1P4, and S1P5 receptor signaling to blunt cytokine storm and also protect mice from a lethal challenge by human pandemic H1N1 2009 A/Wisconsin/WSLH34939/09 (shown) or A/California 04/09 (not shown) viruses.", [["CYM-5442", "CHEMICAL", 25, 33], ["RP-002", "CHEMICAL", 38, 44], ["CYM-5442", "CHEMICAL", 25, 33], ["RP-002", "CHEMICAL", 38, 44], ["S1P1", "GENE_OR_GENE_PRODUCT", 2, 6], ["CYM-5442", "SIMPLE_CHEMICAL", 25, 33], ["RP-002", "SIMPLE_CHEMICAL", 38, 44], ["AAL-R", "GENE_OR_GENE_PRODUCT", 94, 99], ["S1P1", "GENE_OR_GENE_PRODUCT", 122, 126], ["S1P3", "GENE_OR_GENE_PRODUCT", 128, 132], ["S1P4", "GENE_OR_GENE_PRODUCT", 134, 138], ["S1P5 receptor", "GENE_OR_GENE_PRODUCT", 144, 157], ["mice", "ORGANISM", 209, 213], ["human", "ORGANISM", 241, 246], ["A/California 04/09", "ORGANISM", 302, 320], ["S1P1", "PROTEIN", 2, 6], ["S1P1", "PROTEIN", 122, 126], ["S1P3", "PROTEIN", 128, 132], ["S1P4", "PROTEIN", 134, 138], ["S1P5", "PROTEIN", 144, 148], ["cytokine", "PROTEIN", 177, 185], ["mice", "SPECIES", 209, 213], ["human", "SPECIES", 241, 246], ["mice", "SPECIES", 209, 213], ["human pandemic H1N1 2009 A/Wisconsin/WSLH34939/09", "SPECIES", 241, 290], ["A/California 04/09", "SPECIES", 302, 320], ["S1P1 specific agonists", "TEST", 2, 24], ["CYM", "TEST", 25, 28], ["RP", "TEST", 38, 40], ["S1P1", "TEST", 122, 126], ["S1P3", "TEST", 128, 132], ["S1P4", "TREATMENT", 134, 138], ["blunt cytokine storm", "PROBLEM", 171, 191], ["a lethal challenge", "TREATMENT", 219, 237], ["viruses", "PROBLEM", 333, 340]]], ["Panel a:Pulmonary Injury and Disease Associated with Influenza and Resultant Cytokine Storm are Treatable with a Single S1P1 Receptor Agonist MoleculeCartoons of the five S1P receptors and their biologic effects.", [["Pulmonary", "ANATOMY", 8, 17], ["Pulmonary Injury", "DISEASE", 8, 24], ["Influenza", "DISEASE", 53, 62], ["S1P1", "GENE_OR_GENE_PRODUCT", 120, 124], ["S1P", "GENE_OR_GENE_PRODUCT", 171, 174], ["Cytokine", "PROTEIN", 77, 85], ["S1P receptors", "PROTEIN", 171, 184], ["Pulmonary Injury", "PROBLEM", 8, 24], ["Disease", "PROBLEM", 29, 36], ["Influenza", "PROBLEM", 53, 62], ["Resultant Cytokine Storm", "PROBLEM", 67, 91], ["a Single S1P1 Receptor Agonist MoleculeCartoons", "TREATMENT", 111, 158], ["the five S1P receptors", "TREATMENT", 162, 184], ["Pulmonary", "ANATOMY", 8, 17], ["Injury", "OBSERVATION", 18, 24], ["Disease", "OBSERVATION", 29, 36], ["Cytokine Storm", "OBSERVATION", 77, 91]]], ["AAL-R signals on receptors S1P1, S1P3, S1P4, and S1P5 but not S1P2.", [["AAL-R", "GENE_OR_GENE_PRODUCT", 0, 5], ["S1P1", "GENE_OR_GENE_PRODUCT", 27, 31], ["S1P3", "GENE_OR_GENE_PRODUCT", 33, 37], ["S1P4", "GENE_OR_GENE_PRODUCT", 39, 43], ["S1P5", "GENE_OR_GENE_PRODUCT", 49, 53], ["S1P2", "GENE_OR_GENE_PRODUCT", 62, 66], ["S1P1", "PROTEIN", 27, 31], ["S1P3", "PROTEIN", 33, 37], ["S1P4", "PROTEIN", 39, 43], ["S1P5", "PROTEIN", 49, 53], ["S1P2", "PROTEIN", 62, 66], ["receptors", "TEST", 17, 26], ["S1P1", "TEST", 27, 31], ["S1P3", "TEST", 33, 37], ["S1P4", "TEST", 39, 43]]], ["Panel b: S1P1 receptor-specific agonist RP-002 given orally protects mice challenged with H1N1 Thus, severe pulmonary injury and disease associated with influenza infection and resultant cytokine storm were treatable with a preparation composed of only S1P1 receptor agonist molecules, thereby avoiding signaling through S1P2, S1P3, S1P4, and S1P5 receptors.", [["pulmonary", "ANATOMY", 108, 117], ["RP-002", "CHEMICAL", 40, 46], ["pulmonary injury", "DISEASE", 108, 124], ["influenza infection", "DISEASE", 153, 172], ["RP-002", "CHEMICAL", 40, 46], ["S1P1", "GENE_OR_GENE_PRODUCT", 9, 13], ["RP-002", "SIMPLE_CHEMICAL", 40, 46], ["mice", "ORGANISM", 69, 73], ["H1N1", "ORGANISM", 90, 94], ["pulmonary", "ORGAN", 108, 117], ["S1P1", "GENE_OR_GENE_PRODUCT", 253, 257], ["S1P2", "GENE_OR_GENE_PRODUCT", 321, 325], ["S1P3", "GENE_OR_GENE_PRODUCT", 327, 331], ["S1P4", "GENE_OR_GENE_PRODUCT", 333, 337], ["S1P5 receptors", "GENE_OR_GENE_PRODUCT", 343, 357], ["S1P1 receptor", "PROTEIN", 9, 22], ["cytokine", "PROTEIN", 187, 195], ["S1P1 receptor", "PROTEIN", 253, 266], ["S1P2", "PROTEIN", 321, 325], ["S1P3", "PROTEIN", 327, 331], ["S1P4", "PROTEIN", 333, 337], ["S1P5 receptors", "PROTEIN", 343, 357], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 69, 73], ["H1N1", "SPECIES", 90, 94], ["Panel", "TEST", 0, 5], ["S1P1 receptor", "TEST", 9, 22], ["RP", "TEST", 40, 42], ["severe pulmonary injury", "PROBLEM", 101, 124], ["disease", "PROBLEM", 129, 136], ["influenza infection", "PROBLEM", 153, 172], ["resultant cytokine storm", "PROBLEM", 177, 201], ["a preparation", "TREATMENT", 222, 235], ["S1P1 receptor agonist molecules", "TREATMENT", 253, 284], ["signaling through S1P2", "PROBLEM", 303, 325], ["S1P3", "TEST", 327, 331], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["pulmonary", "ANATOMY", 108, 117], ["injury", "OBSERVATION", 118, 124], ["disease", "OBSERVATION", 129, 136], ["influenza", "OBSERVATION_MODIFIER", 153, 162], ["infection", "OBSERVATION", 163, 172], ["cytokine storm", "OBSERVATION", 187, 201]]], ["Pharmaceutically this may be of importance if/when individually S1P2, S1P3, S1P4, or S1P5 signaling might lead to unwanted harmful biologic effects.S1P1 Receptors are Located on Pulmonary Endothelial Cells, Which Serve as the Gatekeepers for Cytokine StormHaving identified S1P1rec signaling as the primary pathway for the initiation of cytokine storm, we sought to identify the cell or cells in the lung that expressed the S1P1 receptor.", [["Pulmonary Endothelial Cells", "ANATOMY", 178, 205], ["cell", "ANATOMY", 379, 383], ["cells", "ANATOMY", 387, 392], ["lung", "ANATOMY", 400, 404], ["S1P2", "GENE_OR_GENE_PRODUCT", 64, 68], ["S1P3", "GENE_OR_GENE_PRODUCT", 70, 74], ["S1P4", "GENE_OR_GENE_PRODUCT", 76, 80], ["S1P5", "GENE_OR_GENE_PRODUCT", 85, 89], ["S1P1", "GENE_OR_GENE_PRODUCT", 148, 152], ["Pulmonary Endothelial Cells", "CELL", 178, 205], ["Cytokine", "GENE_OR_GENE_PRODUCT", 242, 250], ["S1P1rec", "GENE_OR_GENE_PRODUCT", 274, 281], ["cell", "CELL", 379, 383], ["cells", "CELL", 387, 392], ["lung", "ORGAN", 400, 404], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 424, 437], ["S1P2", "PROTEIN", 64, 68], ["S1P3", "PROTEIN", 70, 74], ["S1P4", "PROTEIN", 76, 80], ["S1P5", "PROTEIN", 85, 89], ["S1P1 Receptors", "PROTEIN", 148, 162], ["Pulmonary Endothelial Cells", "CELL_TYPE", 178, 205], ["Cytokine", "PROTEIN", 242, 250], ["S1P1rec", "PROTEIN", 274, 281], ["cytokine", "PROTEIN", 337, 345], ["S1P1 receptor", "PROTEIN", 424, 437], ["S1P2", "TEST", 64, 68], ["S1P3", "TEST", 70, 74], ["Pulmonary Endothelial Cells", "TREATMENT", 178, 205], ["Cytokine StormHaving", "TREATMENT", 242, 262], ["cytokine storm", "TREATMENT", 337, 351], ["Pulmonary", "ANATOMY", 178, 187], ["Endothelial Cells", "OBSERVATION", 188, 205], ["lung", "ANATOMY", 400, 404]]], ["Since epithelial cells are the primary cells infected by influenza viruses, we suspected that S1P1 receptors might be located on those cells.", [["epithelial cells", "ANATOMY", 6, 22], ["primary cells", "ANATOMY", 31, 44], ["cells", "ANATOMY", 135, 140], ["influenza viruses", "DISEASE", 57, 74], ["epithelial cells", "CELL", 6, 22], ["cells", "CELL", 39, 44], ["influenza viruses", "ORGANISM", 57, 74], ["S1P1", "GENE_OR_GENE_PRODUCT", 94, 98], ["cells", "CELL", 135, 140], ["epithelial cells", "CELL_TYPE", 6, 22], ["primary cells", "CELL_TYPE", 31, 44], ["S1P1 receptors", "PROTEIN", 94, 108], ["epithelial cells", "PROBLEM", 6, 22], ["the primary cells", "PROBLEM", 27, 44], ["influenza viruses", "PROBLEM", 57, 74], ["S1P1 receptors", "PROBLEM", 94, 108], ["epithelial cells", "OBSERVATION", 6, 22], ["primary cells", "OBSERVATION", 31, 44], ["infected", "OBSERVATION_MODIFIER", 45, 53], ["influenza viruses", "OBSERVATION", 57, 74]]], ["To determine which pulmonary cell types bear the S1P1 receptor, we took advantage of eGFP-S1P1 receptor knock-in mice made by Stuart Cahalan in the Rosen laboratory (Cahalan et al. 2011, see Cahalan Chap.", [["pulmonary cell", "ANATOMY", 19, 33], ["pulmonary cell", "CELL", 19, 33], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 49, 62], ["eGFP", "GENE_OR_GENE_PRODUCT", 85, 89], ["S1P1", "GENE_OR_GENE_PRODUCT", 90, 94], ["mice", "ORGANISM", 113, 117], ["S1P1 receptor", "PROTEIN", 49, 62], ["eGFP", "PROTEIN", 85, 89], ["S1P1", "PROTEIN", 90, 94], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["eGFP", "TEST", 85, 89], ["S1P1 receptor knock", "TREATMENT", 90, 109], ["pulmonary", "ANATOMY", 19, 28], ["cell types", "OBSERVATION", 29, 39]]], ["In this strain of mice, the native S1P1 receptor was homologously replaced with a functional fused eGFPtagged S1P1 receptor .", [["mice", "ORGANISM", 18, 22], ["S1P1", "GENE_OR_GENE_PRODUCT", 35, 39], ["eGFPtagged S1P1 receptor", "GENE_OR_GENE_PRODUCT", 99, 123], ["native S1P1 receptor", "PROTEIN", 28, 48], ["eGFPtagged S1P1 receptor", "PROTEIN", 99, 123], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["a functional fused eGFPtagged S1P1 receptor", "TREATMENT", 80, 123]]], ["Utilizing this mouse model, we could directly detect eGFP-S1P1 receptor protein expression on pulmonary cells by using antibodies to specific pulmonary cell markers and flow cytometry (Fig. 3, Panel a) .", [["pulmonary cells", "ANATOMY", 94, 109], ["pulmonary cell", "ANATOMY", 142, 156], ["mouse", "ORGANISM", 15, 20], ["eGFP-S1P1 receptor", "GENE_OR_GENE_PRODUCT", 53, 71], ["pulmonary cells", "CELL", 94, 109], ["pulmonary cell", "CELL", 142, 156], ["eGFP", "PROTEIN", 53, 57], ["S1P1 receptor", "PROTEIN", 58, 71], ["pulmonary cells", "CELL_TYPE", 94, 109], ["antibodies", "PROTEIN", 119, 129], ["pulmonary cell markers", "PROTEIN", 142, 164], ["mouse", "SPECIES", 15, 20], ["mouse", "SPECIES", 15, 20], ["this mouse model", "TREATMENT", 10, 26], ["eGFP", "TEST", 53, 57], ["pulmonary cells", "TEST", 94, 109], ["antibodies", "TEST", 119, 129], ["specific pulmonary cell markers", "TEST", 133, 164], ["flow cytometry", "TEST", 169, 183], ["pulmonary cells", "ANATOMY", 94, 109], ["pulmonary", "ANATOMY", 142, 151], ["cell", "OBSERVATION", 152, 156], ["flow cytometry", "OBSERVATION", 169, 183]]], ["Additional substantiation came from biochemical analysis of these purified pulmonary cells (Fig. 3, Panel b) .", [["pulmonary cells", "ANATOMY", 75, 90], ["pulmonary cells", "CELL", 75, 90], ["pulmonary cells", "CELL_TYPE", 75, 90], ["biochemical analysis", "TEST", 36, 56], ["these purified pulmonary cells", "PROBLEM", 60, 90], ["pulmonary cells", "ANATOMY", 75, 90]]], ["S1P1-eGFP receptor expression was plentiful on lung lymphatic (CD45 -, CD31 + , GP38 + ) and vascular (CD45 -, CD31 + , GP38 -) endothelial cells but, surprisingly, was absent on pulmonary epithelial cells (CD45 -, CD31 -, EpCAM + ) (Fig. 3 , Panel a) ).", [["lung lymphatic (CD45 -, CD31 + , GP38 + )", "ANATOMY", 47, 88], ["vascular (CD45 -, CD31 + , GP38 -) endothelial cells", "ANATOMY", 93, 145], ["pulmonary epithelial cells", "ANATOMY", 179, 205], ["S1P1", "GENE_OR_GENE_PRODUCT", 0, 4], ["eGFP receptor", "GENE_OR_GENE_PRODUCT", 5, 18], ["lung lymphatic", "MULTI-TISSUE_STRUCTURE", 47, 61], ["CD45", "GENE_OR_GENE_PRODUCT", 63, 67], ["CD31", "GENE_OR_GENE_PRODUCT", 71, 75], ["GP38", "GENE_OR_GENE_PRODUCT", 80, 84], ["vascular", "MULTI-TISSUE_STRUCTURE", 93, 101], ["CD45", "GENE_OR_GENE_PRODUCT", 103, 107], ["CD31", "GENE_OR_GENE_PRODUCT", 111, 115], ["GP38", "GENE_OR_GENE_PRODUCT", 120, 124], ["pulmonary epithelial cells", "CELL", 179, 205], ["CD45", "GENE_OR_GENE_PRODUCT", 207, 211], ["CD31", "GENE_OR_GENE_PRODUCT", 215, 219], ["EpCAM", "GENE_OR_GENE_PRODUCT", 223, 228], ["S1P1", "PROTEIN", 0, 4], ["eGFP receptor", "PROTEIN", 5, 18], ["CD45", "PROTEIN", 63, 67], ["CD31", "PROTEIN", 71, 75], ["GP38", "PROTEIN", 80, 84], ["CD45", "PROTEIN", 103, 107], ["CD31", "PROTEIN", 111, 115], ["GP38", "PROTEIN", 120, 124], ["endothelial cells", "CELL_TYPE", 128, 145], ["pulmonary epithelial cells", "CELL_TYPE", 179, 205], ["CD45", "PROTEIN", 207, 211], ["CD31", "PROTEIN", 215, 219], ["EpCAM", "PROTEIN", 223, 228], ["S1P1", "TEST", 0, 4], ["CD45", "TEST", 63, 67], ["CD31", "TEST", 71, 75], ["GP38", "TEST", 80, 84], ["vascular", "TEST", 93, 101], ["CD45", "TEST", 103, 107], ["CD31", "TEST", 111, 115], ["GP38", "TEST", 120, 124], ["endothelial cells", "PROBLEM", 128, 145], ["pulmonary epithelial cells", "TEST", 179, 205], ["CD45", "TEST", 207, 211], ["CD31", "TEST", 215, 219], ["EpCAM", "TEST", 223, 228], ["lung", "ANATOMY", 47, 51], ["lymphatic", "ANATOMY", 52, 61], ["vascular", "ANATOMY", 93, 101], ["endothelial cells", "ANATOMY", 128, 145], ["pulmonary epithelial", "ANATOMY", 179, 199]]], ["These results were confirmed by doing Western blots on[98.5 % pure populations of pulmonary endothelial and epithelial cells (Fig. 3, Panel b) .", [["pulmonary endothelial", "ANATOMY", 82, 103], ["epithelial cells", "ANATOMY", 108, 124], ["pulmonary endothelial", "CELL", 82, 103], ["epithelial cells", "CELL", 108, 124], ["pulmonary endothelial", "CELL_TYPE", 82, 103], ["epithelial cells", "CELL_TYPE", 108, 124], ["pulmonary endothelial and epithelial cells", "PROBLEM", 82, 124], ["pulmonary endothelial", "ANATOMY", 82, 103], ["epithelial cells", "OBSERVATION", 108, 124]]], ["As expected and previously reported, CD4 T cells (CD4 + , CD3 + ), CD8 T cells (CD8 + , CD3 + ), and B cells (B200 + , CD19 + ) also expressed the S1P1-eGFP receptor (Fig. 3, Panel a) .", [["CD4 T cells", "ANATOMY", 37, 48], ["CD4 + , CD3 + )", "ANATOMY", 50, 65], ["CD8 T cells", "ANATOMY", 67, 78], ["CD8 + , CD3 + )", "ANATOMY", 80, 95], ["B cells", "ANATOMY", 101, 108], ["B200 + , CD19 +", "ANATOMY", 110, 125], ["CD4 T", "GENE_OR_GENE_PRODUCT", 37, 42], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD3", "GENE_OR_GENE_PRODUCT", 58, 61], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["CD8", "GENE_OR_GENE_PRODUCT", 80, 83], ["CD3", "GENE_OR_GENE_PRODUCT", 88, 91], ["B cells", "CELL", 101, 108], ["B200", "GENE_OR_GENE_PRODUCT", 110, 114], ["CD19", "GENE_OR_GENE_PRODUCT", 119, 123], ["S1P1", "GENE_OR_GENE_PRODUCT", 147, 151], ["eGFP receptor", "GENE_OR_GENE_PRODUCT", 152, 165], ["CD4 T cells", "CELL_TYPE", 37, 48], ["CD4", "PROTEIN", 50, 53], ["CD3", "PROTEIN", 58, 61], ["CD8 T cells", "CELL_TYPE", 67, 78], ["CD8", "PROTEIN", 80, 83], ["CD3", "PROTEIN", 88, 91], ["B cells", "CELL_TYPE", 101, 108], ["B200", "PROTEIN", 110, 114], ["CD19", "PROTEIN", 119, 123], ["S1P1", "PROTEIN", 147, 151], ["eGFP receptor", "PROTEIN", 152, 165], ["CD4 T cells", "TEST", 37, 48], ["CD4", "TEST", 50, 53], ["CD3", "TEST", 58, 61], ["CD8 T cells", "TEST", 67, 78], ["CD8", "TEST", 80, 83], ["CD3", "TEST", 88, 91], ["B cells", "TEST", 101, 108], ["B200", "TEST", 110, 114], ["CD19", "TEST", 119, 123]]], ["In contrast, pulmonary leukocytes, including macrophages/monocytes (CD11c + , CD11b -, F480 + ), dendritic cells (CD11c + , IA-IE + , CD205 + , F480 -), neutrophils, NK cells (NK1.1 + , CD3 -) (Fig. 3, Panel a) , and immature lymphoid cells (LIN -, SCA-1 + ) failed to express significant levels of eGFP-S1P1 receptor protein.", [["pulmonary leukocytes", "ANATOMY", 13, 33], ["macrophages", "ANATOMY", 45, 56], ["monocytes", "ANATOMY", 57, 66], ["CD11c + , CD11b -, F480 + )", "ANATOMY", 68, 95], ["dendritic cells", "ANATOMY", 97, 112], ["CD11c + , IA-IE + , CD205 + , F480 -)", "ANATOMY", 114, 151], ["neutrophils", "ANATOMY", 153, 164], ["NK cells", "ANATOMY", 166, 174], ["NK1.1 + , CD3 -)", "ANATOMY", 176, 192], ["lymphoid cells", "ANATOMY", 226, 240], ["LIN -, SCA-1 +", "ANATOMY", 242, 256], ["pulmonary leukocytes", "CELL", 13, 33], ["macrophages", "CELL", 45, 56], ["monocytes", "CELL", 57, 66], ["CD11c", "GENE_OR_GENE_PRODUCT", 68, 73], ["CD11b", "GENE_OR_GENE_PRODUCT", 78, 83], ["F480", "GENE_OR_GENE_PRODUCT", 87, 91], ["dendritic cells", "CELL", 97, 112], ["CD11c", "GENE_OR_GENE_PRODUCT", 114, 119], ["IA", "GENE_OR_GENE_PRODUCT", 124, 126], ["IE", "GENE_OR_GENE_PRODUCT", 127, 129], ["CD205", "GENE_OR_GENE_PRODUCT", 134, 139], ["neutrophils", "CELL", 153, 164], ["NK cells", "CELL", 166, 174], ["NK1.1", "GENE_OR_GENE_PRODUCT", 176, 181], ["CD3", "GENE_OR_GENE_PRODUCT", 186, 189], ["lymphoid cells", "CELL", 226, 240], ["LIN", "CELL", 242, 245], ["SCA-1 +", "CELL", 249, 256], ["eGFP-S1P1 receptor", "GENE_OR_GENE_PRODUCT", 299, 317], ["pulmonary leukocytes", "CELL_TYPE", 13, 33], ["macrophages", "CELL_TYPE", 45, 56], ["monocytes", "CELL_TYPE", 57, 66], ["CD11c", "PROTEIN", 68, 73], ["CD11b", "PROTEIN", 78, 83], ["F480", "PROTEIN", 87, 91], ["dendritic cells", "CELL_TYPE", 97, 112], ["CD11c", "PROTEIN", 114, 119], ["IA", "PROTEIN", 124, 126], ["IE", "PROTEIN", 127, 129], ["CD205", "PROTEIN", 134, 139], ["F480", "PROTEIN", 144, 148], ["neutrophils", "CELL_TYPE", 153, 164], ["NK cells", "CELL_TYPE", 166, 174], ["NK1.1", "PROTEIN", 176, 181], ["CD3", "PROTEIN", 186, 189], ["immature lymphoid cells", "CELL_TYPE", 217, 240], ["eGFP", "PROTEIN", 299, 303], ["S1P1 receptor protein", "PROTEIN", 304, 325], ["pulmonary leukocytes", "TEST", 13, 33], ["macrophages", "TEST", 45, 56], ["monocytes", "TEST", 57, 66], ["CD11c", "TEST", 68, 73], ["CD11b", "TEST", 78, 83], ["F480", "TEST", 87, 91], ["dendritic cells", "PROBLEM", 97, 112], ["CD11c", "TEST", 114, 119], ["IA", "TEST", 124, 126], ["IE", "TEST", 127, 129], ["CD205", "TEST", 134, 139], ["F480", "TEST", 144, 148], ["neutrophils", "TEST", 153, 164], ["NK cells", "TEST", 166, 174], ["NK1.1", "TEST", 176, 181], ["CD3", "TEST", 186, 189], ["Fig.", "TEST", 194, 198], ["Panel", "TEST", 202, 207], ["LIN", "TEST", 242, 245], ["SCA", "TEST", 249, 252], ["eGFP", "TEST", 299, 303], ["pulmonary leukocytes", "ANATOMY", 13, 33], ["macrophages", "ANATOMY", 45, 56], ["monocytes", "ANATOMY", 57, 66], ["dendritic cells", "OBSERVATION", 97, 112], ["neutrophils", "ANATOMY", 153, 164], ["NK cells", "OBSERVATION", 166, 174], ["immature lymphoid cells", "OBSERVATION", 217, 240]]], ["S1P1-eGFP receptor expression was similar whether cells were harvested from mice that were uninfected or infected with influenza virus.", [["cells", "ANATOMY", 50, 55], ["influenza virus", "DISEASE", 119, 134], ["S1P1", "GENE_OR_GENE_PRODUCT", 0, 4], ["eGFP receptor", "GENE_OR_GENE_PRODUCT", 5, 18], ["cells", "CELL", 50, 55], ["mice", "ORGANISM", 76, 80], ["influenza virus", "ORGANISM", 119, 134], ["S1P1", "PROTEIN", 0, 4], ["eGFP receptor", "PROTEIN", 5, 18], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 76, 80], ["influenza virus", "SPECIES", 119, 134], ["S1P1", "TEST", 0, 4], ["influenza virus", "PROBLEM", 119, 134], ["influenza virus", "OBSERVATION", 119, 134]]], ["Other experiments in infected mice indicated that S1P1-eGFP receptor expression was not altered during influenza virus infection.", [["influenza virus infection", "DISEASE", 103, 128], ["mice", "ORGANISM", 30, 34], ["S1P1", "GENE_OR_GENE_PRODUCT", 50, 54], ["eGFP receptor", "GENE_OR_GENE_PRODUCT", 55, 68], ["influenza virus", "ORGANISM", 103, 118], ["S1P1", "PROTEIN", 50, 54], ["eGFP receptor", "PROTEIN", 55, 68], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["influenza virus", "SPECIES", 103, 118], ["S1P1", "TEST", 50, 54], ["influenza virus infection", "PROBLEM", 103, 128]]], ["Importantly, S1P1 agonist treatment of infected eGFP-S1P1 receptor knock-in mice did not lessen expression of the S1P1-eGFP receptors indicating that administration of specific S1P1 agonist does not degrade the endothelial S1P1 receptor.", [["endothelial", "ANATOMY", 211, 222], ["S1P1", "GENE_OR_GENE_PRODUCT", 13, 17], ["eGFP", "GENE_OR_GENE_PRODUCT", 48, 52], ["S1P1", "GENE_OR_GENE_PRODUCT", 53, 57], ["mice", "ORGANISM", 76, 80], ["S1P1", "GENE_OR_GENE_PRODUCT", 114, 118], ["eGFP", "GENE_OR_GENE_PRODUCT", 119, 123], ["S1P1", "GENE_OR_GENE_PRODUCT", 177, 181], ["endothelial", "CELL", 211, 222], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 223, 236], ["S1P1", "PROTEIN", 13, 17], ["S1P1 receptor", "PROTEIN", 53, 66], ["S1P1", "PROTEIN", 114, 118], ["eGFP receptors", "PROTEIN", 119, 133], ["S1P1", "PROTEIN", 177, 181], ["endothelial S1P1 receptor", "PROTEIN", 211, 236], ["mice", "SPECIES", 76, 80], ["S1P1 agonist treatment", "TREATMENT", 13, 35], ["infected eGFP", "TEST", 39, 52], ["S1P1 receptor knock", "TEST", 53, 72], ["specific S1P1 agonist", "TREATMENT", 168, 189]]], ["These results signify that the functional agonism of S1P1, not its antagonist effect of receptor degradation, was the mechanism by which S1P1 receptor In other studies, pulmonary endothelial cells were processed to a greater than 98.5 % purity during the first 48 h following influenza virus infection and treated with S1P1 agonist.", [["pulmonary endothelial cells", "ANATOMY", 169, 196], ["influenza virus infection", "DISEASE", 276, 301], ["S1P1", "GENE_OR_GENE_PRODUCT", 53, 57], ["S1P1", "GENE_OR_GENE_PRODUCT", 137, 141], ["pulmonary endothelial cells", "CELL", 169, 196], ["influenza virus", "ORGANISM", 276, 291], ["S1P1", "GENE_OR_GENE_PRODUCT", 319, 323], ["S1P1", "PROTEIN", 53, 57], ["S1P1 receptor", "PROTEIN", 137, 150], ["pulmonary endothelial cells", "CELL_TYPE", 169, 196], ["S1P1", "PROTEIN", 319, 323], ["influenza virus", "SPECIES", 276, 291], ["the functional agonism of S1P1", "PROBLEM", 27, 57], ["receptor degradation", "PROBLEM", 88, 108], ["other studies", "TEST", 154, 167], ["pulmonary endothelial cells", "PROBLEM", 169, 196], ["influenza virus infection", "PROBLEM", 276, 301], ["S1P1 agonist", "TREATMENT", 319, 331], ["pulmonary", "ANATOMY", 169, 178], ["endothelial cells", "OBSERVATION", 179, 196]]], ["Assessment of both RNA and protein levels showed that the S1P1 agonist CYM-5442 effectively decreased amounts of cytokines and chemokines made by vascular as well as lymphatic pulmonary endothelial cells (Fig. 3b) .", [["vascular", "ANATOMY", 146, 154], ["lymphatic pulmonary endothelial cells", "ANATOMY", 166, 203], ["CYM-5442", "CHEMICAL", 71, 79], ["CYM-5442", "CHEMICAL", 71, 79], ["S1P1", "GENE_OR_GENE_PRODUCT", 58, 62], ["CYM-5442", "SIMPLE_CHEMICAL", 71, 79], ["vascular", "MULTI-TISSUE_STRUCTURE", 146, 154], ["lymphatic pulmonary endothelial cells", "CELL", 166, 203], ["S1P1", "PROTEIN", 58, 62], ["cytokines", "PROTEIN", 113, 122], ["chemokines", "PROTEIN", 127, 137], ["lymphatic pulmonary endothelial cells", "CELL_TYPE", 166, 203], ["Assessment of both RNA and protein levels", "TEST", 0, 41], ["the S1P1 agonist CYM", "TEST", 54, 74], ["cytokines and chemokines", "TREATMENT", 113, 137], ["lymphatic pulmonary endothelial cells", "PROBLEM", 166, 203], ["vascular", "ANATOMY", 146, 154], ["lymphatic", "ANATOMY_MODIFIER", 166, 175], ["pulmonary endothelial", "ANATOMY", 176, 197]]], ["T and B lymphocytes as well as pulmonary endothelial cells were the only cells within the lung that expressed measurable amounts of S1P1-eGFP protein (Fig. 3 Panel a).", [["B lymphocytes", "ANATOMY", 6, 19], ["pulmonary endothelial cells", "ANATOMY", 31, 58], ["cells", "ANATOMY", 73, 78], ["lung", "ANATOMY", 90, 94], ["T", "CELL", 0, 1], ["B lymphocytes", "CELL", 6, 19], ["pulmonary endothelial cells", "CELL", 31, 58], ["cells", "CELL", 73, 78], ["lung", "ORGAN", 90, 94], ["S1P1", "GENE_OR_GENE_PRODUCT", 132, 136], ["eGFP", "GENE_OR_GENE_PRODUCT", 137, 141], ["T and B lymphocytes", "CELL_TYPE", 0, 19], ["pulmonary endothelial cells", "CELL_TYPE", 31, 58], ["S1P1", "PROTEIN", 132, 136], ["eGFP protein", "PROTEIN", 137, 149], ["T and B lymphocytes", "TEST", 0, 19], ["pulmonary endothelial cells", "PROBLEM", 31, 58], ["S1P1", "TEST", 132, 136], ["lymphocytes", "ANATOMY", 8, 19], ["pulmonary", "ANATOMY", 31, 40], ["endothelial cells", "OBSERVATION", 41, 58], ["lung", "ANATOMY", 90, 94], ["measurable", "OBSERVATION_MODIFIER", 110, 120], ["amounts", "OBSERVATION_MODIFIER", 121, 128]]], ["We therefore determined whether lymphocytes expressing S1P1 receptors were involved in S1P1 agonist inhibition of cytokine storm or were merely bystander cells accompanying the innate immune response to influenza virus infection.", [["lymphocytes", "ANATOMY", 32, 43], ["bystander cells", "ANATOMY", 144, 159], ["influenza virus infection", "DISEASE", 203, 228], ["lymphocytes", "CELL", 32, 43], ["S1P1", "GENE_OR_GENE_PRODUCT", 55, 59], ["S1P1", "GENE_OR_GENE_PRODUCT", 87, 91], ["bystander cells", "CELL", 144, 159], ["influenza virus", "ORGANISM", 203, 218], ["lymphocytes", "CELL_TYPE", 32, 43], ["S1P1 receptors", "PROTEIN", 55, 69], ["S1P1", "PROTEIN", 87, 91], ["cytokine", "PROTEIN", 114, 122], ["bystander cells", "CELL_TYPE", 144, 159], ["influenza virus", "SPECIES", 203, 218], ["influenza virus", "SPECIES", 203, 218], ["lymphocytes expressing S1P1 receptors", "PROBLEM", 32, 69], ["cytokine storm", "PROBLEM", 114, 128], ["merely bystander cells", "PROBLEM", 137, 159], ["influenza virus infection", "PROBLEM", 203, 228], ["cytokine storm", "OBSERVATION", 114, 128]]], ["Since Rag2-/-mice are deficient in lymphocytes, we reasoned that if such mice, when infected with influenza virus, generated a cytokine storm that could be blocked by S1P1 agonist, then lymphocytes were ruled out as initiators of cytokine storms.", [["lymphocytes", "ANATOMY", 35, 46], ["lymphocytes", "ANATOMY", 186, 197], ["influenza virus", "DISEASE", 98, 113], ["Rag2", "GENE_OR_GENE_PRODUCT", 6, 10], ["lymphocytes", "CELL", 35, 46], ["mice", "ORGANISM", 73, 77], ["influenza virus", "ORGANISM", 98, 113], ["S1P1", "GENE_OR_GENE_PRODUCT", 167, 171], ["lymphocytes", "CELL", 186, 197], ["Rag2", "PROTEIN", 6, 10], ["lymphocytes", "CELL_TYPE", 35, 46], ["cytokine", "PROTEIN", 127, 135], ["S1P1", "PROTEIN", 167, 171], ["lymphocytes", "CELL_TYPE", 186, 197], ["cytokine", "PROTEIN", 230, 238], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 73, 77], ["influenza virus", "SPECIES", 98, 113], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 73, 77], ["influenza virus", "SPECIES", 98, 113], ["Rag2", "TEST", 6, 10], ["deficient in lymphocytes", "PROBLEM", 22, 46], ["influenza virus", "PROBLEM", 98, 113], ["a cytokine storm", "TREATMENT", 125, 141], ["lymphocytes", "TEST", 186, 197], ["cytokine storms", "PROBLEM", 230, 245], ["lymphocytes", "ANATOMY", 35, 46], ["cytokine storms", "OBSERVATION", 230, 245]]], ["Our experiments documented that cytokine storm occurred in Rag2-/-mice infected with influenza virus.", [["influenza virus", "DISEASE", 85, 100], ["Rag2", "GENE_OR_GENE_PRODUCT", 59, 63], ["influenza virus", "ORGANISM", 85, 100], ["cytokine", "PROTEIN", 32, 40], ["Rag2", "PROTEIN", 59, 63], ["mice", "SPECIES", 66, 70], ["influenza virus", "SPECIES", 85, 100], ["mice", "SPECIES", 66, 70], ["influenza virus", "SPECIES", 85, 100], ["cytokine storm", "PROBLEM", 32, 46], ["Rag2", "TEST", 59, 63], ["influenza virus", "PROBLEM", 85, 100], ["cytokine storm", "OBSERVATION", 32, 46], ["influenza virus", "OBSERVATION", 85, 100]]], ["Importantly, treatment of infected Rag2-/-mice with the S1P1 agonist CYM-5442 significantly reduced cytokines and chemokines in the bronchial lavage fluids as well as minimalizing the infiltration of innate cells (macrophages/monocytes and NK cells).", [["bronchial lavage fluids", "ANATOMY", 132, 155], ["cells", "ANATOMY", 207, 212], ["macrophages", "ANATOMY", 214, 225], ["monocytes", "ANATOMY", 226, 235], ["NK cells", "ANATOMY", 240, 248], ["CYM-5442", "CHEMICAL", 69, 77], ["CYM-5442", "CHEMICAL", 69, 77], ["Rag2", "GENE_OR_GENE_PRODUCT", 35, 39], ["S1P1", "GENE_OR_GENE_PRODUCT", 56, 60], ["CYM-5442", "SIMPLE_CHEMICAL", 69, 77], ["innate cells", "CELL", 200, 212], ["macrophages", "CELL", 214, 225], ["monocytes", "CELL", 226, 235], ["NK cells", "CELL", 240, 248], ["Rag2", "PROTEIN", 35, 39], ["S1P1", "PROTEIN", 56, 60], ["cytokines", "PROTEIN", 100, 109], ["chemokines", "PROTEIN", 114, 124], ["innate cells", "CELL_TYPE", 200, 212], ["macrophages", "CELL_TYPE", 214, 225], ["monocytes", "CELL_TYPE", 226, 235], ["NK cells", "CELL_TYPE", 240, 248], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 42, 46], ["infected Rag2", "TEST", 26, 39], ["the S1P1 agonist CYM", "TEST", 52, 72], ["significantly reduced cytokines", "PROBLEM", 78, 109], ["chemokines", "TREATMENT", 114, 124], ["the bronchial lavage fluids", "TREATMENT", 128, 155], ["the infiltration of innate cells", "PROBLEM", 180, 212], ["macrophages/monocytes", "TEST", 214, 235], ["infected Rag2", "OBSERVATION", 26, 39], ["reduced", "OBSERVATION_MODIFIER", 92, 99], ["cytokines", "OBSERVATION", 100, 109], ["bronchial", "ANATOMY", 132, 141], ["lavage", "OBSERVATION", 142, 148], ["infiltration", "OBSERVATION", 184, 196], ["innate cells", "OBSERVATION", 200, 212], ["monocytes", "OBSERVATION", 226, 235], ["NK cells", "OBSERVATION", 240, 248]]], ["Recently, John Teijaro (2013), utilizing cell sorting and a biochemical approach, found S1P1 receptor on plasmacytoid dendritic cells (pDC) whose expression was undetectable in the S1P1-c GFP transgenic mouse model.Type I Interferon Signaling is Essential for the Cytokine/Chemokine Response of Cytokine Storm but is not Involved in Recruitment of Innate Inflammatory Cells into the LungAs observed in Fig. 4a and b and detailed in Teijaro et al. 2011 , amounts of type I interferon and almost exclusively the interferon-a species were elevated early after acute influenza virus infection.", [["cell", "ANATOMY", 41, 45], ["plasmacytoid dendritic cells", "ANATOMY", 105, 133], ["pDC", "ANATOMY", 135, 138], ["Cells", "ANATOMY", 368, 373], ["influenza virus infection", "DISEASE", 563, 588], ["cell", "CELL", 41, 45], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 88, 101], ["plasmacytoid dendritic cells", "CELL", 105, 133], ["pDC", "CELL", 135, 138], ["S1P1-c GFP", "GENE_OR_GENE_PRODUCT", 181, 191], ["mouse", "ORGANISM", 203, 208], ["Type I Interferon", "GENE_OR_GENE_PRODUCT", 215, 232], ["Cytokine", "GENE_OR_GENE_PRODUCT", 295, 303], ["Innate Inflammatory Cells", "CELL", 348, 373], ["LungAs", "GENE_OR_GENE_PRODUCT", 383, 389], ["type I interferon", "GENE_OR_GENE_PRODUCT", 465, 482], ["interferon", "GENE_OR_GENE_PRODUCT", 510, 520], ["acute influenza virus", "ORGANISM", 557, 578], ["S1P1 receptor", "PROTEIN", 88, 101], ["plasmacytoid dendritic cells", "CELL_TYPE", 105, 133], ["pDC", "CELL_TYPE", 135, 138], ["S1P1", "PROTEIN", 181, 185], ["Type I Interferon Signaling", "PROTEIN", 215, 242], ["Cytokine", "PROTEIN", 264, 272], ["Cytokine", "PROTEIN", 295, 303], ["Innate Inflammatory Cells", "CELL_TYPE", 348, 373], ["type I interferon", "PROTEIN", 465, 482], ["interferon", "PROTEIN", 510, 520], ["mouse", "SPECIES", 203, 208], ["mouse", "SPECIES", 203, 208], ["cell sorting", "TREATMENT", 41, 53], ["a biochemical approach", "TREATMENT", 58, 80], ["plasmacytoid dendritic cells", "PROBLEM", 105, 133], ["Type I Interferon Signaling", "TREATMENT", 215, 242], ["the Cytokine/Chemokine", "TREATMENT", 260, 282], ["Cytokine Storm", "TREATMENT", 295, 309], ["Innate Inflammatory Cells", "PROBLEM", 348, 373], ["type I interferon", "TREATMENT", 465, 482], ["the interferon", "TREATMENT", 506, 520], ["a species", "PROBLEM", 521, 530], ["acute influenza virus infection", "PROBLEM", 557, 588], ["plasmacytoid dendritic cells", "OBSERVATION", 105, 133], ["Cytokine Storm", "OBSERVATION", 295, 309], ["not Involved", "UNCERTAINTY", 317, 329], ["Inflammatory Cells", "OBSERVATION", 355, 373], ["acute", "OBSERVATION_MODIFIER", 557, 562], ["influenza virus infection", "OBSERVATION", 563, 588]]], ["The release and action of type I interferon was crucial for the production of pro-inflammatory cytokines/chemokines, since blockage of the type I interferon response by using monoclonal antibody to interferon-a-b receptor (IFNAR1) significantly reduced the quantity of pulmonary cytokines/chemokines associated with acute influenza infection (Fig. 4b) .", [["pulmonary", "ANATOMY", 269, 278], ["influenza infection", "DISEASE", 322, 341], ["type I interferon", "GENE_OR_GENE_PRODUCT", 26, 43], ["type I interferon", "GENE_OR_GENE_PRODUCT", 139, 156], ["interferon-a-b receptor", "GENE_OR_GENE_PRODUCT", 198, 221], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 223, 229], ["pulmonary", "ORGAN", 269, 278], ["type I interferon", "PROTEIN", 26, 43], ["pro-inflammatory cytokines", "PROTEIN", 78, 104], ["chemokines", "PROTEIN", 105, 115], ["type I interferon", "PROTEIN", 139, 156], ["monoclonal antibody", "PROTEIN", 175, 194], ["interferon-a-b receptor", "PROTEIN", 198, 221], ["IFNAR1", "PROTEIN", 223, 229], ["pulmonary cytokines", "PROTEIN", 269, 288], ["chemokines", "PROTEIN", 289, 299], ["The release", "TREATMENT", 0, 11], ["type I interferon", "TREATMENT", 26, 43], ["pro-inflammatory cytokines/chemokines", "TREATMENT", 78, 115], ["blockage", "PROBLEM", 123, 131], ["the type I interferon response", "TREATMENT", 135, 165], ["monoclonal antibody", "TREATMENT", 175, 194], ["interferon", "TREATMENT", 198, 208], ["a-b receptor (IFNAR1)", "TREATMENT", 209, 230], ["pulmonary cytokines", "PROBLEM", 269, 288], ["chemokines", "PROBLEM", 289, 299], ["acute influenza infection", "PROBLEM", 316, 341], ["pulmonary", "ANATOMY", 269, 278], ["cytokines", "OBSERVATION", 279, 288], ["acute", "OBSERVATION_MODIFIER", 316, 321], ["influenza", "OBSERVATION", 322, 331]]], ["Further, treatment with S1P1 receptor agonist inhibited the production of interferon-a in the pulmonary bronchial lavage fluid early after initiating influenza virus infection.", [["pulmonary bronchial lavage fluid", "ANATOMY", 94, 126], ["influenza virus infection", "DISEASE", 150, 175], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 24, 37], ["interferon-a", "GENE_OR_GENE_PRODUCT", 74, 86], ["pulmonary bronchial lavage fluid", "ORGANISM_SUBSTANCE", 94, 126], ["influenza virus", "ORGANISM", 150, 165], ["S1P1 receptor", "PROTEIN", 24, 37], ["interferon", "PROTEIN", 74, 84], ["influenza virus", "SPECIES", 150, 165], ["influenza virus", "SPECIES", 150, 165], ["treatment", "TREATMENT", 9, 18], ["S1P1 receptor agonist", "TREATMENT", 24, 45], ["interferon", "TREATMENT", 74, 84], ["the pulmonary bronchial lavage fluid", "TREATMENT", 90, 126], ["influenza virus infection", "PROBLEM", 150, 175], ["pulmonary", "ANATOMY", 94, 103], ["bronchial", "ANATOMY", 104, 113], ["lavage fluid", "OBSERVATION", 114, 126]]], ["Proof that this blunting of interferon-a production was a mechanism by which S1P1 receptor agonist inhibited cytokine storm derived from use of IFNAR1 receptor knock-out mice infected with H1N1 virus and treated with S1P1 receptor agonist CYM-5442.", [["CYM-5442", "CHEMICAL", 239, 247], ["CYM-5442", "CHEMICAL", 239, 247], ["interferon-a", "GENE_OR_GENE_PRODUCT", 28, 40], ["S1P1", "GENE_OR_GENE_PRODUCT", 77, 81], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 144, 150], ["mice", "ORGANISM", 170, 174], ["H1N1 virus", "ORGANISM", 189, 199], ["S1P1", "GENE_OR_GENE_PRODUCT", 217, 221], ["CYM-5442", "SIMPLE_CHEMICAL", 239, 247], ["interferon", "PROTEIN", 28, 38], ["S1P1 receptor", "PROTEIN", 77, 90], ["cytokine", "PROTEIN", 109, 117], ["IFNAR1 receptor", "PROTEIN", 144, 159], ["S1P1 receptor", "PROTEIN", 217, 230], ["mice", "SPECIES", 170, 174], ["H1N1 virus", "SPECIES", 189, 199], ["mice", "SPECIES", 170, 174], ["H1N1 virus", "SPECIES", 189, 199], ["interferon", "TREATMENT", 28, 38], ["S1P1 receptor agonist", "TREATMENT", 77, 98], ["cytokine storm", "PROBLEM", 109, 123], ["IFNAR1 receptor knock", "TREATMENT", 144, 165], ["H1N1 virus", "PROBLEM", 189, 199], ["S1P1 receptor agonist", "TREATMENT", 217, 238], ["CYM", "TEST", 239, 242], ["blunting", "OBSERVATION_MODIFIER", 16, 24]]], ["Such studies showed a significant reduction of cytokines/ chemokines (IFN-a, CCL-2, IL-6 (shown Fig. 4c) , IFN-c, CCL-5, CxCl-0, not shown) in the bronchial lavage fluid when compared to results from similar Fig. 4 Interferon-a is the predominant type 1 interferon produced early following virus infection (Panel a) and is associated with the dysregulation of cytokines and chemokines that causes a cytokine storm.", [["bronchial lavage fluid", "ANATOMY", 147, 169], ["infection", "DISEASE", 296, 305], ["IFN-a", "GENE_OR_GENE_PRODUCT", 70, 75], ["CCL-2", "GENE_OR_GENE_PRODUCT", 77, 82], ["IL-6", "GENE_OR_GENE_PRODUCT", 84, 88], ["Fig. 4c", "GENE_OR_GENE_PRODUCT", 96, 103], ["IFN-c", "GENE_OR_GENE_PRODUCT", 107, 112], ["CCL-5", "GENE_OR_GENE_PRODUCT", 114, 119], ["CxCl-0", "GENE_OR_GENE_PRODUCT", 121, 127], ["bronchial lavage fluid", "ORGANISM_SUBSTANCE", 147, 169], ["Interferon", "GENE_OR_GENE_PRODUCT", 215, 225], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 247, 264], ["cytokines", "PROTEIN", 47, 56], ["chemokines", "PROTEIN", 58, 68], ["IFN", "PROTEIN", 70, 73], ["CCL", "PROTEIN", 77, 80], ["IL-6", "PROTEIN", 84, 88], ["IFN", "PROTEIN", 107, 110], ["CCL", "PROTEIN", 114, 117], ["CxCl", "PROTEIN", 121, 125], ["Interferon", "PROTEIN", 215, 225], ["interferon", "PROTEIN", 254, 264], ["cytokines", "PROTEIN", 360, 369], ["chemokines", "PROTEIN", 374, 384], ["cytokine", "PROTEIN", 399, 407], ["Such studies", "TEST", 0, 12], ["a significant reduction of cytokines", "PROBLEM", 20, 56], ["chemokines", "TEST", 58, 68], ["IFN", "TEST", 70, 73], ["CCL", "TEST", 77, 80], ["IL", "TEST", 84, 86], ["IFN", "TEST", 107, 110], ["CCL", "TEST", 114, 117], ["CxCl", "TEST", 121, 125], ["the bronchial lavage fluid", "TEST", 143, 169], ["Interferon", "TREATMENT", 215, 225], ["the predominant type 1 interferon", "TREATMENT", 231, 264], ["virus infection", "PROBLEM", 290, 305], ["the dysregulation of cytokines", "PROBLEM", 339, 369], ["chemokines", "TREATMENT", 374, 384], ["a cytokine storm", "PROBLEM", 397, 413], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["reduction", "OBSERVATION_MODIFIER", 34, 43], ["bronchial", "ANATOMY", 147, 156], ["lavage", "OBSERVATION", 157, 163], ["cytokine storm", "OBSERVATION", 399, 413]]], ["Antibody to interferon type 1-a-b receptor significantly blocks release of cytokines and chemokines (Panel b).", [["interferon type 1-a-b receptor", "GENE_OR_GENE_PRODUCT", 12, 42], ["Panel b", "GENE_OR_GENE_PRODUCT", 101, 108], ["interferon type 1-a-b receptor", "PROTEIN", 12, 42], ["cytokines", "PROTEIN", 75, 84], ["chemokines", "PROTEIN", 89, 99], ["Panel b", "PROTEIN", 101, 108], ["Antibody", "TEST", 0, 8], ["interferon type", "TEST", 12, 27], ["a-b receptor", "TREATMENT", 30, 42], ["cytokines", "TEST", 75, 84], ["chemokines", "TEST", 89, 99]]], ["Panel c: S1P1 agonist suppression of cytokines is dependent on interferon 1.", [["S1P1", "GENE_OR_GENE_PRODUCT", 9, 13], ["interferon 1", "GENE_OR_GENE_PRODUCT", 63, 75], ["S1P1", "PROTEIN", 9, 13], ["cytokines", "PROTEIN", 37, 46], ["interferon 1", "PROTEIN", 63, 75], ["Panel", "TEST", 0, 5], ["S1P1 agonist suppression of cytokines", "TREATMENT", 9, 46], ["interferon", "TREATMENT", 63, 73], ["S1P1 agonist", "OBSERVATION", 9, 21]]], ["Panel d: Innate inflammatory cell recruitment is independent of interferon-a-b receptor signaling.", [["inflammatory cell", "ANATOMY", 16, 33], ["cell", "CELL", 29, 33], ["interferon-a-b receptor", "GENE_OR_GENE_PRODUCT", 64, 87], ["interferon", "PROTEIN", 64, 74], ["Innate inflammatory cell recruitment", "TREATMENT", 9, 45], ["interferon", "TREATMENT", 64, 74], ["a-b receptor signaling", "TREATMENT", 75, 97], ["inflammatory cell recruitment", "OBSERVATION", 16, 45]]], ["Panel e, left: The majority (75-85 %) of interferon-a released following influenza viral infection is from plasmacytoid dendritic cells (pDCs, use of feeble mice-see text)Type I Interferon Signaling is Essential for the Cytokine/Chemokine Response of Cytokine Storm but is not Involved in Recruitment of Innate Inflammatory Cells into the Lung.", [["plasmacytoid dendritic cells", "ANATOMY", 107, 135], ["pDCs", "ANATOMY", 137, 141], ["Cells", "ANATOMY", 324, 329], ["Lung", "ANATOMY", 339, 343], ["influenza viral infection", "DISEASE", 73, 98], ["interferon", "GENE_OR_GENE_PRODUCT", 41, 51], ["influenza viral", "ORGANISM", 73, 88], ["plasmacytoid dendritic cells", "CELL", 107, 135], ["pDCs", "CELL", 137, 141], ["mice", "ORGANISM", 157, 161], ["Type I Interferon", "GENE_OR_GENE_PRODUCT", 171, 188], ["Cytokine", "GENE_OR_GENE_PRODUCT", 251, 259], ["Innate Inflammatory Cells", "CELL", 304, 329], ["Lung", "ORGAN", 339, 343], ["interferon", "PROTEIN", 41, 51], ["plasmacytoid dendritic cells", "CELL_TYPE", 107, 135], ["pDCs", "CELL_TYPE", 137, 141], ["Type I Interferon Signaling", "PROTEIN", 171, 198], ["Cytokine", "PROTEIN", 220, 228], ["Cytokine", "PROTEIN", 251, 259], ["Innate Inflammatory Cells", "CELL_TYPE", 304, 329], ["mice", "SPECIES", 157, 161], ["Panel e", "TEST", 0, 7], ["interferon", "TREATMENT", 41, 51], ["influenza viral infection", "PROBLEM", 73, 98], ["plasmacytoid dendritic cells", "PROBLEM", 107, 135], ["Type I Interferon Signaling", "TREATMENT", 171, 198], ["the Cytokine/Chemokine", "TREATMENT", 216, 238], ["Cytokine Storm", "TREATMENT", 251, 265], ["Innate Inflammatory Cells into the Lung", "PROBLEM", 304, 343], ["left", "ANATOMY_MODIFIER", 9, 13], ["plasmacytoid dendritic cells", "OBSERVATION", 107, 135], ["Cytokine Storm", "OBSERVATION", 251, 265], ["not Involved", "UNCERTAINTY", 273, 285], ["Inflammatory Cells", "OBSERVATION", 311, 329], ["Lung", "ANATOMY", 339, 343]]], ["Panel e, right: Data from S1P1-eGFP knock-in mice indicating that S1P1 receptors are not present on surfaces of pulmonary pDCs but are found, as expected, on surfaces of pulmonary endothelial cells.", [["pulmonary pDCs", "ANATOMY", 112, 126], ["pulmonary endothelial cells", "ANATOMY", 170, 197], ["S1P1", "GENE_OR_GENE_PRODUCT", 26, 30], ["eGFP", "GENE_OR_GENE_PRODUCT", 31, 35], ["mice", "ORGANISM", 45, 49], ["S1P1", "GENE_OR_GENE_PRODUCT", 66, 70], ["pulmonary pDCs", "CELL", 112, 126], ["pulmonary endothelial cells", "CELL", 170, 197], ["S1P1", "PROTEIN", 26, 30], ["S1P1 receptors", "PROTEIN", 66, 80], ["pulmonary pDCs", "CELL_TYPE", 112, 126], ["pulmonary endothelial cells", "CELL_TYPE", 170, 197], ["mice", "SPECIES", 45, 49], ["Panel e", "TEST", 0, 7], ["S1P1", "TEST", 26, 30], ["eGFP knock", "TEST", 31, 41], ["S1P1 receptors", "PROBLEM", 66, 80], ["pulmonary pDCs", "PROBLEM", 112, 126], ["pulmonary endothelial cells", "PROBLEM", 170, 197], ["right", "ANATOMY_MODIFIER", 9, 14], ["S1P1 receptors", "OBSERVATION", 66, 80], ["pulmonary", "ANATOMY", 112, 121], ["pDCs", "OBSERVATION", 122, 126], ["pulmonary", "ANATOMY", 170, 179], ["endothelial cells", "OBSERVATION", 180, 197]]], ["However, utilizing more sensitive techniques S1P1 receptors are found on pDCs (see text).", [["pDCs", "ANATOMY", 73, 77], ["S1P1", "GENE_OR_GENE_PRODUCT", 45, 49], ["pDCs", "CELL", 73, 77], ["S1P1 receptors", "PROTEIN", 45, 59], ["pDCs", "CELL_TYPE", 73, 77]]], ["Figure reprinted from Teijaro et al. (2011) , with permission from Elsevier experimentation in mice with an intact interferon-a-b receptor signaling ability (Fig. 4c) .", [["mice", "ORGANISM", 95, 99], ["interferon-a-b receptor", "GENE_OR_GENE_PRODUCT", 115, 138], ["interferon", "PROTEIN", 115, 125], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["an intact interferon", "TREATMENT", 105, 125], ["a-b receptor signaling ability", "TREATMENT", 126, 156]]], ["Of interest, blockage of interferon-a-b receptor signaling did not retard pulmonary infiltration by the inflammatory cells-macrophages, monocytes, neutrophils, or NK cells-following S1P1 receptor agonist therapy (Fig. 4d) .", [["pulmonary", "ANATOMY", 74, 83], ["inflammatory cells", "ANATOMY", 104, 122], ["macrophages", "ANATOMY", 123, 134], ["monocytes", "ANATOMY", 136, 145], ["neutrophils", "ANATOMY", 147, 158], ["NK cells", "ANATOMY", 163, 171], ["interferon-a-b receptor", "GENE_OR_GENE_PRODUCT", 25, 48], ["pulmonary", "ORGAN", 74, 83], ["inflammatory cells", "CELL", 104, 122], ["macrophages", "CELL", 123, 134], ["monocytes", "CELL", 136, 145], ["neutrophils", "CELL", 147, 158], ["NK cells", "CELL", 163, 171], ["S1P1", "GENE_OR_GENE_PRODUCT", 182, 186], ["interferon", "PROTEIN", 25, 35], ["inflammatory cells", "CELL_TYPE", 104, 122], ["macrophages", "CELL_TYPE", 123, 134], ["monocytes", "CELL_TYPE", 136, 145], ["neutrophils", "CELL_TYPE", 147, 158], ["NK cells", "CELL_TYPE", 163, 171], ["S1P1 receptor", "PROTEIN", 182, 195], ["interferon", "TREATMENT", 25, 35], ["pulmonary infiltration", "PROBLEM", 74, 96], ["the inflammatory cells", "TEST", 100, 122], ["macrophages", "PROBLEM", 123, 134], ["monocytes", "TEST", 136, 145], ["neutrophils", "TEST", 147, 158], ["NK cells", "PROBLEM", 163, 171], ["S1P1 receptor agonist therapy", "TREATMENT", 182, 211], ["pulmonary", "ANATOMY", 74, 83], ["infiltration", "OBSERVATION", 84, 96], ["inflammatory cells", "OBSERVATION", 104, 122], ["macrophages", "ANATOMY", 123, 134], ["monocytes", "ANATOMY", 136, 145], ["NK cells", "OBSERVATION", 163, 171]]], ["Thus, the infiltration of innate inflammatory cells was blunted only in interferon-a-b sufficient mice but not in interferon-a-b receptor knock-out mice.", [["inflammatory cells", "ANATOMY", 33, 51], ["cells", "CELL", 46, 51], ["interferon-a-b", "GENE_OR_GENE_PRODUCT", 72, 86], ["mice", "ORGANISM", 98, 102], ["interferon-a-b receptor", "GENE_OR_GENE_PRODUCT", 114, 137], ["mice", "ORGANISM", 148, 152], ["innate inflammatory cells", "CELL_TYPE", 26, 51], ["interferon", "PROTEIN", 72, 82], ["interferon", "PROTEIN", 114, 124], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 148, 152], ["mice", "SPECIES", 98, 102], ["the infiltration of innate inflammatory cells", "PROBLEM", 6, 51], ["interferon", "TREATMENT", 72, 82], ["interferon", "TREATMENT", 114, 124], ["infiltration", "OBSERVATION", 10, 22], ["inflammatory cells", "OBSERVATION", 33, 51]]], ["This outcome indicates that regulation of such cell recruitment into the lung was primarily mediated by endothelial cells and was independent of type I interferon signaling .", [["cell", "ANATOMY", 47, 51], ["lung", "ANATOMY", 73, 77], ["endothelial cells", "ANATOMY", 104, 121], ["cell", "CELL", 47, 51], ["lung", "ORGAN", 73, 77], ["endothelial cells", "CELL", 104, 121], ["type I interferon", "GENE_OR_GENE_PRODUCT", 145, 162], ["endothelial cells", "CELL_TYPE", 104, 121], ["type I interferon", "PROTEIN", 145, 162], ["such cell recruitment", "TREATMENT", 42, 63], ["type I interferon signaling", "PROBLEM", 145, 172], ["such cell recruitment", "OBSERVATION", 42, 63], ["lung", "ANATOMY", 73, 77], ["endothelial cells", "OBSERVATION", 104, 121]]], ["Cytokine/chemokine production in the lung was also mediated by pulmonary endothelial cells, and S1P1 receptor agonism of such cells inhibited interferon-a production leading to the significantly diminished inflammatory cytokine/chemokine responses we observed.", [["lung", "ANATOMY", 37, 41], ["pulmonary endothelial cells", "ANATOMY", 63, 90], ["cells", "ANATOMY", 126, 131], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["lung", "ORGAN", 37, 41], ["pulmonary endothelial cells", "CELL", 63, 90], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 96, 109], ["cells", "CELL", 126, 131], ["interferon-a", "GENE_OR_GENE_PRODUCT", 142, 154], ["Cytokine", "PROTEIN", 0, 8], ["chemokine", "PROTEIN", 9, 18], ["pulmonary endothelial cells", "CELL_TYPE", 63, 90], ["S1P1 receptor", "PROTEIN", 96, 109], ["interferon", "PROTEIN", 142, 152], ["inflammatory cytokine", "PROTEIN", 206, 227], ["chemokine", "PROTEIN", 228, 237], ["Cytokine/chemokine production", "TREATMENT", 0, 29], ["pulmonary endothelial cells", "TEST", 63, 90], ["S1P1 receptor agonism", "TEST", 96, 117], ["such cells", "PROBLEM", 121, 131], ["interferon", "TREATMENT", 142, 152], ["the significantly diminished inflammatory cytokine/chemokine responses", "PROBLEM", 177, 247], ["chemokine production", "OBSERVATION", 9, 29], ["lung", "ANATOMY", 37, 41], ["pulmonary endothelial", "ANATOMY", 63, 84], ["diminished", "OBSERVATION_MODIFIER", 195, 205], ["inflammatory", "OBSERVATION_MODIFIER", 206, 218]]], ["Influenza virus infection induces a robust interferon type I response, despite the early induction of the viral NS1 protein that suppresses the cellular induction of and response to interferon I (Fernandez-Sesma 2007).", [["cellular", "ANATOMY", 144, 152], ["Influenza virus infection", "DISEASE", 0, 25], ["Influenza virus", "ORGANISM", 0, 15], ["interferon type I", "GENE_OR_GENE_PRODUCT", 43, 60], ["NS1", "GENE_OR_GENE_PRODUCT", 112, 115], ["cellular", "CELL", 144, 152], ["interferon I", "GENE_OR_GENE_PRODUCT", 182, 194], ["interferon type I", "PROTEIN", 43, 60], ["viral NS1 protein", "PROTEIN", 106, 123], ["interferon I", "PROTEIN", 182, 194], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus infection", "PROBLEM", 0, 25], ["the viral NS1 protein", "TREATMENT", 102, 123], ["the cellular induction", "TREATMENT", 140, 162]]], ["The predominant type I interferon produced early following influenza virus infection is alpha, not beta (Fig. 4a) .", [["influenza virus infection", "DISEASE", 59, 84], ["type I interferon", "GENE_OR_GENE_PRODUCT", 16, 33], ["influenza virus", "ORGANISM", 59, 74], ["alpha", "GENE_OR_GENE_PRODUCT", 88, 93], ["type I interferon", "PROTEIN", 16, 33], ["influenza virus", "SPECIES", 59, 74], ["The predominant type I interferon", "TREATMENT", 0, 33], ["influenza virus infection", "PROBLEM", 59, 84], ["predominant", "OBSERVATION_MODIFIER", 4, 15], ["type I", "OBSERVATION_MODIFIER", 16, 22], ["interferon", "OBSERVATION", 23, 33]]], ["However, the cellular sources of interferon type I-a produced and amounts made by various cell populations have not been clear.", [["cellular", "ANATOMY", 13, 21], ["cell", "ANATOMY", 90, 94], ["cellular", "CELL", 13, 21], ["interferon type I", "GENE_OR_GENE_PRODUCT", 33, 50], ["cell populations", "CELL", 90, 106], ["interferon type I", "PROTEIN", 33, 50], ["interferon type I", "TREATMENT", 33, 50], ["various cell populations", "PROBLEM", 82, 106], ["interferon", "OBSERVATION", 33, 43], ["various cell populations", "OBSERVATION", 82, 106], ["clear", "OBSERVATION", 121, 126]]], ["The two major pulmonary cell populations known to make type I interferon in vivo following respiratory viral infections are pDCs and alveolar macrophages (Kumagai et al. 2007 ).", [["pulmonary cell", "ANATOMY", 14, 28], ["pDCs", "ANATOMY", 124, 128], ["alveolar macrophages", "ANATOMY", 133, 153], ["respiratory viral infections", "DISEASE", 91, 119], ["pulmonary cell populations", "CELL", 14, 40], ["type I interferon", "GENE_OR_GENE_PRODUCT", 55, 72], ["pDCs", "CELL", 124, 128], ["alveolar macrophages", "CELL", 133, 153], ["type I interferon", "PROTEIN", 55, 72], ["pDCs", "CELL_TYPE", 124, 128], ["alveolar macrophages", "CELL_TYPE", 133, 153], ["The two major pulmonary cell populations", "PROBLEM", 0, 40], ["type I interferon", "TREATMENT", 55, 72], ["respiratory viral infections", "PROBLEM", 91, 119], ["alveolar macrophages", "PROBLEM", 133, 153], ["major", "OBSERVATION_MODIFIER", 8, 13], ["pulmonary", "ANATOMY", 14, 23], ["cell populations", "OBSERVATION", 24, 40], ["respiratory", "ANATOMY", 91, 102], ["viral infections", "OBSERVATION", 103, 119], ["alveolar macrophages", "OBSERVATION", 133, 153]]], ["To judge the contribution of pDCs to interferon-a production in the lung, we utilized a novel mouse model recently developed at Scripps by Bruce Beutler and termed ''feeble.''", [["pDCs", "ANATOMY", 29, 33], ["lung", "ANATOMY", 68, 72], ["pDCs", "CELL", 29, 33], ["interferon", "GENE_OR_GENE_PRODUCT", 37, 47], ["lung", "ORGAN", 68, 72], ["mouse", "ORGANISM", 94, 99], ["pDCs", "CELL_TYPE", 29, 33], ["interferon", "PROTEIN", 37, 47], ["mouse", "SPECIES", 94, 99], ["mouse", "SPECIES", 94, 99], ["pDCs", "PROBLEM", 29, 33], ["interferon", "TREATMENT", 37, 47], ["a production in the lung", "PROBLEM", 48, 72], ["a novel mouse model", "TREATMENT", 86, 105], ["pDCs", "OBSERVATION", 29, 33], ["interferon", "OBSERVATION", 37, 47], ["lung", "ANATOMY", 68, 72]]], ["Feeble mice have a specific genetic defect that prevents their pDCs from producing type I interferon and pro-inflammatory cytokines upon activation of TLR7 and TLR9 ligands by influenza virus stimulation (Blasius et al. 2010) .", [["pDCs", "ANATOMY", 63, 67], ["mice", "ORGANISM", 7, 11], ["pDCs", "CELL", 63, 67], ["type I interferon", "GENE_OR_GENE_PRODUCT", 83, 100], ["TLR7", "GENE_OR_GENE_PRODUCT", 151, 155], ["TLR9", "GENE_OR_GENE_PRODUCT", 160, 164], ["influenza virus", "ORGANISM", 176, 191], ["pDCs", "CELL_TYPE", 63, 67], ["type I interferon", "PROTEIN", 83, 100], ["pro-inflammatory cytokines", "PROTEIN", 105, 131], ["TLR7", "PROTEIN", 151, 155], ["TLR9", "PROTEIN", 160, 164], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 7, 11], ["a specific genetic defect", "PROBLEM", 17, 42], ["type I interferon and pro-inflammatory cytokines", "TREATMENT", 83, 131], ["activation of TLR7 and TLR9 ligands", "TREATMENT", 137, 172], ["influenza virus stimulation", "TREATMENT", 176, 203], ["defect", "OBSERVATION", 36, 42]]], ["Importantly, there is no disruption of the numbers or vitality of pDCs, and the feeble mouse defect is specifically restricted to pDCs.", [["pDCs", "ANATOMY", 66, 70], ["pDCs", "ANATOMY", 130, 134], ["pDCs", "CELL", 66, 70], ["mouse", "ORGANISM", 87, 92], ["pDCs", "CELL", 130, 134], ["pDCs", "CELL_TYPE", 66, 70], ["pDCs", "CELL_TYPE", 130, 134], ["mouse", "SPECIES", 87, 92], ["mouse", "SPECIES", 87, 92], ["disruption of the numbers", "PROBLEM", 25, 50], ["the feeble mouse defect", "PROBLEM", 76, 99], ["no", "UNCERTAINTY", 22, 24], ["disruption", "OBSERVATION", 25, 35], ["mouse defect", "OBSERVATION", 87, 99]]], ["As displayed in Fig. 4e , when wild type or feeble mice received H1N1 human 2009 swine influenza with or without S1P1 agonist CYM5442 treatment, 75-85 % of total interferon-a was produced by pDCs.", [["pDCs", "ANATOMY", 191, 195], ["influenza", "DISEASE", 87, 96], ["CYM5442", "CHEMICAL", 126, 133], ["CYM5442", "CHEMICAL", 126, 133], ["feeble mice", "ORGANISM", 44, 55], ["H1N1", "ORGANISM", 65, 69], ["human", "ORGANISM", 70, 75], ["2009 swine influenza", "ORGANISM", 76, 96], ["S1P1", "GENE_OR_GENE_PRODUCT", 113, 117], ["CYM5442", "SIMPLE_CHEMICAL", 126, 133], ["interferon", "GENE_OR_GENE_PRODUCT", 162, 172], ["pDCs", "CELL", 191, 195], ["S1P1", "PROTEIN", 113, 117], ["interferon", "PROTEIN", 162, 172], ["pDCs", "CELL_TYPE", 191, 195], ["mice", "SPECIES", 51, 55], ["human", "SPECIES", 70, 75], ["swine", "SPECIES", 81, 86], ["mice", "SPECIES", 51, 55], ["H1N1 human 2009 swine influenza", "SPECIES", 65, 96], ["influenza", "PROBLEM", 87, 96], ["S1P1 agonist", "TREATMENT", 113, 125], ["treatment", "TREATMENT", 134, 143], ["total interferon", "TREATMENT", 156, 172]]], ["Further, interferon-a release was significantly inhibited by the S1P1 agonist CYM-5442.", [["CYM-5442", "CHEMICAL", 78, 86], ["CYM-5442", "CHEMICAL", 78, 86], ["interferon-a", "GENE_OR_GENE_PRODUCT", 9, 21], ["S1P1", "GENE_OR_GENE_PRODUCT", 65, 69], ["CYM-5442", "SIMPLE_CHEMICAL", 78, 86], ["interferon", "PROTEIN", 9, 19], ["S1P1", "PROTEIN", 65, 69], ["interferon", "TREATMENT", 9, 19], ["the S1P1 agonist CYM", "TEST", 61, 81]]], ["These results were confirmed using a pDC depletion antibody (anti-PDCS-1 clone 120.68), which again resulted in significant depletion of pDCs in the lung and corresponding reductions in interferon-a, CCL2, CCL5, and IL-6.", [["pDCs", "ANATOMY", 137, 141], ["lung", "ANATOMY", 149, 153], ["pDC", "CELL", 37, 40], ["pDCs", "CELL", 137, 141], ["lung", "ORGAN", 149, 153], ["interferon-a", "GENE_OR_GENE_PRODUCT", 186, 198], ["CCL2", "GENE_OR_GENE_PRODUCT", 200, 204], ["CCL5", "GENE_OR_GENE_PRODUCT", 206, 210], ["IL-6", "GENE_OR_GENE_PRODUCT", 216, 220], ["pDC depletion antibody", "PROTEIN", 37, 59], ["PDCS", "PROTEIN", 66, 70], ["pDCs", "CELL_TYPE", 137, 141], ["interferon", "PROTEIN", 186, 196], ["CCL2", "PROTEIN", 200, 204], ["CCL5", "PROTEIN", 206, 210], ["IL-6", "PROTEIN", 216, 220], ["a pDC depletion antibody", "TEST", 35, 59], ["anti-PDCS", "TEST", 61, 70], ["significant depletion of pDCs in the lung", "PROBLEM", 112, 153], ["interferon", "TEST", 186, 196], ["CCL5", "TEST", 206, 210], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["depletion", "OBSERVATION", 124, 133], ["pDCs", "OBSERVATION", 137, 141], ["lung", "ANATOMY", 149, 153], ["reductions", "OBSERVATION_MODIFIER", 172, 182]]], ["Thus, pDCs are the essential and major producers of interferon-a (75-85 %) and involved in amplification of cytokine/chemokine volumes following influenza infection.", [["pDCs", "ANATOMY", 6, 10], ["influenza infection", "DISEASE", 145, 164], ["pDCs", "CELL", 6, 10], ["interferon", "GENE_OR_GENE_PRODUCT", 52, 62], ["pDCs", "CELL_TYPE", 6, 10], ["interferon", "PROTEIN", 52, 62], ["cytokine", "PROTEIN", 108, 116], ["chemokine", "PROTEIN", 117, 126], ["interferon", "TREATMENT", 52, 62], ["cytokine/chemokine volumes", "TREATMENT", 108, 134], ["influenza infection", "PROBLEM", 145, 164], ["infection", "OBSERVATION", 155, 164]]], ["Other depletion studies indicate that most of the remaining interferon-a production (*15-25 %) was by alveolar macrophages.Type I Interferon Signaling is Essential for the Cytokine/Chemokine Response of Cytokine Storm but is not Involved in Recruitment of Innate Inflammatory Cells into the LungSince S1P1 agonist therapy diminished interferon-a production, and the majority of interferon-a produced was by pDCs, it was important to learn whether or not pDCs expressed S1P1 receptors on their surfaces.", [["alveolar macrophages", "ANATOMY", 102, 122], ["Cells", "ANATOMY", 276, 281], ["pDCs", "ANATOMY", 407, 411], ["pDCs", "ANATOMY", 454, 458], ["interferon", "GENE_OR_GENE_PRODUCT", 60, 70], ["alveolar macrophages", "CELL", 102, 122], ["Type I Interferon", "GENE_OR_GENE_PRODUCT", 123, 140], ["Cytokine", "GENE_OR_GENE_PRODUCT", 203, 211], ["Innate Inflammatory Cells", "CELL", 256, 281], ["S1P1", "GENE_OR_GENE_PRODUCT", 301, 305], ["interferon-a", "GENE_OR_GENE_PRODUCT", 333, 345], ["interferon-a", "GENE_OR_GENE_PRODUCT", 378, 390], ["pDCs", "CELL", 407, 411], ["pDCs", "CELL", 454, 458], ["S1P1", "GENE_OR_GENE_PRODUCT", 469, 473], ["interferon", "PROTEIN", 60, 70], ["alveolar macrophages", "CELL_TYPE", 102, 122], ["Type I Interferon Signaling", "PROTEIN", 123, 150], ["Cytokine", "PROTEIN", 172, 180], ["Cytokine", "PROTEIN", 203, 211], ["Innate Inflammatory Cells", "CELL_TYPE", 256, 281], ["S1P1", "PROTEIN", 301, 305], ["interferon", "PROTEIN", 333, 343], ["interferon", "PROTEIN", 378, 388], ["pDCs", "CELL_TYPE", 407, 411], ["pDCs", "CELL_TYPE", 454, 458], ["S1P1 receptors", "PROTEIN", 469, 483], ["Other depletion studies", "TEST", 0, 23], ["Type I Interferon Signaling", "TREATMENT", 123, 150], ["the Cytokine/Chemokine", "TREATMENT", 168, 190], ["Cytokine Storm", "TREATMENT", 203, 217], ["Innate Inflammatory Cells", "PROBLEM", 256, 281], ["the LungSince S1P1 agonist therapy", "TREATMENT", 287, 321], ["diminished interferon", "PROBLEM", 322, 343], ["interferon", "TREATMENT", 378, 388], ["depletion", "OBSERVATION", 6, 15], ["interferon", "OBSERVATION", 60, 70], ["alveolar", "ANATOMY", 102, 110], ["macrophages", "OBSERVATION", 111, 122], ["Cytokine Storm", "OBSERVATION", 203, 217], ["not Involved", "UNCERTAINTY", 225, 237], ["Inflammatory Cells", "OBSERVATION", 263, 281]]], ["We know that alveolar macrophages, the other main albeit minority producers of interferon-a do not express S1P1 receptors (Fig. 2a) .", [["alveolar macrophages", "ANATOMY", 13, 33], ["alveolar macrophages", "CELL", 13, 33], ["interferon", "GENE_OR_GENE_PRODUCT", 79, 89], ["S1P1", "GENE_OR_GENE_PRODUCT", 107, 111], ["alveolar macrophages", "CELL_TYPE", 13, 33], ["interferon", "PROTEIN", 79, 89], ["S1P1 receptors", "PROTEIN", 107, 121], ["alveolar macrophages", "PROBLEM", 13, 33], ["interferon", "TREATMENT", 79, 89], ["alveolar macrophages", "OBSERVATION", 13, 33]]], ["Plasmacytoid dendritic cells were recently found to express S1P1 receptors (Teijaro 2013) .", [["Plasmacytoid dendritic cells", "ANATOMY", 0, 28], ["Plasmacytoid dendritic cells", "CELL", 0, 28], ["S1P1", "GENE_OR_GENE_PRODUCT", 60, 64], ["Plasmacytoid dendritic cells", "CELL_TYPE", 0, 28], ["S1P1 receptors", "PROTEIN", 60, 74], ["Plasmacytoid dendritic cells", "PROBLEM", 0, 28], ["dendritic cells", "OBSERVATION", 13, 28]]], ["However, using the S1P1 eGFP receptor knock-in mice and pDCs of more than 98.5 % purity failed to show that these cells expressed S1P1 receptors (Fig. 4e) .", [["pDCs", "ANATOMY", 56, 60], ["cells", "ANATOMY", 114, 119], ["S1P1", "GENE_OR_GENE_PRODUCT", 19, 23], ["mice", "ORGANISM", 47, 51], ["pDCs", "CELL", 56, 60], ["cells", "CELL", 114, 119], ["S1P1 receptors", "GENE_OR_GENE_PRODUCT", 130, 144], ["S1P1 eGFP receptor", "PROTEIN", 19, 37], ["pDCs", "CELL_TYPE", 56, 60], ["S1P1 receptors", "PROTEIN", 130, 144], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["the S1P1 eGFP receptor knock", "TEST", 15, 43], ["pDCs", "TEST", 56, 60], ["these cells", "PROBLEM", 108, 119]]], ["Thus, the S1P1-specific receptor is found primarily on pulmonary endothelial cells with lesser amounts on pulmonary pDCs.", [["pulmonary endothelial cells", "ANATOMY", 55, 82], ["pulmonary pDCs", "ANATOMY", 106, 120], ["S1P1", "GENE_OR_GENE_PRODUCT", 10, 14], ["pulmonary endothelial cells", "CELL", 55, 82], ["pulmonary pDCs", "CELL", 106, 120], ["S1P1", "PROTEIN", 10, 14], ["pulmonary endothelial cells", "CELL_TYPE", 55, 82], ["pulmonary pDCs", "CELL_TYPE", 106, 120], ["pulmonary endothelial cells", "PROBLEM", 55, 82], ["lesser amounts on pulmonary pDCs", "PROBLEM", 88, 120], ["pulmonary", "ANATOMY", 55, 64], ["endothelial cells", "OBSERVATION", 65, 82], ["lesser", "OBSERVATION_MODIFIER", 88, 94], ["amounts", "OBSERVATION_MODIFIER", 95, 102], ["pulmonary", "ANATOMY", 106, 115], ["pDCs", "OBSERVATION", 116, 120]]], ["S1P1 receptor agonist acts directly on pulmonary endothelial and pDCs and likely indirectly on alveolar macrophages.", [["pulmonary endothelial", "ANATOMY", 39, 60], ["pDCs", "ANATOMY", 65, 69], ["alveolar macrophages", "ANATOMY", 95, 115], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 0, 13], ["pulmonary endothelial", "CELL", 39, 60], ["pDCs", "CELL", 65, 69], ["alveolar macrophages", "CELL", 95, 115], ["S1P1 receptor", "PROTEIN", 0, 13], ["pulmonary endothelial", "CELL_TYPE", 39, 60], ["pDCs", "CELL_TYPE", 65, 69], ["alveolar macrophages", "CELL_TYPE", 95, 115], ["S1P1 receptor agonist", "TREATMENT", 0, 21], ["pulmonary endothelial", "ANATOMY", 39, 60], ["alveolar macrophages", "OBSERVATION", 95, 115]]], ["We have, as yet, been unable to detect S1P1 receptor on alveolar macrophages.Working Model for the Initial Productionof Cytokine Storm and its Chemical Tractability by Single S1P1 Molecules A working model based on the accumulated data for the earliest events of influenza infection is provided in Fig. 5 .", [["alveolar macrophages", "ANATOMY", 56, 76], ["influenza infection", "DISEASE", 263, 282], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 39, 52], ["alveolar macrophages", "CELL", 56, 76], ["S1P1 receptor", "PROTEIN", 39, 52], ["alveolar macrophages", "CELL_TYPE", 56, 76], ["the Initial Productionof Cytokine Storm", "TREATMENT", 95, 134], ["influenza infection", "PROBLEM", 263, 282], ["alveolar macrophages", "OBSERVATION", 56, 76], ["influenza infection", "OBSERVATION", 263, 282]]], ["Although there are several possible scenarios, I selected the simplest one in which S1P1 agonist signals a factor(s) that blocks [negative signal(s)] the release of interferon-a from pulmonary pDCs and the migration of innate inflammatory cells from blood vessels into the lung.", [["pulmonary pDCs", "ANATOMY", 183, 197], ["inflammatory cells", "ANATOMY", 226, 244], ["blood vessels", "ANATOMY", 250, 263], ["lung", "ANATOMY", 273, 277], ["S1P1", "GENE_OR_GENE_PRODUCT", 84, 88], ["interferon-a", "GENE_OR_GENE_PRODUCT", 165, 177], ["pulmonary pDCs", "CELL", 183, 197], ["inflammatory cells", "CELL", 226, 244], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 250, 263], ["lung", "ORGAN", 273, 277], ["S1P1", "PROTEIN", 84, 88], ["interferon", "PROTEIN", 165, 175], ["pulmonary pDCs", "CELL_TYPE", 183, 197], ["innate inflammatory cells", "CELL_TYPE", 219, 244], ["interferon", "TREATMENT", 165, 175], ["pulmonary pDCs", "TREATMENT", 183, 197], ["innate inflammatory cells", "PROBLEM", 219, 244], ["pulmonary", "ANATOMY", 183, 192], ["pDCs", "OBSERVATION", 193, 197], ["migration", "OBSERVATION_MODIFIER", 206, 215], ["inflammatory cells", "OBSERVATION", 226, 244], ["lung", "ANATOMY", 273, 277]]], ["This model is based on presence of S1P1 receptors on pulmonary endothelial and pDCs but their absence on lung epithelial cells and the findings that alveolar macrophages which produce type I interferon do not display S1P1 receptors on their surfaces.", [["pulmonary endothelial", "ANATOMY", 53, 74], ["pDCs", "ANATOMY", 79, 83], ["lung epithelial cells", "ANATOMY", 105, 126], ["alveolar macrophages", "ANATOMY", 149, 169], ["S1P1", "GENE_OR_GENE_PRODUCT", 35, 39], ["pulmonary endothelial", "CELL", 53, 74], ["pDCs", "CELL", 79, 83], ["lung epithelial cells", "CELL", 105, 126], ["alveolar macrophages", "CELL", 149, 169], ["type I interferon", "GENE_OR_GENE_PRODUCT", 184, 201], ["S1P1", "GENE_OR_GENE_PRODUCT", 217, 221], ["S1P1 receptors", "PROTEIN", 35, 49], ["pulmonary endothelial", "CELL_TYPE", 53, 74], ["pDCs", "CELL_TYPE", 79, 83], ["lung epithelial cells", "CELL_TYPE", 105, 126], ["alveolar macrophages", "CELL_TYPE", 149, 169], ["type I interferon", "PROTEIN", 184, 201], ["S1P1 receptors", "PROTEIN", 217, 231], ["S1P1 receptors", "PROBLEM", 35, 49], ["pulmonary endothelial and pDCs", "PROBLEM", 53, 83], ["lung epithelial cells", "PROBLEM", 105, 126], ["alveolar macrophages", "PROBLEM", 149, 169], ["type I interferon", "PROBLEM", 184, 201], ["S1P1 receptors", "OBSERVATION", 35, 49], ["pulmonary endothelial", "ANATOMY", 53, 74], ["lung", "ANATOMY", 105, 109], ["epithelial cells", "OBSERVATION", 110, 126], ["alveolar macrophages", "OBSERVATION", 149, 169]]], ["However, pulmonary endothelial cells and pulmonary pDCs do express S1P1 receptors on their surfaces.", [["pulmonary endothelial cells", "ANATOMY", 9, 36], ["pulmonary pDCs", "ANATOMY", 41, 55], ["pulmonary endothelial cells", "CELL", 9, 36], ["pulmonary pDCs", "CELL", 41, 55], ["S1P1", "GENE_OR_GENE_PRODUCT", 67, 71], ["pulmonary endothelial cells", "CELL_TYPE", 9, 36], ["pulmonary pDCs", "CELL_TYPE", 41, 55], ["S1P1 receptors", "PROTEIN", 67, 81], ["pulmonary endothelial cells", "PROBLEM", 9, 36], ["pulmonary pDCs", "PROBLEM", 41, 55], ["pulmonary", "ANATOMY", 9, 18], ["endothelial cells", "OBSERVATION", 19, 36], ["pulmonary", "ANATOMY", 41, 50], ["pDCs", "OBSERVATION", 51, 55]]], ["Cytokines/chemokines elicit the initial cytokine storm reflective of factors (viral or nonviral) produced by the influenza virusinfected lung epithelial cells per se.", [["lung epithelial cells", "ANATOMY", 137, 158], ["lung epithelial cells", "CELL", 137, 158], ["Cytokines", "PROTEIN", 0, 9], ["chemokines", "PROTEIN", 10, 20], ["cytokine", "PROTEIN", 40, 48], ["influenza virusinfected lung epithelial cells", "CELL_TYPE", 113, 158], ["Cytokines/chemokines", "TREATMENT", 0, 20], ["factors (viral or nonviral)", "PROBLEM", 69, 96], ["the influenza virusinfected lung epithelial cells", "PROBLEM", 109, 158], ["lung", "ANATOMY", 137, 141], ["epithelial cells", "OBSERVATION", 142, 158]]], ["These factors likely activate pulmonary pDCs and alveolar macrophages to release interferon-a.", [["pulmonary pDCs", "ANATOMY", 30, 44], ["alveolar macrophages", "ANATOMY", 49, 69], ["pulmonary pDCs", "CELL", 30, 44], ["alveolar macrophages", "CELL", 49, 69], ["interferon-a", "GENE_OR_GENE_PRODUCT", 81, 93], ["pulmonary pDCs", "CELL_TYPE", 30, 44], ["alveolar macrophages", "CELL_TYPE", 49, 69], ["interferon", "PROTEIN", 81, 91], ["pulmonary pDCs", "PROBLEM", 30, 44], ["alveolar macrophages", "PROBLEM", 49, 69], ["pulmonary", "ANATOMY", 30, 39], ["pDCs", "OBSERVATION", 40, 44], ["alveolar macrophages", "OBSERVATION", 49, 69]]], ["As chemotoxic factors are then liberated into the site of action, infiltrating cells of the innate immune system (macrophages/monocytes, NK cells, leukocytes) are drawn into the inflammatory milieu where they release additional cytokines/chemokines.", [["infiltrating cells", "ANATOMY", 66, 84], ["immune system", "ANATOMY", 99, 112], ["macrophages", "ANATOMY", 114, 125], ["monocytes", "ANATOMY", 126, 135], ["NK cells", "ANATOMY", 137, 145], ["leukocytes", "ANATOMY", 147, 157], ["cells", "CELL", 79, 84], ["macrophages", "CELL", 114, 125], ["monocytes", "CELL", 126, 135], ["NK cells", "CELL", 137, 145], ["leukocytes", "CELL", 147, 157], ["chemotoxic factors", "PROTEIN", 3, 21], ["infiltrating cells", "CELL_TYPE", 66, 84], ["macrophages", "CELL_TYPE", 114, 125], ["monocytes", "CELL_TYPE", 126, 135], ["NK cells", "CELL_TYPE", 137, 145], ["leukocytes", "CELL_TYPE", 147, 157], ["cytokines", "PROTEIN", 228, 237], ["chemokines", "PROTEIN", 238, 248], ["chemotoxic factors", "PROBLEM", 3, 21], ["infiltrating cells", "PROBLEM", 66, 84], ["macrophages/monocytes", "TEST", 114, 135], ["NK cells", "TEST", 137, 145], ["leukocytes", "TEST", 147, 157], ["cytokines/chemokines", "TREATMENT", 228, 248], ["infiltrating cells", "OBSERVATION", 66, 84], ["monocytes", "ANATOMY", 126, 135], ["NK cells", "OBSERVATION", 137, 145], ["inflammatory", "OBSERVATION_MODIFIER", 178, 190]]], ["Here influenza virus-specific T cells are activated and expand numerically in the mediastinal lymph nodes and pulmonary tissues.", [["T cells", "ANATOMY", 30, 37], ["mediastinal lymph nodes", "ANATOMY", 82, 105], ["pulmonary tissues", "ANATOMY", 110, 127], ["influenza virus", "ORGANISM", 5, 20], ["T cells", "CELL", 30, 37], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 94, 105], ["pulmonary tissues", "TISSUE", 110, 127], ["T cells", "CELL_TYPE", 30, 37], ["influenza virus", "SPECIES", 5, 20], ["influenza virus", "PROBLEM", 5, 20], ["mediastinal", "ANATOMY", 82, 93], ["lymph nodes", "OBSERVATION", 94, 105], ["pulmonary tissues", "ANATOMY", 110, 127]]], ["These T cells of the adoptive immune system produce additional inflammatory molecules and lyse influenza virus-infected epithelial cells thereby augmenting cytokine storm and immune-mediated injury.", [["T cells", "ANATOMY", 6, 13], ["immune system", "ANATOMY", 30, 43], ["epithelial cells", "ANATOMY", 120, 136], ["T cells", "CELL", 6, 13], ["immune system", "ANATOMICAL_SYSTEM", 30, 43], ["influenza virus", "ORGANISM", 95, 110], ["epithelial cells", "CELL", 120, 136], ["T cells", "CELL_TYPE", 6, 13], ["inflammatory molecules", "PROTEIN", 63, 85], ["infected epithelial cells", "CELL_TYPE", 111, 136], ["cytokine", "PROTEIN", 156, 164], ["influenza virus", "SPECIES", 95, 110], ["the adoptive immune system", "TREATMENT", 17, 43], ["additional inflammatory molecules", "PROBLEM", 52, 85], ["lyse influenza virus", "PROBLEM", 90, 110], ["infected epithelial cells", "PROBLEM", 111, 136], ["augmenting cytokine storm", "TREATMENT", 145, 170], ["immune-mediated injury", "PROBLEM", 175, 197], ["inflammatory", "OBSERVATION_MODIFIER", 63, 75], ["lyse influenza virus", "OBSERVATION", 90, 110], ["infected epithelial cells", "OBSERVATION", 111, 136], ["cytokine storm", "OBSERVATION", 156, 170], ["injury", "OBSERVATION", 191, 197]]], ["This second phase of tissue injury is primarily influenza virus-specific T cell-mediated and signals through S1P1 but also likely progresses via S1P3 and 4 receptors, as by our preliminary results.", [["tissue", "ANATOMY", 21, 27], ["T cell", "ANATOMY", 73, 79], ["tissue", "TISSUE", 21, 27], ["influenza virus", "ORGANISM", 48, 63], ["T cell", "CELL", 73, 79], ["S1P1", "GENE_OR_GENE_PRODUCT", 109, 113], ["S1P3", "GENE_OR_GENE_PRODUCT", 145, 149], ["4 receptors", "GENE_OR_GENE_PRODUCT", 154, 165], ["S1P1", "PROTEIN", 109, 113], ["S1P3 and 4 receptors", "PROTEIN", 145, 165], ["tissue injury", "PROBLEM", 21, 34], ["influenza virus", "PROBLEM", 48, 63], ["tissue", "ANATOMY", 21, 27], ["injury", "OBSERVATION", 28, 34], ["influenza virus", "OBSERVATION", 48, 63]]], ["However, additional data are required to ensure these observations.", [["additional data", "TEST", 9, 24]]], ["What is clear is that treatment with S1P permissive-AAL-R agonists signaling via S1P1,3,4,5 receptors affect adoptive immune T cell-mediated immunopathology by downregulating MHC and co-stimulatory molecules of DCs located in the mediastinal lymph nodes and the lung parenchyma thereby blunting the arming, expansion, and migration of virus-specific CD4 and CD8 T cells into the lung (Marsolais et al. 2009 ).Working Model for the Initial ProductionThe cytokine pathways blunted by S1P1 agonist signaling are displayed in Fig. 5 by the symbol '.", [["immune T cell", "ANATOMY", 118, 131], ["DCs", "ANATOMY", 211, 214], ["mediastinal lymph nodes", "ANATOMY", 230, 253], ["lung parenchyma", "ANATOMY", 262, 277], ["CD4", "ANATOMY", 350, 353], ["CD8 T cells", "ANATOMY", 358, 369], ["lung", "ANATOMY", 379, 383], ["S1P", "CHEMICAL", 37, 40], ["immunopathology", "DISEASE", 141, 156], ["S1P", "CHEMICAL", 37, 40], ["S1P", "GENE_OR_GENE_PRODUCT", 37, 40], ["AAL-R", "GENE_OR_GENE_PRODUCT", 52, 57], ["S1P1", "GENE_OR_GENE_PRODUCT", 81, 85], ["3,4,5 receptors", "GENE_OR_GENE_PRODUCT", 86, 101], ["adoptive immune T cell", "CELL", 109, 131], ["DCs", "CELL", 211, 214], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 242, 253], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 262, 277], ["CD4", "CELL", 350, 353], ["CD8", "GENE_OR_GENE_PRODUCT", 358, 361], ["lung", "ORGAN", 379, 383], ["S1P1", "GENE_OR_GENE_PRODUCT", 482, 486], ["S1P1,3,4,5 receptors", "PROTEIN", 81, 101], ["MHC", "PROTEIN", 175, 178], ["co-stimulatory molecules", "PROTEIN", 183, 207], ["DCs", "CELL_TYPE", 211, 214], ["virus-specific CD4 and CD8 T cells", "CELL_TYPE", 335, 369], ["cytokine", "PROTEIN", 453, 461], ["S1P1", "PROTEIN", 482, 486], ["S1P permissive", "TREATMENT", 37, 51], ["S1P1", "TEST", 81, 85], ["DCs", "PROBLEM", 211, 214], ["blunting the arming", "PROBLEM", 286, 305], ["expansion", "PROBLEM", 307, 316], ["migration of virus", "PROBLEM", 322, 340], ["mediastinal", "ANATOMY", 230, 241], ["lymph nodes", "OBSERVATION", 242, 253], ["lung", "ANATOMY", 262, 266], ["parenchyma", "ANATOMY_MODIFIER", 267, 277], ["blunting", "OBSERVATION_MODIFIER", 286, 294], ["expansion", "OBSERVATION_MODIFIER", 307, 316], ["migration", "OBSERVATION_MODIFIER", 322, 331], ["lung", "ANATOMY", 379, 383]]], ["Schematic of data presented in the text: Proposed pathways and cell-cell crosstalk in the lung following influenza virus infection and S1P1 receptor agonist signaling.", [["cell", "ANATOMY", 63, 67], ["cell", "ANATOMY", 68, 72], ["lung", "ANATOMY", 90, 94], ["influenza virus infection", "DISEASE", 105, 130], ["cell", "CELL", 63, 67], ["cell", "CELL", 68, 72], ["lung", "ORGAN", 90, 94], ["influenza virus", "ORGANISM", 105, 120], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 135, 148], ["S1P1 receptor", "PROTEIN", 135, 148], ["influenza virus", "SPECIES", 105, 120], ["influenza virus", "SPECIES", 105, 120], ["cell-cell crosstalk in the lung", "PROBLEM", 63, 94], ["influenza virus infection", "PROBLEM", 105, 130], ["S1P1 receptor agonist signaling", "TREATMENT", 135, 166], ["cell crosstalk", "OBSERVATION", 68, 82], ["lung", "ANATOMY", 90, 94], ["influenza virus", "OBSERVATION", 105, 120]]], ["Initial events: Viruses infect lung epithelial cells that release one or more (currently unknown) factors that signal plasmacytoid cells (primary cell-type involved) and alveolar macrophages to release type 1 interferon-a, which dysregulates cytokines/chemokines to elicit cytokine storm.", [["lung epithelial cells", "ANATOMY", 31, 52], ["plasmacytoid cells", "ANATOMY", 118, 136], ["cell", "ANATOMY", 146, 150], ["alveolar macrophages", "ANATOMY", 170, 190], ["lung epithelial cells", "CELL", 31, 52], ["plasmacytoid cells", "CELL", 118, 136], ["cell", "CELL", 146, 150], ["alveolar macrophages", "CELL", 170, 190], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 202, 219], ["lung epithelial cells", "CELL_TYPE", 31, 52], ["plasmacytoid cells", "CELL_TYPE", 118, 136], ["alveolar macrophages", "CELL_TYPE", 170, 190], ["interferon", "PROTEIN", 209, 219], ["cytokines", "PROTEIN", 242, 251], ["chemokines", "PROTEIN", 252, 262], ["cytokine", "PROTEIN", 273, 281], ["Viruses infect lung epithelial cells", "PROBLEM", 16, 52], ["signal plasmacytoid cells", "PROBLEM", 111, 136], ["alveolar macrophages", "PROBLEM", 170, 190], ["chemokines", "TREATMENT", 252, 262], ["cytokine storm", "PROBLEM", 273, 287], ["Viruses", "OBSERVATION", 16, 23], ["lung", "ANATOMY", 31, 35], ["epithelial cells", "OBSERVATION", 36, 52], ["plasmacytoid cells", "OBSERVATION", 118, 136], ["alveolar", "ANATOMY", 170, 178], ["cytokine storm", "OBSERVATION", 273, 287]]], ["Released chemokines attract innate immune inflammatory cells that become activated and release additional chemokines/cytokines to amplify cytokine storm.", [["immune inflammatory cells", "ANATOMY", 35, 60], ["immune inflammatory cells", "CELL", 35, 60], ["chemokines", "PROTEIN", 9, 19], ["innate immune inflammatory cells", "CELL_TYPE", 28, 60], ["chemokines", "PROTEIN", 106, 116], ["cytokines", "PROTEIN", 117, 126], ["cytokine", "PROTEIN", 138, 146], ["immune inflammatory cells", "PROBLEM", 35, 60], ["chemokines/cytokines", "TREATMENT", 106, 126], ["inflammatory cells", "OBSERVATION", 42, 60]]], ["Therapeutic control of cytokine storm: Pulmonary endothelial cells and pDCs contain S1P1 receptors on their surfaces, but S1P1 receptors are absent from lung epithelial cells and alveolar macrophages.", [["Pulmonary endothelial cells", "ANATOMY", 39, 66], ["pDCs", "ANATOMY", 71, 75], ["lung epithelial cells", "ANATOMY", 153, 174], ["alveolar macrophages", "ANATOMY", 179, 199], ["Pulmonary endothelial cells", "CELL", 39, 66], ["pDCs", "CELL", 71, 75], ["S1P1", "GENE_OR_GENE_PRODUCT", 84, 88], ["S1P1", "GENE_OR_GENE_PRODUCT", 122, 126], ["lung epithelial cells", "CELL", 153, 174], ["alveolar macrophages", "CELL", 179, 199], ["cytokine", "PROTEIN", 23, 31], ["Pulmonary endothelial cells", "CELL_TYPE", 39, 66], ["pDCs", "CELL_TYPE", 71, 75], ["S1P1 receptors", "PROTEIN", 84, 98], ["S1P1 receptors", "PROTEIN", 122, 136], ["lung epithelial cells", "CELL_TYPE", 153, 174], ["alveolar macrophages", "CELL_TYPE", 179, 199], ["Pulmonary endothelial cells", "TREATMENT", 39, 66], ["pDCs", "PROBLEM", 71, 75], ["S1P1 receptors", "TREATMENT", 84, 98], ["S1P1 receptors", "TEST", 122, 136], ["cytokine storm", "OBSERVATION", 23, 37], ["Pulmonary", "ANATOMY", 39, 48], ["endothelial cells", "OBSERVATION", 49, 66], ["S1P1 receptors", "OBSERVATION", 84, 98], ["lung", "ANATOMY", 153, 157], ["epithelial cells", "OBSERVATION", 158, 174], ["alveolar macrophages", "OBSERVATION", 179, 199]]], ["The S1P1 receptor agonist signals pulmonary endothelial cells and pDCs likely to release factors that negatively regulate the cytokine storm in terms of both its cytokine/chemokine release and infiltration of innate inflammatory cellsConclusionsCytokine storm plays an essential role in the pathogenesis and clinical outcome of influenza virus infection.", [["pulmonary endothelial cells", "ANATOMY", 34, 61], ["pDCs", "ANATOMY", 66, 70], ["inflammatory cells", "ANATOMY", 216, 234], ["influenza virus infection", "DISEASE", 328, 353], ["S1P1", "GENE_OR_GENE_PRODUCT", 4, 8], ["pulmonary endothelial cells", "CELL", 34, 61], ["pDCs", "CELL", 66, 70], ["inflammatory cells", "CELL", 216, 234], ["Cytokine", "GENE_OR_GENE_PRODUCT", 245, 253], ["influenza virus", "ORGANISM", 328, 343], ["S1P1 receptor", "PROTEIN", 4, 17], ["pulmonary endothelial cells", "CELL_TYPE", 34, 61], ["pDCs", "CELL_TYPE", 66, 70], ["cytokine", "PROTEIN", 126, 134], ["cytokine", "PROTEIN", 162, 170], ["chemokine", "PROTEIN", 171, 180], ["innate inflammatory cells", "CELL_TYPE", 209, 234], ["Cytokine", "PROTEIN", 245, 253], ["influenza virus", "SPECIES", 328, 343], ["influenza virus", "SPECIES", 328, 343], ["pulmonary endothelial cells", "PROBLEM", 34, 61], ["pDCs", "PROBLEM", 66, 70], ["its cytokine/chemokine release", "TREATMENT", 158, 188], ["innate inflammatory cells", "PROBLEM", 209, 234], ["Cytokine storm", "TREATMENT", 245, 259], ["influenza virus infection", "PROBLEM", 328, 353], ["pulmonary", "ANATOMY", 34, 43], ["endothelial cells", "OBSERVATION", 44, 61], ["cytokine storm", "OBSERVATION", 126, 140], ["inflammatory cells", "OBSERVATION", 216, 234]]], ["Blockade of cytokine storm provides greater protection than does antiviral therapy, like that with a neuraminidase inhibitor, and does so without compromising the control and clearance of viruses.", [["cytokine", "PROTEIN", 12, 20], ["Blockade of cytokine storm", "TREATMENT", 0, 26], ["antiviral therapy", "TREATMENT", 65, 82], ["a neuraminidase inhibitor", "TREATMENT", 99, 124], ["viruses", "PROBLEM", 188, 195], ["cytokine storm", "OBSERVATION", 12, 26]]], ["Moreover, optimal therapy is achieved by combining S1P agonists with anti-neuraminidase treatment.", [["S1P", "CHEMICAL", 51, 54], ["anti-neuraminidase", "CHEMICAL", 69, 87], ["S1P", "GENE_OR_GENE_PRODUCT", 51, 54], ["anti-neuraminidase", "SIMPLE_CHEMICAL", 69, 87], ["optimal therapy", "TREATMENT", 10, 25], ["combining S1P agonists", "TREATMENT", 41, 63], ["anti-neuraminidase treatment", "TREATMENT", 69, 97]]], ["For the foregoing observations, human pathogenic H1N1 09 influenza virus and mouse adapted H1N1 influenza virus were used.ConclusionsSphingosine-1-phosphate (S1P) receptor agonists blunt cytokine storm.", [["influenza virus", "DISEASE", 96, 111], ["Sphingosine-1-phosphate", "CHEMICAL", 133, 156], ["S1P", "CHEMICAL", 158, 161], ["Sphingosine-1-phosphate", "CHEMICAL", 133, 156], ["S1P", "CHEMICAL", 158, 161], ["human pathogenic", "ORGANISM", 32, 48], ["H1N1 09 influenza virus", "ORGANISM", 49, 72], ["mouse", "ORGANISM", 77, 82], ["H1N1 influenza virus", "ORGANISM", 91, 111], ["Sphingosine-1-phosphate", "GENE_OR_GENE_PRODUCT", 133, 156], ["S1P", "GENE_OR_GENE_PRODUCT", 158, 161], ["cytokine", "PROTEIN", 187, 195], ["human", "SPECIES", 32, 37], ["H1N1 09 influenza virus", "SPECIES", 49, 72], ["mouse", "SPECIES", 77, 82], ["H1N1 influenza virus", "SPECIES", 91, 111], ["human pathogenic H1N1 09 influenza virus", "SPECIES", 32, 72], ["mouse", "SPECIES", 77, 82], ["H1N1 influenza virus", "SPECIES", 91, 111], ["human pathogenic H1N1", "PROBLEM", 32, 53], ["influenza virus", "PROBLEM", 57, 72], ["mouse adapted H1N1 influenza virus", "TREATMENT", 77, 111], ["Conclusions", "TEST", 122, 133], ["Sphingosine", "TEST", 133, 144], ["phosphate (S1P) receptor agonists", "TREATMENT", 147, 180], ["blunt cytokine storm", "PROBLEM", 181, 201], ["cytokine storm", "OBSERVATION", 187, 201]]], ["Importantly, cytokine storm is chemically disarmed by administering one of the five S1P receptors: S1P1.ConclusionsThe molecular mechanism of this event involves S1P1 receptor signaling on pulmonary endothelial cells and pulmonary pDCs but not virally infected epithelial cells or alveolar macrophages.", [["pulmonary endothelial cells", "ANATOMY", 189, 216], ["pulmonary pDCs", "ANATOMY", 221, 235], ["epithelial cells", "ANATOMY", 261, 277], ["alveolar macrophages", "ANATOMY", 281, 301], ["S1P", "GENE_OR_GENE_PRODUCT", 84, 87], ["S1P1", "GENE_OR_GENE_PRODUCT", 99, 103], ["S1P1 receptor", "GENE_OR_GENE_PRODUCT", 162, 175], ["pulmonary endothelial cells", "CELL", 189, 216], ["pulmonary pDCs", "CELL", 221, 235], ["epithelial cells", "CELL", 261, 277], ["alveolar macrophages", "CELL", 281, 301], ["cytokine", "PROTEIN", 13, 21], ["S1P receptors", "PROTEIN", 84, 97], ["S1P1", "PROTEIN", 99, 103], ["S1P1 receptor", "PROTEIN", 162, 175], ["pulmonary endothelial cells", "CELL_TYPE", 189, 216], ["pulmonary pDCs", "CELL_TYPE", 221, 235], ["virally infected epithelial cells", "CELL_TYPE", 244, 277], ["alveolar macrophages", "CELL_TYPE", 281, 301], ["this event", "PROBLEM", 142, 152], ["pulmonary endothelial cells", "PROBLEM", 189, 216], ["pulmonary pDCs", "PROBLEM", 221, 235], ["virally infected epithelial cells", "PROBLEM", 244, 277], ["alveolar macrophages", "PROBLEM", 281, 301], ["pulmonary endothelial cells", "OBSERVATION", 189, 216], ["pulmonary", "ANATOMY", 221, 230], ["pDCs", "OBSERVATION", 231, 235], ["not", "UNCERTAINTY", 240, 243], ["virally", "OBSERVATION_MODIFIER", 244, 251], ["infected", "OBSERVATION_MODIFIER", 252, 260], ["epithelial cells", "OBSERVATION", 261, 277], ["alveolar macrophages", "OBSERVATION", 281, 301]]], ["Pulmonary endothelial cells are the major gateway combined with pulmonary pDCs to precipitate a cytokine storm.", [["Pulmonary endothelial cells", "ANATOMY", 0, 27], ["pulmonary pDCs", "ANATOMY", 64, 78], ["Pulmonary endothelial cells", "CELL", 0, 27], ["pulmonary pDCs", "CELL", 64, 78], ["Pulmonary endothelial cells", "CELL_TYPE", 0, 27], ["pulmonary pDCs", "CELL_TYPE", 64, 78], ["cytokine", "PROTEIN", 96, 104], ["Pulmonary endothelial cells", "PROBLEM", 0, 27], ["pulmonary pDCs", "PROBLEM", 64, 78], ["a cytokine storm", "PROBLEM", 94, 110], ["endothelial cells", "OBSERVATION", 10, 27], ["pulmonary", "ANATOMY", 64, 73], ["pDCs", "OBSERVATION", 74, 78], ["cytokine storm", "OBSERVATION", 96, 110]]], ["S1P1 agonism suppresses the recruitment of both cytokines, innate and adoptive immune cells.ConclusionsBlunting of innate immune cell function and virus-specific T cell activity lessens morbidity and prevents mortality associated with experimental models of influenza virus infection in mice and ferrets.", [["immune cells", "ANATOMY", 79, 91], ["immune cell", "ANATOMY", 122, 133], ["T cell", "ANATOMY", 162, 168], ["influenza virus infection", "DISEASE", 258, 283], ["S1P1", "GENE_OR_GENE_PRODUCT", 0, 4], ["adoptive immune cells", "CELL", 70, 91], ["immune cell", "CELL", 122, 133], ["T cell", "CELL", 162, 168], ["influenza virus", "ORGANISM", 258, 273], ["mice", "ORGANISM", 287, 291], ["ferrets", "ORGANISM", 296, 303], ["S1P1", "PROTEIN", 0, 4], ["cytokines", "PROTEIN", 48, 57], ["innate and adoptive immune cells", "CELL_TYPE", 59, 91], ["mice", "SPECIES", 287, 291], ["ferrets", "SPECIES", 296, 303], ["influenza virus", "SPECIES", 258, 273], ["mice", "SPECIES", 287, 291], ["ferrets", "SPECIES", 296, 303], ["S1P1 agonism", "TREATMENT", 0, 12], ["both cytokines", "TREATMENT", 43, 57], ["innate and adoptive immune cells", "TREATMENT", 59, 91], ["Blunting of innate immune cell function", "PROBLEM", 103, 142], ["virus", "PROBLEM", 147, 152], ["specific T cell activity lessens morbidity", "PROBLEM", 153, 195], ["influenza virus infection", "PROBLEM", 258, 283], ["recruitment", "OBSERVATION_MODIFIER", 28, 39], ["Blunting", "OBSERVATION_MODIFIER", 103, 111], ["innate immune cell function", "OBSERVATION", 115, 142], ["influenza virus", "OBSERVATION", 258, 273]]], ["In both species, there is a sufficient antiviral response remaining to terminate the virus infection and provide immune memory upon rechallenge.ConclusionsImmune cell infiltration and cytokine production are distinct events, but both are orchestrated by endothelial and pDC cells.", [["ConclusionsImmune cell", "ANATOMY", 144, 166], ["endothelial", "ANATOMY", 254, 265], ["pDC cells", "ANATOMY", 270, 279], ["infection", "DISEASE", 91, 100], ["ConclusionsImmune cell", "CELL", 144, 166], ["endothelial", "CELL", 254, 265], ["pDC cells", "CELL", 270, 279], ["cytokine", "PROTEIN", 184, 192], ["endothelial and pDC cells", "CELL_TYPE", 254, 279], ["the virus infection", "PROBLEM", 81, 100], ["ConclusionsImmune cell infiltration", "PROBLEM", 144, 179], ["cytokine production", "PROBLEM", 184, 203], ["distinct events", "PROBLEM", 208, 223], ["both species", "OBSERVATION", 3, 15], ["antiviral response", "OBSERVATION", 39, 57], ["virus", "OBSERVATION_MODIFIER", 85, 90], ["infection", "OBSERVATION", 91, 100], ["cell infiltration", "OBSERVATION", 162, 179], ["cytokine production", "OBSERVATION", 184, 203], ["endothelial", "ANATOMY", 254, 265], ["pDC cells", "OBSERVATION", 270, 279]]], ["Pro-inflammatory cytokine responses depend on type I interferon signaling; IFN-a is the predominant interferon made.", [["type I interferon", "GENE_OR_GENE_PRODUCT", 46, 63], ["IFN", "GENE_OR_GENE_PRODUCT", 75, 78], ["interferon", "GENE_OR_GENE_PRODUCT", 100, 110], ["Pro-inflammatory cytokine", "PROTEIN", 0, 25], ["IFN", "PROTEIN", 75, 78], ["interferon", "PROTEIN", 100, 110], ["Pro-inflammatory cytokine responses", "PROBLEM", 0, 35], ["type I interferon signaling", "PROBLEM", 46, 73]]], ["The predominant pulmonary cell making type I interferon is the pDC (over 75-85 %); alveolar macrophages make most of the rest.Future Studies1.", [["pulmonary cell", "ANATOMY", 16, 30], ["pDC", "ANATOMY", 63, 66], ["alveolar macrophages", "ANATOMY", 83, 103], ["pulmonary cell", "CELL", 16, 30], ["type I interferon", "GENE_OR_GENE_PRODUCT", 38, 55], ["pDC", "CELL", 63, 66], ["alveolar macrophages", "CELL", 83, 103], ["I interferon", "PROTEIN", 43, 55], ["pDC", "CELL_TYPE", 63, 66], ["alveolar macrophages", "CELL_TYPE", 83, 103], ["The predominant pulmonary cell", "PROBLEM", 0, 30], ["type I interferon", "TREATMENT", 38, 55], ["alveolar macrophages", "PROBLEM", 83, 103], ["Future Studies1", "TEST", 126, 141], ["predominant", "OBSERVATION_MODIFIER", 4, 15], ["pulmonary", "ANATOMY", 16, 25], ["cell", "OBSERVATION", 26, 30], ["alveolar", "ANATOMY", 83, 91], ["macrophages", "OBSERVATION", 92, 103]]], ["Investigate interferon I as to the cellular source and signaling pathway(s) in the influenza system.", [["cellular", "ANATOMY", 35, 43], ["influenza", "DISEASE", 83, 92], ["interferon I", "GENE_OR_GENE_PRODUCT", 12, 24], ["cellular", "CELL", 35, 43], ["interferon I", "PROTEIN", 12, 24], ["signaling pathway(s) in the influenza system", "PROBLEM", 55, 99], ["influenza system", "ANATOMY", 83, 99]]], ["Dissect crosstalk and signaling between pulmonary endothelial cells, infected epithelial cells, and interferon-producing pDCs.", [["pulmonary endothelial cells", "ANATOMY", 40, 67], ["epithelial cells", "ANATOMY", 78, 94], ["pDCs", "ANATOMY", 121, 125], ["pulmonary endothelial cells", "CELL", 40, 67], ["epithelial cells", "CELL", 78, 94], ["interferon", "GENE_OR_GENE_PRODUCT", 100, 110], ["pDCs", "CELL", 121, 125], ["pulmonary endothelial cells", "CELL_TYPE", 40, 67], ["infected epithelial cells", "CELL_TYPE", 69, 94], ["interferon-producing pDCs", "CELL_TYPE", 100, 125], ["signaling between pulmonary endothelial cells", "PROBLEM", 22, 67], ["infected epithelial cells", "PROBLEM", 69, 94], ["interferon", "TREATMENT", 100, 110], ["pDCs", "PROBLEM", 121, 125], ["pulmonary endothelial", "ANATOMY", 40, 61], ["cells", "OBSERVATION", 62, 67], ["infected epithelial cells", "OBSERVATION", 69, 94]]], ["Identify the molecules involved.", [["molecules", "OBSERVATION", 13, 22]]], ["Determine generalities for other acute respiratory infections, e.g., Hantavirus, respiratory syncytial virus, SARS, pneumococcal pneumonia, in which cytokine storm plays a prominent role.", [["respiratory", "ANATOMY", 39, 50], ["respiratory infections", "DISEASE", 39, 61], ["Hantavirus", "DISEASE", 69, 79], ["respiratory syncytial virus", "DISEASE", 81, 108], ["SARS", "DISEASE", 110, 114], ["pneumococcal pneumonia", "DISEASE", 116, 138], ["respiratory syncytial virus", "ORGANISM", 81, 108], ["cytokine", "PROTEIN", 149, 157], ["respiratory syncytial virus", "SPECIES", 81, 108], ["respiratory syncytial virus", "SPECIES", 81, 108], ["pneumococcal", "SPECIES", 116, 128], ["other acute respiratory infections", "PROBLEM", 27, 61], ["Hantavirus", "PROBLEM", 69, 79], ["respiratory syncytial virus", "PROBLEM", 81, 108], ["SARS", "PROBLEM", 110, 114], ["pneumococcal pneumonia", "PROBLEM", 116, 138], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory", "ANATOMY", 39, 50], ["infections", "OBSERVATION", 51, 61], ["respiratory syncytial", "ANATOMY", 81, 102], ["pneumococcal", "OBSERVATION_MODIFIER", 116, 128], ["pneumonia", "OBSERVATION", 129, 138], ["prominent", "OBSERVATION_MODIFIER", 172, 181]]], ["Study an animal model (subhuman primates) more reflective of influenza in humans.", [["influenza", "DISEASE", 61, 70], ["primates", "ORGANISM", 32, 40], ["humans", "ORGANISM", 74, 80], ["humans", "SPECIES", 74, 80], ["humans", "SPECIES", 74, 80], ["Study", "TEST", 0, 5], ["influenza", "PROBLEM", 61, 70], ["influenza", "OBSERVATION", 61, 70]]], ["Results from our studies in ferrets (Teijaro et al. 2013 ) mirror the protection supplied by S1P1 agonist therapy in defending against influenza virus infection in the murine model.", [["influenza virus infection", "DISEASE", 135, 160], ["ferrets", "ORGANISM", 28, 35], ["S1P1", "GENE_OR_GENE_PRODUCT", 93, 97], ["influenza virus", "ORGANISM", 135, 150], ["murine", "ORGANISM", 168, 174], ["S1P1", "PROTEIN", 93, 97], ["ferrets", "SPECIES", 28, 35], ["influenza virus", "SPECIES", 135, 150], ["murine", "SPECIES", 168, 174], ["influenza virus", "SPECIES", 135, 150], ["our studies", "TEST", 13, 24], ["mirror the protection", "TREATMENT", 59, 80], ["S1P1 agonist therapy", "TREATMENT", 93, 113], ["influenza virus infection", "PROBLEM", 135, 160]]], ["Define the S1P pathway and design a genetic screen to identify humans who are the most susceptible to cytokine storm.", [["S1P", "GENE_OR_GENE_PRODUCT", 11, 14], ["humans", "ORGANISM", 63, 69], ["cytokine", "PROTEIN", 102, 110], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 63, 69], ["a genetic screen", "TEST", 34, 50]]], ["Develop specific S1P receptor agonists and antagonists for human therapeutics, focusing initially on S1P1 molecules.", [["S1P receptor", "GENE_OR_GENE_PRODUCT", 17, 29], ["human", "ORGANISM", 59, 64], ["S1P1", "GENE_OR_GENE_PRODUCT", 101, 105], ["S1P1 molecules", "PROTEIN", 101, 115], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["specific S1P receptor agonists", "TREATMENT", 8, 38], ["antagonists", "TREATMENT", 43, 54], ["human therapeutics", "TREATMENT", 59, 77], ["S1P1 molecules", "TREATMENT", 101, 115]]]], "d736741d156bcac7f75cd375e65c6ba2a0b6a434": [["Since March 2020, the world is facing COVID-19 pandemic.", [["pandemic", "PROBLEM", 47, 55]]], ["So far, to treat patients needing life support has been the main concern.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["life support", "TREATMENT", 34, 46]]], ["After the recovery from COVID-19, the infection and the long hospitalization period can lead to medium-or long-term outcomes, such as muscle strength and cardiorespiratory performance reduction, neuropathy, and other possible post-infectious neurological syndromes as Guillain-Barr\u00e8 syndrome (Baig et al. 2020; Sedaghat and Karimi 2020) , residual immune imbalance (Wang et al. 2020) , anxiety, depression, post-traumatic stress, or cognitive disorders (Talan 2020) , all requiring appropriate therapeutic intervention also after the discharge from hospital.", [["muscle", "ANATOMY", 134, 140], ["neurological", "ANATOMY", 242, 254], ["infection", "DISEASE", 38, 47], ["neuropathy", "DISEASE", 195, 205], ["neurological syndromes", "DISEASE", 242, 264], ["Guillain-Barr\u00e8 syndrome", "DISEASE", 268, 291], ["immune imbalance", "DISEASE", 348, 364], ["anxiety", "DISEASE", 386, 393], ["depression", "DISEASE", 395, 405], ["traumatic stress", "DISEASE", 412, 428], ["cognitive disorders", "DISEASE", 433, 452], ["muscle", "ORGAN", 134, 140], ["COVID", "TEST", 24, 29], ["the infection", "PROBLEM", 34, 47], ["long-term outcomes", "PROBLEM", 106, 124], ["muscle strength", "PROBLEM", 134, 149], ["cardiorespiratory performance reduction", "TREATMENT", 154, 193], ["neuropathy", "PROBLEM", 195, 205], ["post-infectious neurological syndromes", "PROBLEM", 226, 264], ["Barr\u00e8 syndrome", "PROBLEM", 277, 291], ["Sedaghat and Karimi", "TREATMENT", 311, 330], ["residual immune imbalance", "PROBLEM", 339, 364], ["anxiety", "PROBLEM", 386, 393], ["depression", "PROBLEM", 395, 405], ["post-traumatic stress", "PROBLEM", 407, 428], ["cognitive disorders", "PROBLEM", 433, 452], ["appropriate therapeutic intervention", "TREATMENT", 482, 518], ["infection", "OBSERVATION", 38, 47], ["muscle", "ANATOMY", 134, 140], ["neuropathy", "OBSERVATION", 195, 205], ["infectious", "OBSERVATION_MODIFIER", 231, 241], ["immune imbalance", "OBSERVATION", 348, 364], ["traumatic stress", "OBSERVATION", 412, 428]]], ["Considering the high number of patients who develops a severe form of the infection (Jin et al. 2020) , many subjects require a rehabilitative intervention after the discharge, practicable after patients tested negative for COVID-19.", [["infection", "DISEASE", 74, 83], ["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 195, 203], ["the infection", "PROBLEM", 70, 83], ["a rehabilitative intervention", "TREATMENT", 126, 155], ["COVID", "TEST", 224, 229], ["high number", "OBSERVATION_MODIFIER", 16, 27], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["infection", "OBSERVATION", 74, 83]]], ["Unfortunately, there are no specific structures offering a comprehensive treatment to these subjects, even if it is important to start a multidisciplinary rehabilitation program as soon as possible (Grabowski and Joynt Maddox 2020) , in order to contain the infection outcomes and the residual disabilities, in particular in subjects having multiple comorbidities such as advanced age, chronic diseases, and obesity.", [["infection", "DISEASE", 258, 267], ["chronic diseases", "DISEASE", 386, 402], ["obesity", "DISEASE", 408, 415], ["a multidisciplinary rehabilitation program", "TREATMENT", 135, 177], ["the infection outcomes", "PROBLEM", 254, 276], ["the residual disabilities", "PROBLEM", 281, 306], ["multiple comorbidities", "PROBLEM", 341, 363], ["chronic diseases", "PROBLEM", 386, 402], ["obesity", "PROBLEM", 408, 415], ["no", "UNCERTAINTY", 25, 27], ["infection", "OBSERVATION", 258, 267], ["chronic", "OBSERVATION_MODIFIER", 386, 393], ["diseases", "OBSERVATION", 394, 402], ["obesity", "OBSERVATION", 408, 415]]], ["To face the novelty of this health emergency, it is necessary to propose to the healthcare systems innovative, suitable, and accessible models of therapy.", [["therapy", "TREATMENT", 146, 153]]], ["Hence, our proposal for an innovative post-hospitalization rehabilitative treatment, taking advantage of health resort medicine as suitable setting to take care of discharged subjects tested negative for COVID-19.", [["COVID-19", "CHEMICAL", 204, 212], ["an innovative post-hospitalization rehabilitative treatment", "TREATMENT", 24, 83], ["health resort medicine", "TREATMENT", 105, 127], ["COVID", "TEST", 204, 209]]], ["Core elements of interventions in health resorts are balneotherapy, hydrotherapy, and climatotherapy in combination with other rehabilitation strategies (Gutenbrunner et al. 2010) .", [["balneotherapy", "TREATMENT", 53, 66], ["hydrotherapy", "TREATMENT", 68, 80], ["climatotherapy", "TREATMENT", 86, 100], ["other rehabilitation strategies", "TREATMENT", 121, 152], ["elements", "OBSERVATION_MODIFIER", 5, 13]]], ["Rehabilitation strategies in health resort medicine may include therapeutic massage, water massage, physical modalities, numerous forms of exercise such as water exercise, breathing, balance, and muscle-strengthening exercises, health education, psychological interventions, and treatments complementary to balneotherapy (Masiero et al. 2019b ).", [["muscle", "ANATOMY", 196, 202], ["muscle", "ORGAN", 196, 202], ["Rehabilitation strategies", "TREATMENT", 0, 25], ["therapeutic massage", "TREATMENT", 64, 83], ["water massage", "TREATMENT", 85, 98], ["physical modalities", "TREATMENT", 100, 119], ["health education", "TREATMENT", 228, 244], ["psychological interventions", "TREATMENT", 246, 273], ["treatments", "TREATMENT", 279, 289], ["balneotherapy", "TREATMENT", 307, 320], ["muscle", "ANATOMY", 196, 202]]], ["These procedures can represent a therapeutic opportunity to treat neuro-musculoskeletal and cardiorespiratory outcomes as well as to recover mental health and psychosocial disabilities in post COVID-19 subjects.", [["neuro-musculoskeletal", "ANATOMY", 66, 87], ["psychosocial disabilities", "DISEASE", 159, 184], ["These procedures", "TREATMENT", 0, 16], ["neuro-musculoskeletal and cardiorespiratory outcomes", "PROBLEM", 66, 118]]], ["The main goals of the rehabilitation treatment in post COVID-19 subjects discharged from hospital should be indeed individually tailored to the recovery from muscular disorders and neurological deficits, the cardiorespiratory reconditioning, the improvement in cognitive symptoms, and the education to a healthy lifestyle.", [["muscular", "ANATOMY", 158, 166], ["neurological", "ANATOMY", 181, 193], ["muscular disorders", "DISEASE", 158, 176], ["neurological deficits", "DISEASE", 181, 202], ["muscular", "ORGAN", 158, 166], ["the rehabilitation treatment", "TREATMENT", 18, 46], ["muscular disorders", "PROBLEM", 158, 176], ["neurological deficits", "PROBLEM", 181, 202], ["the cardiorespiratory reconditioning", "TREATMENT", 204, 240], ["cognitive symptoms", "PROBLEM", 261, 279], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["In addition, it may be necessary to treat a n y a s s o ci a t e d c o m o r bi d i t i e s ( e. g . , o b es i t y a n d osteoarthritis).", [["osteoarthritis", "DISEASE", 122, 136], ["e. g", "TEST", 94, 98], ["a n d osteoarthritis)", "PROBLEM", 116, 137], ["osteoarthritis", "OBSERVATION", 122, 136]]]], "c09cb225accff22b63d79186069028bcbd2822f2": [["IntroductionThe discovery and synthesis of the immobile DNA junction by Seeman, nearly 4 decades ago 1 , emerged as a cornerstone of DNA nanotechnology, an expanding field with unique technological potential.", [["DNA", "CELLULAR_COMPONENT", 56, 59], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["synthesis of the immobile DNA junction", "TREATMENT", 30, 68], ["DNA nanotechnology", "TREATMENT", 133, 151]]], ["The immobile junction enabled, for the first time, programming and control of the spatial positioning of matter at a single DNA base resolution, or approximately 3.5 \u212b 2-4 .", [["DNA", "CELLULAR_COMPONENT", 124, 127], ["The immobile junction", "TREATMENT", 0, 21], ["immobile", "OBSERVATION_MODIFIER", 4, 12], ["junction", "OBSERVATION", 13, 21], ["resolution", "OBSERVATION_MODIFIER", 133, 143]]], ["This discovery was followed by a range of works which explored various geometries, scales, construction methods, application, and behaviors [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .IntroductionThe term DNA nanotechnology could be used to define a more loose group of phenomena and applications, based on nucleic acid functions beyond the context of carrying and manipulating genetic information, both artificial and naturally occurring.", [["[5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18]", "CHEMICAL", 140, 204], ["[5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 140, 204], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["The term DNA nanotechnology", "TREATMENT", 218, 245], ["a more loose group of phenomena", "PROBLEM", 270, 301], ["nucleic acid functions", "TEST", 329, 351]]], ["Some of these functions are molecular computation [19] [20] [21] , ribo-and deoxyribozymes [22] [23] [24] [25] [26] ; aptamers 27,28 ; and toehold-mediated strand displacement reactions 29-32 .", [["[19] [20] [21] , ribo-and deoxyribozymes", "CHEMICAL", 50, 90], ["[19] [20] [21]", "SIMPLE_CHEMICAL", 50, 64], ["ribo-", "SIMPLE_CHEMICAL", 67, 72], ["deoxyribozymes [22] [23] [24] [25] [26]", "SIMPLE_CHEMICAL", 76, 115], ["toehold", "SIMPLE_CHEMICAL", 139, 146], ["ribo", "TEST", 67, 71], ["deoxyribozymes", "TEST", 76, 90], ["aptamers", "TEST", 118, 126], ["toehold", "TEST", 139, 146], ["strand displacement reactions", "TEST", 156, 185]]], ["Such systems have been recently implemented in combination in several of the works referenced above in order to obtain complex functions and high level of logical control.", [["logical control", "TREATMENT", 155, 170]]], ["Of particular impact in this progress has been the existence of high-quality computer-aided design (CAD) tools to program, simulate, and reliably analyze these systems [33] [34] [35] [36] [37] .IntroductionThe ability to integrate various aspects of DNA nanotechnology in simple and relatively-tractable designs has highlighted a fascinating and long-standing aim -the design and fabrication of nanoscale robots, an achievement envisioned by prominent 20th century thinkers like Richard Feynman, John Von Neumann, and Isaac Asimov 38-41 .", [["[33] [34] [35] [36]", "CHEMICAL", 168, 187], ["[33] [34] [35] [36] [37]", "SIMPLE_CHEMICAL", 168, 192], ["DNA", "CELLULAR_COMPONENT", 250, 253], ["aided design (CAD) tools", "PROBLEM", 86, 110], ["DNA nanotechnology", "TREATMENT", 250, 268], ["fabrication of nanoscale robots", "TREATMENT", 380, 411]]], ["Indeed, several diverse designs of true robots -defined here as automata which are capable of sensing environmental cues and responding by actuation, and are guided by a non-random set of rules or logic -based on DNA, have been recently described [42] [43] [44] [45] [46] [47] [48] [49] [50] .", [["[42] [43] [44] [45] [46] [47] [48] [49]", "CHEMICAL", 247, 286], ["DNA", "CELLULAR_COMPONENT", 213, 216], ["[42] [43] [44] [45] [46] [47] [48] [49] [50]", "SIMPLE_CHEMICAL", 247, 291], ["several", "OBSERVATION_MODIFIER", 8, 15], ["diverse", "OBSERVATION_MODIFIER", 16, 23], ["true robots", "OBSERVATION", 35, 46]]], ["DNA-based molecular machines offer a unique approach to challenges in domains such as manufacturing and medicine, which would be extremely hard or even impossible to tackle by conventional macroscopic or chemical means.IntroductionPerhaps the most remarkable property of such machines could be the ability to self-replicate.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "PROBLEM", 0, 3], ["a unique approach", "TREATMENT", 35, 52], ["medicine", "TREATMENT", 104, 112], ["IntroductionPerhaps", "TREATMENT", 219, 238], ["such machines", "TREATMENT", 271, 284]]], ["A hallmark of living organisms, self-replication has been synthetically emulated in several systems and scales 51, 52 , with some successful designs stemming directly from DNA nanotechnology [53] [54] [55] .", [["DNA", "CELLULAR_COMPONENT", 172, 175], ["A hallmark of living organisms", "PROBLEM", 0, 30], ["scales", "TEST", 104, 110]]], ["The construction of self-replicating agents with direct application in a realistic setting is highly desired and has been explored in the past [56] [57] [58] .", [["self-replicating agents", "TREATMENT", 20, 43], ["direct application", "TREATMENT", 49, 67]]], ["A particular field in which self replication could provide a crucial advantage over existing solutions is therapeutics, especially against replicating and evolving targets such as viruses, bacteria, and tumor cells.IntroductionConventional drugs are typically administered constantly until the pathogen is either eliminated or becomes resistant.", [["tumor cells", "ANATOMY", 203, 214], ["tumor", "DISEASE", 203, 208], ["tumor cells", "CELL", 203, 214], ["tumor cells", "CELL_TYPE", 203, 214], ["self replication", "TREATMENT", 28, 44], ["a crucial advantage over existing solutions", "TREATMENT", 59, 102], ["therapeutics", "TREATMENT", 106, 118], ["viruses", "PROBLEM", 180, 187], ["bacteria", "PROBLEM", 189, 197], ["tumor cells", "PROBLEM", 203, 214], ["IntroductionConventional drugs", "TREATMENT", 215, 245], ["the pathogen", "PROBLEM", 290, 302], ["tumor cells", "OBSERVATION", 203, 214]]], ["On the other hand, self-replicating therapeutics could be administered at extremely low starting doses, or high doses of raw, inactive building blocks, and then replicate.IntroductionThus, they could track the target population until its elimination, and eventually be cleared from the system.", [["inactive building blocks", "TREATMENT", 126, 150]]], ["Existing examples of self-replicating therapeutics include oncolytic viruses 59 and RNA vaccines 60 , although the latter is essentially a delivery system for vaccines rather than a self-replicating therapeutic agent.", [["oncolytic viruses 59", "ORGANISM", 59, 79], ["self-replicating therapeutics", "TREATMENT", 21, 50], ["oncolytic viruses", "TREATMENT", 59, 76], ["RNA vaccines", "TREATMENT", 84, 96], ["a delivery system", "TREATMENT", 137, 154], ["vaccines", "TREATMENT", 159, 167], ["a self-replicating therapeutic agent", "TREATMENT", 180, 216]]], ["Both examples are modified versions of natural viruses.", [["natural viruses", "PROBLEM", 39, 54], ["natural viruses", "OBSERVATION", 39, 54]]], ["The ability to design an entirely synthetic, self-replicating therapeutic machine remains a significant technological challenge.IntroductionIn this work, a preliminary working prototype of such a system is reported.", [["a significant technological challenge", "TREATMENT", 90, 127]]], ["We describe a machine, or automaton, assembled from DNA and RNA, which incorporates structural and functional principles of DNA nanotechnology.", [["DNA", "CELLULAR_COMPONENT", 52, 55], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["DNA and RNA", "PROBLEM", 52, 63], ["DNA nanotechnology", "TREATMENT", 124, 142]]], ["The automaton is designed as an immobile, DNA:RNA 4-way junction assembled from 3 parts, and contains a single gene which encodes a hammerhead ribozyme (HHR).", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["hammerhead ribozyme", "PROTEIN", 132, 151], ["HHR", "PROTEIN", 153, 156], ["a hammerhead ribozyme", "TREATMENT", 130, 151], ["immobile", "OBSERVATION", 32, 40], ["hammerhead ribozyme", "OBSERVATION", 132, 151]]], ["Full assembly of the automaton's body from its parts enables the subsequent transcription of HHR molecules and HHR-mediated digestion of the target molecule.IntroductionThis digestion renders the target suitable for participation in the assembly of more copies of the automaton, essentially mimicking biological heterotrophy.", [["body", "ANATOMY", 33, 37], ["body", "ORGANISM_SUBDIVISION", 33, 37], ["HHR molecules", "GENE_OR_GENE_PRODUCT", 93, 106], ["HHR", "SIMPLE_CHEMICAL", 111, 114], ["HHR molecules", "PROTEIN", 93, 106], ["HHR", "PROTEIN", 111, 114], ["HHR molecules", "PROBLEM", 93, 106], ["HHR", "TEST", 111, 114], ["This digestion", "TREATMENT", 169, 183], ["essentially mimicking biological heterotrophy", "PROBLEM", 279, 324], ["target molecule", "OBSERVATION", 141, 156], ["biological heterotrophy", "OBSERVATION", 301, 324]]], ["The starting material for self-replication, and for the subsequent \"lifecycle\" of the automaton, is a small seed population of fully-assembled machines, and a non-limiting amount of the separate DNA parts required for the assembly of new copies of the machine.IntroductionThe automaton we describe here was inspired by pathogenic viruses and viroids, and is designed to be delivered into and operate inside living, virus-infected cells.", [["cells", "ANATOMY", 430, 435], ["DNA", "CELLULAR_COMPONENT", 195, 198], ["cells", "CELL", 430, 435], ["virus-infected cells", "CELL_TYPE", 415, 435], ["self-replication", "TREATMENT", 26, 42], ["the separate DNA parts", "TREATMENT", 182, 204], ["the machine", "TREATMENT", 248, 259], ["pathogenic viruses", "PROBLEM", 319, 337], ["viroids", "TREATMENT", 342, 349], ["infected cells", "PROBLEM", 421, 435], ["small", "OBSERVATION_MODIFIER", 102, 107], ["seed", "OBSERVATION_MODIFIER", 108, 112], ["viruses", "OBSERVATION", 330, 337], ["infected cells", "OBSERVATION", 421, 435]]], ["Inside the cells, the automaton's goal is to counter viral infection by utilizing viral RNA as \"food\".", [["cells", "ANATOMY", 11, 16], ["infection", "DISEASE", 59, 68], ["cells", "CELL", 11, 16], ["viral RNA", "RNA", 82, 91], ["viral infection", "PROBLEM", 53, 68], ["cells", "ANATOMY", 11, 16], ["infection", "OBSERVATION", 59, 68]]], ["As a proof of principle towards therapeutic application, we designed an automaton that targets Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV) RNA, characterized its assembly chemistry and activity in-vitro , and calibrated the precise stoichiometric packaging of its parts, along with the enzymatic machinery required for HHR transcription from this particular machine design, into therapeutically-compatible formulations.", [["Autographa californica", "ORGANISM", 95, 117], ["multicapsid nucleopolyhedrovirus", "ORGANISM", 118, 150], ["AcMNPV", "ORGANISM", 152, 158], ["multicapsid nucleopolyhedrovirus (AcMNPV) RNA", "RNA", 118, 163], ["HHR", "PROTEIN", 340, 343], ["Autographa californica", "SPECIES", 95, 117], ["Autographa californica multicapsid nucleopolyhedrovirus", "SPECIES", 95, 150], ["AcMNPV", "SPECIES", 152, 158], ["therapeutic application", "TREATMENT", 32, 55], ["Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV) RNA", "TREATMENT", 95, 163], ["the enzymatic machinery", "TREATMENT", 303, 326], ["HHR transcription", "TREATMENT", 340, 357]]], ["This machine effectively suppressed virus ability to create infective virions in AcMNPV-infected cells, exhibiting predator/prey dynamics with the infecting virus.", [["virions", "ANATOMY", 70, 77], ["cells", "ANATOMY", 97, 102], ["AcMNPV", "ORGANISM", 81, 87], ["cells", "CELL", 97, 102], ["infected cells", "CELL_TYPE", 88, 102], ["AcMNPV", "SPECIES", 81, 87], ["infective virions", "PROBLEM", 60, 77], ["AcMNPV", "PROBLEM", 81, 87], ["infected cells", "PROBLEM", 88, 102], ["the infecting virus", "PROBLEM", 143, 162], ["infective virions", "OBSERVATION", 60, 77], ["infected cells", "OBSERVATION", 88, 102], ["infecting virus", "OBSERVATION", 147, 162]]], ["Moreover, it significantly reduced viral infection in terms of potent virions titer, as well as rate of infection spreading, stress signaling, and innate immune activation inside AcMNPV-infected adult insects.IntroductionThe design reported here is modular, and can be adapted rapidly to counter new targets, for example viruses once their genome has been sequenced.", [["viral infection", "DISEASE", 35, 50], ["infection", "DISEASE", 104, 113], ["AcMNPV", "ORGANISM", 179, 185], ["adult insects", "ORGANISM", 195, 208], ["AcMNPV", "SPECIES", 179, 185], ["viral infection", "PROBLEM", 35, 50], ["potent virions titer", "PROBLEM", 63, 83], ["infection spreading", "PROBLEM", 104, 123], ["stress signaling", "PROBLEM", 125, 141], ["example viruses", "PROBLEM", 313, 328], ["significantly", "OBSERVATION_MODIFIER", 13, 26], ["reduced", "OBSERVATION_MODIFIER", 27, 34], ["viral", "OBSERVATION_MODIFIER", 35, 40], ["infection", "OBSERVATION", 41, 50], ["potent", "OBSERVATION_MODIFIER", 63, 69], ["virions titer", "OBSERVATION", 70, 83], ["infection", "OBSERVATION", 104, 113], ["infected", "OBSERVATION_MODIFIER", 186, 194], ["modular", "OBSERVATION_MODIFIER", 249, 256]]], ["In addition, it could lead to new types of biologically-inspired, programmable agents for a range of therapeutic applications.IntroductionInterestingly, this machine highlights complex anatomy and a hypothetical, rudimentary mechanism for predation, plausible features of molecular life forms from the RNA world.", [["programmable agents", "TREATMENT", 66, 85], ["therapeutic applications", "TREATMENT", 101, 125]]], ["In this schematic, R is depicted as consisting of two subunits, but in reality R is a single part formed from a variety of possible target molecules, as shown and discussed below.", [["target molecules", "PROTEIN", 132, 148]]], ["Fully assembled automata were visualized by atomic force microscopy (AFM) using DNA origami rectangles as reference objects (Fig. 1C, Supplementary note 3, Fig. S7 ) .", [["DNA", "CELLULAR_COMPONENT", 80, 83], ["DNA origami rectangles", "DNA", 80, 102], ["atomic force microscopy", "TEST", 44, 67], ["DNA origami rectangles", "TREATMENT", 80, 102], ["automata", "OBSERVATION", 16, 24]]], ["Complete automaton assembly occurs on the order of 1 h (Fig. 1D) .", [["automaton", "OBSERVATION", 9, 18]]], ["The assembly reaction correlated with stoichiometry of parts L, S, and R, and at a 1:1:1 stoichiometry was measured to be 63\u00b110% (Fig. 1E ) .", [["a 1:1:1 stoichiometry", "TEST", 81, 102]]], ["Automata were stable on the shelf for at least 29 days (Supplementary note 1, Fig. S3 ) .IntroductionUpon assembly of the automaton, part S undergoes elongation by DNA polymerase, using L as template ( Fig. 2A, 2B) , creating a dsDNA region which functions as a gene controlled by the T7 promoter and encodes a hammerhead ribozyme (HHR).", [["DNA", "CELLULAR_COMPONENT", 164, 167], ["T7", "GENE_OR_GENE_PRODUCT", 285, 287], ["HHR", "GENE_OR_GENE_PRODUCT", 332, 335], ["S", "DNA", 138, 139], ["DNA polymerase", "PROTEIN", 164, 178], ["dsDNA region", "DNA", 228, 240], ["T7 promoter", "DNA", 285, 296], ["hammerhead ribozyme", "PROTEIN", 311, 330], ["HHR", "PROTEIN", 332, 335], ["DNA polymerase", "TEST", 164, 178], ["a dsDNA region", "PROBLEM", 226, 240], ["the T7 promoter", "TREATMENT", 281, 296], ["a hammerhead ribozyme", "TREATMENT", 309, 330], ["stable", "OBSERVATION_MODIFIER", 14, 20], ["dsDNA", "OBSERVATION", 228, 233]]], ["T7 RNA polymerase next transcribes the gene to synthesize HHR molecules (Fig. S8 ) which digests a specific RNA target.IntroductionDigestion of this target molecule is the key driver of automaton self-replication.", [["HHR", "GENE_OR_GENE_PRODUCT", 58, 61], ["Fig. S8", "GENE_OR_GENE_PRODUCT", 73, 80], ["T7 RNA polymerase", "PROTEIN", 0, 17], ["HHR molecules", "PROTEIN", 58, 71], ["Fig. S8", "PROTEIN", 73, 80], ["T7 RNA polymerase", "TEST", 0, 17]]], ["It is essentially a metabolic reaction that converts the target molecule into a building block capable of participating in the assembly of additional copies of the automaton from its parts L and S. This mechanism is analogous to biological heterotrophy, which is defined as the nutritional type that utilizes an exogenous source of carbon as food 61 .", [["carbon", "CHEMICAL", 332, 338], ["carbon", "SIMPLE_CHEMICAL", 332, 338], ["a metabolic reaction", "PROBLEM", 18, 38], ["biological heterotrophy", "PROBLEM", 229, 252], ["metabolic reaction", "OBSERVATION", 20, 38], ["heterotrophy", "OBSERVATION", 240, 252]]], ["For this reason, we designed a specific RNA target composed of a ubiquitous structural stem-loop motif, such that digestion converts the molecule from a stem-loop structure into a stem with two open ends, which comprises the part designated as R (Fig. 2C) .", [["stem", "ANATOMY", 180, 184], ["ubiquitous structural stem-loop motif", "PROTEIN", 65, 102], ["stem-loop structure", "PROTEIN", 153, 172], ["a ubiquitous structural stem-loop motif", "TREATMENT", 63, 102], ["digestion", "PROBLEM", 114, 123], ["two open ends", "TREATMENT", 190, 203], ["stem", "ANATOMY", 153, 157], ["loop structure", "OBSERVATION", 158, 172], ["stem", "ANATOMY_MODIFIER", 180, 184], ["open", "OBSERVATION_MODIFIER", 194, 198], ["ends", "OBSERVATION_MODIFIER", 199, 203]]], ["We used ribosoft 62 in the design of HHR molecules specific to target RNA (Fig. 2D) .", [["ribosoft 62", "PROTEIN", 8, 19], ["HHR molecules", "PROTEIN", 37, 50], ["target RNA", "RNA", 63, 73], ["ribosoft", "TREATMENT", 8, 16], ["HHR molecules", "PROBLEM", 37, 50]]], ["Binding of HHR to its target is mediated by Watson-Crick pairing via two separate regions of the HHR as previously described 62 .", [["HHR", "GENE_OR_GENE_PRODUCT", 11, 14], ["HHR", "PROTEIN", 11, 14], ["HHR", "DNA", 97, 100]]], ["Various loop sizes within the target RNA motif were tested to highlight an optimal structure that enables efficient HHR activity without supporting an L-S interaction without digestion.", [["L-S", "CHEMICAL", 151, 154], ["target RNA motif", "DNA", 30, 46], ["HHR", "PROTEIN", 116, 119], ["Various loop sizes", "TREATMENT", 0, 18], ["digestion", "PROBLEM", 175, 184], ["loop", "OBSERVATION_MODIFIER", 8, 12], ["sizes", "OBSERVATION_MODIFIER", 13, 18], ["target", "OBSERVATION_MODIFIER", 30, 36], ["RNA motif", "OBSERVATION", 37, 46]]], ["A length allowing 8 nt in addition to the regions complementary to L and S was found to represent this optimum (Fig. 2E ) .", [["L and S", "DNA", 67, 74]]], ["In the present design, a single automaton synthesized HHR molecules at a rate of approximately 30 molecules/h (Fig. 2F, 2G) .", [["HHR molecules", "PROTEIN", 54, 67]]], ["The transcribed HHR molecules efficiently digested the target RNA, converting it to part R (Fig. 2H ) .", [["HHR", "GENE_OR_GENE_PRODUCT", 16, 19], ["HHR molecules", "PROTEIN", 16, 29], ["target RNA", "RNA", 55, 65], ["The transcribed HHR molecules", "PROBLEM", 0, 29], ["the target RNA", "PROBLEM", 51, 65], ["target RNA", "OBSERVATION", 55, 65]]], ["We calculated a target digestion rate constant of approximately k~0.14 min -1 at 37\u00b0C, which is lower than the k~1 min -1 observed for linear RNA 63 , and an EC 50 of approximately 1 mol HHR per 5 mol target RNA (Fig. 2I, 2J , Fig. S9 -S10) .", [["S9 -S10", "GENE_OR_GENE_PRODUCT", 232, 239], ["S9", "PROTEIN", 232, 234], ["linear RNA", "TEST", 135, 145], ["an EC", "TEST", 155, 160]]], ["The entire \"life-cycle\" of the machine, starting from the low machine/high target state and ending with the high machine/low target one was visualized by gel electrophoresis (Fig. 2K ) .IntroductionIn addition to this automaton, we designed and tested several alternative automata to explore design flexibility and additional features (Supplementary note 5, Fig. S11 -S17, Table S2 & Table S3 ) .", [["S11", "PROTEIN", 363, 366], ["S17", "PROTEIN", 368, 371], ["gel electrophoresis", "TEST", 154, 173]]], ["For example, we incorporated a \"sensory organ\" based on toehold-mediated strand displacement.", [["organ", "ANATOMY", 40, 45], ["organ", "ORGAN", 40, 45], ["a \"sensory organ\"", "PROBLEM", 29, 46], ["mediated strand displacement", "PROBLEM", 64, 92], ["strand displacement", "OBSERVATION", 73, 92]]], ["This part is designed to respond to the presence of the target by structural remodeling of the HHR gene region and enabling its transcription, which is otherwise disabled.IntroductionSuch a feature could provide an additional layer of control and specificity to the automaton's activity, triggering its operation only in the presence of its target.", [["HHR", "GENE_OR_GENE_PRODUCT", 95, 98], ["HHR gene region", "DNA", 95, 110], ["an additional layer of control", "TREATMENT", 212, 242], ["its operation", "TREATMENT", 299, 312], ["remodeling", "OBSERVATION", 77, 87]]], ["We next validated the automaton's compatibility for delivery into live cells and its stability therein.", [["cells", "ANATOMY", 71, 76], ["cells", "CELL", 71, 76], ["live cells", "CELL_TYPE", 66, 76], ["the automaton's compatibility", "TREATMENT", 18, 47], ["delivery into live cells", "TREATMENT", 52, 76]]], ["DNA and RNA nanostructures have been stably generated and studied in live cells 64, 65 , and recent works have reported the successful delivery of DNA nanostructures into cells 66, 67 as well as packing DNA nanostructures in liposomes 68, 69 , which improves their in-vivo stability.", [["cells", "ANATOMY", 74, 79], ["cells", "ANATOMY", 171, 176], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["cells", "CELL", 74, 79], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["cells", "CELL", 171, 176], ["DNA", "CELLULAR_COMPONENT", 203, 206], ["DNA and RNA nanostructures", "PROBLEM", 0, 26], ["DNA nanostructures into cells", "PROBLEM", 147, 176], ["packing DNA nanostructures in liposomes", "TREATMENT", 195, 234], ["RNA nanostructures", "OBSERVATION", 8, 26]]], ["We first studied several variants of the automaton, in which parts L and S were modified with either locked nucleic acids (LNA) or 2-O-methoxyethyl RNA (2-MOE) at various lengths along the regions complementary to part R (3, 5, and 7 nt).", [["nucleic acids", "CHEMICAL", 108, 121], ["LNA", "CHEMICAL", 123, 126], ["2-O-methoxyethyl RNA (2-MOE", "CHEMICAL", 131, 158], ["2-O-methoxyethyl RNA", "CHEMICAL", 131, 151], ["2-MOE", "CHEMICAL", 153, 158], ["nucleic acids", "SIMPLE_CHEMICAL", 108, 121], ["LNA", "SIMPLE_CHEMICAL", 123, 126], ["2-O-methoxyethyl RNA", "SIMPLE_CHEMICAL", 131, 151], ["2-MOE", "SIMPLE_CHEMICAL", 153, 158], ["locked nucleic acids", "TREATMENT", 101, 121], ["methoxyethyl RNA", "TREATMENT", 135, 151]]], ["We found that both modifications were effective in protecting the assembled automaton from RNase H, with stability correlating with modification length (Fig. 3A, 3B, Fig. S4 ) .", [["RNase H", "GENE_OR_GENE_PRODUCT", 91, 98], ["RNase H", "PROTEIN", 91, 98]]], ["The modified automata were also resistant to the junction resolvases RuvAB and RuvABC (Fig. 3C) .", [["RuvAB", "GENE_OR_GENE_PRODUCT", 69, 74], ["RuvAB", "PROTEIN", 69, 74], ["RuvABC", "PROTEIN", 79, 85], ["Fig. 3C", "PROTEIN", 87, 94]]], ["These experiments also confirmed that the modifications did not alter oligonucleotide assembly behavior and specificity ( Fig. 3A -C , \"LS\" traces ) ; rather, they significantly increased junction formation efficiency (Fig. S3) .IntroductionIn order to demonstrate automaton activity inside living cells, we designed variants that specifically target the genes of an infecting virus.", [["junction", "ANATOMY", 188, 196], ["cells", "ANATOMY", 298, 303], ["cells", "CELL", 298, 303], ["specificity", "TEST", 108, 119], ["Fig", "TEST", 122, 125], ["an infecting virus", "PROBLEM", 364, 382], ["automaton activity", "OBSERVATION", 265, 283], ["infecting virus", "OBSERVATION", 367, 382]]], ["As a model virus, we used AcMNPV to infect Sf9 cells in culture (Supplementary notes 6, Fig. S18-S19 ) .", [["Sf9 cells", "ANATOMY", 43, 52], ["AcMNPV", "ORGANISM", 26, 32], ["Sf9 cells", "CELL", 43, 52], ["S18-S19", "GENE_OR_GENE_PRODUCT", 93, 100], ["Sf9 cells", "CELL_LINE", 43, 52], ["S18", "PROTEIN", 93, 96], ["AcMNPV", "SPECIES", 26, 32], ["Sf9", "SPECIES", 43, 46], ["a model virus", "PROBLEM", 3, 16], ["AcMNPV", "TREATMENT", 26, 32], ["culture", "TEST", 56, 63]]], ["As the target gene we chose GP64, the critical envelope glycoprotein mediating host cell recognition and entry 70 .", [["cell", "ANATOMY", 84, 88], ["GP64", "GENE_OR_GENE_PRODUCT", 28, 32], ["host cell", "CELL", 79, 88], ["target gene", "DNA", 7, 18], ["GP64", "PROTEIN", 28, 32], ["envelope glycoprotein", "PROTEIN", 47, 68], ["GP64", "TREATMENT", 28, 32], ["the critical envelope glycoprotein", "TREATMENT", 34, 68], ["host cell", "OBSERVATION", 79, 88]]], ["Several HHR molecules were designed against specific target sites in GP64, and were tested on GP64 RNA in-vitro (Fig. 3D) .", [["GP64", "GENE_OR_GENE_PRODUCT", 69, 73], ["GP64", "GENE_OR_GENE_PRODUCT", 94, 98], ["HHR molecules", "PROTEIN", 8, 21], ["target sites", "DNA", 53, 65], ["GP64", "DNA", 69, 73], ["GP64 RNA", "RNA", 94, 102], ["Several HHR molecules", "PROBLEM", 0, 21], ["GP64", "TEST", 69, 73], ["GP64 RNA", "TEST", 94, 102]]], ["The most effective molecule (Fig. 3E ) was used as a design constraint for LNA-modified, GP64-targeting automata that exhibited efficient assembly (Supplementary note 7, Fig. S24 -S26, Table S4 ).", [["LNA", "CHEMICAL", 75, 78], ["GP64", "CHEMICAL", 89, 93], ["LNA", "SIMPLE_CHEMICAL", 75, 78], ["GP64", "SIMPLE_CHEMICAL", 89, 93], ["GP64", "PROTEIN", 89, 93], ["S24", "PROTEIN", 175, 178], ["LNA", "TEST", 75, 78], ["GP64", "TREATMENT", 89, 93], ["most effective", "OBSERVATION_MODIFIER", 4, 18]]], ["These automata were not toxic to cells during 4 days of exposure at a high dose (250 pmol) (Fig. 3F) .", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["toxic to cells", "PROBLEM", 24, 38], ["exposure", "TREATMENT", 56, 64], ["not", "UNCERTAINTY", 20, 23], ["toxic", "OBSERVATION_MODIFIER", 24, 29]]], ["Compared with the infected untreated population, which contained 95\u00b12% GFP + cells, the population treated once with GP64-targeting automata showed a striking reduction of infection, to between 10\u00b17% GFP + cells ( P <10 -4 ) (Fig. 3G, 3H, Supplementary note 7) .", [["GFP + cells", "ANATOMY", 71, 82], ["GFP + cells", "ANATOMY", 200, 211], ["GP64", "CHEMICAL", 117, 121], ["infection", "DISEASE", 172, 181], ["GFP", "GENE_OR_GENE_PRODUCT", 71, 74], ["cells", "CELL", 77, 82], ["GP64", "SIMPLE_CHEMICAL", 117, 121], ["GFP", "GENE_OR_GENE_PRODUCT", 200, 203], ["GFP", "PROTEIN", 71, 74], ["GP64", "PROTEIN", 117, 121], ["GFP", "PROTEIN", 200, 203], ["the infected untreated population", "PROBLEM", 14, 47], ["GP64", "TEST", 117, 121], ["targeting automata", "TEST", 122, 140], ["a striking reduction of infection", "PROBLEM", 148, 181], ["cells", "TEST", 206, 211], ["P", "TEST", 214, 215], ["infected", "OBSERVATION_MODIFIER", 18, 26], ["untreated", "OBSERVATION_MODIFIER", 27, 36], ["population", "OBSERVATION", 37, 47], ["GFP + cells", "OBSERVATION", 71, 82], ["striking", "OBSERVATION_MODIFIER", 150, 158], ["reduction", "OBSERVATION_MODIFIER", 159, 168], ["infection", "OBSERVATION", 172, 181]]], ["The sham-treated group showed no difference from the infected group.", [["no", "UNCERTAINTY", 30, 32], ["infected", "OBSERVATION", 53, 61]]], ["In order to observe the temporal dynamics of automata activity relative to the target virus, cell populations were sampled at intervals of 24 h from 0 to 96 h, and the de-novo transcribed HHR molecules per cell were counted using in-situ hybridization quantitative flow cytometry.", [["cell", "ANATOMY", 93, 97], ["cell", "ANATOMY", 206, 210], ["cell populations", "CELL", 93, 109], ["HHR", "GENE_OR_GENE_PRODUCT", 188, 191], ["cell", "CELL", 206, 210], ["HHR molecules", "PROTEIN", 188, 201], ["the target virus", "PROBLEM", 75, 91], ["cell populations", "TEST", 93, 109], ["flow cytometry", "OBSERVATION", 265, 279]]], ["Interestingly, HHR transcription produced an approximate average of 800 copies per cell at 24 h ( P =0.002), and to approximately 3000 copies per cell at 48 h ( P <10 -4 ).", [["cell", "ANATOMY", 83, 87], ["cell", "ANATOMY", 146, 150], ["HHR", "GENE_OR_GENE_PRODUCT", 15, 18], ["cell", "CELL", 83, 87], ["cell", "CELL", 146, 150], ["HHR", "PROTEIN", 15, 18]]], ["No HHR molecules were significantly observed above the background at 72 and 96 h, and HHR counts did not significantly change with time in uninfected cells treated with equal amounts of automata.", [["cells", "ANATOMY", 150, 155], ["HHR", "GENE_OR_GENE_PRODUCT", 3, 6], ["cells", "CELL", 150, 155], ["HHR molecules", "PROTEIN", 3, 16], ["uninfected cells", "CELL_TYPE", 139, 155], ["HHR molecules", "PROBLEM", 3, 16], ["HHR counts", "TEST", 86, 96], ["HHR", "OBSERVATION_MODIFIER", 3, 6], ["molecules", "OBSERVATION", 7, 16], ["uninfected cells", "OBSERVATION", 139, 155]]], ["Interestingly, the dynamics of HHR appeared to track that of GP64 RNA as measured by qPCR with an approximate lag of 24 h (Fig. 3I ) .", [["HHR", "GENE_OR_GENE_PRODUCT", 31, 34], ["GP64", "GENE_OR_GENE_PRODUCT", 61, 65], ["HHR", "PROTEIN", 31, 34], ["GP64 RNA", "RNA", 61, 69], ["GP64 RNA", "PROBLEM", 61, 69], ["qPCR", "TEST", 85, 89]]], ["This tracking behavior suggests that the de-novo transcription of HHR responds to the cellular viral load.IntroductionLastly, we investigated the potential effect of the GP64-targeting automata on viral load and consequently on the innate immune response to AcMNPV infection in adult insects.", [["cellular", "ANATOMY", 86, 94], ["GP64", "CHEMICAL", 170, 174], ["AcMNPV infection", "DISEASE", 258, 274], ["HHR", "GENE_OR_GENE_PRODUCT", 66, 69], ["cellular", "CELL", 86, 94], ["GP64", "GENE_OR_GENE_PRODUCT", 170, 174], ["AcMNPV", "ORGANISM", 258, 264], ["HHR", "PROTEIN", 66, 69], ["GP64", "PROTEIN", 170, 174], ["AcMNPV", "SPECIES", 258, 264], ["the de-novo transcription of HHR", "PROBLEM", 37, 69], ["the cellular viral load", "PROBLEM", 82, 105], ["the GP64", "TREATMENT", 166, 174], ["viral load", "PROBLEM", 197, 207], ["AcMNPV infection", "PROBLEM", 258, 274], ["viral load", "OBSERVATION", 95, 105], ["viral load", "OBSERVATION", 197, 207], ["infection", "OBSERVATION", 265, 274]]], ["To this end, we infected adult Blaberus discoidalis with AcMNPV by a systemic injection of 4\u00d710 5 cells, out of which 40,000 were infected and expected to release approximately 100 virions per cell over the course of the next 48 h.", [["4\u00d710 5 cells", "ANATOMY", 91, 103], ["cell", "ANATOMY", 193, 197], ["Blaberus discoidalis", "ORGANISM", 31, 51], ["AcMNPV", "ORGANISM", 57, 63], ["cells", "CELL", 98, 103], ["cell", "CELL", 193, 197], ["4\u00d710 5 cells", "CELL_LINE", 91, 103], ["Blaberus discoidalis", "SPECIES", 31, 51], ["Blaberus discoidalis", "SPECIES", 31, 51], ["AcMNPV", "SPECIES", 57, 63], ["AcMNPV", "TREATMENT", 57, 63], ["a systemic injection of 4\u00d710 5 cells", "TREATMENT", 67, 103], ["infected", "OBSERVATION", 16, 24], ["Blaberus discoidalis", "OBSERVATION", 31, 51], ["infected", "OBSERVATION", 130, 138]]], ["Hemolymph was extracted from the insects at 2.5 d post infection, and flow cytometry was used to measure the fluorescence of GFP molecules phagocytosed by resident plasmatocytes, as well as the phosphorylation states of p38 MAPK and ERK, which are upregulated in stress and innate immune activation in insects in response to viral infection 71 .", [["Hemolymph", "ANATOMY", 0, 9], ["plasmatocytes", "ANATOMY", 164, 177], ["viral infection", "DISEASE", 325, 340], ["GFP", "GENE_OR_GENE_PRODUCT", 125, 128], ["plasmatocytes", "CELL", 164, 177], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 220, 228], ["ERK", "GENE_OR_GENE_PRODUCT", 233, 236], ["GFP molecules", "PROTEIN", 125, 138], ["resident plasmatocytes", "CELL_TYPE", 155, 177], ["p38 MAPK", "PROTEIN", 220, 228], ["ERK", "PROTEIN", 233, 236], ["Hemolymph", "TEST", 0, 9], ["infection", "PROBLEM", 55, 64], ["flow cytometry", "TEST", 70, 84], ["p38 MAPK", "TEST", 220, 228], ["ERK", "TEST", 233, 236], ["stress", "PROBLEM", 263, 269], ["innate immune activation", "TREATMENT", 274, 298], ["viral infection", "PROBLEM", 325, 340], ["infection", "OBSERVATION", 55, 64], ["viral infection", "OBSERVATION", 325, 340]]], ["One group of animals received GP64-targeting automata by injection at t = 0.IntroductionAnimals injected with infected cells exhibited increased plasmatocyte GFP compared to animals injected with healthy cells ( P <10 -4 ); however, treatment with GP64-targeting automata reduced GFP levels significantly ( P <10 -4 ) (Fig. 3J) , indicating a reduction in viral load.", [["cells", "ANATOMY", 119, 124], ["plasmatocyte", "ANATOMY", 145, 157], ["cells", "ANATOMY", 204, 209], ["GP64", "CHEMICAL", 30, 34], ["GP64", "CHEMICAL", 248, 252], ["animals", "ORGANISM", 13, 20], ["GP64", "SIMPLE_CHEMICAL", 30, 34], ["cells", "CELL", 119, 124], ["GFP", "GENE_OR_GENE_PRODUCT", 158, 161], ["cells", "CELL", 204, 209], ["GP64", "SIMPLE_CHEMICAL", 248, 252], ["GFP", "GENE_OR_GENE_PRODUCT", 280, 283], ["GP64", "PROTEIN", 30, 34], ["infected cells", "CELL_TYPE", 110, 124], ["plasmatocyte GFP", "PROTEIN", 145, 161], ["healthy cells", "CELL_TYPE", 196, 209], ["GP64", "PROTEIN", 248, 252], ["GFP", "PROTEIN", 280, 283], ["GP64", "TREATMENT", 30, 34], ["IntroductionAnimals", "TREATMENT", 76, 95], ["infected cells", "PROBLEM", 110, 124], ["increased plasmatocyte GFP", "PROBLEM", 135, 161], ["GP64", "TEST", 248, 252], ["GFP levels", "TEST", 280, 290], ["a reduction in viral load", "PROBLEM", 341, 366], ["infected cells", "OBSERVATION", 110, 124], ["increased", "OBSERVATION_MODIFIER", 135, 144], ["plasmatocyte GFP", "OBSERVATION", 145, 161], ["reduction", "OBSERVATION_MODIFIER", 343, 352], ["viral load", "OBSERVATION", 356, 366]]], ["Automata-treated animals also showed near-complete reversal of stress and innate immunity signals (Fig. 3K) .IntroductionParticularly, p38 MAPK and ERK phosphorylation were significantly reversed (phospho-p38 MAPK, P <10 -4 ; phospho-ERK, P <10 -4 ) (Fig. 3L ) , indicating that both the innate immune response and the systemic stress were significantly reduced as a consequence of viral load reduction by the GP64-targeting automata.DiscussionIn this work we describe a working prototype of a synthetic molecular automaton, which digests viral RNA and utilizes it as \"food\" for assembling additional copies of itself inside living cells.", [["cells", "ANATOMY", 632, 637], ["phospho", "CHEMICAL", 197, 204], ["phospho", "CHEMICAL", 226, 233], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 135, 143], ["ERK", "GENE_OR_GENE_PRODUCT", 148, 151], ["phospho-p38 MAPK", "GENE_OR_GENE_PRODUCT", 197, 213], ["phospho-ERK", "GENE_OR_GENE_PRODUCT", 226, 237], ["GP64", "GENE_OR_GENE_PRODUCT", 410, 414], ["cells", "CELL", 632, 637], ["p38 MAPK", "PROTEIN", 135, 143], ["ERK", "PROTEIN", 148, 151], ["phospho", "PROTEIN", 197, 204], ["p38 MAPK", "PROTEIN", 205, 213], ["phospho", "PROTEIN", 226, 233], ["ERK", "PROTEIN", 234, 237], ["GP64", "PROTEIN", 410, 414], ["viral RNA", "RNA", 539, 548], ["living cells", "CELL_TYPE", 625, 637], ["Automata", "TEST", 0, 8], ["stress", "PROBLEM", 63, 69], ["innate immunity signals", "TEST", 74, 97], ["p38 MAPK", "TEST", 135, 143], ["ERK phosphorylation", "TEST", 148, 167], ["phospho", "TEST", 197, 204], ["MAPK", "TEST", 209, 213], ["P", "TEST", 215, 216], ["phospho", "TEST", 226, 233], ["ERK", "TEST", 234, 237], ["P", "TEST", 239, 240], ["the systemic stress", "PROBLEM", 315, 334], ["viral load reduction", "TREATMENT", 382, 402], ["the GP64", "TEST", 406, 414], ["a synthetic molecular automaton", "PROBLEM", 492, 523], ["viral load", "OBSERVATION", 382, 392]]], ["This combination of heterotrophy and self-replication, both inspired by living organisms, with the automaton's nucleic acid-based architecture, is unique among therapeutic agents, and provides several benefits. are still ongoing.", [["nucleic acid", "CHEMICAL", 111, 123], ["heterotrophy", "PROBLEM", 20, 32], ["self-replication", "PROBLEM", 37, 53], ["therapeutic agents", "TREATMENT", 160, 178], ["heterotrophy", "OBSERVATION", 20, 32]]], ["Like other silencing therapeutics, the automaton (specifically its HHR core) can be rapidly designed ab-initio and screened against pathogen RNA once it is sequenced, which could enable a rapid response to future outbreaks.DiscussionThe tracking behavior of the automaton, expanding and decaying depending on the concentration of its target, is a unique pharmacological advantage.", [["HHR core", "DNA", 67, 75], ["pathogen RNA", "RNA", 132, 144], ["ab-initio", "TREATMENT", 101, 110], ["pathogen RNA", "PROBLEM", 132, 144]]], ["It makes it possible to designate the automaton's building blocks as an inactive prodrug, enabling their safe delivery in large amounts.", [["an inactive prodrug", "TREATMENT", 69, 88], ["their safe delivery", "TREATMENT", 99, 118]]], ["Only in the presence of its \"prey\" (i.e. when the host cell is infected by the target virus), can the automaton assemble and begin replicating.", [["cell", "ANATOMY", 55, 59], ["host cell", "CELL", 50, 59]]], ["The in-vivo stability of the automaton is programmable to an extent, using synthetic modifications in specific base stretches, such as LNA and MOE, as shown in this study.", [["LNA", "CHEMICAL", 135, 138], ["LNA", "SIMPLE_CHEMICAL", 135, 138], ["synthetic modifications", "TREATMENT", 75, 98], ["this study", "TEST", 160, 170], ["stability", "OBSERVATION_MODIFIER", 12, 21], ["automaton", "OBSERVATION", 29, 38]]], ["Like many viruses, which package and carry the protein machinery required for their replication in the destination cell, and like experimental CRISPR/Cas-based therapeutic formulations, the automaton is delivered along with its protein machinery.", [["cell", "ANATOMY", 115, 119], ["cell", "CELL", 115, 119], ["Cas", "GENE_OR_GENE_PRODUCT", 150, 153], ["destination cell", "CELL_TYPE", 103, 119], ["CRISPR", "DNA", 143, 149], ["Cas", "PROTEIN", 150, 153], ["many viruses", "PROBLEM", 5, 17], ["the protein machinery", "TREATMENT", 43, 64], ["experimental CRISPR/Cas", "TREATMENT", 130, 153], ["therapeutic formulations", "TREATMENT", 160, 184], ["its protein machinery", "TREATMENT", 224, 245], ["many", "OBSERVATION_MODIFIER", 5, 9], ["viruses", "OBSERVATION", 10, 17], ["destination cell", "OBSERVATION", 103, 119]]], ["For purposes of this proof-of-principle study we used off-the-shelf enzymes.", [["off-the-shelf enzymes", "PROTEIN", 54, 75], ["principle study", "TEST", 30, 45], ["the-shelf enzymes", "TEST", 58, 75]]], ["However, future designs could include human enzymes isolated or optimized specifically for the automaton, although this study has shown that delivery of the automaton packages is both efficient and non-toxic in insect cells and adult insects.", [["cells", "ANATOMY", 218, 223], ["human", "ORGANISM", 38, 43], ["insect cells", "CELL", 211, 223], ["human enzymes", "PROTEIN", 38, 51], ["insect cells", "CELL_TYPE", 211, 223], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["human enzymes", "TEST", 38, 51], ["the automaton", "TEST", 91, 104], ["this study", "TEST", 115, 125], ["the automaton packages", "PROBLEM", 153, 175], ["non-toxic in insect cells", "PROBLEM", 198, 223], ["non-toxic", "OBSERVATION_MODIFIER", 198, 207]]], ["It may be even possible to design automata that entirely utilize the endogenous cellular machinery, which would simplify its delivery and formulation.DiscussionInterestingly, several structural and functional features of the automaton could highlight plausible features of molecular life forms from the RNA world 75 .", [["cellular", "ANATOMY", 80, 88], ["cellular", "CELL", 80, 88], ["its delivery and formulation", "TREATMENT", 121, 149], ["may be even possible", "UNCERTAINTY", 3, 23]]], ["For example, the automaton has multiple parts that compose a complex body plan.", [["body", "ANATOMY", 69, 73], ["body", "ORGANISM_SUBDIVISION", 69, 73], ["a complex body plan", "TREATMENT", 59, 78]]], ["This model has been previously suggested as underlying mechanism for structural and functional diversity in the RNA world, since it is assumed that ancient RNA polymerizing ribozymes had generally low processivity, thus likely capable of synthesizing relatively short species 76 (it is important to note that recent studies described synthetic, single-chain ribozymes with impressive catalytic performance 23,77,78 ).DiscussionSecond, it contains a metabolic ribozyme, which is capable of breaking down other molecules in order to utilize them as a source of building blocks.", [["ancient RNA polymerizing ribozymes", "PROBLEM", 148, 182], ["generally low processivity", "PROBLEM", 187, 213], ["synthesizing relatively short species", "PROBLEM", 238, 275], ["recent studies", "TEST", 309, 323], ["synthetic, single-chain ribozymes", "TREATMENT", 334, 367], ["impressive catalytic performance", "TEST", 373, 405], ["a metabolic ribozyme", "TREATMENT", 447, 467], ["building blocks", "TREATMENT", 559, 574], ["polymerizing ribozymes", "OBSERVATION", 160, 182], ["low processivity", "OBSERVATION_MODIFIER", 197, 213], ["likely capable", "UNCERTAINTY", 220, 234], ["metabolic ribozyme", "OBSERVATION", 449, 467]]], ["Although the terms \"molecular ecology\" and \"molecular predators\" have been previously suggested for synthetic systems and in bacterial small RNA networks, 79-81 the concept is essentially descriptive of specific dynamics, and has not been constructed at a metabolic level.", [["\"molecular predators", "PROBLEM", 43, 63], ["synthetic systems", "PROBLEM", 100, 117], ["bacterial small RNA networks", "PROBLEM", 125, 153]]], ["In this narrow sense, the present automaton could emulate realistic predatory behavior.DiscussionThird, some designs which we tested only briefly (and are described in Supplementary note 5 ) included a sensory part or \"organ\", enabling the automaton to sense its target and respond to it.", [["organ", "ANATOMY", 219, 224], ["organ", "ORGAN", 219, 224]]], ["Sensing of and response to environmental cues such as temperature, light, food, prey, and predators, is a hallmark feature of living organisms, and the chemistry of nucleic acids provides primitive mechanisms for sensory capabilities.", [["nucleic acids", "CHEMICAL", 165, 178], ["nucleic acids", "SIMPLE_CHEMICAL", 165, 178], ["environmental cues", "TREATMENT", 27, 45], ["living organisms", "PROBLEM", 126, 142], ["nucleic acids", "TREATMENT", 165, 178]]], ["A simple example would be based on base pairing in toehold-mediated strand displacement, translating hybridization to actuation.DiscussionAnother mechanism could be the recognition of a 3D structure, similar to aptamers and their targets, with the coupled actuator similar in principle to the concept of structure-switching aptamer-based sensors 82 .", [["toehold", "SIMPLE_CHEMICAL", 51, 58], ["strand displacement", "PROBLEM", 68, 87], ["the coupled actuator", "TREATMENT", 244, 264], ["strand displacement", "OBSERVATION", 68, 87]]], ["An intriguing feature of this type of sensing mechanism, is that it induces structural remodeling of the automaton that exposes the HHR gene to be transcribed, which could be viewed as analogous to chromatin remodeling in higher organisms, in response to various cues.", [["chromatin", "ANATOMY", 198, 207], ["HHR", "GENE_OR_GENE_PRODUCT", 132, 135], ["chromatin", "CELLULAR_COMPONENT", 198, 207], ["HHR gene", "DNA", 132, 140], ["chromatin", "DNA", 198, 207], ["chromatin remodeling in higher organisms", "PROBLEM", 198, 238], ["structural", "OBSERVATION_MODIFIER", 76, 86], ["remodeling", "OBSERVATION", 87, 97], ["higher organisms", "OBSERVATION", 222, 238]]], ["Sensing and response provide an additional layer of control over the automaton, contributing to a less leaky, more stringent system.", [["an additional layer of control", "TREATMENT", 29, 59], ["a less leaky, more stringent system", "PROBLEM", 96, 131], ["less", "OBSERVATION_MODIFIER", 98, 102], ["leaky", "OBSERVATION", 103, 108]]], ["Gene silencing and RNA-based therapeutics are still an emerging field of therapeutics, although it can be traced back four decades ago 83, 84 .", [["Gene silencing and RNA", "PROBLEM", 0, 22]]], ["RNA-based therapeutics offer many advantages over other classes of pharmaceuticals and biologics, among them target flexibility, facile and precisely-defined chemical synthesis, cost effectiveness, shelf stability, very low immunogenicity, and nearly on-demand design.", [["RNA", "TEST", 0, 3], ["pharmaceuticals", "TREATMENT", 67, 82], ["biologics", "TREATMENT", 87, 96], ["very low immunogenicity", "PROBLEM", 215, 238], ["low immunogenicity", "OBSERVATION_MODIFIER", 220, 238]]], ["Traditional issues such as in-vivo stability and nuclease resistance have been simplified by modern methods for synthesis and base modification.", [["nuclease", "PROTEIN", 49, 57], ["Traditional issues", "PROBLEM", 0, 18], ["nuclease resistance", "PROBLEM", 49, 68], ["modern methods", "TREATMENT", 93, 107], ["synthesis and base modification", "TREATMENT", 112, 143]]], ["Their rapid design and platforms for evolution have made it possible to tailor oligonucleotides for variable targets in cancer 85 .", [["cancer", "ANATOMY", 120, 126], ["cancer", "DISEASE", 120, 126], ["cancer", "CANCER", 120, 126], ["tailor oligonucleotides", "TREATMENT", 72, 95], ["variable targets in cancer", "PROBLEM", 100, 126], ["cancer", "OBSERVATION", 120, 126]]], ["The automaton described here, and improved versions of it, could be utilized as engines to drive the intracellular synthesis of RNA-based therapeutics such that they track their gene target, as a unique mode of control over the activity of the drug.DiscussionInterestingly, nucleic acid-based therapeutics are unique in being very highly \"distributable\": once an oligonucleotide-based drug has been designed and its efficacy and safety confirmed, it can be sent digitally as a sequence file and synthesized locally on commercially available synthesizers.", [["intracellular", "ANATOMY", 101, 114], ["nucleic acid", "CHEMICAL", 274, 286], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 114], ["nucleic acid", "SIMPLE_CHEMICAL", 274, 286], ["the intracellular synthesis of RNA", "TREATMENT", 97, 131], ["nucleic acid", "TEST", 274, 286]]], ["We have recently shown using network models 86 that even when the oligonucleotide therapeutic is much less effective than \"chemical\" drugs (e.g. a small molecule or antibody), its rapid distribution -compared to shipping via sea and air -consistently enabled us to save more people.", [["people", "ORGANISM", 275, 281], ["people", "SPECIES", 275, 281], ["chemical\" drugs", "TREATMENT", 123, 138], ["a small molecule or antibody)", "PROBLEM", 145, 174], ["rapid", "OBSERVATION_MODIFIER", 180, 185], ["distribution", "OBSERVATION_MODIFIER", 186, 198]]], ["Importantly, distributing \"chemical\" drugs by shipping creates profound inequalities, inevitably leading to some populations receiving more material than needed, while others remain completely deprived of it.", [["profound inequalities", "PROBLEM", 63, 84]]], ["In stark contrast, nucleic acid therapeutics could lead to a significantly more equal distribution.", [["nucleic acid", "CHEMICAL", 19, 31], ["nucleic acid", "SIMPLE_CHEMICAL", 19, 31], ["nucleic acid therapeutics", "TREATMENT", 19, 44], ["equal", "OBSERVATION_MODIFIER", 80, 85], ["distribution", "OBSERVATION_MODIFIER", 86, 98]]], ["In this regard, the current COVID-19 crisis highlights the important of these, traditionally overlooked, advantages of nucleic acid therapeutics.MethodsOligonucleotides.", [["nucleic acid", "CHEMICAL", 119, 131], ["nucleic acid", "SIMPLE_CHEMICAL", 119, 131], ["the current COVID", "TEST", 16, 33], ["nucleic acid therapeutics", "TREATMENT", 119, 144], ["MethodsOligonucleotides", "TREATMENT", 145, 168]]], ["DNA and RNA oligonucleotides, including any modification, were ordered from Integrated DNA Technologies (IDT), reconstituted to 100 \u03bcM with ultrapure, DNase/RNase free water (Biological Industries, Israel), and stored at \u221220\u00b0C. DNA/RNA sequences are listed in Table S1 .MethodsAutomaton design and assembly.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["DNase", "GENE_OR_GENE_PRODUCT", 151, 156], ["RNase", "GENE_OR_GENE_PRODUCT", 157, 162], ["DNA", "CELLULAR_COMPONENT", 228, 231], ["DNase", "PROTEIN", 151, 156], ["RNase", "PROTEIN", 157, 162], ["DNA/RNA sequences", "DNA", 228, 245], ["DNA", "PROBLEM", 0, 3], ["RNA oligonucleotides", "TREATMENT", 8, 28], ["ultrapure", "TREATMENT", 140, 149], ["DNase/RNase free water", "TREATMENT", 151, 173], ["DNA/RNA sequences", "TEST", 228, 245], ["RNA oligonucleotides", "OBSERVATION", 8, 28]]], ["HHR molecules for given target sequences were designed using Ribosoft 62 .", [["HHR molecules", "PROTEIN", 0, 13], ["target sequences", "TEST", 24, 40], ["Ribosoft", "TEST", 61, 69]]], ["Automaton structure was then designed using a custom code ensuring its fit to the cleavage sites and the HHR, as well as compliance with the rules defined by DNA origami folding.", [["DNA", "CELLULAR_COMPONENT", 158, 161], ["HHR", "DNA", 105, 108], ["a custom code", "TREATMENT", 44, 57], ["the cleavage sites", "TREATMENT", 78, 96], ["DNA origami folding", "TREATMENT", 158, 177], ["DNA origami", "OBSERVATION", 158, 169]]], ["Previously-described DNA rectangles 8 were re-designed using caDNAno 33 to include 6 edge staples comprising the automaton S strand on its 3' to enable rectangle-based assembly.", [["DNA", "CELLULAR_COMPONENT", 21, 24], ["DNA rectangles 8", "DNA", 21, 37], ["caDNAno 33", "DNA", 61, 71], ["automaton S strand", "DNA", 113, 131], ["caDNAno", "TREATMENT", 61, 68], ["6 edge staples", "TREATMENT", 83, 97], ["the automaton S strand", "TREATMENT", 109, 131]]], ["M13mp18 ssDNA (7,249 base long) genome was ordered from New England BioLabs (N4040S) and used as scaffold strand.", [["M13mp18", "GENE_OR_GENE_PRODUCT", 0, 7], ["M13mp18 ssDNA", "DNA", 0, 13], ["7,249 base long) genome", "DNA", 15, 38], ["M13mp18 ssDNA", "TREATMENT", 0, 13], ["base long) genome", "TREATMENT", 21, 38], ["scaffold strand", "OBSERVATION", 97, 112]]], ["DNA staples were ordered from IDT.MethodsAll DNA sequences are listed in Supplementary note 3.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 45, 48], ["DNA sequences", "DNA", 45, 58], ["DNA staples", "TREATMENT", 0, 11], ["staples", "OBSERVATION", 4, 11]]], ["Folding was carried out at a 1:10 scaffold:staple ratio (scaffold concentration 10 nM) in 1\u00d7 TAE buffer (Invitrogen), 12.5 mM MgCl 2 (Ambion) in a BioRad C1000 Touch Thermal Cycler, using the following annealing ramp: 5 min at 85\u00b0C , 85\u00b0C to 60\u00b0C at -1\u00b0C/15min, 60\u00b0C to 25\u00b0C at -1\u00b0C/3hr.", [["MgCl 2", "CHEMICAL", 126, 132], ["TAE", "CHEMICAL", 93, 96], ["MgCl 2", "CHEMICAL", 126, 132], ["staple ratio (scaffold concentration", "TREATMENT", 43, 79], ["TAE buffer (Invitrogen)", "TREATMENT", 93, 116], ["a BioRad C1000 Touch Thermal Cycler", "TREATMENT", 145, 180]]], ["Rectangles were purified by centrifugal gel filtration.", [["centrifugal gel filtration", "TREATMENT", 28, 54], ["centrifugal gel filtration", "OBSERVATION", 28, 54]]], ["Finally, automaton oligos (except for S) were added at a concentration of 500 nM.MethodsAtomic force microscopy.", [["automaton oligos", "TREATMENT", 9, 25], ["MethodsAtomic force microscopy", "TEST", 81, 111]]], ["Samples were imaged in a JPK/Bruker NanoWizard Ultra AFM III instrument.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a JPK/Bruker NanoWizard Ultra AFM III instrument", "TREATMENT", 23, 71]]], ["The scans were performed at room temperature in FastScan-AC mode using ultra-short cantilevers with a force constant of 0.3 N/m (79427F7L1218, Nano World).", [["The scans", "TEST", 0, 9], ["FastScan", "TEST", 48, 56], ["ultra-short cantilevers", "TREATMENT", 71, 94], ["a force constant", "TEST", 100, 116]]], ["For imaging, 20 \u03bcL (concentration of 1-2 nM) of sample was deposited on freshly cleaved mica (Grade V1, 10 mm, #50, Ted Pella, Inc.) for 5 min, followed by a gentle wash with 1\u00d7 TAE buffer with 12.5 mM MgCl 2 .", [["sample", "ANATOMY", 48, 54], ["TAE", "CHEMICAL", 178, 181], ["MgCl 2", "CHEMICAL", 202, 208], ["imaging", "TEST", 4, 11], ["Ted Pella", "TREATMENT", 116, 125], ["a gentle wash", "TREATMENT", 156, 169], ["TAE buffer", "TREATMENT", 178, 188]]], ["Finally, 1 mL of washing buffer was added for scanning in solution and not in dry conditions.", [["washing buffer", "TREATMENT", 17, 31], ["scanning in solution", "TREATMENT", 46, 66]]], ["Images were analyzed using JPK Data Processing v6.1.96.High-performance liquid chromatography (HPLC).", [["Images", "TEST", 0, 6], ["JPK Data Processing", "TEST", 27, 46]]], ["Samples were analyzed on anAgilent 1260 infinity II HPLC instrument, using a ProSEC 300S Size Exclusion 300\u00d77.5 mm column (Agilent).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a ProSEC 300S Size Exclusion", "TREATMENT", 75, 103]]], ["The solvent was 1\u00d7 Dulbecco's Phosphate Buffered Saline (PBS, Biological Industries).", [["Phosphate", "CHEMICAL", 30, 39], ["Phosphate", "CHEMICAL", 30, 39], ["Phosphate Buffered Saline", "SIMPLE_CHEMICAL", 30, 55], ["Dulbecco's Phosphate Buffered Saline (PBS, Biological Industries", "TREATMENT", 19, 83]]], ["Flow rate was set to 1 mL/min and samples were injected in 1\u00d7 PBS.", [["samples", "ANATOMY", 34, 41], ["Flow rate", "TEST", 0, 9], ["samples", "TEST", 34, 41]]], ["Detection was measured at 260 nm, at 30\u00b0c.", [["Detection", "TEST", 0, 9]]], ["Fractions from HPLC were collected according to their relevant retention time as set by standard oligonucleotides ordered (IDT) analyzed by HPLC under identical conditions.", [["HPLC", "TEST", 15, 19]]], ["HPLC fractions were concentrated using Ultra 0.5mL centrifugal filters Ultracel\u00ae 10K (Merck Millipore LTD).", [["HPLC fractions", "TEST", 0, 14], ["Ultra 0.5mL centrifugal filters Ultracel\u00ae", "TREATMENT", 39, 80]]], ["Concentration and purity of fractions were measured using NanoDrop (Thermo Scientific) and gel electrophoresis.", [["NanoDrop", "TREATMENT", 58, 66], ["gel electrophoresis", "TEST", 91, 110]]], ["RNA was synthesized from the prepared plasmid using MEGAscript T7 in vitro transcription kit (Thermo scientific) according to the manufacturer's instructions, using 12 \u00b5g plasmid DNA as template.", [["plasmid", "ANATOMY", 38, 45], ["DNA", "CELLULAR_COMPONENT", 179, 182], ["RNA", "RNA", 0, 3], ["MEGAscript T7", "DNA", 52, 65], ["\u00b5g plasmid DNA", "DNA", 168, 182], ["MEGAscript T7", "TREATMENT", 52, 65], ["12 \u00b5g plasmid DNA", "TREATMENT", 165, 182]]], ["DNAse treatment with Turbo-DNAse (Thermo scientific) was used to clean the RNA.High-performance liquid chromatography (HPLC).", [["DNAse", "GENE_OR_GENE_PRODUCT", 0, 5], ["Turbo-DNAse", "GENE_OR_GENE_PRODUCT", 21, 32], ["DNAse", "PROTEIN", 0, 5], ["DNAse", "PROTEIN", 27, 32], ["DNAse treatment", "TREATMENT", 0, 15], ["Turbo-DNAse (Thermo scientific)", "TREATMENT", 21, 52], ["RNA", "ANATOMY", 75, 78]]], ["Samples were analyzed on anTranscribed RNA was purified with the MEGAclear kit (Thermo scientific) according to the manufacturer's instructions, and re-suspended in ultrapure, nuclease-free water.", [["Samples", "ANATOMY", 0, 7], ["anTranscribed RNA", "RNA", 25, 42], ["nuclease", "PROTEIN", 176, 184], ["Samples", "TEST", 0, 7], ["anTranscribed RNA", "TREATMENT", 25, 42]]], ["Agarose gel electrophoresis and NanoDrop analysis were used to validate the integrity, quality, and concentration of the transcripts.", [["Agarose", "SIMPLE_CHEMICAL", 0, 7], ["Agarose gel electrophoresis", "TEST", 0, 27], ["NanoDrop analysis", "TEST", 32, 49]]], ["Animal studies.", [["Animal studies", "TEST", 0, 14]]], ["Adult B. discoidalis of both sexes were purchased from two independent farms, Yaldei Ha-teva or Beit Haiut (Israel), and housed at room temperature and humidity in large plastic containers.", [["B. discoidalis", "ORGANISM", 6, 20], ["B. discoidalis", "SPECIES", 6, 20], ["B. discoidalis", "SPECIES", 6, 20], ["large", "OBSERVATION_MODIFIER", 164, 169], ["plastic containers", "OBSERVATION", 170, 188]]], ["Insects were supplied with dry pet food, fresh fruit, and water ad libitum .High-performance liquid chromatography (HPLC).", [["fruit", "ANATOMY", 47, 52], ["Insects", "ORGANISM", 0, 7]]], ["Samples were analyzed on anEgg cartons were used as light shelters.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["anEgg cartons", "TREATMENT", 25, 38]]], ["Samples were analyzed on anFor injection, insects were anesthetized one by one, by placement at -20\u00b0C for 7-8 min (depending on animal behavior) in a fresh glass beaker.", [["Samples", "ANATOMY", 0, 7], ["anFor", "SIMPLE_CHEMICAL", 25, 30], ["Samples", "TEST", 0, 7], ["anFor injection", "TREATMENT", 25, 40], ["glass beaker", "OBSERVATION", 156, 168]]], ["Once an insect has been anesthetized, a 15 \u03bc L containing 4\u00d710 5 Sf9 cells either non-treated, infected, or infected and delivered with automaton payload were injected into the hemocoel using a Hamilton syringe.", [["cells", "ANATOMY", 69, 74], ["hemocoel", "ANATOMY", 177, 185], ["Sf9", "ORGANISM", 65, 68], ["cells", "CELL", 69, 74], ["4\u00d710 5 Sf9 cells", "CELL_LINE", 58, 74], ["a 15 \u03bc L containing 4\u00d710 5 Sf9 cells", "TREATMENT", 38, 74], ["infected", "PROBLEM", 95, 103], ["infected", "PROBLEM", 108, 116], ["automaton payload", "TREATMENT", 136, 153], ["a Hamilton syringe", "TREATMENT", 192, 210], ["infected", "OBSERVATION", 108, 116], ["hemocoel", "ANATOMY", 177, 185]]], ["Infection was done at MOI of 0.1.", [["Infection", "PROBLEM", 0, 9], ["MOI", "TEST", 22, 25]]], ["Injection was carried out through the soft membrane between the 2nd-3rd abdominal sternites, close to the lateral body margin.", [["soft membrane", "ANATOMY", 38, 51], ["abdominal sternites", "ANATOMY", 72, 91], ["lateral body margin", "ANATOMY", 106, 125], ["soft membrane", "MULTI-TISSUE_STRUCTURE", 38, 51], ["lateral body", "TISSUE", 106, 118], ["Injection", "TREATMENT", 0, 9], ["the 2nd-3rd abdominal sternites", "TREATMENT", 60, 91], ["soft membrane", "ANATOMY", 38, 51], ["3rd", "ANATOMY_MODIFIER", 68, 71], ["abdominal", "ANATOMY", 72, 81], ["lateral", "ANATOMY_MODIFIER", 106, 113], ["body", "ANATOMY_MODIFIER", 114, 118], ["margin", "OBSERVATION_MODIFIER", 119, 125]]], ["Following injection, insects were left to recuperate.", [["injection", "TREATMENT", 10, 19]]], ["For hemolymph extraction, insects were anesthetized as described above.High-performance liquid chromatography (HPLC).", [["hemolymph", "ANATOMY", 4, 13], ["hemolymph", "ORGANISM_SUBSTANCE", 4, 13], ["hemolymph extraction", "TREATMENT", 4, 24]]], ["Samples were analyzed on anHemolymph was extracted by puncturing the arthrodial membrane at the base of either metathoracic leg with an ice-cold needle dipped in anticoagulation buffer (30 mM citric acid, 30 mM sodium citrate, 1 mM EDTA).", [["Samples", "ANATOMY", 0, 7], ["arthrodial membrane", "ANATOMY", 69, 88], ["leg", "ANATOMY", 124, 127], ["citric acid", "CHEMICAL", 192, 203], ["sodium citrate", "CHEMICAL", 211, 225], ["citric acid", "CHEMICAL", 192, 203], ["sodium citrate", "CHEMICAL", 211, 225], ["EDTA", "CHEMICAL", 232, 236], ["arthrodial membrane", "MULTI-TISSUE_STRUCTURE", 69, 88], ["leg", "ORGANISM_SUBDIVISION", 124, 127], ["citric acid", "SIMPLE_CHEMICAL", 192, 203], ["sodium citrate", "SIMPLE_CHEMICAL", 211, 225], ["EDTA", "SIMPLE_CHEMICAL", 232, 236], ["Samples", "TEST", 0, 7], ["an ice-cold needle", "TREATMENT", 133, 151], ["anticoagulation buffer", "TREATMENT", 162, 184], ["30 mM citric acid", "TREATMENT", 186, 203], ["30 mM sodium citrate", "TREATMENT", 205, 225], ["arthrodial membrane", "OBSERVATION", 69, 88], ["base", "ANATOMY_MODIFIER", 96, 100], ["metathoracic leg", "ANATOMY", 111, 127]]], ["25-50 \u00b5L of hemolymph were pipetted into a similar volume of ice-cold buffer and immediately diluted into 300 \u00b5L of ice-cold buffer in a fresh tube on ice.High-performance liquid chromatography (HPLC).", [["hemolymph", "ANATOMY", 12, 21], ["hemolymph", "ORGANISM_SUBSTANCE", 12, 21], ["tube", "TISSUE", 143, 147], ["ice-cold buffer", "TREATMENT", 61, 76], ["a fresh tube on ice", "TREATMENT", 135, 154], ["fresh tube", "OBSERVATION", 137, 147]]], ["Samples were analyzed on anStatistical analysis.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["anStatistical analysis", "TEST", 25, 47]]], ["Statistical tests were performed with GraphPad Prism (version 8.3.0).", [["Statistical tests", "TEST", 0, 17], ["version", "TEST", 54, 61]]], ["P -values in each experiment were determined by unpaired two-tailed Student's t test with 95% confidence interval.", [["P", "DNA", 0, 1], ["P -values", "TEST", 0, 9]]], ["In all flow cytometric experiments two biological replicates were acquired per group, and a minimum of 10,000 total events was collected.", [["all", "OBSERVATION_MODIFIER", 3, 6], ["flow cytometric", "OBSERVATION", 7, 22]]], ["Mean and %CV of gated events were used to derive SD for determination of statistical significance.Declaration of interestsAll authors are employees and/or shareholders in Augmanity, a research company based in Rehovot, Israel, developing technologies reported in this paper, and are listed as inventors on patents related to technologies reported in this paper.", [["Mean", "TEST", 0, 4], ["gated events", "PROBLEM", 16, 28]]], ["Tables Table S1 .", [["S1", "ANATOMY", 13, 15]]], ["Automaton (prototype) sequence listPrototype design and simulationThe design of the target was based on incorporation of the cleavage site of the chosen HHR (from the self-limiting automata (3WJ) design) into a random sequence in the loop site of a loop and stem structure that after HHR-mediated cleavage form a stable stem with flanking arms (Fig. S1 ) .Prototype design and simulationThe automata consist of two DNA oligonucleotides that have an eight base complementation to each other and eight base complementation to regions in the cleaved target molecule.", [["stem structure", "ANATOMY", 258, 272], ["stem", "ANATOMY", 320, 324], ["HHR", "GENE_OR_GENE_PRODUCT", 284, 287], ["stem", "CANCER", 320, 324], ["DNA", "CELLULAR_COMPONENT", 415, 418], ["HHR", "PROTEIN", 153, 156], ["HHR", "PROTEIN", 284, 287], ["flanking arms", "DNA", 330, 343], ["cleaved target molecule", "PROTEIN", 539, 562], ["Automaton (prototype)", "TREATMENT", 0, 21], ["the cleavage site", "PROBLEM", 121, 138], ["a random sequence", "TEST", 209, 226], ["a loop and stem structure", "TREATMENT", 247, 272], ["HHR", "TREATMENT", 284, 287], ["two DNA oligonucleotides", "TREATMENT", 411, 435], ["an eight base complementation", "TREATMENT", 446, 475], ["loop", "OBSERVATION", 249, 253], ["stem structure", "OBSERVATION", 258, 272], ["stable", "OBSERVATION_MODIFIER", 313, 319], ["stem", "OBSERVATION_MODIFIER", 320, 324], ["eight", "OBSERVATION_MODIFIER", 449, 454], ["base", "OBSERVATION_MODIFIER", 455, 459], ["complementation", "OBSERVATION", 460, 475], ["base", "OBSERVATION_MODIFIER", 500, 504], ["complementation", "OBSERVATION", 505, 520], ["target molecule", "OBSERVATION", 547, 562]]], ["The L strand consists of a T7 promoter sequence, a complementary sequence of the HHR gene and a 3' phosphorylation modification to prevent elongation from the L strand.Prototype design and simulationThe automaton can be assembled only in the presence of R (cleaved target), which consists of two subunits that form a stable stem with flanking arms which represent a cleaved target molecule (Fig. S2 ).Prototype design and simulationMoreover, we tested the stability and shelf life time of the LNA-modified automaton comprising 7 LNA bases in L and S strands at room temperature over 29 days .The LNA-modified version remained intact.", [["LNA", "CHEMICAL", 493, 496], ["LNA", "CHEMICAL", 596, 599], ["HHR", "GENE_OR_GENE_PRODUCT", 81, 84], ["L strand", "DNA", 4, 12], ["T7 promoter sequence", "DNA", 27, 47], ["HHR gene", "DNA", 81, 89], ["L strand", "DNA", 159, 167], ["R (cleaved target", "PROTEIN", 254, 271], ["cleaved target molecule", "PROTEIN", 366, 389], ["S2", "PROTEIN", 396, 398], ["a T7 promoter sequence", "TREATMENT", 25, 47], ["the HHR gene", "TREATMENT", 77, 89], ["a 3' phosphorylation modification", "TREATMENT", 94, 127], ["elongation", "PROBLEM", 139, 149], ["the L strand", "TREATMENT", 155, 167], ["flanking arms", "PROBLEM", 334, 347], ["a cleaved target molecule", "PROBLEM", 364, 389], ["the LNA", "TEST", 489, 496], ["The LNA", "TEST", 592, 599], ["L", "ANATOMY_MODIFIER", 4, 5], ["L", "ANATOMY_MODIFIER", 159, 160], ["stable", "OBSERVATION_MODIFIER", 317, 323], ["stem", "OBSERVATION", 324, 328], ["target molecule", "OBSERVATION", 374, 389], ["Fig", "OBSERVATION_MODIFIER", 391, 394], ["LNA", "ANATOMY", 493, 496], ["L", "ANATOMY_MODIFIER", 542, 543], ["LNA", "OBSERVATION", 596, 599], ["intact", "OBSERVATION", 626, 632]]], ["In addition, the assembly continued to occur as indicated by the increased intensity of the bands (Fig. S3) .Prototype design and simulationTo protect the assembled automaton from RNase H, several variants were tested in which parts L and S were modified with either locked nucleic acids (LNA) or 2-O-methoxyethyl RNAM13mp18 Scaffold >M13mp18 [length=7249] [version=09-MAY-2008] [topology=circular] Cloning vectorM13mp18, complete sequence.M13mp18 Scaffold >M13mp18 [length=7249] [version=09-MAY-2008] [topology=circular] Cloning vectorAATGCTACTACTATTAGTAGAATTGATGCCACCTTTTCAGCTCGCGCCCCAAATGAAAATATAGCTAAACAGGTTATTGACCATT TGCGAAATGTATCTAATGGTCAAACTAAATCTACTCGTTCGCAGAATTGGGAATCAACTGTTATATGGAATGAAACTTCCAGACA CCGTACTTTAGTTGCATATTTAAAACATGTTGAGCTACAGCATTATATTCAGCAATTAAGCTCTAAGCCATCCGCAAAAATGACC TCTTATCAAAAGGAGCAATTAAAGGTACTCTCTAATCCTGACCTGTTGGAGTTTGCTTCCGGTCTGGTTCGCTTTGAAGCTCGAA TTAAAACGCGATATTTGAAGTCTTTCGGGCTTCCTCTTAATCTTTTTGATGCAATCCGCTTTGCTTCTGACTATAATAGTCAGGG TAAAGACCTGATTTTTGATTTATGGTCATTCTCGTTTTCTGAACTGTTTAAAGCATTTGAGGGGGATTCAATGAATATTTATGAC GATTCCGCAGTATTGGACGCTATCCAGTCTAAACATTTTACTATTACCCCCTCTGGCAAAACTTCTTTTGCAAAAGCCTCTCGCT ATTTTGGTTTTTATCGTCGTCTGGTAAACGAGGGTTATGATAGTGTTGCTCTTACTATGCCTCGTAATTCCTTTTGGCGTTATGT ATCTGCATTAGTTGAATGTGGTATTCCTAAATCTCAACTGATGAATCTTTCTACCTGTAATAATGTTGTTCCGTTAGTTCGTTTT ATTAACGTAGATTTTTCTTCCCAACGTCCTGACTGGTATAATGAGCCAGTTCTTAAAATCGCATAAGGTAATTCACAATGATTAA AGTTGAAATTAAACCATCTCAAGCCCAATTTACTACTCGTTCTGGTGTTTCTCGTCAGGGCAAGCCTTATTCACTGAATGAGCAG CTTTGTTACGTTGATTTGGGTAATGAATATCCGGTTCTTGTCAAGATTACTCTTGATGAAGGTCAGCCAGCCTATGCGCCTGGTC TGTACACCGTTCATCTGTCCTCTTTCAAAGTTGGTCAGTTCGGTTCCCTTATGATTGACCGTCTGCGCCTCGTTCCGGCTAAGTA ACATGGAGCAGGTCGCGGATTTCGACACAATTTATCAGGCGATGATACAAATCTCCGTTGTACTTTGTTTCGCGCTTGGTATAAT CGCTGGGGGTCAAAGATGAGTGTTTTAGTGTATTCTTTTGCCTCTTTCGTTTTAGGTTGGTGCCTTCGTAGTGGCATTACGTATT TTACCCGTTTAATGGAAACTTCCTCATGAAAAAGTCTTTAGTCCTCAAAGCCTCTGTAGCCGTTGCTACCCTCGTTCCGATGCTG TCTTTCGCTGCTGAGGGTGACGATCCCGCAAAAGCGGCCTTTAACTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTATGCGT GGGCGATGGTTGTTGTCATTGTCGGCGCAACTATCGGTATCAAGCTGTTTAAGAAATTCACCTCGAAAGCAAGCTGATAAACCGA TACAATTAAAGGCTCCTTTTGGAGCCTTTTTTTTGGAGATTTTCAACGTGAAAAAATTATTATTCGCAATTCCTTTAGTTGTTCC TTTCTATTCTCACTCCGCTGAAACTGTTGAAAGTTGTTTAGCAAAATCCCATACAGAAAATTCATTTACTAACGTCTGGAAAGAC GACAAAACTTTAGATCGTTACGCTAACTATGAGGGCTGTCTGTGGAATGCTACAGGCGTTGTAGTTTGTACTGGTGACGAAACTC AGTGTTACGGTACATGGGTTCCTATTGGGCTTGCTATCCCTGAAAATGAGGGTGGTGGCTCTGAGGGTGGCGGTTCTGAGGGTGG CGGTTCTGAGGGTGGCGGTACTAAACCTCCTGAGTACGGTGATACACCTATTCCGGGCTATACTTATATCAACCCTCTCGACGGC ACTTATCCGCCTGGTACTGAGCAAAACCCCGCTAATCCTAATCCTTCTCTTGAGGAGTCTCAGCCTCTTAATACTTTCATGTTTC AGAATAATAGGTTCCGAAATAGGCAGGGGGCATTAACTGTTTATACGGGCACTGTTACTCAAGGCACTGACCCCGTTAAAACTTA TTACCAGTACACTCCTGTATCATCAAAAGCCATGTATGACGCTTACTGGAACGGTAAATTCAGAGACTGCGCTTTCCATTCTGGC TTTAATGAGGATTTATTTGTTTGTGAATATCAAGGCCAATCGTCTGACCTGCCTCAACCTCCTGTCAATGCTGGCGGCGGCTCTG GTGGTGGTTCTGGTGGCGGCTCTGAGGGTGGTGGCTCTGAGGGTGGCGGTTCTGAGGGTGGCGGCTCTGAGGGAGGCGGTTCCGG TGGTGGCTCTGGTTCCGGTGATTTTGATTATGAAAAGATGGCAAACGCTAATAAGGGGGCTATGACCGAAAATGCCGATGAAAAC GCGCTACAGTCTGACGCTAAAGGCAAACTTGATTCTGTCGCTACTGATTACGGTGCTGCTATCGATGGTTTCATTGGTGACGTTT CCGGCCTTGCTAATGGTAATGGTGCTACTGGTGATTTTGCTGGCTCTAATTCCCAAATGGCTCAAGTCGGTGACGGTGATAATTC ACCTTTAATGAATAATTTCCGTCAATATTTACCTTCCCTCCCTCAATCGGTTGAATGTCGCCCTTTTGTCTTTGGCGCTGGTAAA CCATATGAATTTTCTATTGATTGTGACAAAATAAACTTATTCCGTGGTGTCTTTGCGTTTCTTTTATATGTTGCCACCTTTATGT ATGTATTTTCTACGTTTGCTAACATACTGCGTAATAAGGAGTCTTAATCATGCCAGTTCTTTTGGGTATTCCGTTATTATTGCGT TTCCTCGGTTTCCTTCTGGTAACTTTGTTCGGCTATCTGCTTACTTTTCTTAAAAAGGGCTTCGGTAAGATAGCTATTGCTATTT CATTGTTTCTTGCTCTTATTATTGGGCTTAACTCAATTCTTGTGGGTTATCTCTCTGATATTAGCGCTCAATTACCCTCTGACTT TGTTCAGGGTGTTCAGTTAATTCTCCCGTCTAATGCGCTTCCCTGTTTTTATGTTATTCTCTCTGTAAAGGCTGCTATTTTCATT TTTGACGTTAAACAAAAAATCGTTTCTTATTTGGATTGGGATAAATAATATGGCTGTTTATTTTGTAACTGGCAAATTAGGCTCT GGAAAGACGCTCGTTAGCGTTGGTAAGATTCAGGATAAAATTGTAGCTGGGTGCAAAATAGCAACTAATCTTGATTTAAGGCTTC AAAACCTCCCGCAAGTCGGGAGGTTCGCTAAAACGCCTCGCGTTCTTAGAATACCGGATAAGCCTTCTATATCTGATTTGCTTGC TATTGGGCGCGGTAATGATTCCTACGATGAAAATAAAAACGGCTTGCTTGTTCTCGATGAGTGCGGTACTTGGTTTAATACCCGT TCTTGGAATGATAAGGAAAGACAGCCGATTATTGATTGGTTTCTACATGCTCGTAAATTAGGATGGGATATTATTTTTCTTGTTC AGGACTTATCTATTGTTGATAAACAGGCGCGTTCTGCATTAGCTGAACATGTTGTTTATTGTCGTCGTCTGGACAGAATTACTTT ACCTTTTGTCGGTACTTTATATTCTCTTATTACTGGCTCGAAAATGCCTCTGCCTAAATTACATGTTGGCGTTGTTAAATATGGC GATTCTCAATTAAGCCCTACTGTTGAGCGTTGGCTTTATACTGGTAAGAATTTGTATAACGCATATGATACTAAACAGGCTTTTT CTAGTAATTATGATTCCGGTGTTTATTCTTATTTAACGCCTTATTTATCACACGGTCGGTATTTCAAACCATTAAATTTAGGTCA GAAGATGAAATTAACTAAAATATATTTGAAAAAGTTTTCTCGCGTTCTTTGTCTTGCGATTGGATTTGCATCAGCATTTACATAT AGTTATATAACCCAACCTAAGCCGGAGGTTAAAAAGGTAGTCTCTCAGACCTATGATTTTGATAAATTCACTATTGACTCTTCTC AGCGTCTTAATCTAAGCTATCGCTATGTTTTCAAGGATTCTAAGGGAAAATTAATTAATAGCGACGATTTACAGAAGCAAGGTTA TTCACTCACATATATTGATTTATGTACTGTTTCCATTAAAAAAGGTAATTCAAATGAAATTGTTAAATGTAATTAATTTTGTTTT CTTGATGTTTGTTTCATCATCTTCTTTTGCTCAGGTAATTGAAATGAATAATTCGCCTCTGCGCGATTTTGTAACTTGGTATTCA AAGCAATCAGGCGAATCCGTTATTGTTTCTCCCGATGTAAAAGGTACTGTTACTGTATATTCATCTGACGTTAAACCTGAAAATC TACGCAATTTCTTTATTTCTGTTTTACGTGCAAATAATTTTGATATGGTAGGTTCTAACCCTTCCATTATTCAGAAGTATAATCC AAACAATCAGGATTATATTGATGAATTGCCATCATCTGATAATCAGGAATATGATGATAATTCCGCTCCTTCTGGTGGTTTCTTT GTTCCGCAAAATGATAATGTTACTCAAACTTTTAAAATTAATAACGTTCGGGCAAAGGATTTAATACGAGTTGTCGAATTGTTTG TAAAGTCTAATACTTCTAAATCCTCAAATGTATTATCTATTGACGGCTCTAATCTATTAGTTGTTAGTGCTCCTAAAGATATTTT AGATAACCTTCCTCAATTCCTTTCAACTGTTGATTTGCCAACTGACCAGATATTGATTGAGGGTTTGATATTTGAGGTTCAGCAA GGTGATGCTTTAGATTTTTCATTTGCTGCTGGCTCTCAGCGTGGCACTGTTGCAGGCGGTGTTAATACTGACCGCCTCACCTCTG TTTTATCTTCTGCTGGTGGTTCGTTCGGTATTTTTAATGGCGATGTTTTAGGGCTATCAGTTCGCGCATTAAAGACTAATAGCCA TTCAAAAATATTGTCTGTGCCACGTATTCTTACGCTTTCAGGTCAGAAGGGTTCTATCTCTGTTGGCCAGAATGTCCCTTTTATT ACTGGTCGTGTGACTGGTGAATCTGCCAATGTAAATAATCCATTTCAGACGATTGAGCGTCAAAATGTAGGTATTTCCATGAGCG TTTTTCCTGTTGCAATGGCTGGCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTCAGGCAAG TGATGTTATTACTAATCAAAGAAGTATTGCTACAACGGTTAATTTGCGTGATGGACAGACTCTTTTACTCGGTGGCCTCACTGAT TATAAAAACACTTCTCAGGATTCTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTCTGATT CTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGG TGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTT CGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAA CTTGATTTGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTA ATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTC GGAACCACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGA AGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCT CACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACA GGAAACAGCTATGACCATGATTACGAATTCGAGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCA CTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCA GCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGGTT TCCGGCACCAGAAGCGGTGCCGGAAAGCTGGCTGGAGTGCGATCTTCCTGAGGCCGATACTGTCGTCGTCCCCTCAAACTGGCAG ATGCACGGTTACGATGCGCCCATCTACACCAACGTGACCTATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGA CGGGTTGTTACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTATTTTTGATGGCGTTCCTAT TGGTTAAAAAATGAGCTGATTTAACAAAAATTTAATGCGAATTTTAACAAAATATTAACGTTTACAATTTAAATATTTGCTTATA CAATCTTCCTGTTTTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGATTGACATGCTAGTTTTACGATTACCGTTCATCGA TTCTCTTGTTTGCTCCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGATCTCTCAAAAATAGCTACCCTCTCCGGCATTAAT TTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCCGGCCTTTCTCACCCTTTTGAATCTTTACCTACAC ATTACTCAGGCATTGCATTTAAAATATATGAGGGTTCTAAAAATTTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAAAAGT ATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGGCTTTATTGCTTAATTTTGCTAATTCTTTGCCT TGCCTGTATGATTTATTGGATGTTSupplementary note 4 HHR activity gelsIn this study we used gel electrophoresis to measure various HHR reaction kinetics.", [["nucleic acids", "CHEMICAL", 274, 287], ["LNA", "CHEMICAL", 289, 292], ["2-O-methoxyethyl", "CHEMICAL", 297, 313], ["2-O-methoxyethyl RNAM13mp18", "CHEMICAL", 297, 324], ["RNase H", "GENE_OR_GENE_PRODUCT", 180, 187], ["nucleic acids", "SIMPLE_CHEMICAL", 274, 287], ["LNA", "SIMPLE_CHEMICAL", 289, 292], ["2-O-methoxyethyl RNAM13mp18", "SIMPLE_CHEMICAL", 297, 324], ["vectorM13mp18", "GENE_OR_GENE_PRODUCT", 407, 420], ["RNase H", "PROTEIN", 180, 187], ["M13mp18", "PROTEIN", 335, 342], ["vectorM13mp18", "PROTEIN", 407, 420], ["the increased intensity of the bands (Fig", "PROBLEM", 61, 102], ["several variants", "PROBLEM", 189, 205], ["Scaffold", "TEST", 325, 333], ["length", "TEST", 344, 350], ["version", "TEST", 358, 365], ["circular] Cloning vectorM13mp18", "TREATMENT", 389, 420], ["Scaffold", "TEST", 448, 456], ["length", "TEST", 467, 473], ["version", "TEST", 481, 488], ["AGTTGAAATTAAACCATCTCAAGCCCAATTTACTACTCGTTCTGGTGTTTCTCGTCAGGGCAAGCCTTATTCACTGAATGAGCAG", "TEST", 1396, 1481], ["TTACCCGTTTAATGGAAACTTCCTCATGAAAAAGTCTTTAGTCCTCAAAGCCTCTGTAGCCGTTGCTACCCTCGTTCCGATGCTG", "TEST", 1826, 1911], ["TCTTTCGCTGCTGAGGGTGACGATCCCGCAAAAGCGGCCTTTAACTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTATGCGT", "TEST", 1912, 1997], ["GGGCGATGGTTGTTGTCATTGTCGGCGCAACTATCGGTATCAAGCTGTTTAAGAAATTCACCTCGAAAGCAAGCTGATAAACCGA", "TEST", 1998, 2083], ["TTTCTATTCTCACTCCGCTGAAACTGTTGAAAGTTGTTTAGCAAAATCCCATACAGAAAATTCATTTACTAACGTCTGGAAAGAC", "TEST", 2170, 2255], ["CGGTTCTGAGGGTGGCGGTACTAAACCTCCTGAGTACGGTGATACACCTATTCCGGGCTATACTTATATCAACCCTCTCGACGGC", "TEST", 2428, 2513], ["ACTTATCCGCCTGGTACTGAGCAAAACCCCGCTAATCCTAATCCTTCTCTTGAGGAGTCTCAGCCTCTTAATACTTTCATGTTTC", "TEST", 2514, 2599], ["AGAATAATAGGTTCCGAAATAGGCAGGGGGCATTAACTGTTTATACGGGCACTGTTACTCAAGGCACTGACCCCGTTAAAACTTA", "TEST", 2600, 2685], ["TTTAATGAGGATTTATTTGTTTGTGAATATCAAGGCCAATCGTCTGACCTGCCTCAACCTCCTGTCAATGCTGGCGGCGGCTCTG", "TEST", 2772, 2857], ["TGGTGGCTCTGGTTCCGGTGATTTTGATTATGAAAAGATGGCAAACGCTAATAAGGGGGCTATGACCGAAAATGCCGATGAAAAC", "TEST", 2944, 3029], ["GCGCTACAGTCTGACGCTAAAGGCAAACTTGATTCTGTCGCTACTGATTACGGTGCTGCTATCGATGGTTTCATTGGTGACGTTT", "TEST", 3030, 3115], ["CCGGCCTTGCTAATGGTAATGGTGCTACTGGTGATTTTGCTGGCTCTAATTCCCAAATGGCTCAAGTCGGTGACGGTGATAATTC", "TEST", 3116, 3201], ["ACCTTTAATGAATAATTTCCGTCAATATTTACCTTCCCTCCCTCAATCGGTTGAATGTCGCCCTTTTGTCTTTGGCGCTGGTAAA", "TEST", 3202, 3287], ["CCATATGAATTTTCTATTGATTGTGACAAAATAAACTTATTCCGTGGTGTCTTTGCGTTTCTTTTATATGTTGCCACCTTTATGT", "TEST", 3288, 3373], ["ATGTATTTTCTACGTTTGCTAACATACTGCGTAATAAGGAGTCTTAATCATGCCAGTTCTTTTGGGTATTCCGTTATTATTGCGT", "TEST", 3374, 3459], ["TTCCTCGGTTTCCTTCTGGTAACTTTGTTCGGCTATCTGCTTACTTTTCTTAAAAAGGGCTTCGGTAAGATAGCTATTGCTATTT", "TEST", 3460, 3545], ["CATTGTTTCTTGCTCTTATTATTGGGCTTAACTCAATTCTTGTGGGTTATCTCTCTGATATTAGCGCTCAATTACCCTCTGACTT", "TEST", 3546, 3631], ["TGTTCAGGGTGTTCAGTTAATTCTCCCGTCTAATGCGCTTCCCTGTTTTTATGTTATTCTCTCTGTAAAGGCTGCTATTTTCATT", "TEST", 3632, 3717], ["TTTGACGTTAAACAAAAAATCGTTTCTTATTTGGATTGGGATAAATAATATGGCTGTTTATTTTGTAACTGGCAAATTAGGCTCT", "TEST", 3718, 3803], ["GGAAAGACGCTCGTTAGCGTTGGTAAGATTCAGGATAAAATTGTAGCTGGGTGCAAAATAGCAACTAATCTTGATTTAAGGCTTC", "TEST", 3804, 3889], ["AAAACCTCCCGCAAGTCGGGAGGTTCGCTAAAACGCCTCGCGTTCTTAGAATACCGGATAAGCCTTCTATATCTGATTTGCTTGC", "TEST", 3890, 3975], ["TATTGGGCGCGGTAATGATTCCTACGATGAAAATAAAAACGGCTTGCTTGTTCTCGATGAGTGCGGTACTTGGTTTAATACCCGT", "TEST", 3976, 4061], ["TCTTGGAATGATAAGGAAAGACAGCCGATTATTGATTGGTTTCTACATGCTCGTAAATTAGGATGGGATATTATTTTTCTTGTTC", "TEST", 4062, 4147], ["AGGACTTATCTATTGTTGATAAACAGGCGCGTTCTGCATTAGCTGAACATGTTGTTTATTGTCGTCGTCTGGACAGAATTACTTT", "TEST", 4148, 4233], ["ACCTTTTGTCGGTACTTTATATTCTCTTATTACTGGCTCGAAAATGCCTCTGCCTAAATTACATGTTGGCGTTGTTAAATATGGC", "TEST", 4234, 4319], ["GATTCTCAATTAAGCCCTACTGTTGAGCGTTGGCTTTATACTGGTAAGAATTTGTATAACGCATATGATACTAAACAGGCTTTTT", "TEST", 4320, 4405], ["CTAGTAATTATGATTCCGGTGTTTATTCTTATTTAACGCCTTATTTATCACACGGTCGGTATTTCAAACCATTAAATTTAGGTCA", "TEST", 4406, 4491], ["GAAGATGAAATTAACTAAAATATATTTGAAAAAGTTTTCTCGCGTTCTTTGTCTTGCGATTGGATTTGCATCAGCATTTACATAT", "TEST", 4492, 4577], ["AGTTATATAACCCAACCTAAGCCGGAGGTTAAAAAGGTAGTCTCTCAGACCTATGATTTTGATAAATTCACTATTGACTCTTCTC", "TEST", 4578, 4663], ["AGCGTCTTAATCTAAGCTATCGCTATGTTTTCAAGGATTCTAAGGGAAAATTAATTAATAGCGACGATTTACAGAAGCAAGGTTA", "TEST", 4664, 4749], ["CTTGATGTTTGTTTCATCATCTTCTTTTGCTCAGGTAATTGAAATGAATAATTCGCCTCTGCGCGATTTTGTAACTTGGTATTCA", "TEST", 4836, 4921], ["AAGCAATCAGGCGAATCCGTTATTGTTTCTCCCGATGTAAAAGGTACTGTTACTGTATATTCATCTGACGTTAAACCTGAAAATC", "TEST", 4922, 5007], ["TACGCAATTTCTTTATTTCTGTTTTACGTGCAAATAATTTTGATATGGTAGGTTCTAACCCTTCCATTATTCAGAAGTATAATCC", "TEST", 5008, 5093], ["AAACAATCAGGATTATATTGATGAATTGCCATCATCTGATAATCAGGAATATGATGATAATTCCGCTCCTTCTGGTGGTTTCTTT", "TEST", 5094, 5179], ["TAAAGTCTAATACTTCTAAATCCTCAAATGTATTATCTATTGACGGCTCTAATCTATTAGTTGTTAGTGCTCCTAAAGATATTTT", "TEST", 5266, 5351], ["AGATAACCTTCCTCAATTCCTTTCAACTGTTGATTTGCCAACTGACCAGATATTGATTGAGGGTTTGATATTTGAGGTTCAGCAA", "TEST", 5352, 5437], ["GGTGATGCTTTAGATTTTTCATTTGCTGCTGGCTCTCAGCGTGGCACTGTTGCAGGCGGTGTTAATACTGACCGCCTCACCTCTG", "TEST", 5438, 5523], ["TTTTATCTTCTGCTGGTGGTTCGTTCGGTATTTTTAATGGCGATGTTTTAGGGCTATCAGTTCGCGCATTAAAGACTAATAGCCA", "TEST", 5524, 5609], ["TTCAAAAATATTGTCTGTGCCACGTATTCTTACGCTTTCAGGTCAGAAGGGTTCTATCTCTGTTGGCCAGAATGTCCCTTTTATT", "TEST", 5610, 5695], ["ACTGGTCGTGTGACTGGTGAATCTGCCAATGTAAATAATCCATTTCAGACGATTGAGCGTCAAAATGTAGGTATTTCCATGAGCG", "TEST", 5696, 5781], ["TTTTTCCTGTTGCAATGGCTGGCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTCAGGCAAG", "TEST", 5782, 5867], ["TGATGTTATTACTAATCAAAGAAGTATTGCTACAACGGTTAATTTGCGTGATGGACAGACTCTTTTACTCGGTGGCCTCACTGAT", "TEST", 5868, 5953], ["TATAAAAACACTTCTCAGGATTCTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTCTGATT", "TEST", 5954, 6039], ["CTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGG", "TEST", 6040, 6125], ["TGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTT", "TEST", 6126, 6211], ["CGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAA", "TEST", 6212, 6297], ["CTTGATTTGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTA", "TEST", 6298, 6383], ["ATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTC", "TEST", 6384, 6469], ["GGAACCACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGA", "TEST", 6470, 6555], ["AGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT", "TEST", 6556, 6641], ["GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCT", "TEST", 6642, 6727], ["CACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACA", "TEST", 6728, 6813], ["GGAAACAGCTATGACCATGATTACGAATTCGAGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCA", "TEST", 6814, 6899], ["CTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCA", "TEST", 6900, 6985], ["CAATCTTCCTGTTTTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGATTGACATGCTAGTTTTACGATTACCGTTCATCGA TTCTCTTGTTTGCTCCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGATCTCTCAAAAATAGCTACCCTCTCCGGCATTAAT TTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCCGGCCTTTCTCACCCTTTTGAATCTTTACCTACAC ATTACTCAGGCATTGCATTTAAAATATATGAGGGTTCTAAAAATTTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAAAAGT ATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGGCTTTATTGCTTAATTTTGCTAATTCTTTGCCT TGCCTGTATGATTTATTGGATGTTSupplementary", "TREATMENT", 7416, 7883], ["this study", "TEST", 7911, 7921], ["gel electrophoresis", "TREATMENT", 7930, 7949], ["various HHR reaction kinetics", "TREATMENT", 7961, 7990], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["intensity", "OBSERVATION_MODIFIER", 75, 84]]], ["These automata are composed of two ssDNA (L,S) that have short complementary sequences to each other and to the target and only then, they can form a three way junction (3WJ) (Fig. S11, S12 ) .", [["ssDNA", "CELLULAR_COMPONENT", 35, 40], ["S12", "PROTEIN", 186, 189], ["short complementary sequences", "PROBLEM", 57, 86]]], ["The L strand contains a T7 promoter sequence and a complementary sequence of the HHR.Supplementary note 4 HHR activity gelsUpon the 3WJ formation, DNA polymerase can elongate the S strand ( Fig. S13 ) that produces active ds T7 promoter which in the presence of T7 RNA polymerase transcribes HHR (Fig. S14 ) .Supplementary note 4 HHR activity gelsIn turn, the transcribed HHR cleavages the target and reduces the target amount (Fig S15) .", [["3WJ", "SIMPLE_CHEMICAL", 132, 135], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["Fig. S13", "GENE_OR_GENE_PRODUCT", 190, 198], ["T7", "GENE_OR_GENE_PRODUCT", 225, 227], ["Fig. S14", "GENE_OR_GENE_PRODUCT", 297, 305], ["HHR", "GENE_OR_GENE_PRODUCT", 372, 375], ["S15", "GENE_OR_GENE_PRODUCT", 432, 435], ["L strand", "DNA", 4, 12], ["T7 promoter sequence", "DNA", 24, 44], ["HHR", "DNA", 81, 84], ["DNA polymerase", "PROTEIN", 147, 161], ["S strand", "DNA", 179, 187], ["ds T7 promoter", "DNA", 222, 236], ["T7 RNA polymerase", "PROTEIN", 262, 279], ["HHR", "PROTEIN", 292, 295], ["Fig. S14", "PROTEIN", 297, 305], ["HHR", "DNA", 372, 375], ["a T7 promoter sequence", "TREATMENT", 22, 44], ["the 3WJ formation", "TREATMENT", 128, 145], ["DNA polymerase", "PROBLEM", 147, 161], ["the S strand ( Fig. S13", "PROBLEM", 175, 198], ["active ds T7 promoter", "PROBLEM", 215, 236], ["the transcribed HHR cleavages", "TREATMENT", 356, 385], ["L", "ANATOMY_MODIFIER", 4, 5], ["strand", "ANATOMY_MODIFIER", 6, 12], ["T7", "ANATOMY", 24, 26], ["active", "OBSERVATION_MODIFIER", 215, 221], ["T7", "ANATOMY", 262, 264], ["amount", "OBSERVATION_MODIFIER", 420, 426]]], ["The reduction of the target diminishes the amount of the 3WJ and sequentially the HHR amount decreases.", [["HHR", "PROTEIN", 82, 85], ["the 3WJ", "TREATMENT", 53, 60], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["target", "OBSERVATION_MODIFIER", 21, 27], ["diminishes", "OBSERVATION_MODIFIER", 28, 38], ["amount", "OBSERVATION_MODIFIER", 43, 49], ["HHR", "OBSERVATION_MODIFIER", 82, 85], ["amount", "OBSERVATION_MODIFIER", 86, 92], ["decreases", "OBSERVATION_MODIFIER", 93, 102]]], ["Target before cleavage (blue), HHR (red) and cleavage reaction (green).Design of a sensing automatonThe idea is to build a molecular automaton, with complex recognition and sensing capabilities.Design of a sensing automatonFirst, the automaton assembles only in the presence of its specific target RNA (R) just like the prototype automaton.", [["HHR", "SIMPLE_CHEMICAL", 31, 34], ["target RNA", "RNA", 291, 301], ["cleavage (blue", "TREATMENT", 14, 28], ["cleavage reaction", "PROBLEM", 45, 62], ["a sensing automatonFirst", "TREATMENT", 204, 228], ["sensing automaton", "OBSERVATION", 83, 100]]], ["Upon assembly the sensor automaton is inactive as long as it doesn't encounter the activating molecule.Design of a sensing automatonThe sensor automaton design is based on the prototype automaton (Supplementary note 1, Table S3 ) , and works via toehold mediated strand displacement mechanism.", [["activating molecule", "PROTEIN", 83, 102], ["sensing automaton", "OBSERVATION", 115, 132], ["strand displacement", "OBSERVATION", 263, 282]]], ["Two changes were done: first, L strand was extended at 5' with thoehold-T7 (10 and 17 bases respectively).", [["thoehold-T7", "DNA", 63, 74], ["T7", "ANATOMY", 72, 74]]], ["This addition leads to conformational changes in L strand, which result in a formation of a hairpin loop, making the T7* and the HHR* sequences less accessible.", [["T7* and the HHR* sequences", "DNA", 117, 143], ["conformational changes in L strand", "PROBLEM", 23, 57], ["a hairpin loop", "TREATMENT", 90, 104], ["the HHR* sequences", "TEST", 125, 143], ["L strand", "OBSERVATION_MODIFIER", 49, 57], ["hairpin loop", "OBSERVATION", 92, 104], ["T7", "ANATOMY", 117, 119]]], ["The new L is denoted by sL.Design of a sensing automatonSecond, T7 sequence was added to 5' of R strand (Fig. S16A, B) .", [["sL", "GENE_OR_GENE_PRODUCT", 24, 26], ["S16A", "GENE_OR_GENE_PRODUCT", 110, 114], ["B", "GENE_OR_GENE_PRODUCT", 116, 117], ["sL", "PROTEIN", 24, 26], ["T7 sequence", "DNA", 64, 75], ["R strand", "DNA", 95, 103], ["S16A", "PROTEIN", 110, 114], ["B", "PROTEIN", 116, 117], ["a sensing automatonSecond, T7 sequence", "TREATMENT", 37, 75], ["new", "OBSERVATION_MODIFIER", 4, 7], ["L", "OBSERVATION_MODIFIER", 8, 9], ["sL", "OBSERVATION_MODIFIER", 24, 26]]], ["The new L and R are denoted by sL and sR, respectively.", [["R", "GENE_OR_GENE_PRODUCT", 14, 15], ["sL", "GENE_OR_GENE_PRODUCT", 31, 33], ["sR", "GENE_OR_GENE_PRODUCT", 38, 40], ["sL", "PROTEIN", 31, 33], ["sR", "PROTEIN", 38, 40], ["new", "OBSERVATION_MODIFIER", 4, 7], ["L", "ANATOMY_MODIFIER", 8, 9], ["R", "ANATOMY_MODIFIER", 14, 15], ["sL", "OBSERVATION_MODIFIER", 31, 33]]], ["The assembly of the sensor automaton was analyzed by NUPACK 37 simulations (Fig. S16C, D) and verified by in-vitro assembly assay following gel electrophoresis as described in the materials and method section.", [["the sensor automaton", "TEST", 16, 36], ["gel electrophoresis", "TEST", 140, 159], ["method section", "TREATMENT", 194, 208]]], ["(Fig. S17) .Design of a sensing automatonAnother sensing mechanism can be an aptamer-target and ligand-protein interactions, where such interactions lead to unwinding of the L strand, and activation of the sensor automaton. ( Fig. S18 ).Design of a sensing automatonTime dependent kinetics were determined for each MOI by harvesting infected wells at different time points post infection, a MOI dependent kinetics were observed ( Fig. S19 ).Design of a sensing automatonSince our automaton targets RNA coding for GP64, which is being expressed starting at the early stages of infection, as opposed to our reporter gene GFP which is being expressed under the very late promoter of polyhedrin, we needed to assess the actual definite amount of GP64 RNA for a specific time point post infection and a specific MOI ( Fig. S20 ).", [["infection", "DISEASE", 378, 387], ["infection", "DISEASE", 576, 585], ["infection", "DISEASE", 782, 791], ["GP64", "GENE_OR_GENE_PRODUCT", 513, 517], ["GFP", "GENE_OR_GENE_PRODUCT", 619, 622], ["polyhedrin", "GENE_OR_GENE_PRODUCT", 680, 690], ["GP64", "GENE_OR_GENE_PRODUCT", 742, 746], ["GP64", "PROTEIN", 513, 517], ["reporter gene GFP", "DNA", 605, 622], ["polyhedrin", "DNA", 680, 690], ["GP64 RNA", "RNA", 742, 750], ["a sensing automaton", "TREATMENT", 22, 41], ["the L strand", "TREATMENT", 170, 182], ["a sensing automatonTime dependent kinetics", "TREATMENT", 247, 289], ["each MOI", "PROBLEM", 310, 318], ["infected wells", "PROBLEM", 333, 347], ["infection", "PROBLEM", 378, 387], ["a MOI dependent kinetics", "PROBLEM", 389, 413], ["GP64", "PROBLEM", 513, 517], ["infection", "PROBLEM", 576, 585], ["our reporter gene GFP", "PROBLEM", 601, 622], ["polyhedrin", "TREATMENT", 680, 690], ["GP64 RNA", "PROBLEM", 742, 750], ["infection", "PROBLEM", 782, 791], ["infection", "OBSERVATION", 378, 387], ["infection", "OBSERVATION", 576, 585], ["GP64 RNA", "OBSERVATION", 742, 750], ["infection", "OBSERVATION", 782, 791]]], ["GP64 RNA copy number served us for assessing the therapeutic dose of automaton we delivered as a viral infection treatment.", [["viral infection", "DISEASE", 97, 112], ["GP64", "GENE_OR_GENE_PRODUCT", 0, 4], ["GP64", "PROTEIN", 0, 4], ["automaton", "TREATMENT", 69, 78], ["a viral infection treatment", "TREATMENT", 95, 122], ["viral", "OBSERVATION_MODIFIER", 97, 102], ["infection", "OBSERVATION", 103, 112]]], ["In order to assess the size distribution of our liposomes, we made use of DLS Malven Nano-ZS, ZEN3600 DLS instrument.", [["liposomes", "SIMPLE_CHEMICAL", 48, 57], ["DLS Malven Nano", "TREATMENT", 74, 89], ["ZEN3600 DLS instrument", "TREATMENT", 94, 116], ["size", "OBSERVATION_MODIFIER", 23, 27]]], ["Samples of liposomes were prepared according to manufacturer's recommendations.", [["Samples", "ANATOMY", 0, 7], ["liposomes", "ANATOMY", 11, 20], ["liposomes", "SIMPLE_CHEMICAL", 11, 20], ["Samples of liposomes", "TREATMENT", 0, 20]]], ["The vast majority of the liposomes are ~1 \u00b5m diameter ( Fig. S21 ).Design of a sensing automatonEfficiency of enzyme delivery by liposome was done by fluorescently labeling a T7 RNA polymerase and test treated vs. non-treated cells by FACS ( Fig. S22 ).Design and simulation of GP64 automatonTo test our concept in cells (Sf9) and in-vivo (Adult Blaberus discoidalis ) we designed a molecular automaton that targets the GP64 gene in AcMNPV.", [["liposomes", "ANATOMY", 25, 34], ["cells", "ANATOMY", 226, 231], ["cells", "ANATOMY", 315, 320], ["Sf9", "ANATOMY", 322, 325], ["liposomes", "SIMPLE_CHEMICAL", 25, 34], ["liposome", "SIMPLE_CHEMICAL", 129, 137], ["cells", "CELL", 226, 231], ["cells", "CELL", 315, 320], ["Sf9", "CELL", 322, 325], ["Blaberus discoidalis", "ORGANISM", 346, 366], ["GP64", "GENE_OR_GENE_PRODUCT", 420, 424], ["AcMNPV", "ORGANISM", 433, 439], ["T7 RNA polymerase", "PROTEIN", 175, 192], ["Sf9", "CELL_LINE", 322, 325], ["GP64 gene", "DNA", 420, 429], ["Blaberus discoidalis", "SPECIES", 346, 366], ["Blaberus discoidalis", "SPECIES", 346, 366], ["AcMNPV", "SPECIES", 433, 439], ["a sensing automatonEfficiency of enzyme delivery", "TREATMENT", 77, 125], ["liposome", "TREATMENT", 129, 137], ["a T7 RNA polymerase", "TEST", 173, 192], ["test", "TEST", 197, 201], ["non-treated cells", "PROBLEM", 214, 231], ["GP64 automaton", "TEST", 278, 292], ["a molecular automaton", "PROBLEM", 381, 402], ["the GP64 gene in AcMNPV", "TREATMENT", 416, 439], ["vast", "OBSERVATION_MODIFIER", 4, 8], ["majority", "OBSERVATION_MODIFIER", 9, 17], ["liposomes", "ANATOMY", 25, 34], ["~1 \u00b5m diameter", "OBSERVATION_MODIFIER", 39, 53], ["automatonEfficiency", "OBSERVATION", 87, 106]]], ["GP64 CDS sequence was downloaded from NCBI (NC_001623.1) and used Ribosoft 62 to identify possible HHRs and cleavage sites.", [["GP64", "GENE_OR_GENE_PRODUCT", 0, 4], ["HHRs", "GENE_OR_GENE_PRODUCT", 99, 103], ["GP64 CDS sequence", "DNA", 0, 17], ["HHRs and cleavage sites", "DNA", 99, 122], ["GP64 CDS sequence", "TEST", 0, 17], ["Ribosoft", "TREATMENT", 66, 74], ["HHRs", "PROBLEM", 99, 103], ["cleavage sites", "PROBLEM", 108, 122]]], ["Four HHRs that were ranked first were chosen for further cleavage assays (Fig. 3D ).", [["HHRs", "DNA", 5, 9], ["Four HHRs", "TEST", 0, 9], ["further cleavage assays", "PROBLEM", 49, 72]]], ["The cleavage assays were performed on a GP64 transcripts obtained by in vitro-transcription reaction on a plasmid comprising a GP64 gene (Fig. 3D,Fig. S23 ).", [["plasmid", "ANATOMY", 106, 113], ["GP64", "GENE_OR_GENE_PRODUCT", 40, 44], ["GP64", "GENE_OR_GENE_PRODUCT", 127, 131], ["GP64 transcripts", "RNA", 40, 56], ["plasmid", "DNA", 106, 113], ["GP64 gene", "DNA", 127, 136], ["The cleavage assays", "TEST", 0, 19], ["a GP64 transcripts", "TREATMENT", 38, 56], ["a plasmid", "TREATMENT", 104, 113], ["a GP64 gene", "TREATMENT", 125, 136]]], ["Based on the results and GP64 secondary structure as predicted by mFold 89 , we proceeded with HHR that targets GP64 at position 262-264 (Fig. S24A) .", [["GP64", "SIMPLE_CHEMICAL", 25, 29], ["HHR", "SIMPLE_CHEMICAL", 95, 98], ["GP64", "GENE_OR_GENE_PRODUCT", 112, 116], ["262-264", "AMINO_ACID", 129, 136], ["GP64", "PROTEIN", 25, 29], ["mFold 89", "PROTEIN", 66, 74], ["HHR", "PROTEIN", 95, 98], ["GP64", "PROTEIN", 112, 116], ["GP64", "TEST", 112, 116]]], ["A full molecular automaton comprising L, S and the cleaved GP64 as R was designed manually (Table S4 ) .", [["GP64", "GENE_OR_GENE_PRODUCT", 59, 63], ["GP64", "PROTEIN", 59, 63], ["R", "PROTEIN", 67, 68], ["the cleaved GP64", "PROBLEM", 47, 63]]], ["L and S complement the RNA sequence (Fig. S24B) .", [["RNA sequence", "DNA", 23, 35], ["the RNA sequence", "TEST", 19, 35]]], ["As in the prototype automaton, the L strand consists of a T7 promoter sequence, a complementary sequence of the HHR gene and a 3' phosphorylation modification to prevent elongation from the L strand.Design and simulation of GP64 automatonAssembly of the automaton was verified by NUPACK 37 simulations.", [["HHR", "GENE_OR_GENE_PRODUCT", 112, 115], ["L strand", "DNA", 35, 43], ["T7 promoter sequence", "DNA", 58, 78], ["HHR gene", "DNA", 112, 120], ["L strand", "DNA", 190, 198], ["a T7 promoter sequence", "TREATMENT", 56, 78], ["the HHR gene", "TREATMENT", 108, 120], ["a 3' phosphorylation modification", "TREATMENT", 125, 158], ["elongation", "PROBLEM", 170, 180], ["the L strand", "TREATMENT", 186, 198], ["elongation", "OBSERVATION_MODIFIER", 170, 180], ["L", "ANATOMY_MODIFIER", 190, 191], ["strand", "ANATOMY_MODIFIER", 192, 198]]], ["L and S undergo assembly to form a stable 4 way junction preferably when the target RNA is cleaved by the HHR, making the bases that participate in the hybridization more accessible (Fig. S25) .", [["HHR", "GENE_OR_GENE_PRODUCT", 106, 109], ["target RNA", "RNA", 77, 87], ["HHR", "PROTEIN", 106, 109], ["a stable 4 way junction", "TREATMENT", 33, 56], ["the target RNA", "PROBLEM", 73, 87], ["the hybridization", "TEST", 148, 165], ["stable", "OBSERVATION", 35, 41], ["bases", "ANATOMY_MODIFIER", 122, 127]]], ["We verified that such a 4-way junction can be assembled in vitro, by using FAM labeled L arm and dark-FQ quencher S arm, and following the decrease in the fluorescence by RT-PCR.", [["FAM", "CHEMICAL", 75, 78], ["FAM", "SIMPLE_CHEMICAL", 75, 78], ["a 4-way junction", "TREATMENT", 22, 38], ["dark-FQ quencher S arm", "TREATMENT", 97, 119], ["the fluorescence", "TEST", 151, 167], ["PCR", "TEST", 174, 177], ["arm", "ANATOMY", 89, 92], ["arm", "ANATOMY", 116, 119], ["decrease", "OBSERVATION_MODIFIER", 139, 147]]], ["As R strand we used the R from the prototype design with different arms complementary to GP64 (Fig. S26) .", [["GP64", "DNA", 89, 93]]], ["To increase the assembly and the stability of the automaton in-vivo , we elongated the L and S arms by 4 bases -'GATA' was added to 3' of L arm and 'GACG' was added to 5' of S arm.", [["GATA", "GENE_OR_GENE_PRODUCT", 113, 117], ["L and S arms", "DNA", 87, 99], ["L arm", "DNA", 138, 143], ["GACG'", "DNA", 149, 154], ["5' of S arm", "DNA", 168, 179], ["GATA'", "TREATMENT", 113, 118], ["'GACG'", "TREATMENT", 148, 154], ["L", "ANATOMY_MODIFIER", 87, 88], ["arm", "ANATOMY", 140, 143], ["arm", "ANATOMY", 176, 179]]], ["In addition, we modified 7 bases in the complementary parts to the target with LNA bases, so the hybridization to the target RNA will be stronger.", [["target RNA", "RNA", 118, 128], ["LNA bases", "TREATMENT", 79, 88], ["the hybridization", "TREATMENT", 93, 110], ["LNA", "OBSERVATION", 79, 82], ["bases", "ANATOMY_MODIFIER", 83, 88]]]], "91590e22b6d261f71d1756047a8dc32fb0a68f9e": [], "7d780290822a5408a54dfdf2ae32139cf1a2892c": [["IntroductionInfections are the major cause of mobility and mortality in children who are undergoing hematopoietic cell transplantation (HCT) or chemotherapy due to malignancy.", [["hematopoietic cell", "ANATOMY", 100, 118], ["HCT", "ANATOMY", 136, 139], ["IntroductionInfections", "DISEASE", 0, 22], ["malignancy", "DISEASE", 164, 174], ["children", "ORGANISM", 72, 80], ["hematopoietic cell", "CELL", 100, 118], ["children", "SPECIES", 72, 80], ["IntroductionInfections", "TREATMENT", 0, 22], ["hematopoietic cell transplantation", "TREATMENT", 100, 134], ["HCT)", "TREATMENT", 136, 140], ["chemotherapy", "TREATMENT", 144, 156], ["malignancy", "PROBLEM", 164, 174], ["mobility", "OBSERVATION", 46, 54], ["hematopoietic cell transplantation", "OBSERVATION", 100, 134], ["malignancy", "OBSERVATION", 164, 174]]], ["[1] [2] [3] According to the Center for International Blood and Marrow Transplant Research (CIBMTR), infectious complications were the cause of death in 7% of autologous HCT (auto-HCT), 11% of matched sibling donor HCT (MSD-HCT) and 13% of matched unrelated donor HCT (MUD-HCT) recipients.", [["Blood", "ANATOMY", 54, 59], ["Marrow", "ANATOMY", 64, 70], ["HCT", "ANATOMY", 170, 173], ["HCT", "ANATOMY", 264, 267], ["infectious complications", "DISEASE", 101, 125], ["death", "DISEASE", 144, 149], ["HCT", "CANCER", 170, 173], ["HCT", "CANCER", 215, 218], ["MSD-HCT", "CANCER", 220, 227], ["MUD-HCT", "CANCER", 269, 276], ["recipients", "ORGANISM", 278, 288], ["International Blood", "TEST", 40, 59], ["infectious complications", "PROBLEM", 101, 125], ["death", "PROBLEM", 144, 149], ["autologous HCT", "TEST", 159, 173], ["auto-HCT", "TEST", 175, 183], ["donor HCT", "TEST", 209, 218], ["MSD", "TEST", 220, 223], ["HCT", "TEST", 224, 227], ["donor HCT", "TEST", 258, 267], ["MUD-HCT) recipients", "TREATMENT", 269, 288], ["Marrow", "ANATOMY", 64, 70], ["Transplant", "OBSERVATION", 71, 81]]], ["2 Infectious complications in children after HCT were noted in 82% of children after allogeneic HCT (allo-HCT) 4 and in 21% of children with solid tumor or lymphoma in pediatric auto-HCT setting.", [["solid tumor", "ANATOMY", 141, 152], ["lymphoma", "ANATOMY", 156, 164], ["tumor", "DISEASE", 147, 152], ["lymphoma", "DISEASE", 156, 164], ["children", "ORGANISM", 30, 38], ["HCT", "CANCER", 45, 48], ["children", "ORGANISM", 70, 78], ["children", "ORGANISM", 127, 135], ["solid tumor", "CANCER", 141, 152], ["lymphoma", "CANCER", 156, 164], ["children", "SPECIES", 30, 38], ["children", "SPECIES", 70, 78], ["children", "SPECIES", 127, 135], ["HCT", "TEST", 45, 48], ["allogeneic HCT", "TEST", 85, 99], ["allo-HCT)", "TREATMENT", 101, 110], ["solid tumor", "PROBLEM", 141, 152], ["lymphoma", "PROBLEM", 156, 164], ["Infectious", "OBSERVATION_MODIFIER", 2, 12], ["complications", "OBSERVATION", 13, 26], ["solid", "OBSERVATION_MODIFIER", 141, 146], ["tumor", "OBSERVATION", 147, 152], ["lymphoma", "OBSERVATION", 156, 164]]], ["5 The incidence of viral infection after allo-HCT was observed in 19.3% of patients during the first 30 days after transplantation, 18.5% between 31 and 100 days, and in 20% after day +101 up to 2 years after HCT.", [["viral infection", "DISEASE", 19, 34], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["viral infection", "PROBLEM", 19, 34], ["allo-HCT", "TREATMENT", 41, 49], ["transplantation", "TREATMENT", 115, 130], ["HCT", "TEST", 209, 212], ["viral", "OBSERVATION_MODIFIER", 19, 24], ["infection", "OBSERVATION", 25, 34]]], ["4 In the auto-HCT setting viral infections were observed only in 11% of patients with median onset of 10 days post-transplant.", [["viral infections", "DISEASE", 26, 42], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["viral infections", "PROBLEM", 26, 42], ["-transplant", "TREATMENT", 114, 125], ["infections", "OBSERVATION", 32, 42]]], ["5 Viruses that cause infection after HCT can be classified as latent or \"episodic\" in nature, with the latter acquired typically after exposure rather than as a result of a reactivation event.", [["infection", "DISEASE", 21, 30], ["HCT", "CANCER", 37, 40], ["5 Viruses", "PROBLEM", 0, 9], ["infection", "PROBLEM", 21, 30], ["HCT", "TEST", 37, 40], ["a reactivation event", "PROBLEM", 171, 191], ["infection", "OBSERVATION", 21, 30], ["latent", "OBSERVATION_MODIFIER", 62, 68], ["reactivation", "OBSERVATION", 173, 185]]], ["6 In the early post-transplant period herpes simplex virus (HSV) reactivation was the most frequent viral infection both in allo-HCT and auto-HCT patients.", [["allo-HCT", "ANATOMY", 124, 132], ["herpes simplex virus (HSV) reactivation", "DISEASE", 38, 77], ["viral infection", "DISEASE", 100, 115], ["herpes simplex virus", "ORGANISM", 38, 58], ["HSV", "ORGANISM", 60, 63], ["allo-HCT", "CANCER", 124, 132], ["patients", "ORGANISM", 146, 154], ["herpes simplex virus", "SPECIES", 38, 58], ["patients", "SPECIES", 146, 154], ["herpes simplex virus", "SPECIES", 38, 58], ["HSV", "SPECIES", 60, 63], ["herpes simplex virus (HSV) reactivation", "PROBLEM", 38, 77], ["frequent viral infection", "PROBLEM", 91, 115], ["auto-HCT patients", "TREATMENT", 137, 154], ["simplex virus", "OBSERVATION", 45, 58], ["most frequent", "OBSERVATION_MODIFIER", 86, 99], ["viral", "OBSERVATION_MODIFIER", 100, 105], ["infection", "OBSERVATION", 106, 115]]], ["4, 5 Overall, 8% of allo-HCT patient died primarily due to infections and 24% of these infections were viral.", [["infections", "DISEASE", 59, 69], ["infections", "DISEASE", 87, 97], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["allo-HCT patient", "TREATMENT", 20, 36], ["infections", "PROBLEM", 59, 69], ["these infections", "PROBLEM", 81, 97], ["viral", "PROBLEM", 103, 108], ["infections", "OBSERVATION", 59, 69], ["infections", "OBSERVATION", 87, 97]]], ["4 In auto-HCT patients deaths due to infections were episodic.", [["auto-HCT", "DISEASE", 5, 13], ["deaths", "DISEASE", 23, 29], ["infections", "DISEASE", 37, 47], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["infections", "PROBLEM", 37, 47], ["episodic", "PROBLEM", 53, 61], ["infections", "OBSERVATION", 37, 47]]], ["5 Some major improvements in outcomes were associated with the application of drugs and molecular tests to detect and prevent early bacterial infections, HSV, cytomegalovirus (CMV), and pre-engraftment candidal infections.", [["candidal", "ANATOMY", 202, 210], ["bacterial infections", "DISEASE", 132, 152], ["HSV, cytomegalovirus (CMV)", "DISEASE", 154, 180], ["candidal infections", "DISEASE", 202, 221], ["HSV", "ORGANISM", 154, 157], ["cytomegalovirus", "ORGANISM", 159, 174], ["CMV", "ORGANISM", 176, 179], ["HSV", "SPECIES", 154, 157], ["CMV", "SPECIES", 176, 179], ["drugs", "TREATMENT", 78, 83], ["molecular tests", "TEST", 88, 103], ["early bacterial infections", "PROBLEM", 126, 152], ["HSV", "PROBLEM", 154, 157], ["cytomegalovirus (CMV)", "PROBLEM", 159, 180], ["pre-engraftment candidal infections", "PROBLEM", 186, 221], ["major", "OBSERVATION_MODIFIER", 7, 12], ["improvements", "OBSERVATION_MODIFIER", 13, 25], ["bacterial", "OBSERVATION_MODIFIER", 132, 141], ["infections", "OBSERVATION", 142, 152], ["cytomegalovirus", "OBSERVATION", 159, 174], ["candidal", "OBSERVATION_MODIFIER", 202, 210], ["infections", "OBSERVATION", 211, 221]]], ["6 Screening for reactivation with pre-emptive treatment or application of prophylaxis in seropositive recipients plays a role in preventing diseases caused by latent herpesviruses such as CMV, human herpesvirus 6 (HHV-6), and varicellazoster virus (VZV).", [["recipients", "ORGANISM", 102, 112], ["herpesviruses", "ORGANISM", 166, 179], ["CMV", "ORGANISM", 188, 191], ["human herpesvirus 6", "ORGANISM", 193, 212], ["HHV-6)", "ORGANISM", 214, 220], ["varicellazoster virus", "ORGANISM", 226, 247], ["VZV", "ORGANISM", 249, 252], ["human", "SPECIES", 193, 198], ["herpesvirus", "SPECIES", 199, 210], ["HHV-6", "SPECIES", 214, 219], ["varicellazoster virus", "SPECIES", 226, 247], ["CMV", "SPECIES", 188, 191], ["human herpesvirus 6 (HHV-6", "SPECIES", 193, 219], ["VZV", "SPECIES", 249, 252], ["reactivation", "PROBLEM", 16, 28], ["pre-emptive treatment", "TREATMENT", 34, 55], ["prophylaxis", "TREATMENT", 74, 85], ["seropositive recipients", "TREATMENT", 89, 112], ["diseases", "PROBLEM", 140, 148], ["latent herpesviruses", "PROBLEM", 159, 179], ["CMV", "PROBLEM", 188, 191], ["human herpesvirus", "TEST", 193, 210], ["HHV", "TEST", 214, 217], ["varicellazoster virus", "PROBLEM", 226, 247], ["latent", "OBSERVATION_MODIFIER", 159, 165], ["herpesviruses", "OBSERVATION", 166, 179]]], ["6 Implementation of diagnostic and therapeutic strategies for management of Epstein-Barr virus (EBV) infection, on the basis of monitoring of EBV-DNA-emia and pre-emptive or targeted therapy with rituximab, has reduced the incidence of mortality from post-transplant lymphoproliferative disease (EBV-PTLD) from 84% before the year 2000 to 30% in 2013.", [["Epstein-Barr virus (EBV) infection", "DISEASE", 76, 110], ["rituximab", "CHEMICAL", 196, 205], ["lymphoproliferative disease", "DISEASE", 267, 294], ["EBV-PTLD", "DISEASE", 296, 304], ["Epstein-Barr virus", "ORGANISM", 76, 94], ["EBV", "ORGANISM", 96, 99], ["EBV", "ORGANISM", 142, 145], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["rituximab", "SIMPLE_CHEMICAL", 196, 205], ["EBV", "ORGANISM", 296, 299], ["Epstein-Barr virus", "SPECIES", 76, 94], ["EBV", "SPECIES", 96, 99], ["therapeutic strategies", "TREATMENT", 35, 57], ["management", "TREATMENT", 62, 72], ["Epstein", "PROBLEM", 76, 83], ["Barr virus (EBV) infection", "PROBLEM", 84, 110], ["EBV", "PROBLEM", 142, 145], ["DNA", "PROBLEM", 146, 149], ["emia", "TREATMENT", 150, 154], ["pre-emptive", "TREATMENT", 159, 170], ["targeted therapy", "TREATMENT", 174, 190], ["rituximab", "TREATMENT", 196, 205], ["post-transplant lymphoproliferative disease", "PROBLEM", 251, 294], ["EBV", "TEST", 296, 299], ["Barr virus", "OBSERVATION", 84, 94], ["transplant", "ANATOMY", 256, 266], ["lymphoproliferative disease", "OBSERVATION", 267, 294]]], ["7 Ganciclovir (GCV) can reduce EBV replication, but neither ganciclovir/foscarnet (FCV) nor cidofovir (CDV) therapy/prophylaxis have any impact on development of EBV-PTLD, so antiviral agents are not recommended.", [["Ganciclovir", "CHEMICAL", 2, 13], ["GCV", "CHEMICAL", 15, 18], ["ganciclovir", "CHEMICAL", 60, 71], ["foscarnet", "CHEMICAL", 72, 81], ["FCV", "CHEMICAL", 83, 86], ["cidofovir", "CHEMICAL", 92, 101], ["CDV", "CHEMICAL", 103, 106], ["PTLD", "DISEASE", 166, 170], ["Ganciclovir", "CHEMICAL", 2, 13], ["GCV", "CHEMICAL", 15, 18], ["ganciclovir", "CHEMICAL", 60, 71], ["foscarnet", "CHEMICAL", 72, 81], ["cidofovir", "CHEMICAL", 92, 101], ["Ganciclovir", "SIMPLE_CHEMICAL", 2, 13], ["GCV", "ORGANISM", 15, 18], ["EBV", "ORGANISM", 31, 34], ["ganciclovir", "SIMPLE_CHEMICAL", 60, 71], ["foscarnet", "SIMPLE_CHEMICAL", 72, 81], ["FCV", "ORGANISM", 83, 86], ["cidofovir", "SIMPLE_CHEMICAL", 92, 101], ["CDV", "ORGANISM", 103, 106], ["EBV", "ORGANISM", 162, 165], ["EBV", "SPECIES", 31, 34], ["FCV", "SPECIES", 83, 86], ["CDV", "SPECIES", 103, 106], ["EBV", "SPECIES", 162, 165], ["Ganciclovir (GCV", "TREATMENT", 2, 18], ["EBV replication", "TREATMENT", 31, 46], ["neither ganciclovir", "TREATMENT", 52, 71], ["foscarnet (FCV", "TREATMENT", 72, 86], ["cidofovir (CDV) therapy", "TREATMENT", 92, 115], ["prophylaxis", "TREATMENT", 116, 127], ["EBV", "PROBLEM", 162, 165], ["PTLD", "PROBLEM", 166, 170], ["antiviral agents", "TREATMENT", 175, 191], ["PTLD", "OBSERVATION", 166, 170]]], ["8 In this multicenter nationwide study we present analysis of the epidemiology, risk factors and outcome of viral infections in children and adolescents after HCT over a period of 72 consecutive months.", [["viral infections", "DISEASE", 108, 124], ["children", "ORGANISM", 128, 136], ["children", "SPECIES", 128, 136], ["adolescents", "SPECIES", 141, 152], ["this multicenter nationwide study", "TEST", 5, 38], ["viral infections", "PROBLEM", 108, 124], ["HCT", "TEST", 159, 162]]], ["Special attention was given to antiviral drugs usage and incidence of EBV infection after HCT.Design of the StudyThe study was designed as multicenter nationwide cohort analysis performed on behalf of the Polish Society of Pediatric Oncology and Hematology.", [["EBV infection", "DISEASE", 70, 83], ["EBV", "ORGANISM", 70, 73], ["EBV", "SPECIES", 70, 73], ["Special attention", "TREATMENT", 0, 17], ["antiviral drugs", "TREATMENT", 31, 46], ["EBV infection", "PROBLEM", 70, 83], ["HCT", "TEST", 90, 93], ["the Study", "TEST", 104, 113], ["The study", "TEST", 113, 122], ["cohort analysis", "TEST", 162, 177], ["EBV", "OBSERVATION_MODIFIER", 70, 73], ["infection", "OBSERVATION", 74, 83]]], ["Viral infections diagnosed during a six-year period (between January 1, 2012 and December 31, 2017), were reported by all Polish pediatric HCT centers (Bydgoszcz, Krakow, Lublin, Poznan, Wroclaw) and data were analyzed centrally by two independent researchers.", [["Viral infections", "DISEASE", 0, 16], ["Viral", "ORGANISM", 0, 5], ["Viral infections", "PROBLEM", 0, 16], ["infections", "OBSERVATION", 6, 16]]], ["Data from the first 2-year period were collected retrospectively, then prospectively afterwards.Pathogen DiagnosisViral infections were classified as episodic (diagnosed on the basis of clinical manifestation and supplemented with appropriate tests) or latent (requiring monitoring at the molecular level).", [["DiagnosisViral infections", "DISEASE", 105, 130], ["Pathogen DiagnosisViral infections", "PROBLEM", 96, 130], ["appropriate tests", "TEST", 231, 248], ["infections", "OBSERVATION", 120, 130]]], ["6, 8, 9 The following latent viruses were included in the analysis: CMV, EBV, HHV6, HSV, VZV, polyoma BK virus (BKV), while episodic viruses included influenza A and B (FLUAV and FLUBV, respectively) and other communityacquired respiratory viruses (CARV), such as parainfluenza (HPIV), human metapneumovirus (hMPV), respiratory syncytial virus (RSV), rhinovirus (RhV), as well as parvovirus B19 (PVB19), hepatotropic viruses, adenovirus (ADV), rotavirus (RV), and norovirus (NoV).", [["episodic viruses", "DISEASE", 124, 140], ["influenza A and B", "DISEASE", 150, 167], ["communityacquired respiratory viruses", "DISEASE", 210, 247], ["parainfluenza (HPIV), human metapneumovirus (hMPV)", "DISEASE", 264, 314], ["respiratory syncytial virus (RSV), rhinovirus (RhV)", "DISEASE", 316, 367], ["parvovirus B19", "DISEASE", 380, 394], ["adenovirus (ADV), rotavirus (RV), and norovirus", "DISEASE", 426, 473], ["CMV", "ORGANISM", 68, 71], ["EBV", "ORGANISM", 73, 76], ["HHV6", "GENE_OR_GENE_PRODUCT", 78, 82], ["HSV", "ORGANISM", 84, 87], ["VZV", "ORGANISM", 89, 92], ["polyoma BK virus", "ORGANISM", 94, 110], ["BKV", "ORGANISM", 112, 115], ["influenza A", "ORGANISM", 150, 161], ["B", "GENE_OR_GENE_PRODUCT", 166, 167], ["FLUAV", "ORGANISM", 169, 174], ["FLUBV", "GENE_OR_GENE_PRODUCT", 179, 184], ["communityacquired respiratory viruses", "ORGANISM", 210, 247], ["parainfluenza", "ORGANISM", 264, 277], ["human metapneumovirus", "ORGANISM", 286, 307], ["hMPV", "ORGANISM", 309, 313], ["respiratory syncytial virus", "ORGANISM", 316, 343], ["RSV", "ORGANISM", 345, 348], ["rhinovirus", "ORGANISM", 351, 361], ["parvovirus B19", "ORGANISM", 380, 394], ["PVB19", "GENE_OR_GENE_PRODUCT", 396, 401], ["hepatotropic viruses", "ORGANISM", 404, 424], ["adenovirus", "ORGANISM", 426, 436], ["ADV", "ORGANISM", 438, 441], ["rotavirus", "ORGANISM", 444, 453], ["VZV", "SPECIES", 89, 92], ["polyoma BK virus", "SPECIES", 94, 110], ["parainfluenza", "SPECIES", 264, 277], ["human", "SPECIES", 286, 291], ["metapneumovirus", "SPECIES", 292, 307], ["hMPV", "SPECIES", 309, 313], ["respiratory syncytial virus", "SPECIES", 316, 343], ["parvovirus B19", "SPECIES", 380, 394], ["CMV", "SPECIES", 68, 71], ["EBV", "SPECIES", 73, 76], ["HHV6", "SPECIES", 78, 82], ["HSV", "SPECIES", 84, 87], ["VZV", "SPECIES", 89, 92], ["polyoma BK virus", "SPECIES", 94, 110], ["BKV", "SPECIES", 112, 115], ["FLUAV", "SPECIES", 169, 174], ["FLUBV", "SPECIES", 179, 184], ["communityacquired respiratory viruses", "SPECIES", 210, 247], ["CARV", "SPECIES", 249, 253], ["HPIV", "SPECIES", 279, 283], ["human metapneumovirus", "SPECIES", 286, 307], ["hMPV", "SPECIES", 309, 313], ["respiratory syncytial virus", "SPECIES", 316, 343], ["RSV", "SPECIES", 345, 348], ["RhV", "SPECIES", 363, 366], ["parvovirus B19", "SPECIES", 380, 394], ["PVB19", "SPECIES", 396, 401], ["adenovirus", "SPECIES", 426, 436], ["ADV", "SPECIES", 438, 441], ["rotavirus", "SPECIES", 444, 453], ["RV", "SPECIES", 455, 457], ["NoV", "SPECIES", 475, 478], ["latent viruses", "PROBLEM", 22, 36], ["the analysis", "TEST", 54, 66], ["CMV", "TEST", 68, 71], ["EBV", "TEST", 73, 76], ["HHV6", "TEST", 78, 82], ["HSV", "PROBLEM", 84, 87], ["VZV", "PROBLEM", 89, 92], ["polyoma BK virus", "PROBLEM", 94, 110], ["episodic viruses", "PROBLEM", 124, 140], ["influenza A", "PROBLEM", 150, 161], ["other communityacquired respiratory viruses", "PROBLEM", 204, 247], ["parainfluenza", "PROBLEM", 264, 277], ["human metapneumovirus (hMPV)", "TEST", 286, 314], ["respiratory syncytial virus", "PROBLEM", 316, 343], ["rhinovirus", "PROBLEM", 351, 361], ["parvovirus B19", "TEST", 380, 394], ["hepatotropic viruses", "PROBLEM", 404, 424], ["adenovirus", "PROBLEM", 426, 436], ["rotavirus", "PROBLEM", 444, 453], ["norovirus", "PROBLEM", 464, 473], ["respiratory viruses", "OBSERVATION", 228, 247], ["respiratory syncytial", "ANATOMY", 316, 337], ["hepatotropic viruses", "OBSERVATION", 404, 424], ["RV", "ANATOMY", 455, 457], ["norovirus", "OBSERVATION", 464, 473]]], ["Detection of RV and NoV in the stool was performed using a serological method.", [["stool", "ANATOMY", 31, 36], ["RV", "MULTI-TISSUE_STRUCTURE", 13, 15], ["NoV", "ORGANISM", 20, 23], ["stool", "ORGANISM_SUBSTANCE", 31, 36], ["RV", "SPECIES", 13, 15], ["NoV", "SPECIES", 20, 23], ["RV and NoV in the stool", "PROBLEM", 13, 36], ["a serological method", "TEST", 57, 77], ["RV", "ANATOMY", 13, 15], ["NoV", "OBSERVATION", 20, 23], ["stool", "OBSERVATION", 31, 36]]], ["For all other viruses polymerase chain reaction (PCR)-based analysis was used for the diagnosis of viral infections of material derived from blood, urine, cerebrospinal fluid, respiratory swabs or bronchoalveolar lavage.", [["blood", "ANATOMY", 141, 146], ["urine", "ANATOMY", 148, 153], ["cerebrospinal fluid", "ANATOMY", 155, 174], ["respiratory swabs", "ANATOMY", 176, 193], ["bronchoalveolar lavage", "ANATOMY", 197, 219], ["viral infections", "DISEASE", 99, 115], ["blood", "ORGANISM_SUBSTANCE", 141, 146], ["urine", "ORGANISM_SUBSTANCE", 148, 153], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 155, 174], ["swabs", "ORGANISM_SUBSTANCE", 188, 193], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 197, 219], ["all other viruses polymerase chain reaction", "PROBLEM", 4, 47], ["PCR", "TEST", 49, 52], ["based analysis", "TEST", 54, 68], ["viral infections of material", "PROBLEM", 99, 127], ["blood, urine", "TEST", 141, 153], ["cerebrospinal fluid", "TEST", 155, 174], ["respiratory swabs", "TEST", 176, 193], ["bronchoalveolar lavage", "TEST", 197, 219], ["viral", "OBSERVATION_MODIFIER", 99, 104], ["infections", "OBSERVATION", 105, 115], ["cerebrospinal", "ANATOMY", 155, 168], ["fluid", "OBSERVATION", 169, 174], ["respiratory", "ANATOMY", 176, 187], ["bronchoalveolar lavage", "OBSERVATION", 197, 219]]], ["According to recommendations of the European Conference on Infections in Leukaemia (ECIL), a pre-emptive quantitative approach was introduced for infections with CMV and EBV in allo-HCT patients.", [["Leukaemia", "ANATOMY", 73, 82], ["Infections", "DISEASE", 59, 69], ["Leukaemia", "DISEASE", 73, 82], ["infections", "DISEASE", 146, 156], ["Leukaemia", "CANCER", 73, 82], ["CMV", "ORGANISM", 162, 165], ["EBV", "ORGANISM", 170, 173], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["CMV", "SPECIES", 162, 165], ["EBV", "SPECIES", 170, 173], ["a pre-emptive quantitative approach", "TREATMENT", 91, 126], ["infections", "PROBLEM", 146, 156], ["CMV", "TREATMENT", 162, 165], ["EBV in allo-HCT patients", "TREATMENT", 170, 194], ["Infections", "OBSERVATION", 59, 69]]], ["8, 9 Recurrent viral infection was defined as a new episode of viral infection in a patient with previous evidence of the same viral infection in whom the virus has not been detected for at least 4 weeks during active surveillance.", [["viral infection", "DISEASE", 15, 30], ["viral infection", "DISEASE", 63, 78], ["viral infection", "DISEASE", 127, 142], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Recurrent viral infection", "PROBLEM", 5, 30], ["viral infection", "PROBLEM", 63, 78], ["the same viral infection", "PROBLEM", 118, 142], ["the virus", "PROBLEM", 151, 160], ["active surveillance", "TEST", 211, 230], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["new", "OBSERVATION_MODIFIER", 48, 51], ["viral", "OBSERVATION_MODIFIER", 63, 68], ["infection", "OBSERVATION", 69, 78], ["viral", "OBSERVATION_MODIFIER", 127, 132], ["infection", "OBSERVATION", 133, 142]]], ["Recurrent infection could have resulted from reactivation of latent virus or exogenous reinfection.", [["infection", "DISEASE", 10, 19], ["latent virus", "ORGANISM", 61, 73], ["Recurrent infection", "PROBLEM", 0, 19], ["latent virus", "PROBLEM", 61, 73], ["exogenous reinfection", "PROBLEM", 77, 98], ["infection", "OBSERVATION", 10, 19], ["latent", "OBSERVATION_MODIFIER", 61, 67], ["virus", "OBSERVATION", 68, 73], ["exogenous", "OBSERVATION_MODIFIER", 77, 86], ["reinfection", "OBSERVATION", 87, 98]]], ["10 Multiple viral infections were defined as infections with two or more viruses in one patient in any time in the study period.", [["viral infections", "DISEASE", 12, 28], ["infections", "DISEASE", 45, 55], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["Multiple viral infections", "PROBLEM", 3, 28], ["infections", "PROBLEM", 45, 55], ["Multiple", "OBSERVATION_MODIFIER", 3, 11], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["infections", "OBSERVATION", 18, 28]]], ["Significant plasma CMV-DNA-emia and EBV-DNA-emia were defined with the threshold value \u22651000 copies/mL.Anti-Infective ManagementStandard uniform prophylaxis has been applied for all patients undergoing HCT.", [["plasma", "ANATOMY", 12, 18], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["CMV", "ORGANISM", 19, 22], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["EBV", "ORGANISM", 36, 39], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["patients", "ORGANISM", 182, 190], ["HCT", "CANCER", 202, 205], ["EBV-DNA", "DNA", 36, 43], ["patients", "SPECIES", 182, 190], ["Significant plasma CMV", "TEST", 0, 22], ["DNA", "PROBLEM", 23, 26], ["emia", "TEST", 27, 31], ["EBV", "TEST", 36, 39], ["the threshold value", "TEST", 67, 86], ["Anti-Infective Management", "TREATMENT", 103, 128], ["Standard uniform prophylaxis", "TREATMENT", 128, 156], ["HCT", "TEST", 202, 205], ["plasma CMV", "OBSERVATION", 12, 22], ["Infective", "OBSERVATION_MODIFIER", 108, 117]]], ["8, 9, 11 Commonly accepted strategies were performed for prophylactic, empirical and targeted anti-infectious therapy with various agents.", [["prophylactic", "TREATMENT", 57, 69], ["empirical", "TREATMENT", 71, 80], ["targeted anti-infectious therapy", "TREATMENT", 85, 117], ["various agents", "TREATMENT", 123, 137], ["anti-infectious therapy", "OBSERVATION", 94, 117]]], ["8, 9, 11, 12 In the case of significant CMV-DNA-emia and EBV-DNA -emia and/or CMV-or EBV-disease, specific treatment was implemented.Statistical AnalysisAn event was defined as the diagnosis of a first specific infectious disorder.", [["CMV-or EBV-disease", "DISEASE", 78, 96], ["infectious disorder", "DISEASE", 211, 230], ["CMV", "ORGANISM", 40, 43], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["EBV", "ORGANISM", 57, 60], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["CMV", "ORGANISM", 78, 81], ["EBV", "ORGANISM", 85, 88], ["CMV", "SPECIES", 40, 43], ["CMV", "SPECIES", 78, 81], ["EBV", "SPECIES", 85, 88], ["significant CMV", "PROBLEM", 28, 43], ["DNA", "TEST", 44, 47], ["emia", "TEST", 48, 52], ["EBV", "TEST", 57, 60], ["DNA", "PROBLEM", 61, 64], ["emia", "PROBLEM", 66, 70], ["CMV", "PROBLEM", 78, 81], ["EBV", "PROBLEM", 85, 88], ["disease", "PROBLEM", 89, 96], ["specific treatment", "TREATMENT", 98, 116], ["a first specific infectious disorder", "PROBLEM", 194, 230], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["CMV", "OBSERVATION", 40, 43], ["disease", "OBSERVATION", 89, 96], ["infectious", "OBSERVATION", 211, 221]]], ["Categorical variables were compared by the chi-square test, while non-categorical variables were compared by the Mann-Whitney U test.", [["Categorical variables", "TEST", 0, 21], ["the chi-square test", "TEST", 39, 58]]], ["Hazard ratio (HR) and confidence intervals (CI) were calculated for the difference in occurrence of infections in patients.", [["infections", "DISEASE", 100, 110], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["Hazard ratio", "TEST", 0, 12], ["CI", "TEST", 44, 46], ["infections", "PROBLEM", 100, 110], ["infections", "OBSERVATION", 100, 110]]], ["Cumulative incidences of viral infections were calculated using competing risk analysis, 13 starting from the day of transplantation to the day of the first specific infection.", [["viral infections", "DISEASE", 25, 41], ["infection", "DISEASE", 166, 175], ["viral infections", "PROBLEM", 25, 41], ["competing risk analysis", "TEST", 64, 87], ["transplantation", "TREATMENT", 117, 132], ["the first specific infection", "PROBLEM", 147, 175], ["viral infections", "OBSERVATION", 25, 41], ["infection", "OBSERVATION", 166, 175]]], ["Death was considered as the competing event.", [["Death", "DISEASE", 0, 5], ["Death", "PROBLEM", 0, 5]]], ["The Kaplan-Meier method was used to determine infection-related mortality and overall survival.", [["infection", "DISEASE", 46, 55], ["The Kaplan-Meier method", "TREATMENT", 0, 23], ["infection", "PROBLEM", 46, 55], ["infection", "OBSERVATION", 46, 55]]], ["14 Logistic regression method was used for the multivariate analysis.", [["Logistic regression method", "TREATMENT", 3, 29], ["the multivariate analysis", "TEST", 43, 68]]], ["All reported p-values are two-sided; p<0.05 was considered statistically significant.DemographicsOver the analysis period of 72 consecutive months, a total of 971 HCT (741 allo-HCT; 230 auto-HCT) were performed.", [["HCT", "DISEASE", 163, 166], ["p-values", "TEST", 13, 21], ["HCT", "TEST", 163, 166], ["allo", "TEST", 172, 176], ["HCT", "TEST", 177, 180], ["auto-HCT)", "TEST", 186, 195]]], ["Indications for HCTs were: acute lymphoblastic leukemia (ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138), primary immunodeficiencies (n=113), bone marrow failure syndromes (n=101), Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD, n=65), Ewing sarcoma (n=44), myelodysplastic syndrome (n=38) and other indications (n=88).", [["acute lymphoblastic leukemia", "ANATOMY", 27, 55], ["ALL", "ANATOMY", 57, 60], ["acute myeloblastic leukemia", "ANATOMY", 70, 97], ["AML", "ANATOMY", 99, 102], ["neuroblastoma", "ANATOMY", 112, 125], ["bone marrow", "ANATOMY", 171, 182], ["Non-Hodgkin Lymphoma", "ANATOMY", 210, 230], ["Hodgkin Lymphoma", "ANATOMY", 235, 251], ["NHL", "ANATOMY", 253, 256], ["Ewing sarcoma", "ANATOMY", 268, 281], ["HCTs", "DISEASE", 16, 20], ["acute lymphoblastic leukemia", "DISEASE", 27, 55], ["ALL", "DISEASE", 57, 60], ["acute myeloblastic leukemia", "DISEASE", 70, 97], ["AML", "DISEASE", 99, 102], ["neuroblastoma", "DISEASE", 112, 125], ["primary immunodeficiencies", "DISEASE", 135, 161], ["bone marrow failure syndromes", "DISEASE", 171, 200], ["Non-Hodgkin Lymphoma", "DISEASE", 210, 230], ["Hodgkin Lymphoma", "DISEASE", 235, 251], ["NHL", "DISEASE", 253, 256], ["HD", "DISEASE", 257, 259], ["Ewing sarcoma", "DISEASE", 268, 281], ["myelodysplastic syndrome", "DISEASE", 290, 314], ["acute lymphoblastic leukemia", "CANCER", 27, 55], ["ALL", "CANCER", 57, 60], ["acute myeloblastic leukemia", "CANCER", 70, 97], ["AML", "CANCER", 99, 102], ["neuroblastoma", "CANCER", 112, 125], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 171, 182], ["Non-Hodgkin Lymphoma", "CANCER", 210, 230], ["Hodgkin Lymphoma", "CANCER", 235, 251], ["NHL", "CANCER", 253, 256], ["Ewing sarcoma", "CANCER", 268, 281], ["HCTs", "TEST", 16, 20], ["acute lymphoblastic leukemia", "PROBLEM", 27, 55], ["acute myeloblastic leukemia", "PROBLEM", 70, 97], ["AML", "PROBLEM", 99, 102], ["neuroblastoma", "PROBLEM", 112, 125], ["primary immunodeficiencies (n=113)", "PROBLEM", 135, 169], ["bone marrow failure syndromes", "PROBLEM", 171, 200], ["Non-Hodgkin Lymphoma", "PROBLEM", 210, 230], ["Hodgkin Lymphoma", "PROBLEM", 235, 251], ["NHL/HD", "TREATMENT", 253, 259], ["Ewing sarcoma", "PROBLEM", 268, 281], ["myelodysplastic syndrome", "PROBLEM", 290, 314], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["lymphoblastic leukemia", "OBSERVATION", 33, 55], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["myeloblastic leukemia", "OBSERVATION", 76, 97], ["neuroblastoma", "OBSERVATION", 112, 125], ["bone", "ANATOMY", 171, 175], ["marrow failure", "OBSERVATION", 176, 190], ["Non-Hodgkin Lymphoma", "OBSERVATION", 210, 230], ["Hodgkin Lymphoma", "OBSERVATION", 235, 251], ["Ewing", "ANATOMY", 268, 273], ["sarcoma", "OBSERVATION", 274, 281], ["myelodysplastic syndrome", "OBSERVATION", 290, 314]]], ["Table 1) were diagnosed in allo-HCT, and 13 (11 primary infections and 2 recurrent infections) in auto-HCT patients (Supplementary Table 1 ).Incidence of InfectionThe cumulative incidence of viral infections was 57.9% (95% CI=56.1-59.7) in allo-HCT patients, and 4.8% in auto-HCT patients (95% CI=3.4-6.2) (p<0.001) ( Figure 1A ).", [["infections", "DISEASE", 56, 66], ["infections", "DISEASE", 83, 93], ["Infection", "DISEASE", 154, 163], ["viral infections", "DISEASE", 191, 207], ["HCT", "DISEASE", 245, 248], ["HCT", "DISEASE", 276, 279], ["allo-HCT", "CANCER", 27, 35], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 249, 257], ["patients", "ORGANISM", 280, 288], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 249, 257], ["patients", "SPECIES", 280, 288], ["allo-HCT", "TEST", 27, 35], ["primary infections", "PROBLEM", 48, 66], ["2 recurrent infections", "PROBLEM", 71, 93], ["auto-HCT patients", "TREATMENT", 98, 115], ["Infection", "PROBLEM", 154, 163], ["viral infections", "PROBLEM", 191, 207], ["CI", "TEST", 223, 225], ["allo-HCT patients", "TEST", 240, 257], ["auto", "TEST", 271, 275], ["CI", "TEST", 294, 296], ["Infection", "OBSERVATION", 154, 163], ["viral", "OBSERVATION_MODIFIER", 191, 196], ["infections", "OBSERVATION", 197, 207]]], ["Due to the small number of infections in the auto-HCT setting, these data were excluded from further analysis and are presented in Supplementary Table 1.Incidence of InfectionIn the allo-HCT setting, viral infection with a single pathogen occurred in 54.0% of patients, while there were multiple viral infections in 46.0% of patients (29.0% with two viruses, 13.7% with three viruses, 2.6% with four viruses and 0.7% with five viruses).Incidence of InfectionThe cumulative incidence of viral infections was 28.9% for CMV, 23.8% for BKV, 22.7% for EBV, 10.7% for ADV, 5.0% for RV, 1.9% for FLUAV, 1.2% for VZV, 1.2% for HHV-6, 0.7% for RSV, 0.5% NoV, 0.4% for HPIV, 0.4% for RhV, 0.3% for HSV, 0.1% for hMPV, 0.1% for PVB19 and 0.1% for HBV.", [["infections", "DISEASE", 27, 37], ["viral infection", "DISEASE", 200, 215], ["viral infections", "DISEASE", 296, 312], ["Infection", "DISEASE", 449, 458], ["viral infections", "DISEASE", 486, 502], ["ADV", "CHEMICAL", 562, 565], ["VZV", "DISEASE", 605, 608], ["RSV", "DISEASE", 635, 638], ["HPIV", "DISEASE", 659, 663], ["hMPV", "DISEASE", 702, 706], ["patients", "ORGANISM", 260, 268], ["patients", "ORGANISM", 325, 333], ["CMV", "ORGANISM", 517, 520], ["BKV", "ORGANISM", 532, 535], ["EBV", "ORGANISM", 547, 550], ["VZV", "ORGANISM", 605, 608], ["HHV-6", "ORGANISM", 619, 624], ["RSV", "ORGANISM", 635, 638], ["HSV", "ORGANISM", 688, 691], ["hMPV", "ORGANISM", 702, 706], ["HBV", "ORGANISM", 736, 739], ["patients", "SPECIES", 260, 268], ["patients", "SPECIES", 325, 333], ["CMV", "SPECIES", 517, 520], ["BKV", "SPECIES", 532, 535], ["EBV", "SPECIES", 547, 550], ["ADV", "SPECIES", 562, 565], ["RV", "SPECIES", 576, 578], ["FLUAV", "SPECIES", 589, 594], ["VZV", "SPECIES", 605, 608], ["HHV-6", "SPECIES", 619, 624], ["RSV", "SPECIES", 635, 638], ["NoV", "SPECIES", 645, 648], ["HPIV", "SPECIES", 659, 663], ["RhV", "SPECIES", 674, 677], ["HSV", "SPECIES", 688, 691], ["hMPV", "SPECIES", 702, 706], ["PVB19", "SPECIES", 717, 722], ["HBV", "SPECIES", 736, 739], ["infections", "PROBLEM", 27, 37], ["the auto-HCT setting", "TREATMENT", 41, 61], ["these data", "TEST", 63, 73], ["further analysis", "TEST", 93, 109], ["InfectionIn", "PROBLEM", 166, 177], ["the allo-HCT setting", "TREATMENT", 178, 198], ["viral infection", "PROBLEM", 200, 215], ["a single pathogen", "PROBLEM", 221, 238], ["multiple viral infections", "PROBLEM", 287, 312], ["two viruses", "TEST", 346, 357], ["three viruses", "TEST", 370, 383], ["four viruses", "TEST", 395, 407], ["Infection", "PROBLEM", 449, 458], ["viral infections", "PROBLEM", 486, 502], ["CMV", "TEST", 517, 520], ["BKV", "TEST", 532, 535], ["EBV", "TEST", 547, 550], ["ADV", "TEST", 562, 565], ["RV", "TEST", 576, 578], ["FLUAV", "TEST", 589, 594], ["VZV", "TEST", 605, 608], ["HHV", "TEST", 619, 622], ["RSV", "TEST", 635, 638], ["HPIV", "TEST", 659, 663], ["RhV", "TEST", 674, 677], ["HSV", "TEST", 688, 691], ["hMPV", "TEST", 702, 706], ["PVB19", "TEST", 717, 722], ["HBV", "PROBLEM", 736, 739], ["small", "OBSERVATION_MODIFIER", 11, 16], ["number", "OBSERVATION_MODIFIER", 17, 23], ["infections", "OBSERVATION", 27, 37], ["viral", "OBSERVATION_MODIFIER", 200, 205], ["infection", "OBSERVATION", 206, 215], ["multiple", "OBSERVATION_MODIFIER", 287, 295], ["viral", "OBSERVATION_MODIFIER", 296, 301], ["infections", "OBSERVATION", 302, 312], ["Infection", "OBSERVATION", 449, 458], ["viral", "OBSERVATION_MODIFIER", 486, 491], ["infections", "OBSERVATION", 492, 502]]], ["The incidence of CMV, BKV and EBV infections were significantly higher than ADV (p<0.001) and other viral infections.", [["CMV, BKV and EBV infections", "DISEASE", 17, 44], ["viral infections", "DISEASE", 100, 116], ["CMV", "ORGANISM", 17, 20], ["BKV", "ORGANISM", 22, 25], ["EBV", "ORGANISM", 30, 33], ["CMV", "SPECIES", 17, 20], ["BKV", "SPECIES", 22, 25], ["EBV", "SPECIES", 30, 33], ["ADV", "SPECIES", 76, 79], ["CMV", "PROBLEM", 17, 20], ["BKV", "PROBLEM", 22, 25], ["EBV infections", "PROBLEM", 30, 44], ["other viral infections", "PROBLEM", 94, 116], ["CMV", "OBSERVATION", 17, 20], ["BKV", "OBSERVATION", 22, 25], ["EBV", "OBSERVATION_MODIFIER", 30, 33], ["infections", "OBSERVATION", 34, 44], ["higher", "OBSERVATION_MODIFIER", 64, 70], ["viral", "OBSERVATION_MODIFIER", 100, 105], ["infections", "OBSERVATION", 106, 116]]], ["The cumulative incidence of four most frequent viral infections is shown in Figure 1B .Incidence of InfectionMost of the viral infections occurred within the first 4 months from allo-HCT.", [["viral infections", "DISEASE", 47, 63], ["viral infections", "DISEASE", 121, 137], ["frequent viral infections", "PROBLEM", 38, 63], ["Infection", "PROBLEM", 100, 109], ["the viral infections", "PROBLEM", 117, 137], ["allo-HCT", "TREATMENT", 178, 186], ["cumulative", "OBSERVATION_MODIFIER", 4, 14], ["four most", "OBSERVATION_MODIFIER", 28, 37], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["infections", "OBSERVATION", 53, 63], ["Infection", "OBSERVATION", 100, 109], ["viral", "OBSERVATION_MODIFIER", 121, 126], ["infections", "OBSERVATION", 127, 137]]], ["There were no differences in the median patient age and median time from allo-HCT to specific viral infection, with respective values ranging from 0.4 to 3.8 months.", [["viral infection", "DISEASE", 94, 109], ["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["allo-HCT", "TEST", 73, 81], ["specific viral infection", "PROBLEM", 85, 109], ["respective values", "TEST", 116, 133], ["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25], ["viral", "OBSERVATION_MODIFIER", 94, 99], ["infection", "OBSERVATION", 100, 109]]], ["Only in cases of VZV, HSV and NoV were late infections observed, with a median time 6.5, 7.4 and 7.9 months, respectively (Supplementary Table 2 ).TreatmentOf 788 specific viral infections (726 primary infections and 62 recurrent infections) in 631 (80.1%) episodes therapies were performed: 583 (92.4%) pharmacotherapies and 48 (7.6%) symptomatic therapies.", [["infections", "DISEASE", 44, 54], ["viral infections", "DISEASE", 172, 188], ["primary infections", "DISEASE", 194, 212], ["infections", "DISEASE", 230, 240], ["VZV", "ORGANISM", 17, 20], ["HSV", "ORGANISM", 22, 25], ["NoV", "ORGANISM", 30, 33], ["VZV", "SPECIES", 17, 20], ["HSV", "SPECIES", 22, 25], ["NoV", "SPECIES", 30, 33], ["VZV", "PROBLEM", 17, 20], ["HSV", "PROBLEM", 22, 25], ["NoV", "PROBLEM", 30, 33], ["late infections", "PROBLEM", 39, 54], ["specific viral infections", "PROBLEM", 163, 188], ["primary infections", "PROBLEM", 194, 212], ["recurrent infections", "PROBLEM", 220, 240], ["episodes therapies", "TREATMENT", 257, 275], ["pharmacotherapies", "TREATMENT", 304, 321], ["symptomatic therapies", "TREATMENT", 336, 357], ["VZV", "OBSERVATION", 17, 20], ["viral infections", "OBSERVATION", 172, 188]]], ["In all episodes of HHV-6, VZV, HPIV, HSV, hMPV infections, and in 97.6% of CMV, 92.6% FLUAV, 81.7% EBV, 60.0% ADV and 53.0% BKV infectious episodes specific antiviral pharmacotherapy was used.", [["hMPV infections", "DISEASE", 42, 57], ["BKV infectious episodes", "DISEASE", 124, 147], ["HHV-6", "ORGANISM", 19, 24], ["VZV", "ORGANISM", 26, 29], ["HPIV", "ORGANISM", 31, 35], ["HSV", "ORGANISM", 37, 40], ["hMPV", "ORGANISM", 42, 46], ["CMV", "ORGANISM", 75, 78], ["FLUAV", "CANCER", 86, 91], ["EBV", "ORGANISM", 99, 102], ["BKV", "ORGANISM", 124, 127], ["HHV-6", "SPECIES", 19, 24], ["VZV", "SPECIES", 26, 29], ["HPIV", "SPECIES", 31, 35], ["HSV", "SPECIES", 37, 40], ["hMPV", "SPECIES", 42, 46], ["CMV", "SPECIES", 75, 78], ["FLUAV", "SPECIES", 86, 91], ["EBV", "SPECIES", 99, 102], ["ADV", "SPECIES", 110, 113], ["BKV", "SPECIES", 124, 127], ["HHV", "PROBLEM", 19, 22], ["VZV", "PROBLEM", 26, 29], ["HPIV", "PROBLEM", 31, 35], ["HSV", "PROBLEM", 37, 40], ["hMPV infections", "PROBLEM", 42, 57], ["CMV", "TEST", 75, 78], ["FLUAV", "TEST", 86, 91], ["EBV", "TEST", 99, 102], ["ADV", "TEST", 110, 113], ["BKV infectious episodes", "PROBLEM", 124, 147], ["specific antiviral pharmacotherapy", "TREATMENT", 148, 182], ["HHV", "OBSERVATION", 19, 22], ["HSV", "ANATOMY", 37, 40], ["hMPV infections", "OBSERVATION", 42, 57], ["infectious", "OBSERVATION_MODIFIER", 128, 138], ["antiviral pharmacotherapy", "OBSERVATION", 157, 182]]], ["No specific pharmacotherapy was used for RV, RhV, NoV, PVB19 and HBV.", [["RhV", "GENE_OR_GENE_PRODUCT", 45, 48], ["NoV", "ORGANISM", 50, 53], ["PVB19", "GENE_OR_GENE_PRODUCT", 55, 60], ["HBV", "ORGANISM", 65, 68], ["RV", "SPECIES", 41, 43], ["RhV", "SPECIES", 45, 48], ["NoV", "SPECIES", 50, 53], ["HBV", "SPECIES", 65, 68], ["specific pharmacotherapy", "TREATMENT", 3, 27], ["RV", "TEST", 41, 43], ["HBV", "PROBLEM", 65, 68], ["specific", "OBSERVATION_MODIFIER", 3, 11], ["pharmacotherapy", "OBSERVATION", 12, 27], ["HBV", "OBSERVATION", 65, 68]]], ["The most frequent symptomatic therapies were used in RV (19/48), ADV (10/48), BKV (5/48) infections ( Table 1 ).", [["ADV", "CHEMICAL", 65, 68], ["BKV (5/48) infections", "DISEASE", 78, 99], ["BKV", "ORGANISM", 78, 81], ["BKV", "SPECIES", 78, 81], ["The most frequent symptomatic therapies", "TREATMENT", 0, 39], ["RV", "TEST", 53, 55], ["BKV", "TEST", 78, 81], ["infections", "PROBLEM", 89, 99], ["RV", "ANATOMY", 53, 55]]], ["The median time of treatment of specific viral infection range from 7 days for EBV, RV, FLUAV, RhV, NoV to 22.5 days for BKV and 24 days for CMV infections (Supplementary Table 2 ).Survival After InfectionsThere were no deaths related to RV, HHV-6, VZV, RSV, RhV, NoV, HSV, hMPV, and PVB19 infection.", [["viral infection", "DISEASE", 41, 56], ["CMV infections", "DISEASE", 141, 155], ["Infections", "DISEASE", 196, 206], ["deaths", "DISEASE", 220, 226], ["infection", "DISEASE", 290, 299], ["EBV", "ORGANISM", 79, 82], ["BKV", "ORGANISM", 121, 124], ["CMV", "ORGANISM", 141, 144], ["HHV-6", "ORGANISM", 242, 247], ["VZV", "ORGANISM", 249, 252], ["RSV", "ORGANISM", 254, 257], ["RhV", "GENE_OR_GENE_PRODUCT", 259, 262], ["NoV", "ORGANISM", 264, 267], ["HSV", "ORGANISM", 269, 272], ["hMPV", "ORGANISM", 274, 278], ["PVB19", "GENE_OR_GENE_PRODUCT", 284, 289], ["EBV", "SPECIES", 79, 82], ["RV", "SPECIES", 84, 86], ["FLUAV", "SPECIES", 88, 93], ["RhV", "SPECIES", 95, 98], ["NoV", "SPECIES", 100, 103], ["BKV", "SPECIES", 121, 124], ["CMV", "SPECIES", 141, 144], ["VZV", "SPECIES", 249, 252], ["RSV", "SPECIES", 254, 257], ["RhV", "SPECIES", 259, 262], ["NoV", "SPECIES", 264, 267], ["HSV", "SPECIES", 269, 272], ["hMPV", "SPECIES", 274, 278], ["PVB19", "SPECIES", 284, 289], ["treatment", "TREATMENT", 19, 28], ["specific viral infection", "PROBLEM", 32, 56], ["EBV", "PROBLEM", 79, 82], ["RV", "TEST", 84, 86], ["BKV", "PROBLEM", 121, 124], ["CMV infections", "PROBLEM", 141, 155], ["Infections", "PROBLEM", 196, 206], ["deaths", "PROBLEM", 220, 226], ["RV", "TEST", 238, 240], ["HHV", "TEST", 242, 245], ["VZV", "PROBLEM", 249, 252], ["RSV", "PROBLEM", 254, 257], ["RhV", "PROBLEM", 259, 262], ["NoV", "PROBLEM", 264, 267], ["HSV", "PROBLEM", 269, 272], ["hMPV", "PROBLEM", 274, 278], ["PVB19 infection", "PROBLEM", 284, 299], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infection", "OBSERVATION", 47, 56], ["RV", "ANATOMY", 84, 86], ["Infections", "OBSERVATION", 196, 206], ["no", "UNCERTAINTY", 217, 219], ["RV", "ANATOMY", 238, 240], ["HHV", "OBSERVATION", 242, 245], ["RSV", "ANATOMY", 254, 257], ["hMPV", "OBSERVATION", 274, 278], ["infection", "OBSERVATION", 290, 299]]], ["For episodic viral infections one death was related to FLUAV (survival 92.9%) and one to HPIV (survival 66.7%).", [["episodic viral infections", "DISEASE", 4, 29], ["death", "DISEASE", 34, 39], ["HPIV", "SPECIES", 89, 93], ["episodic viral infections one death", "PROBLEM", 4, 39], ["FLUAV (survival", "TREATMENT", 55, 70], ["survival", "TEST", 95, 103], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["infections", "OBSERVATION", 19, 29]]], ["For the four most frequent viral infections (CMV, BKV, EBV and ADV) survival rate ranged between 90.3% for ADV infection and 95.4 for EBV infection and did not differ between specific viral infection (p=0.3) (Figure 2A) .", [["viral infections", "DISEASE", 27, 43], ["ADV", "CHEMICAL", 107, 110], ["infection", "DISEASE", 111, 120], ["EBV infection", "DISEASE", 134, 147], ["viral infection", "DISEASE", 184, 199], ["CMV", "ORGANISM", 45, 48], ["BKV", "ORGANISM", 50, 53], ["EBV", "ORGANISM", 55, 58], ["EBV", "ORGANISM", 134, 137], ["CMV", "SPECIES", 45, 48], ["BKV", "SPECIES", 50, 53], ["EBV", "SPECIES", 55, 58], ["ADV", "SPECIES", 63, 66], ["ADV", "SPECIES", 107, 110], ["EBV", "SPECIES", 134, 137], ["frequent viral infections", "PROBLEM", 18, 43], ["CMV", "TEST", 45, 48], ["BKV", "PROBLEM", 50, 53], ["EBV", "PROBLEM", 55, 58], ["survival rate", "TEST", 68, 81], ["ADV infection", "PROBLEM", 107, 120], ["EBV infection", "PROBLEM", 134, 147], ["specific viral infection", "PROBLEM", 175, 199], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["infections", "OBSERVATION", 33, 43], ["infection", "OBSERVATION", 138, 147], ["viral", "OBSERVATION_MODIFIER", 184, 189], ["infection", "OBSERVATION", 190, 199]]], ["With respect to primary diagnosis, survival from viral infection was 97.4% (95% CI=95.9-98.9) in AML and 92.4% (95% CI=90.6-94.2%) in ALL patients and did not statistically differ between these two (p=0.073) ( Figure 2B ) and other primary diseases.Risk Factor Analysis Risk Factors for Viral InfectionsIn multivariate analysis, the risk of infections was higher after allo-HCT (HR=18.0; p<0.001) than auto-HCT.", [["AML", "ANATOMY", 97, 100], ["ALL", "ANATOMY", 134, 137], ["viral infection", "DISEASE", 49, 64], ["AML", "DISEASE", 97, 100], ["ALL", "DISEASE", 134, 137], ["primary diseases", "DISEASE", 232, 248], ["Viral Infections", "DISEASE", 287, 303], ["infections", "DISEASE", 341, 351], ["AML", "CANCER", 97, 100], ["ALL", "CANCER", 134, 137], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["viral infection", "PROBLEM", 49, 64], ["CI", "TEST", 80, 82], ["AML", "TEST", 97, 100], ["CI", "TEST", 116, 118], ["other primary diseases", "PROBLEM", 226, 248], ["Viral Infections", "PROBLEM", 287, 303], ["multivariate analysis", "TEST", 306, 327], ["infections", "PROBLEM", 341, 351], ["allo-HCT", "TEST", 369, 377], ["HR", "TEST", 379, 381], ["auto-HCT", "TEST", 402, 410], ["primary diseases", "OBSERVATION", 232, 248], ["Infections", "OBSERVATION", 293, 303], ["infections", "OBSERVATION", 341, 351]]], ["In allo-HCT patients, the risk was higher in acute leukemia patients vs other (HR=1.9; p<0.001), MUD vs MSD (HR=2.", [["allo-HCT", "ANATOMY", 3, 11], ["acute leukemia", "ANATOMY", 45, 59], ["acute leukemia", "DISEASE", 45, 59], ["MUD", "DISEASE", 97, 100], ["MSD", "DISEASE", 104, 107], ["allo-HCT", "CANCER", 3, 11], ["patients", "ORGANISM", 12, 20], ["acute leukemia", "CANCER", 45, 59], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 60, 68], ["acute leukemia", "PROBLEM", 45, 59], ["HR", "TEST", 79, 81], ["HR", "TEST", 109, 111], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["leukemia", "OBSERVATION", 51, 59]]], ["6Viral Infections Preceding EBV InfectionIn order to assess the impact of antivirals on the reactivation of EBV-DNA-emia, we analyzed the use of all antiviral drugs within 60 days before the onset of significant EBV-DNA-emia.", [["EBV", "ORGANISM", 28, 31], ["EBV", "ORGANISM", 108, 111], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["EBV", "ORGANISM", 212, 215], ["DNA", "CELLULAR_COMPONENT", 216, 219], ["EBV", "SPECIES", 108, 111], ["6Viral Infections", "PROBLEM", 0, 17], ["antivirals", "TREATMENT", 74, 84], ["EBV", "PROBLEM", 108, 111], ["all antiviral drugs", "TREATMENT", 145, 164], ["significant EBV", "PROBLEM", 200, 215], ["significant", "OBSERVATION_MODIFIER", 200, 211], ["EBV", "OBSERVATION", 212, 215]]], ["Of 175 EBV infectious episodes, in 66 (37.7%) cases, the infection was preceded by another viral infection, including CMV (n=21), BKV (n=20), ADV (n=4), RVDiscussionThe primary causes of morbidity and non-relapse mortality following HCT are acute and chronic GVHD, organ dysfunction and infection.", [["organ", "ANATOMY", 265, 270], ["EBV infectious episodes", "DISEASE", 7, 30], ["infection", "DISEASE", 57, 66], ["viral infection", "DISEASE", 91, 106], ["BKV", "DISEASE", 130, 133], ["ADV", "DISEASE", 142, 145], ["RVDiscussion", "DISEASE", 153, 165], ["HCT", "DISEASE", 233, 236], ["GVHD", "DISEASE", 259, 263], ["organ dysfunction", "DISEASE", 265, 282], ["infection", "DISEASE", 287, 296], ["EBV", "ORGANISM", 7, 10], ["CMV", "ORGANISM", 118, 121], ["BKV", "ORGANISM", 130, 133], ["organ", "ORGAN", 265, 270], ["CMV", "SPECIES", 118, 121], ["BKV", "SPECIES", 130, 133], ["ADV", "SPECIES", 142, 145], ["EBV infectious episodes", "PROBLEM", 7, 30], ["the infection", "PROBLEM", 53, 66], ["another viral infection", "PROBLEM", 83, 106], ["CMV", "TEST", 118, 121], ["BKV", "TEST", 130, 133], ["morbidity", "PROBLEM", 187, 196], ["non-relapse mortality", "PROBLEM", 201, 222], ["HCT", "TEST", 233, 236], ["acute", "PROBLEM", 241, 246], ["chronic GVHD", "PROBLEM", 251, 263], ["organ dysfunction", "PROBLEM", 265, 282], ["infection", "PROBLEM", 287, 296], ["EBV", "OBSERVATION_MODIFIER", 7, 10], ["infectious", "OBSERVATION_MODIFIER", 11, 21], ["infection", "OBSERVATION", 57, 66], ["viral", "OBSERVATION_MODIFIER", 91, 96], ["infection", "OBSERVATION", 97, 106], ["acute", "OBSERVATION_MODIFIER", 241, 246], ["chronic", "OBSERVATION_MODIFIER", 251, 258], ["GVHD", "OBSERVATION", 259, 263], ["organ", "ANATOMY", 265, 270], ["dysfunction", "OBSERVATION", 271, 282], ["infection", "OBSERVATION", 287, 296]]], ["15 Changes in the transplantation procedure and the implementation of effective supportive care strategies have decreased the incidence of infectious complications early after conditioning therapy for allo-HCT, but have also prolonged the risks beyond day +100.", [["the transplantation procedure", "TREATMENT", 14, 43], ["effective supportive care strategies", "TREATMENT", 70, 106], ["infectious complications", "PROBLEM", 139, 163], ["conditioning therapy", "TREATMENT", 176, 196], ["allo-HCT", "TREATMENT", 201, 209], ["transplantation", "OBSERVATION", 18, 33], ["infectious", "OBSERVATION_MODIFIER", 139, 149]]], ["6 These late infections might be caused by all types of microorganisms; however, the risks are predictable and surmountable with the use of tailored prevention strategies.", [["infections", "DISEASE", 13, 23], ["These late infections", "PROBLEM", 2, 23], ["microorganisms", "PROBLEM", 56, 70], ["tailored prevention strategies", "TREATMENT", 140, 170], ["late", "OBSERVATION_MODIFIER", 8, 12], ["infections", "OBSERVATION", 13, 23], ["microorganisms", "OBSERVATION", 56, 70]]], ["6 There are only a few articles focused on viral complications in children after HCT.", [["children", "ORGANISM", 66, 74], ["children", "SPECIES", 66, 74], ["viral complications", "PROBLEM", 43, 62], ["HCT", "TEST", 81, 84], ["few", "OBSERVATION_MODIFIER", 19, 22], ["articles", "OBSERVATION", 23, 31], ["viral complications", "OBSERVATION", 43, 62]]], ["4, 5, 16, 17 Herein we reported the results of multicenter nationwide study of the epidemiology, risk factors and outcome of viral infections in children and adolescents after HCT over a period of six consecutive years.", [["viral infections", "DISEASE", 125, 141], ["children", "ORGANISM", 145, 153], ["children", "SPECIES", 145, 153], ["adolescents", "SPECIES", 158, 169], ["multicenter nationwide study", "TEST", 47, 75], ["viral infections", "PROBLEM", 125, 141], ["HCT", "TEST", 176, 179], ["viral", "OBSERVATION_MODIFIER", 125, 130], ["infections", "OBSERVATION", 131, 141]]], ["All patients were treated with the same therapeutic protocols, using comparable principles of supportive therapy.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the same therapeutic protocols", "TREATMENT", 31, 61], ["supportive therapy", "TREATMENT", 94, 112]]], ["We shown high incidence of viral infections in allo-HCT patients whereas in auto-HCT patients the incidence was episodic, comparably with other studies.", [["allo-HCT", "ANATOMY", 47, 55], ["viral infections", "DISEASE", 27, 43], ["allo-HCT", "CANCER", 47, 55], ["patients", "ORGANISM", 56, 64], ["auto-HCT", "ORGANISM", 76, 84], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 85, 93], ["viral infections", "PROBLEM", 27, 43], ["episodic", "PROBLEM", 112, 120], ["other studies", "TEST", 138, 151], ["high", "OBSERVATION_MODIFIER", 9, 13], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["infections", "OBSERVATION", 33, 43]]], ["4, 5 This disproportion is a result of allogeneic source of stem cells, T-cell depletion or CD34 selection, moderate-to-severe GVHD and use of immunosuppressive drugs (especially steroids) in allo-HCT patients.", [["stem cells", "ANATOMY", 60, 70], ["T-cell", "ANATOMY", 72, 78], ["allo-HCT", "ANATOMY", 192, 200], ["GVHD", "DISEASE", 127, 131], ["steroids", "CHEMICAL", 179, 187], ["steroids", "CHEMICAL", 179, 187], ["stem cells", "CELL", 60, 70], ["T-cell", "CELL", 72, 78], ["CD34", "GENE_OR_GENE_PRODUCT", 92, 96], ["allo-HCT", "CELL", 192, 200], ["patients", "ORGANISM", 201, 209], ["stem cells", "CELL_TYPE", 60, 70], ["CD34", "PROTEIN", 92, 96], ["patients", "SPECIES", 201, 209], ["stem cells", "PROBLEM", 60, 70], ["T-cell depletion", "PROBLEM", 72, 88], ["CD34 selection", "PROBLEM", 92, 106], ["severe GVHD", "PROBLEM", 120, 131], ["immunosuppressive drugs", "TREATMENT", 143, 166], ["steroids", "TREATMENT", 179, 187], ["allo-HCT patients", "TREATMENT", 192, 209], ["stem cells", "OBSERVATION", 60, 70], ["cell depletion", "OBSERVATION", 74, 88], ["moderate", "OBSERVATION_MODIFIER", 108, 116], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["GVHD", "OBSERVATION", 127, 131]]], ["11 We observed that CMV had the highest incidence from all viral infections.", [["viral infections", "DISEASE", 59, 75], ["CMV", "ORGANISM", 20, 23], ["CMV", "SPECIES", 20, 23], ["CMV", "PROBLEM", 20, 23], ["all viral infections", "PROBLEM", 55, 75], ["CMV", "OBSERVATION", 20, 23], ["viral infections", "OBSERVATION", 59, 75]]], ["CMV is one of the most difficult infections that occur after allo-HCT.", [["infections", "DISEASE", 33, 43], ["CMV", "ORGANISM", 0, 3], ["CMV", "SPECIES", 0, 3], ["CMV", "PROBLEM", 0, 3], ["difficult infections", "PROBLEM", 23, 43], ["allo-HCT", "TREATMENT", 61, 69], ["one of the most difficult", "OBSERVATION_MODIFIER", 7, 32], ["infections", "OBSERVATION", 33, 43]]], ["18 The CMV serostatus of the donor and recipient before transplantation significantly influence the incidence of CMV recurrence, whereas the immunosuppressive status of the recipient is the most important factor for CMV infection.", [["CMV infection", "DISEASE", 216, 229], ["CMV", "ORGANISM", 7, 10], ["CMV", "ORGANISM", 113, 116], ["CMV", "ORGANISM", 216, 219], ["CMV", "SPECIES", 7, 10], ["CMV", "SPECIES", 113, 116], ["CMV", "SPECIES", 216, 219], ["the donor", "TREATMENT", 25, 34], ["transplantation", "TREATMENT", 56, 71], ["CMV recurrence", "PROBLEM", 113, 127], ["CMV infection", "PROBLEM", 216, 229], ["CMV", "OBSERVATION", 7, 10], ["CMV recurrence", "OBSERVATION", 113, 127], ["infection", "OBSERVATION", 220, 229]]], ["10 Monitoring by a sensitive technique such as PCR tests of whole blood allows intervention before development of CMV disease.", [["whole blood", "ANATOMY", 60, 71], ["CMV disease", "DISEASE", 114, 125], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["CMV", "ORGANISM", 114, 117], ["CMV", "SPECIES", 114, 117], ["PCR tests", "TEST", 47, 56], ["intervention", "TREATMENT", 79, 91], ["CMV disease", "PROBLEM", 114, 125], ["CMV disease", "OBSERVATION", 114, 125]]], ["Pre-emptive therapy can be used as a standalone strategy or combined with antiviral prophylaxis.", [["Pre-emptive therapy", "TREATMENT", 0, 19], ["a standalone strategy", "TREATMENT", 35, 56], ["antiviral prophylaxis", "TREATMENT", 74, 95]]], ["Recently, letermovir, given as prophylaxis, was shown to reduce the risk of clinically significant CMV infection.", [["letermovir", "CHEMICAL", 10, 20], ["CMV infection", "DISEASE", 99, 112], ["letermovir", "CHEMICAL", 10, 20], ["letermovir", "SIMPLE_CHEMICAL", 10, 20], ["CMV", "ORGANISM", 99, 102], ["CMV", "SPECIES", 99, 102], ["letermovir", "TREATMENT", 10, 20], ["prophylaxis", "TREATMENT", 31, 42], ["clinically significant CMV infection", "PROBLEM", 76, 112], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["CMV infection", "OBSERVATION", 99, 112]]], ["18 We have shown that ganciclovir and foscarnet were the most frequently used drugs in our cohort for the therapy of CMV reactivation; accordingly to currently recommended first-line preemptive treatment.", [["ganciclovir", "CHEMICAL", 22, 33], ["foscarnet", "CHEMICAL", 38, 47], ["ganciclovir", "CHEMICAL", 22, 33], ["foscarnet", "CHEMICAL", 38, 47], ["ganciclovir", "SIMPLE_CHEMICAL", 22, 33], ["foscarnet", "SIMPLE_CHEMICAL", 38, 47], ["CMV", "ORGANISM", 117, 120], ["CMV", "SPECIES", 117, 120], ["ganciclovir", "TREATMENT", 22, 33], ["foscarnet", "TREATMENT", 38, 47], ["drugs", "TREATMENT", 78, 83], ["the therapy", "TREATMENT", 102, 113], ["CMV reactivation", "PROBLEM", 117, 133], ["first-line preemptive treatment", "TREATMENT", 172, 203], ["ganciclovir", "OBSERVATION", 22, 33]]], ["18 Nevertheless, management of patients with resistant or refractory CMV infection or CMV disease is a challenge.", [["CMV infection", "DISEASE", 69, 82], ["CMV disease", "DISEASE", 86, 97], ["patients", "ORGANISM", 31, 39], ["CMV", "ORGANISM", 69, 72], ["CMV", "ORGANISM", 86, 89], ["patients", "SPECIES", 31, 39], ["CMV", "SPECIES", 69, 72], ["CMV", "SPECIES", 86, 89], ["refractory CMV infection", "PROBLEM", 58, 82], ["CMV disease", "PROBLEM", 86, 97], ["refractory", "OBSERVATION_MODIFIER", 58, 68], ["CMV infection", "OBSERVATION", 69, 82], ["CMV disease", "OBSERVATION", 86, 97]]], ["Combination therapy (ganciclovir and foscarnet), cidofovir, leflunomide or artesunate can be considered in patients resistant or refractory to other second-line and third-line antiviral drugs, and immunosuppression should always be reduced, if possible.", [["ganciclovir", "CHEMICAL", 21, 32], ["foscarnet", "CHEMICAL", 37, 46], ["cidofovir", "CHEMICAL", 49, 58], ["leflunomide", "CHEMICAL", 60, 71], ["artesunate", "CHEMICAL", 75, 85], ["ganciclovir", "CHEMICAL", 21, 32], ["foscarnet", "CHEMICAL", 37, 46], ["cidofovir", "CHEMICAL", 49, 58], ["leflunomide", "CHEMICAL", 60, 71], ["artesunate", "CHEMICAL", 75, 85], ["ganciclovir", "SIMPLE_CHEMICAL", 21, 32], ["foscarnet", "SIMPLE_CHEMICAL", 37, 46], ["cidofovir", "SIMPLE_CHEMICAL", 49, 58], ["leflunomide", "SIMPLE_CHEMICAL", 60, 71], ["artesunate", "SIMPLE_CHEMICAL", 75, 85], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["Combination therapy (ganciclovir", "TREATMENT", 0, 32], ["foscarnet)", "TREATMENT", 37, 47], ["cidofovir", "TREATMENT", 49, 58], ["leflunomide", "TREATMENT", 60, 71], ["artesunate", "TREATMENT", 75, 85], ["other second-line", "TREATMENT", 143, 160], ["third-line antiviral drugs", "TREATMENT", 165, 191], ["immunosuppression", "TREATMENT", 197, 214], ["antiviral drugs", "OBSERVATION", 176, 191]]], ["18 We observed that cumulative incidence of BKV infection was 23.8% with survival rate of 90.7%.", [["BKV infection", "DISEASE", 44, 57], ["BKV", "ORGANISM", 44, 47], ["BKV", "SPECIES", 44, 47], ["BKV infection", "PROBLEM", 44, 57], ["survival rate", "TEST", 73, 86], ["BKV", "OBSERVATION", 44, 47]]], ["Cesaro et al. reported that BKV-related hemorrhagic cystitis occurred in 8-25% of pediatric and 7-54% of adult recipients undergoing allo-HCT.", [["hemorrhagic cystitis", "DISEASE", 40, 60], ["BKV", "ORGANISM", 28, 31], ["recipients", "ORGANISM", 111, 121], ["BKV", "TEST", 28, 31], ["hemorrhagic cystitis", "PROBLEM", 40, 60], ["allo-HCT", "TREATMENT", 133, 141], ["BKV", "OBSERVATION", 28, 31], ["hemorrhagic", "OBSERVATION_MODIFIER", 40, 51], ["cystitis", "OBSERVATION", 52, 60]]], ["19 Specific anti-BKV prophylaxis is not available and fluoroquinolones are not recommended given the lack of significant effects on BKV replication and hemorrhagic cystitis severity, and the selection of antibiotic resistance.", [["anti-BKV", "CHEMICAL", 12, 20], ["fluoroquinolones", "CHEMICAL", 54, 70], ["hemorrhagic cystitis", "DISEASE", 152, 172], ["fluoroquinolones", "CHEMICAL", 54, 70], ["anti-BKV", "CANCER", 12, 20], ["fluoroquinolones", "SIMPLE_CHEMICAL", 54, 70], ["BKV", "ORGANISM", 132, 135], ["anti-BKV", "SPECIES", 12, 20], ["BKV", "SPECIES", 132, 135], ["Specific anti-BKV prophylaxis", "TREATMENT", 3, 32], ["fluoroquinolones", "TREATMENT", 54, 70], ["BKV replication", "TREATMENT", 132, 147], ["hemorrhagic cystitis severity", "PROBLEM", 152, 181], ["antibiotic resistance", "TREATMENT", 204, 225], ["BKV", "OBSERVATION", 132, 135], ["hemorrhagic", "OBSERVATION_MODIFIER", 152, 163], ["cystitis", "OBSERVATION", 164, 172], ["antibiotic resistance", "OBSERVATION", 204, 225]]], ["19 In our study cidofovir was the most frequently used drug in the treatment of BKV infection.", [["cidofovir", "CHEMICAL", 16, 25], ["BKV infection", "DISEASE", 80, 93], ["cidofovir", "CHEMICAL", 16, 25], ["cidofovir", "SIMPLE_CHEMICAL", 16, 25], ["BKV", "ORGANISM", 80, 83], ["BKV", "SPECIES", 80, 83], ["cidofovir", "TREATMENT", 16, 25], ["BKV infection", "PROBLEM", 80, 93], ["BKV", "OBSERVATION", 80, 83], ["infection", "OBSERVATION", 84, 93]]], ["Cidofovir at a dose of 3-5 mg/kg every 1-2 weeks with probenecid, or 0.5-1.5 mg/kg 1-3 times/week without probenecid, were used by other authors for the treatment of BKV hemorrhagic cystitis, although without strong recommendation on its use in these doses.", [["Cidofovir", "CHEMICAL", 0, 9], ["probenecid", "CHEMICAL", 54, 64], ["probenecid", "CHEMICAL", 106, 116], ["BKV hemorrhagic cystitis", "DISEASE", 166, 190], ["Cidofovir", "CHEMICAL", 0, 9], ["probenecid", "CHEMICAL", 54, 64], ["probenecid", "CHEMICAL", 106, 116], ["Cidofovir", "SIMPLE_CHEMICAL", 0, 9], ["probenecid", "SIMPLE_CHEMICAL", 54, 64], ["probenecid", "SIMPLE_CHEMICAL", 106, 116], ["BKV", "ORGANISM", 166, 169], ["BKV", "SPECIES", 166, 169], ["Cidofovir", "TREATMENT", 0, 9], ["probenecid", "TREATMENT", 54, 64], ["probenecid", "TREATMENT", 106, 116], ["BKV hemorrhagic cystitis", "PROBLEM", 166, 190], ["BKV", "OBSERVATION", 166, 169], ["hemorrhagic", "OBSERVATION_MODIFIER", 170, 181], ["cystitis", "OBSERVATION", 182, 190]]], ["19 The clinical manifestations of ADV infections in immunocompetent hosts include upper respiratory disease, gastroenteritis or (kerato-)conjunctivitis and are self-limited in most cases, although severe manifestations including encephalitis, myocarditis, and pneumonia have been sporadically observed.", [["respiratory", "ANATOMY", 88, 99], ["ADV", "CHEMICAL", 34, 37], ["infections", "DISEASE", 38, 48], ["upper respiratory disease", "DISEASE", 82, 107], ["gastroenteritis", "DISEASE", 109, 124], ["kerato-)conjunctivitis", "DISEASE", 129, 151], ["encephalitis", "DISEASE", 229, 241], ["myocarditis", "DISEASE", 243, 254], ["pneumonia", "DISEASE", 260, 269], ["ADV", "ORGANISM", 34, 37], ["ADV", "SPECIES", 34, 37], ["ADV infections", "PROBLEM", 34, 48], ["upper respiratory disease", "PROBLEM", 82, 107], ["gastroenteritis", "PROBLEM", 109, 124], ["kerato-)conjunctivitis", "PROBLEM", 129, 151], ["severe manifestations", "PROBLEM", 197, 218], ["encephalitis", "PROBLEM", 229, 241], ["myocarditis", "PROBLEM", 243, 254], ["pneumonia", "PROBLEM", 260, 269], ["ADV infections", "OBSERVATION", 34, 48], ["upper", "ANATOMY_MODIFIER", 82, 87], ["respiratory disease", "OBSERVATION", 88, 107], ["gastroenteritis", "OBSERVATION", 109, 124], ["conjunctivitis", "OBSERVATION", 137, 151], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["encephalitis", "OBSERVATION", 229, 241], ["myocarditis", "OBSERVATION", 243, 254], ["pneumonia", "OBSERVATION", 260, 269]]], ["In immunocompromised patients, ADV can cause systemic disease and lethal organ damage.", [["organ", "ANATOMY", 73, 78], ["ADV", "CHEMICAL", 31, 34], ["systemic disease", "DISEASE", 45, 61], ["organ damage", "DISEASE", 73, 85], ["patients", "ORGANISM", 21, 29], ["organ", "ORGAN", 73, 78], ["patients", "SPECIES", 21, 29], ["ADV", "SPECIES", 31, 34], ["ADV", "TREATMENT", 31, 34], ["systemic disease", "PROBLEM", 45, 61], ["lethal organ damage", "PROBLEM", 66, 85], ["immunocompromised", "OBSERVATION", 3, 20]]], ["20 Prophylactic antiviral therapy with available antiviral drugs is currently not recommended and intravenous cidofovir is currently regarded as a standard of care in cases of ADV disease.", [["intravenous", "ANATOMY", 98, 109], ["cidofovir", "CHEMICAL", 110, 119], ["ADV disease", "DISEASE", 176, 187], ["cidofovir", "CHEMICAL", 110, 119], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 109], ["cidofovir", "SIMPLE_CHEMICAL", 110, 119], ["ADV", "SPECIES", 176, 179], ["Prophylactic antiviral therapy", "TREATMENT", 3, 33], ["available antiviral drugs", "TREATMENT", 39, 64], ["intravenous cidofovir", "TREATMENT", 98, 119], ["ADV disease", "PROBLEM", 176, 187], ["antiviral therapy", "OBSERVATION", 16, 33], ["ADV disease", "OBSERVATION", 176, 187]]], ["20 Children are more frequently affected with ADV than adults (6-28% vs 0-6%, respectively); 20 we observed 10.7% incidence of ADV infection with 90.3% survival rate.DiscussionA relatively low percentage of infections with CARV origin was observed in our analysis.", [["ADV", "DISEASE", 46, 49], ["ADV", "CHEMICAL", 127, 130], ["infection", "DISEASE", 131, 140], ["infections", "DISEASE", 207, 217], ["Children", "ORGANISM", 3, 11], ["CARV", "CANCER", 223, 227], ["Children", "SPECIES", 3, 11], ["ADV", "SPECIES", 46, 49], ["ADV", "SPECIES", 127, 130], ["ADV infection", "PROBLEM", 127, 140], ["survival rate", "TEST", 152, 165], ["infections", "PROBLEM", 207, 217], ["CARV origin", "PROBLEM", 223, 234], ["our analysis", "TEST", 251, 263], ["infection", "OBSERVATION", 131, 140], ["low percentage", "OBSERVATION_MODIFIER", 189, 203], ["infections", "OBSERVATION", 207, 217]]], ["CARV respiratory tract infections have been recognized as a significant cause of morbidity and mortality in patients with leukemia and those undergoing HCT.", [["respiratory tract", "ANATOMY", 5, 22], ["leukemia", "ANATOMY", 122, 130], ["respiratory tract infections", "DISEASE", 5, 33], ["leukemia", "DISEASE", 122, 130], ["CARV respiratory tract", "ORGANISM", 0, 22], ["patients", "ORGANISM", 108, 116], ["leukemia", "CANCER", 122, 130], ["HCT", "CANCER", 152, 155], ["patients", "SPECIES", 108, 116], ["CARV respiratory tract infections", "PROBLEM", 0, 33], ["morbidity", "PROBLEM", 81, 90], ["leukemia", "PROBLEM", 122, 130], ["HCT", "TEST", 152, 155], ["respiratory tract", "ANATOMY", 5, 22], ["infections", "OBSERVATION", 23, 33], ["morbidity", "OBSERVATION", 81, 90], ["leukemia", "OBSERVATION", 122, 130]]], ["12, 21 In the late 1990s the frequency of documented respiratory virus infections was 3.5% among allo-HCT and 0.4% among auto-HCT.", [["respiratory virus infections", "DISEASE", 53, 81], ["documented respiratory virus infections", "PROBLEM", 42, 81], ["HCT", "TEST", 102, 105], ["respiratory", "ANATOMY", 53, 64], ["virus", "OBSERVATION", 65, 70]]], ["22 However, in that time period, viral antigen detection by immunofluorescence or enzyme immunoassays were used in diagnostics.", [["viral antigen detection", "TEST", 33, 56], ["immunofluorescence", "TEST", 60, 78], ["enzyme immunoassays", "TEST", 82, 101]]], ["22 During the last decade, rapid and highly sensitive molecular tests have been developed and made available, with the most recent multiplex PCR platform that can detect multiple viral pathogens.", [["rapid and highly sensitive molecular tests", "PROBLEM", 27, 69], ["multiplex PCR platform", "TEST", 131, 153], ["multiple viral pathogens", "PROBLEM", 170, 194], ["multiple", "OBSERVATION_MODIFIER", 170, 178], ["viral pathogens", "OBSERVATION", 179, 194]]], ["21 Choi et al. reported in allo-HCT children the incidence 28.1% of RhV infection, 25.8% RSV, 18% HPIV, 1.1% hMPV; yet more than half of the infections were acquired during hospitalization.", [["infection", "DISEASE", 72, 81], ["RSV", "DISEASE", 89, 92], ["HPIV", "DISEASE", 98, 102], ["hMPV", "DISEASE", 109, 113], ["infections", "DISEASE", 141, 151], ["allo-HCT", "CELL", 27, 35], ["children", "ORGANISM", 36, 44], ["RhV", "CANCER", 68, 71], ["RSV", "ORGANISM", 89, 92], ["hMPV", "ORGANISM", 109, 113], ["children", "SPECIES", 36, 44], ["RhV", "SPECIES", 68, 71], ["RSV", "SPECIES", 89, 92], ["HPIV", "SPECIES", 98, 102], ["hMPV", "SPECIES", 109, 113], ["RhV infection", "PROBLEM", 68, 81], ["RSV", "TEST", 89, 92], ["HPIV", "TEST", 98, 102], ["1.1% hMPV", "PROBLEM", 104, 113], ["the infections", "PROBLEM", 137, 151], ["infection", "OBSERVATION", 72, 81], ["infections", "OBSERVATION", 141, 151]]], ["17 In the case of CARV infections, ribavirin and intravenous immunoglobulin are recommended in hMPV, HPIV and RSV infections, while there is insufficient evidence for the specific recommendation against infections caused by coronavirus and RhV.", [["intravenous", "ANATOMY", 49, 60], ["infections", "DISEASE", 23, 33], ["ribavirin", "CHEMICAL", 35, 44], ["RSV infections", "DISEASE", 110, 124], ["infections", "DISEASE", 203, 213], ["coronavirus", "DISEASE", 224, 235], ["ribavirin", "CHEMICAL", 35, 44], ["CARV", "ORGANISM", 18, 22], ["ribavirin", "SIMPLE_CHEMICAL", 35, 44], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 49, 75], ["hMPV", "ORGANISM", 95, 99], ["RSV", "ORGANISM", 110, 113], ["coronavirus", "ORGANISM", 224, 235], ["intravenous immunoglobulin", "PROTEIN", 49, 75], ["CARV", "SPECIES", 18, 22], ["hMPV", "SPECIES", 95, 99], ["HPIV", "SPECIES", 101, 105], ["RSV", "SPECIES", 110, 113], ["CARV infections", "PROBLEM", 18, 33], ["ribavirin", "TREATMENT", 35, 44], ["intravenous immunoglobulin", "TREATMENT", 49, 75], ["hMPV", "PROBLEM", 95, 99], ["HPIV", "TREATMENT", 101, 105], ["RSV infections", "PROBLEM", 110, 124], ["infections", "PROBLEM", 203, 213], ["coronavirus", "PROBLEM", 224, 235], ["infections", "OBSERVATION", 23, 33], ["RSV infections", "OBSERVATION", 110, 124]]], ["12 We observed a relatively low (1.2%) rate of influenza A infection, with no cases of influenza B infection, which may be due to environmental prophylaxis (annual vaccination of patients, household contacts, and hospital and prophylactic use of neuraminidase inhibitors during influenza season in some cases).", [["influenza A infection", "DISEASE", 47, 68], ["influenza B infection", "DISEASE", 87, 108], ["influenza", "DISEASE", 278, 287], ["influenza B", "ORGANISM", 87, 98], ["patients", "ORGANISM", 179, 187], ["neuraminidase inhibitors", "GENE_OR_GENE_PRODUCT", 246, 270], ["patients", "SPECIES", 179, 187], ["influenza A", "SPECIES", 47, 58], ["a relatively low (1.2%) rate of influenza A infection", "PROBLEM", 15, 68], ["influenza B infection", "PROBLEM", 87, 108], ["environmental prophylaxis", "TREATMENT", 130, 155], ["neuraminidase inhibitors", "TREATMENT", 246, 270], ["influenza", "PROBLEM", 278, 287], ["relatively", "OBSERVATION_MODIFIER", 17, 27], ["low", "OBSERVATION_MODIFIER", 28, 31], ["influenza", "OBSERVATION", 47, 56], ["infection", "OBSERVATION", 59, 68], ["influenza", "OBSERVATION", 87, 96], ["infection", "OBSERVATION", 99, 108], ["may be due to", "UNCERTAINTY", 116, 129]]], ["The current guidelines of the 4th European Conference of Infections in Leukemia (ECIL-4) recommend diagnosis based on PCR of material collected from the respiratory tract, especially broncho-alveolar lavage.", [["Leukemia", "ANATOMY", 71, 79], ["respiratory tract", "ANATOMY", 153, 170], ["broncho-alveolar lavage", "ANATOMY", 183, 206], ["Infections", "DISEASE", 57, 67], ["Leukemia", "DISEASE", 71, 79], ["Leukemia", "CANCER", 71, 79], ["respiratory tract", "ORGANISM_SUBDIVISION", 153, 170], ["alveolar lavage", "ORGANISM_SUBSTANCE", 191, 206], ["Infections in Leukemia", "PROBLEM", 57, 79], ["PCR", "TEST", 118, 121], ["the respiratory tract", "TEST", 149, 170], ["broncho-alveolar lavage", "TREATMENT", 183, 206], ["Infections", "OBSERVATION", 57, 67], ["Leukemia", "OBSERVATION", 71, 79], ["respiratory tract", "ANATOMY", 153, 170], ["alveolar lavage", "OBSERVATION", 191, 206]]], ["23 Neuraminidase inhibitors (oral oseltamivir or inhalation of zanamivir) are currently the most effective therapeutic agents for influenza.", [["oral", "ANATOMY", 29, 33], ["oseltamivir", "CHEMICAL", 34, 45], ["zanamivir", "CHEMICAL", 63, 72], ["influenza", "DISEASE", 130, 139], ["oseltamivir", "CHEMICAL", 34, 45], ["zanamivir", "CHEMICAL", 63, 72], ["Neuraminidase inhibitors", "SIMPLE_CHEMICAL", 3, 27], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["oseltamivir", "SIMPLE_CHEMICAL", 34, 45], ["zanamivir", "SIMPLE_CHEMICAL", 63, 72], ["23 Neuraminidase inhibitors", "TREATMENT", 0, 27], ["oral oseltamivir", "TREATMENT", 29, 45], ["zanamivir", "TREATMENT", 63, 72], ["therapeutic agents", "TREATMENT", 107, 125], ["influenza", "PROBLEM", 130, 139]]], ["23 RV and NoV are important pathogens of viral gastroenteritis in children.", [["viral gastroenteritis", "DISEASE", 41, 62], ["NoV", "ORGANISM", 10, 13], ["children", "ORGANISM", 66, 74], ["children", "SPECIES", 66, 74], ["NoV", "SPECIES", 10, 13], ["viral gastroenteritis", "PROBLEM", 41, 62], ["NoV", "OBSERVATION", 10, 13], ["viral gastroenteritis", "OBSERVATION", 41, 62]]], ["We observed that cumulative incidence of RV was 5% while NoV was 0.5%, treated only with symptomatic therapy and no deaths were observed.", [["deaths", "DISEASE", 116, 122], ["NoV", "SPECIES", 57, 60], ["RV", "TEST", 41, 43], ["symptomatic therapy", "TREATMENT", 89, 108], ["deaths", "PROBLEM", 116, 122], ["RV", "ANATOMY", 41, 43]]], ["In other studies the incidence of RV infection varied from 2.3% in adult allo-HCT and auto-HCT recipients up to 19.6% in pediatric allo-HCT recipients.", [["RV", "ANATOMY", 34, 36], ["allo-HCT", "ANATOMY", 73, 81], ["RV infection", "DISEASE", 34, 46], ["RV", "ORGAN", 34, 36], ["RV", "SPECIES", 34, 36], ["other studies", "TEST", 3, 16], ["RV infection", "PROBLEM", 34, 46], ["auto", "TEST", 86, 90], ["HCT recipients", "TEST", 91, 105], ["pediatric allo-HCT recipients", "TREATMENT", 121, 150], ["RV", "ANATOMY", 34, 36], ["infection", "OBSERVATION", 37, 46]]], ["24, 25 In pediatric HCT, the incidence of NoV-associated gastroenteritis was reported in 12.9% with no NoV-related mortality.", [["HCT", "DISEASE", 20, 23], ["NoV", "DISEASE", 42, 45], ["gastroenteritis", "DISEASE", 57, 72], ["NoV", "ORGANISM", 42, 45], ["pediatric HCT", "TEST", 10, 23], ["NoV", "PROBLEM", 42, 45], ["gastroenteritis", "PROBLEM", 57, 72], ["NoV", "PROBLEM", 103, 106], ["NoV", "OBSERVATION", 42, 45], ["gastroenteritis", "OBSERVATION", 57, 72]]], ["26 PCR as well virus antigen detection in stool are commonly used in diagnosis of RV and NoV infection.", [["stool", "ANATOMY", 42, 47], ["NoV infection", "DISEASE", 89, 102], ["stool", "ORGANISM_SUBSTANCE", 42, 47], ["NoV", "ORGANISM", 89, 92], ["RV", "SPECIES", 82, 84], ["NoV", "SPECIES", 89, 92], ["26 PCR", "TEST", 0, 6], ["virus antigen detection", "TEST", 15, 38], ["RV and NoV infection", "PROBLEM", 82, 102], ["RV", "ANATOMY", 82, 84], ["NoV", "OBSERVATION", 89, 92], ["infection", "OBSERVATION", 93, 102]]], ["No specific prophylaxis against RV-and NoV-related gastroenterocolitis is available; however, oral immunoglobulins and nitazoxanide were used in some studies.", [["oral", "ANATOMY", 94, 98], ["gastroenterocolitis", "DISEASE", 51, 70], ["nitazoxanide", "CHEMICAL", 119, 131], ["nitazoxanide", "CHEMICAL", 119, 131], ["NoV", "ORGANISM", 39, 42], ["oral", "ORGANISM_SUBDIVISION", 94, 98], ["immunoglobulins", "SIMPLE_CHEMICAL", 99, 114], ["nitazoxanide", "SIMPLE_CHEMICAL", 119, 131], ["RV", "SPECIES", 32, 34], ["NoV", "SPECIES", 39, 42], ["specific prophylaxis", "TREATMENT", 3, 23], ["RV", "TEST", 32, 34], ["NoV", "PROBLEM", 39, 42], ["related gastroenterocolitis", "PROBLEM", 43, 70], ["oral immunoglobulins", "TREATMENT", 94, 114], ["nitazoxanide", "TREATMENT", 119, 131], ["some studies", "TEST", 145, 157], ["prophylaxis", "OBSERVATION", 12, 23]]], ["24, 27 In immunocompetent individuals primary EBV infection or reactivation induces usually asymptomatic infection or infectious mononucleosis.", [["primary EBV infection", "DISEASE", 38, 59], ["infection", "DISEASE", 105, 114], ["infectious mononucleosis", "DISEASE", 118, 142], ["EBV", "ORGANISM", 46, 49], ["EBV", "SPECIES", 46, 49], ["primary EBV infection", "PROBLEM", 38, 59], ["asymptomatic infection", "PROBLEM", 92, 114], ["infectious mononucleosis", "PROBLEM", 118, 142], ["immunocompetent", "OBSERVATION_MODIFIER", 10, 25], ["primary", "OBSERVATION_MODIFIER", 38, 45], ["EBV infection", "OBSERVATION", 46, 59], ["asymptomatic", "OBSERVATION_MODIFIER", 92, 104], ["infection", "OBSERVATION", 105, 114], ["infectious", "OBSERVATION_MODIFIER", 118, 128], ["mononucleosis", "OBSERVATION", 129, 142]]], ["28 In immunocompromised patients most EBV reactivations are subclinical and require no therapy.", [["patients", "ORGANISM", 24, 32], ["EBV", "ORGANISM", 38, 41], ["patients", "SPECIES", 24, 32], ["EBV", "SPECIES", 38, 41], ["EBV reactivations", "PROBLEM", 38, 55], ["therapy", "TREATMENT", 87, 94], ["immunocompromised", "OBSERVATION", 6, 23], ["EBV reactivations", "OBSERVATION", 38, 55]]], ["8 However, it may be manifested as encephalitis/myelitis, pneumonia, hepatitis and EBV-associated tumors as PTLD.", [["tumors", "ANATOMY", 98, 104], ["encephalitis", "DISEASE", 35, 47], ["myelitis", "DISEASE", 48, 56], ["pneumonia", "DISEASE", 58, 67], ["hepatitis", "DISEASE", 69, 78], ["tumors", "DISEASE", 98, 104], ["PTLD", "DISEASE", 108, 112], ["EBV", "ORGANISM", 83, 86], ["tumors", "CANCER", 98, 104], ["encephalitis", "PROBLEM", 35, 47], ["myelitis", "PROBLEM", 48, 56], ["pneumonia", "PROBLEM", 58, 67], ["hepatitis", "PROBLEM", 69, 78], ["EBV", "PROBLEM", 83, 86], ["associated tumors", "PROBLEM", 87, 104], ["PTLD", "PROBLEM", 108, 112], ["may be manifested", "UNCERTAINTY", 14, 31], ["encephalitis", "OBSERVATION", 35, 47], ["myelitis", "OBSERVATION", 48, 56], ["pneumonia", "OBSERVATION", 58, 67], ["hepatitis", "OBSERVATION", 69, 78], ["tumors", "OBSERVATION", 98, 104]]], ["8, 29 After transplantation 14-65% of recipients developed EBV reactivation, 28 while the incidence of EBV-PTLD varies from 0.45% to 29%, according to the source of hematopoietic cells, the associated cell manipulation, and the details of immunosuppressive regimens used.", [["hematopoietic cells", "ANATOMY", 165, 184], ["cell", "ANATOMY", 201, 205], ["PTLD", "DISEASE", 107, 111], ["recipients", "ORGANISM", 38, 48], ["EBV", "ORGANISM", 59, 62], ["EBV", "ORGANISM", 103, 106], ["hematopoietic cells", "CELL", 165, 184], ["cell", "CELL", 201, 205], ["hematopoietic cells", "CELL_TYPE", 165, 184], ["transplantation", "TEST", 12, 27], ["EBV reactivation", "PROBLEM", 59, 75], ["EBV", "TEST", 103, 106], ["PTLD", "PROBLEM", 107, 111], ["hematopoietic cells", "PROBLEM", 165, 184], ["the associated cell manipulation", "TREATMENT", 186, 218], ["immunosuppressive regimens", "TREATMENT", 239, 265], ["EBV reactivation", "OBSERVATION", 59, 75], ["PTLD", "OBSERVATION", 107, 111], ["hematopoietic cells", "OBSERVATION", 165, 184], ["cell manipulation", "OBSERVATION", 201, 218]]], ["30 We observed high incidence of EBV infection (22.7%) in allo-HCT patients, while there were no cases in auto-HCT setting.", [["EBV infection", "DISEASE", 33, 46], ["EBV", "ORGANISM", 33, 36], ["allo-HCT", "CANCER", 58, 66], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["EBV", "SPECIES", 33, 36], ["EBV infection", "PROBLEM", 33, 46], ["allo-HCT patients", "TEST", 58, 75], ["high", "OBSERVATION_MODIFIER", 15, 19], ["EBV", "OBSERVATION_MODIFIER", 33, 36], ["infection", "OBSERVATION", 37, 46]]], ["In 80.3% (143/175) of EBV reactivations rituximab was used and 93.3% of patients survived this infection.", [["rituximab", "CHEMICAL", 40, 49], ["infection", "DISEASE", 95, 104], ["EBV", "ORGANISM", 22, 25], ["rituximab", "SIMPLE_CHEMICAL", 40, 49], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["EBV", "SPECIES", 22, 25], ["EBV reactivations rituximab", "TREATMENT", 22, 49], ["this infection", "PROBLEM", 90, 104], ["infection", "OBSERVATION", 95, 104]]], ["We also observed that in almost 1/3 of EBV reactivations, these episodes were preceded by other viral infection treated with antivirals, which did not prevent the development of significant EBV-DNAemia with the need of rituximab treatment.", [["viral infection", "DISEASE", 96, 111], ["EBV-DNAemia", "DISEASE", 190, 201], ["rituximab", "CHEMICAL", 219, 228], ["EBV", "ORGANISM", 39, 42], ["EBV", "ORGANISM", 190, 193], ["rituximab", "SIMPLE_CHEMICAL", 219, 228], ["EBV", "SPECIES", 39, 42], ["EBV reactivations", "PROBLEM", 39, 56], ["these episodes", "PROBLEM", 58, 72], ["other viral infection", "PROBLEM", 90, 111], ["antivirals", "TREATMENT", 125, 135], ["significant EBV", "PROBLEM", 178, 193], ["DNAemia", "PROBLEM", 194, 201], ["rituximab treatment", "TREATMENT", 219, 238], ["EBV reactivations", "OBSERVATION", 39, 56], ["viral", "OBSERVATION_MODIFIER", 96, 101], ["infection", "OBSERVATION", 102, 111], ["significant", "OBSERVATION_MODIFIER", 178, 189], ["EBV", "OBSERVATION", 190, 193], ["DNAemia", "OBSERVATION", 194, 201]]], ["This is clinically proven evidence that antiviral drugs do not prevent EBV reactivation in allo-HCT pediatric patients.", [["EBV", "ORGANISM", 71, 74], ["allo-HCT", "CANCER", 91, 99], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["EBV", "SPECIES", 71, 74], ["antiviral drugs", "TREATMENT", 40, 55], ["EBV reactivation", "PROBLEM", 71, 87]]], ["Antiviral agents, such as ganciclovir, are not active against EBV, presumably because of low levels of viral thymidine kinase expression during lytic phase, and a lack of expression during latency.", [["ganciclovir", "CHEMICAL", 26, 37], ["thymidine", "CHEMICAL", 109, 118], ["ganciclovir", "CHEMICAL", 26, 37], ["thymidine", "CHEMICAL", 109, 118], ["ganciclovir", "SIMPLE_CHEMICAL", 26, 37], ["EBV", "ORGANISM", 62, 65], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 109, 125], ["viral thymidine kinase", "PROTEIN", 103, 125], ["EBV", "SPECIES", 62, 65], ["Antiviral agents", "TREATMENT", 0, 16], ["ganciclovir", "TREATMENT", 26, 37], ["EBV", "PROBLEM", 62, 65], ["low levels of viral thymidine kinase expression", "PROBLEM", 89, 136], ["lytic phase", "TEST", 144, 155], ["viral thymidine kinase", "OBSERVATION", 103, 125], ["lytic phase", "OBSERVATION_MODIFIER", 144, 155]]], ["8 Intravenous immunoglobulins also have no impact in PTLD.", [["PTLD", "DISEASE", 53, 57], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 14, 29], ["Intravenous immunoglobulins", "TREATMENT", 2, 29], ["PTLD", "PROBLEM", 53, 57], ["PTLD", "OBSERVATION", 53, 57]]], ["Neither ganciclovir/foscarnet nor cidofovir therapy/prophylaxis have any impact on the development of EBV-PTLD, so antiviral agents are not recommended.", [["ganciclovir", "CHEMICAL", 8, 19], ["foscarnet", "CHEMICAL", 20, 29], ["cidofovir", "CHEMICAL", 34, 43], ["PTLD", "DISEASE", 106, 110], ["ganciclovir", "CHEMICAL", 8, 19], ["foscarnet", "CHEMICAL", 20, 29], ["cidofovir", "CHEMICAL", 34, 43], ["ganciclovir", "SIMPLE_CHEMICAL", 8, 19], ["foscarnet", "SIMPLE_CHEMICAL", 20, 29], ["cidofovir", "SIMPLE_CHEMICAL", 34, 43], ["EBV", "ORGANISM", 102, 105], ["EBV", "SPECIES", 102, 105], ["ganciclovir", "TREATMENT", 8, 19], ["foscarnet", "TREATMENT", 20, 29], ["cidofovir therapy", "TREATMENT", 34, 51], ["prophylaxis", "TREATMENT", 52, 63], ["EBV", "PROBLEM", 102, 105], ["PTLD", "PROBLEM", 106, 110], ["antiviral agents", "TREATMENT", 115, 131], ["PTLD", "OBSERVATION", 106, 110]]], ["8 Prospective monitoring of EBV-DNA-emia is recommended in patients after allo-HCT, and these patients should be closely monitored for symptoms and/or signs attributable to EBV infection and PTLD.", [["EBV infection", "DISEASE", 173, 186], ["PTLD", "DISEASE", 191, 195], ["EBV", "ORGANISM", 28, 31], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 94, 102], ["EBV", "ORGANISM", 173, 176], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 94, 102], ["EBV", "SPECIES", 173, 176], ["Prospective monitoring", "TEST", 2, 24], ["EBV", "TEST", 28, 31], ["allo-HCT", "TREATMENT", 74, 82], ["symptoms", "PROBLEM", 135, 143], ["signs", "PROBLEM", 151, 156], ["EBV infection", "PROBLEM", 173, 186], ["PTLD", "PROBLEM", 191, 195], ["EBV infection", "OBSERVATION", 173, 186]]], ["8 The following pre-emptive therapies are recommended after high-risk allo-HCT: rituximab (375 mg/m 2 / weekly), reduction of immunosuppressive therapy (if possible), donor EBV-specific cytotoxic T-cells (EBV-CTL) infusion (if available).", [["cytotoxic T-cells", "ANATOMY", 186, 203], ["rituximab", "CHEMICAL", 80, 89], ["rituximab", "SIMPLE_CHEMICAL", 80, 89], ["EBV", "ORGANISM", 173, 176], ["cytotoxic T-cells", "CELL", 186, 203], ["EBV", "ORGANISM", 205, 208], ["cytotoxic T-cells", "CELL_TYPE", 186, 203], ["pre-emptive therapies", "TREATMENT", 16, 37], ["rituximab", "TREATMENT", 80, 89], ["immunosuppressive therapy", "TREATMENT", 126, 151], ["donor EBV", "TEST", 167, 176], ["EBV-CTL) infusion", "TREATMENT", 205, 222]]], ["8 Compared with rituximab, adoptive cellular immunotherapy has higher response rate (50-88%) and fewer relapse.", [["cellular", "ANATOMY", 36, 44], ["rituximab", "CHEMICAL", 16, 25], ["rituximab", "SIMPLE_CHEMICAL", 16, 25], ["cellular", "CELL", 36, 44], ["rituximab", "TREATMENT", 16, 25], ["adoptive cellular immunotherapy", "TREATMENT", 27, 58], ["response rate", "TEST", 70, 83], ["fewer", "OBSERVATION_MODIFIER", 97, 102], ["relapse", "OBSERVATION", 103, 110]]], ["28 We found that allo-HCT, acute leukemia, a/cGVHD, MUD/MMUD-HCT were the risk factors for viral infections.", [["allo-HCT", "ANATOMY", 17, 25], ["acute leukemia", "ANATOMY", 27, 41], ["acute leukemia", "DISEASE", 27, 41], ["cGVHD", "DISEASE", 45, 50], ["viral infections", "DISEASE", 91, 107], ["acute leukemia", "CANCER", 27, 41], ["allo", "TEST", 17, 21], ["acute leukemia", "PROBLEM", 27, 41], ["cGVHD", "PROBLEM", 45, 50], ["MMUD", "PROBLEM", 56, 60], ["HCT", "PROBLEM", 61, 64], ["the risk factors", "PROBLEM", 70, 86], ["viral infections", "PROBLEM", 91, 107], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["leukemia", "OBSERVATION", 33, 41], ["viral", "OBSERVATION_MODIFIER", 91, 96], ["infections", "OBSERVATION", 97, 107]]], ["CMV donor/recipient serostatus, era of transplantation, MUD-HCT, and cGVHD were found in other studies as risk factors for viral infection.", [["MUD-HCT", "DISEASE", 56, 63], ["cGVHD", "DISEASE", 69, 74], ["viral infection", "DISEASE", 123, 138], ["CMV", "ORGANISM", 0, 3], ["CMV", "SPECIES", 0, 3], ["transplantation", "TREATMENT", 39, 54], ["MUD", "TEST", 56, 59], ["HCT", "TEST", 60, 63], ["cGVHD", "PROBLEM", 69, 74], ["other studies", "TEST", 89, 102], ["viral infection", "PROBLEM", 123, 138], ["infection", "OBSERVATION", 129, 138]]], ["4 We have also found that CMV-IgG seropositivity in ALL recipients, and MUD/ MMUD-HCT were the risk factors for deaths from viral infection in children after HCT.", [["ALL", "ANATOMY", 52, 55], ["ALL", "DISEASE", 52, 55], ["deaths", "DISEASE", 112, 118], ["viral infection", "DISEASE", 124, 139], ["CMV", "ORGANISM", 26, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["ALL", "CANCER", 52, 55], ["children", "ORGANISM", 143, 151], ["IgG", "PROTEIN", 30, 33], ["children", "SPECIES", 143, 151], ["CMV", "TEST", 26, 29], ["IgG seropositivity", "PROBLEM", 30, 48], ["HCT", "TEST", 82, 85], ["viral infection", "PROBLEM", 124, 139], ["HCT", "TEST", 158, 161], ["CMV", "OBSERVATION", 26, 29], ["viral", "OBSERVATION_MODIFIER", 124, 129], ["infection", "OBSERVATION", 130, 139]]], ["This is a unique observation, as there is no study available analyzing this issue.ConclusionsThe incidence of viral infections was high in allo-HCT patients while in auto-HCT patients viral infections were episodic.", [["allo-HCT", "ANATOMY", 139, 147], ["viral infections", "DISEASE", 110, 126], ["viral infections", "DISEASE", 184, 200], ["patients", "ORGANISM", 148, 156], ["auto-HCT", "ORGANISM", 166, 174], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 148, 156], ["patients", "SPECIES", 175, 183], ["study", "TEST", 45, 50], ["viral infections", "PROBLEM", 110, 126], ["viral infections", "PROBLEM", 184, 200], ["episodic", "PROBLEM", 206, 214], ["viral", "OBSERVATION_MODIFIER", 110, 115], ["infections", "OBSERVATION", 116, 126], ["viral infections", "OBSERVATION", 184, 200]]], ["The most frequent viral infection after allo-HCT were CMV, BKV and EBV.", [["viral infection", "DISEASE", 18, 33], ["CMV, BKV and EBV", "DISEASE", 54, 70], ["CMV", "ORGANISM", 54, 57], ["BKV", "ORGANISM", 59, 62], ["EBV", "ORGANISM", 67, 70], ["CMV", "SPECIES", 54, 57], ["BKV", "SPECIES", 59, 62], ["EBV", "SPECIES", 67, 70], ["The most frequent viral infection", "PROBLEM", 0, 33], ["allo-HCT", "TREATMENT", 40, 48], ["CMV", "PROBLEM", 54, 57], ["BKV", "PROBLEM", 59, 62], ["EBV", "PROBLEM", 67, 70], ["most frequent", "OBSERVATION_MODIFIER", 4, 17], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 24, 33]]], ["Most viral infections occurred within the first 4 months after allo-HCT and over 80% required pharmacotherapy or symptomatic therapy.", [["viral infections", "DISEASE", 5, 21], ["Most viral infections", "PROBLEM", 0, 21], ["allo-HCT", "TREATMENT", 63, 71], ["pharmacotherapy", "TREATMENT", 94, 109], ["symptomatic therapy", "TREATMENT", 113, 132], ["viral", "OBSERVATION_MODIFIER", 5, 10], ["infections", "OBSERVATION", 11, 21]]], ["The median time of treatment of specific viral infection ranged from 7 (for EBV) to 24 days (for CMV).", [["viral infection", "DISEASE", 41, 56], ["EBV", "ORGANISM", 76, 79], ["CMV", "ORGANISM", 97, 100], ["CMV", "SPECIES", 97, 100], ["treatment", "TREATMENT", 19, 28], ["specific viral infection", "PROBLEM", 32, 56], ["CMV", "PROBLEM", 97, 100], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infection", "OBSERVATION", 47, 56]]], ["The highest infection-related mortality was observed in case of CMV infection, whereas primary diagnosis did not influence survival from viral infection.", [["infection", "DISEASE", 12, 21], ["CMV infection", "DISEASE", 64, 77], ["viral infection", "DISEASE", 137, 152], ["CMV", "ORGANISM", 64, 67], ["CMV", "SPECIES", 64, 67], ["The highest infection", "PROBLEM", 0, 21], ["CMV infection", "PROBLEM", 64, 77], ["viral infection", "PROBLEM", 137, 152], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["infection", "OBSERVATION", 12, 21], ["CMV infection", "OBSERVATION", 64, 77], ["viral", "OBSERVATION_MODIFIER", 137, 142], ["infection", "OBSERVATION", 143, 152]]], ["The risk factors for viral infections were allo-HCT, acute leukemia, a/cGVHD, MUD/MMUD vs MSD.", [["acute leukemia", "ANATOMY", 53, 67], ["viral infections", "DISEASE", 21, 37], ["acute leukemia", "DISEASE", 53, 67], ["cGVHD", "DISEASE", 71, 76], ["MUD", "DISEASE", 78, 81], ["MMUD", "DISEASE", 82, 86], ["MSD", "DISEASE", 90, 93], ["acute leukemia", "CANCER", 53, 67], ["The risk factors", "PROBLEM", 0, 16], ["viral infections", "PROBLEM", 21, 37], ["allo", "TEST", 43, 47], ["HCT", "TEST", 48, 51], ["acute leukemia", "PROBLEM", 53, 67], ["MMUD", "PROBLEM", 82, 86], ["MSD", "PROBLEM", 90, 93], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["leukemia", "OBSERVATION", 59, 67]]], ["The risk factor for death from viral infection were CMV-IgG seropositivity in acute lymphoblastic leukemia recipients, MUD/MMUD vs MSD.", [["acute lymphoblastic leukemia", "ANATOMY", 78, 106], ["death", "DISEASE", 20, 25], ["viral infection", "DISEASE", 31, 46], ["acute lymphoblastic leukemia", "DISEASE", 78, 106], ["MSD", "DISEASE", 131, 134], ["CMV", "ORGANISM", 52, 55], ["IgG", "GENE_OR_GENE_PRODUCT", 56, 59], ["acute lymphoblastic leukemia", "CANCER", 78, 106], ["IgG", "PROTEIN", 56, 59], ["CMV", "SPECIES", 52, 55], ["The risk factor", "PROBLEM", 0, 15], ["death", "PROBLEM", 20, 25], ["viral infection", "PROBLEM", 31, 46], ["CMV", "TEST", 52, 55], ["IgG seropositivity", "PROBLEM", 56, 74], ["acute lymphoblastic leukemia recipients", "PROBLEM", 78, 117], ["MSD", "PROBLEM", 131, 134], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["lymphoblastic leukemia recipients", "OBSERVATION", 84, 117]]], ["The incidence of EBV infection requiring pre-emptive treatment with rituximab in allo-HSCT children was 19.3%.", [["EBV infection", "DISEASE", 17, 30], ["rituximab", "CHEMICAL", 68, 77], ["EBV", "ORGANISM", 17, 20], ["rituximab", "SIMPLE_CHEMICAL", 68, 77], ["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["EBV", "SPECIES", 17, 20], ["EBV infection", "PROBLEM", 17, 30], ["pre-emptive treatment", "TREATMENT", 41, 62], ["rituximab", "TREATMENT", 68, 77], ["EBV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30]]], ["In 30.8% of cases of EBV infection, these episodes were preceded by other viral infection treated with antivirals, which did not prevent development of significant EBV-DNA-emia with the need of rituximab treatment in 81.5% of cases.", [["EBV infection", "DISEASE", 21, 34], ["viral infection", "DISEASE", 74, 89], ["rituximab", "CHEMICAL", 194, 203], ["EBV", "ORGANISM", 21, 24], ["EBV", "ORGANISM", 164, 167], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["rituximab", "SIMPLE_CHEMICAL", 194, 203], ["EBV", "SPECIES", 21, 24], ["EBV infection", "PROBLEM", 21, 34], ["these episodes", "PROBLEM", 36, 50], ["other viral infection", "PROBLEM", 68, 89], ["antivirals", "TREATMENT", 103, 113], ["significant EBV", "PROBLEM", 152, 167], ["DNA", "PROBLEM", 168, 171], ["rituximab treatment", "TREATMENT", 194, 213], ["EBV infection", "OBSERVATION", 21, 34], ["viral", "OBSERVATION_MODIFIER", 74, 79], ["infection", "OBSERVATION", 80, 89], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["EBV", "OBSERVATION", 164, 167]]], ["This is clinically proven evidence that antiviral drugs do not prevent EBV reactivation in allo-HCT pediatric patients.", [["EBV", "ORGANISM", 71, 74], ["allo-HCT", "CANCER", 91, 99], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["EBV", "SPECIES", 71, 74], ["antiviral drugs", "TREATMENT", 40, 55], ["EBV reactivation", "PROBLEM", 71, 87]]], ["Additionally, in 47.7% of these cases GVHD was a risk factor, possibly facilitating development of significant EBV-DNA-emia during antiviral therapy of other infections.Ethics StatementThis study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun.", [["GVHD", "DISEASE", 38, 42], ["infections", "DISEASE", 158, 168], ["EBV", "ORGANISM", 111, 114], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["these cases GVHD", "PROBLEM", 26, 42], ["a risk factor", "PROBLEM", 47, 60], ["significant EBV", "PROBLEM", 99, 114], ["DNA", "PROBLEM", 115, 118], ["emia", "PROBLEM", 119, 123], ["antiviral therapy", "TREATMENT", 131, 148], ["other infections", "PROBLEM", 152, 168], ["This study", "TEST", 185, 195], ["GVHD", "OBSERVATION", 38, 42], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["EBV", "OBSERVATION", 111, 114], ["DNA", "OBSERVATION", 115, 118], ["infections", "OBSERVATION", 158, 168]]], ["All patient data were analyzed in anonymity.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["As neither individual data were published nor any intervention was performed on patients, patient consent was waived by the ethics committee.AbbreviationsACV, aciclovir; ADV, adenovirus; a/cGVHD, acute/chronic graft versus host disease; ALL, acute lymphoblastic leukemia; allo-, allogeneic; AML, acute myeloblastic leukemia; ANC, absolute neutrophil count; ARAC, cytarabine; auto-, autologous; BCNU, carmustine; BKV, polyoma BK virus; BM, bone marrow; CARV, community-acquired respiratory virus; CI, confidence intervals; CIBMTR, Center for International Blood and Marrow Transplant Research; CMV, cytomegalovirus; D, days;", [["graft", "ANATOMY", 210, 215], ["ALL", "ANATOMY", 237, 240], ["acute lymphoblastic leukemia", "ANATOMY", 242, 270], ["allo-", "ANATOMY", 272, 277], ["AML", "ANATOMY", 291, 294], ["acute myeloblastic leukemia", "ANATOMY", 296, 323], ["ANC", "ANATOMY", 325, 328], ["neutrophil", "ANATOMY", 339, 349], ["BM", "ANATOMY", 435, 437], ["bone marrow", "ANATOMY", 439, 450], ["Blood", "ANATOMY", 555, 560], ["Marrow", "ANATOMY", 565, 571], ["aciclovir", "CHEMICAL", 159, 168], ["ADV", "CHEMICAL", 170, 173], ["cGVHD", "DISEASE", 189, 194], ["chronic graft versus host disease", "DISEASE", 202, 235], ["ALL", "DISEASE", 237, 240], ["acute lymphoblastic leukemia", "DISEASE", 242, 270], ["AML", "DISEASE", 291, 294], ["acute myeloblastic leukemia", "DISEASE", 296, 323], ["cytarabine", "CHEMICAL", 363, 373], ["BCNU", "CHEMICAL", 394, 398], ["carmustine", "CHEMICAL", 400, 410], ["aciclovir", "CHEMICAL", 159, 168], ["cytarabine", "CHEMICAL", 363, 373], ["BCNU", "CHEMICAL", 394, 398], ["carmustine", "CHEMICAL", 400, 410], ["patients", "ORGANISM", 80, 88], ["patient", "ORGANISM", 90, 97], ["aciclovir", "SIMPLE_CHEMICAL", 159, 168], ["adenovirus", "ORGANISM", 175, 185], ["graft versus host", "CANCER", 210, 227], ["ALL", "CANCER", 237, 240], ["acute lymphoblastic leukemia", "CANCER", 242, 270], ["AML", "CANCER", 291, 294], ["acute myeloblastic leukemia", "CANCER", 296, 323], ["ANC", "CELL", 325, 328], ["neutrophil", "CELL", 339, 349], ["ARAC", "SIMPLE_CHEMICAL", 357, 361], ["cytarabine", "SIMPLE_CHEMICAL", 363, 373], ["BCNU", "SIMPLE_CHEMICAL", 394, 398], ["carmustine", "SIMPLE_CHEMICAL", 400, 410], ["BKV", "ORGANISM", 412, 415], ["polyoma BK virus", "ORGANISM", 417, 433], ["BM", "CELL", 435, 437], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 439, 450], ["CMV", "ORGANISM", 593, 596], ["cytomegalovirus", "ORGANISM", 598, 613], ["patients", "SPECIES", 80, 88], ["patient", "SPECIES", 90, 97], ["polyoma BK virus", "SPECIES", 417, 433], ["polyoma BK virus", "SPECIES", 417, 433], ["AbbreviationsACV", "TREATMENT", 141, 157], ["aciclovir", "TREATMENT", 159, 168], ["adenovirus", "PROBLEM", 175, 185], ["a/cGVHD", "PROBLEM", 187, 194], ["acute/chronic graft versus host disease", "PROBLEM", 196, 235], ["ALL, acute lymphoblastic leukemia", "PROBLEM", 237, 270], ["allo-, allogeneic", "PROBLEM", 272, 289], ["AML", "PROBLEM", 291, 294], ["acute myeloblastic leukemia", "PROBLEM", 296, 323], ["ANC", "TEST", 325, 328], ["absolute neutrophil count", "TEST", 330, 355], ["ARAC", "TREATMENT", 357, 361], ["cytarabine", "TREATMENT", 363, 373], ["auto-, autologous", "TREATMENT", 375, 392], ["BCNU", "TREATMENT", 394, 398], ["carmustine", "TREATMENT", 400, 410], ["BKV", "PROBLEM", 412, 415], ["polyoma BK virus", "PROBLEM", 417, 433], ["acquired respiratory virus", "PROBLEM", 468, 494], ["International Blood", "TEST", 541, 560], ["CMV", "PROBLEM", 593, 596], ["cytomegalovirus", "PROBLEM", 598, 613], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["chronic", "OBSERVATION_MODIFIER", 202, 209], ["graft versus host disease", "OBSERVATION", 210, 235], ["acute", "OBSERVATION_MODIFIER", 242, 247], ["lymphoblastic leukemia", "OBSERVATION", 248, 270], ["acute", "OBSERVATION_MODIFIER", 296, 301], ["myeloblastic leukemia", "OBSERVATION", 302, 323], ["neutrophil count", "OBSERVATION", 339, 355], ["bone marrow", "ANATOMY", 439, 450], ["respiratory virus", "ANATOMY", 477, 494], ["Marrow", "ANATOMY", 565, 571]]]]}